[
  {
    "objectID": "history.html",
    "href": "history.html",
    "title": "Change History",
    "section": "",
    "text": "Below is the history of detected changes for the monitored trials.\nNo history recorded yet.\nBack to Status Summary"
  },
  {
    "objectID": "history.html#historical-updates",
    "href": "history.html#historical-updates",
    "title": "Change History",
    "section": "",
    "text": "Below is the history of detected changes for the monitored trials.\nNo history recorded yet.\nBack to Status Summary"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "This page monitors specific clinical trials and highlights any updates in their status or key fields.\nDownload Status Summary (CSV)\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT04818619\nAssiut University\nðŸŸ¢ No Change\nUNKNOWN\nChronic Myeloid Leukemia\nN/A\n2021-04\n2022-12\n65\n2021-03-25\n\n\nNCT04150965\nMultiple Myeloma Research Consortium\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nPHASE1, PHASE2\n2020-07-10\n2024-08-30\n14\n2025-02-12\n\n\nNCT05607563\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumor\nPHASE1\n2022-11-21\n2023-12\n54\n2023-02-07\n\n\nNCT05394168\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced/Metastatic Solid Tumors\nPHASE1\n2022-12-09\n2025-03-04\n12\n2024-03-28\n\n\nNCT07171307\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nConjunctivitis, Allergic\nN/A\n2026-01-01\n2026-09\n60\n2025-09-15\n\n\nNCT04995523\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small-Cell Lung Carcinoma\nPHASE1, PHASE2\n2021-09-14\n2028-03-16\n210\n2025-11-21\n\n\nNCT03119428\nOncoMed Pharmaceuticals, Inc.\nðŸŸ¢ No Change\nTERMINATED\nLocally Advanced Cancer, Metastatic Cancer\nPHASE1\n2017-05-02\n2019-05-15\n33\n2020-08-10\n\n\nNCT04500678\nUniversity of Hawaii\nðŸŸ¢ No Change\nUNKNOWN\nHIV/AIDS\nPHASE2, PHASE3\n2019-02-01\n2022-12-31\n38\n2020-08-04\n\n\nNCT05483400\nUniversity Medical Center Groningen\nðŸŸ¢ No Change\nRECRUITING\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\nPHASE2\n2023-10-18\n2027-09\n97\n2025-03-28\n\n\nNCT05390528\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors, Lymphoma, Metastatic Tumors\nPHASE1, PHASE2\n2022-06-20\n2024-12-30\n30\n2023-08-07\n\n\nNCT06250036\nRoyal Marsden NHS Foundation Trust\nðŸŸ¢ No Change\nRECRUITING\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer\nPHASE2\n2025-02-20\n2031-09-01\n50\n2025-08-19\n\n\nNCT05653284\nAkeso\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignant Tumors\nPHASE1\n2023-02-09\n2024-05-30\n19\n2024-08-11\n\n\nNCT05102214\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2022-05-03\n2024-02\n150\n2023-08-07\n\n\nNCT05023109\nShanghai Zhongshan Hospital\nðŸŸ¢ No Change\nUNKNOWN\nBiliary Tract Carcinoma\nPHASE2\n2021-02-01\n2024-12-01\n45\n2023-08-12\n\n\nNCT05130177\nDiwakar Davar\nðŸŸ¢ No Change\nRECRUITING\nMelanoma\nPHASE2\n2022-03-16\n2031-01\n26\n2025-05-02\n\n\nNCT04047862\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced and Metastatic Solid Tumors\nPHASE1\n2019-08-15\n2024-08-07\n446\n2025-08-04\n\n\nNCT05537051\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumours\nPHASE1\n2023-10-30\n2025-12-31\n30\n2023-02-07\n\n\nNCT05019677\nFudan University\nðŸŸ¢ No Change\nWITHDRAWN\nIntrahepatic Cholangiocarcinoma\nPHASE2\n2021-09-01\n2024-12-01\n0\n2022-03-22\n\n\nNCT05061628\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors\nPHASE1\n2021-04-21\n2024-09-30\n176\n2021-09-21\n\n\nNCT04656535\nYale University\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nEARLY_PHASE1\n2021-04-21\n2026-12-31\n46\n2026-01-06\n\n\nNCT06773507\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPHASE1\n2025-05-12\n2027-06\n80\n2025-07-07\n\n\nNCT06349980\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Hepatocellular\nPHASE2\n2024-08-05\n2027-02-10\n117\n2024-12-15\n\n\nNCT05706207\nHuabo Biopharm Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nPHASE1\n2021-12-21\n2023-09-30\n36\n2023-01-20\n\n\nNCT05060432\niTeos Belgium SA\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nPHASE1, PHASE2\n2021-09-06\n2025-07\n153\n2024-06-19\n\n\nNCT06713798\nGustave Roussy, Cancer Campus, Grand Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\nPHASE2\n2025-07\n2030-01\n115\n2025-06-23\n\n\nNCT05394337\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nMetastatic Malignancy\nPHASE1, PHASE2\n2023-02-23\n2025-12-31\n10\n2025-10-07\n\n\nNCT05253105\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nWITHDRAWN\nPreviously Treated, Advanced, Malignancies\nPHASE1\n2022-03-15\n2027-01\n0\n2022-05-24\n\n\nNCT04270942\nProvention Bio, a Sanofi Company\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes Mellitus, Type 1\nPHASE2\n2020-02-26\n2024-01-22\n6\n2025-01-20\n\n\nNCT05294952\nAssiut University\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nPre-Eclampsia\nPHASE4\n2025-01-01\n2025-11-04\n82\n2024-02-01\n\n\nNCT06754501\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nCancer\nPHASE2\n2025-04-11\n2029-07-01\n35\n2025-10-01\n\n\nNCT05757492\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nPHASE1\n2023-04-26\n2024-07-31\n22\n2025-04-30\n\n\nNCT04952597\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLimited Stage Small Cell Lung Cancer\nPHASE2\n2021-07-15\n2023-07-26\n126\n2024-10-23\n\n\nNCT05805501\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRenal Cell Carcinoma\nPHASE2\n2023-04-21\n2026-07-31\n199\n2025-11-12\n\n\nNCT03447678\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\nðŸŸ¢ No Change\nUNKNOWN\nNon Small Cell Lung Cancer (NSCLC)\nPHASE2\n2018-05-23\n2022-05-31\n65\n2021-06-08\n\n\nNCT04672369\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-06-06\n2023-06-01\n42\n2023-06-18\n\n\nNCT04672356\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-01-25\n2023-06-01\n19\n2023-06-18\n\n\nNCT05009069\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRectal Neoplasms, Rectal Cancer\nPHASE2\n2022-03-18\n2026-11-06\n58\n2026-01-16\n\n\nNCT04353830\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignancies\nPHASE1\n2020-05-22\n2022-05-11\n34\n2023-02-28\n\n\nNCT07337447\nHospices Civils de Lyon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCarcinoma, Neuroendocrine\nPHASE2\n2026-04\n2030-04\n122\n2026-01-07\n\n\nNCT04354246\nCompugen Ltd\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC\nPHASE1\n2020-03-31\n2025-12-30\n110\n2025-05-18\n\n\nNCT04933227\nHoffmann-La Roche\nðŸŸ¢ No Change\nTERMINATED\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\nPHASE2\n2021-08-06\n2023-11-17\n29\n2024-11-11\n\n\nNCT05414032\nUniversity Health Network, Toronto\nðŸŸ¢ No Change\nRECRUITING\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\nPHASE2\n2023-07-12\n2026-07\n200\n2025-03-25\n\n\nNCT06003621\nOmico\nðŸŸ¢ No Change\nRECRUITING\nSolid Tumor, Adult\nPHASE2\n2023-12-15\n2028-11-01\n96\n2024-11-13\n\n\nNCT05568095\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nPHASE3\n2022-11-21\n2026-06\n1040\n2026-01-30\n\n\nNCT06777628\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\nðŸŸ¢ No Change\nRECRUITING\nLiver Cancer, Adult\nN/A\n2024-09-15\n2028-10-15\n100\n2025-01-14\n\n\nNCT06773481\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHO Grade IV\nPHASE1\n2025-04-07\n2026-12\n40\n2025-07-07\n\n\nNCT03708224\nAlain Algazi\nðŸŸ¢ No Change\nRECRUITING\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nPHASE2\n2019-03-08\n2028-06-30\n55\n2025-01-24\n\n\nNCT03652402\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nCOMPLETED\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nN/A\n2018-11-27\n2021-10-28\n558\n2024-06-04\n\n\nNCT03486119\nYonsei University\nðŸŸ¢ No Change\nCOMPLETED\nNon -Small Cell Lung Cancer\nN/A\n2018-02-05\n2020-07-07\n60\n2020-10-14\n\n\nNCT05120375\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nSolid Tumor\nPHASE1\n2022-02-17\n2023-04-07\n5\n2023-10-08\n\n\nNCT05327530\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nLocally Advanced or Metastatic Urothelial Carcinoma\nPHASE2\n2022-08-17\n2026-06-25\n256\n2026-01-23\n\n\nNCT04570839\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nPHASE1, PHASE2\n2020-08-31\n2024-05-15\n48\n2024-07-17\n\n\nNCT05520294\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nN/A\n2022-09-01\n2024-08-31\n90\n2024-04-15\n\n\nNCT05417321\nShanghai Huaota Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor, NSCLC\nPHASE1, PHASE2\n2022-08-25\n2025-08-01\n80\n2025-01-02\n\n\nNCT06328036\nNational Cancer Institute (NCI)\nðŸŸ¢ No Change\nWITHDRAWN\nRecurrent Glioblastoma, IDH-Wildtype\nPHASE2\n2025-04-30\n2025-07-01\n0\n2024-12-27\n\n\nNCT04465643\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nðŸŸ¢ No Change\nCOMPLETED\nNerve Sheath Tumors\nPHASE1\n2021-06-08\n2025-07-30\n13\n2025-10-02\n\n\nNCT04262856\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2020-05-28\n2025-07-09\n151\n2025-08-25\n\n\nNCT04736173\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2021-02-08\n2027-05\n169\n2025-12-09\n\n\nNCT05126537\nSoutheast University, China\nðŸŸ¢ No Change\nUNKNOWN\n28 Day Mortality\nN/A\n2022-01-01\n2022-12-31\n100\n2022-11-25\n\n\nNCT05289492\niTeos Therapeutics\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma\nPHASE1\n2022-05-01\n2023-11-29\n16\n2024-10-23\n\n\nNCT07115043\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma\nPHASE1, PHASE2\n2025-07-29\n2029-10-02\n60\n2025-12-18\n\n\nNCT05743504\nNational Taiwan University Hospital\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced Esophageal Squamous Cell Carcinoma\nPHASE1, PHASE2\n2023-09-18\n2025-11-30\n32\n2024-01-31\n\n\nNCT05073484\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor\nPHASE1\n2021-10-29\n2023-03-30\n13\n2023-10-09\n\n\nNCT07376512\nCentre Georges Francois Leclerc\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nN/A\n2026-03-01\n2030-03-01\n378\n2026-01-22\n\n\nNCT05904886\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nHepatocellular Carcinoma\nPHASE3\n2023-09-14\n2026-09-01\n687\n2025-12-30\n\n\nNCT03739710\nGlaxoSmithKline\nðŸŸ¢ No Change\nCOMPLETED\nNeoplasms\nPHASE2\n2019-01-24\n2024-05-02\n175\n2025-06-13\n\n\nNCT04791839\nWashington University School of Medicine\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\nPHASE2\n2021-08-04\n2030-06-30\n30\n2025-11-04\n\n\nNCT05020912\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nBasal Cell Carcinoma\nPHASE2\n2021-12-13\n2027-12\n28\n2025-11-25\n\n\nNCT06334406\nCentre Hospitalier Universitaire de Besancon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nBladder Cancer\nN/A\n2024-04-02\n2026-04-02\n33\n2024-03-19\n\n\nNCT07343310\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\nPHASE1\n2024-08-27\n2025-04-14\n9\n2026-01-15\n\n\nNCT03342417\nExcellaBio LLC\nðŸŸ¢ No Change\nTERMINATED\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nPHASE2\n2018-02-14\n2019-05-29\n5\n2021-11-05\n\n\nNCT04682665\nUniversity of Leeds\nðŸŸ¢ No Change\nCOMPLETED\nColon Cancer Liver Metastasis\nN/A\n2021-09-16\n2024-07-31\n81\n2024-12-03\n\n\nNCT05123482\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer\nPHASE1, PHASE2\n2021-10-18\n2027-09-29\n460\n2025-12-02\n\n\nNCT07161414\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1\n2025-11-25\n2029-07-24\n40\n2025-12-18\n\n\nNCT07015164\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nHIV\nN/A\n2025-06-10\n2026-09-11\n80\n2025-06-03\n\n\nNCT05702229\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer\nPHASE2\n2023-01-16\n2027-09-28\n240\n2025-11-14\n\n\nNCT07213882\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\n2025-10-02\n\n\nNCT03628677\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Unspecified, Adult\nPHASE1\n2018-09-12\n2025-01-23\n75\n2025-02-03\n\n\nNCT06897436\nMedical University of Lublin\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nEndometriosis\nN/A\n2025-05-01\n2029-12-31\n60\n2025-03-24\n\n\nNCT05633927\nHospitales Universitarios Virgen del RocÃ­o\nðŸŸ¢ No Change\nCOMPLETED\nSARS-CoV-2 RNA Vaccines, HIV Infection\nN/A\n2021-04-01\n2022-12-01\n48\n2024-10-09\n\n\nNCT04836507\nCurocell Inc.\nðŸŸ¢ No Change\nRECRUITING\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)\nPHASE1, PHASE2\n2021-03-02\n2028-02\n91\n2021-04-29\n\n\nNCT05775159\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Biliary Tract Cancer\nPHASE2\n2023-04-24\n2027-10-28\n294\n2025-11-12\n\n\nNCT06338657\nUniversity of Southern California\nðŸŸ¢ No Change\nTERMINATED\nHead and Neck Squamous Cell Carcinoma\nPHASE1\n2024-04-01\n2025-09-09\n1\n2025-09-09\n\n\nNCT06860815\nCity of Hope Medical Center\nðŸŸ¢ No Change\nRECRUITING\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver\nPHASE2\n2026-04-01\n2027-01-30\n11\n2026-01-27\n\n\nNCT04624828\nIstituto Clinico Humanitas\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\nNA\n2020-10-19\n2026-07\n40\n2025-04-22\n\n\nNCT05574335\nNational Institute of Allergy and Infectious Diseases (NIAID)\nðŸŸ¢ No Change\nTERMINATED\nType 1 Diabetes Mellitus\nPHASE1, PHASE2\n2023-04-26\n2025-10-20\n8\n2026-01-05\n\n\nNCT06302556\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nLung Transplant Rejection\nN/A\n2024-04\n2026-02\n280\n2024-03-06\n\n\nNCT04761198\nMereo BioPharma\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\nPHASE1, PHASE2\n2021-03-23\n2023-10-30\n76\n2025-03-07\n\n\nNCT04693234\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nCervical Cancer\nPHASE2\n2021-02-15\n2023-08-31\n178\n2025-04-09\n\n\nNCT03563716\nGenentech, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon-small Cell Lung Cancer\nPHASE2\n2018-08-10\n2025-11-24\n135\n2025-12-30\n\n\nNCT07324642\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nHealthy Volunteers\nPHASE1\n2025-05-26\n2025-08-25\n24\n2025-12-24\n\n\nNCT05809895\nNovartis Pharmaceuticals\nðŸŸ¢ No Change\nWITHDRAWN\nTriple Negative Breast Cancer\nPHASE2\n2023-09-15\n2029-07-18\n0\n2023-07-21\n\n\nNCT04732494\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nEsophageal Squamous Cell Carcinoma\nPHASE2\n2021-03-31\n2023-12-26\n125\n2024-12-23\n\n\nNCT05645692\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nUrothelial Cancer\nPHASE2\n2023-04-13\n2026-12-31\n204\n2026-01-28\n\n\nNCT04457778\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nMetastatic Solid Tumors\nPHASE1\n2020-07-10\n2023-06-23\n58\n2023-12-07\n\n\nNCT03772899\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1\n2019-03-27\n2026-08\n20\n2025-03-26\n\n\nNCT04374877\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer\nPHASE1\n2020-04-22\n2025-06-05\n145\n2025-11-06\n\n\nNCT06346197\nCentre Leon Berard\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\nPHASE3\n2025-12-08\n2028-05-15\n132\n2025-12-19\n\n\nNCT05780073\nFundaciÃ³ Institut Germans Trias i Pujol\nðŸŸ¢ No Change\nCOMPLETED\nHIV Infection Primary\nPHASE2\n2023-10-16\n2025-04-01\n60\n2025-09-16\n\n\nNCT03667716\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer\nPHASE1\n2018-09-06\n2024-01-30\n121\n2025-01-15\n\n\nNCT06784947\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV\nPHASE2\n2025-03-25\n2028-05\n13\n2025-10-01\n\n\nNCT05014815\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV\nPHASE2\n2021-11-16\n2024-09-04\n272\n2025-08-28\n\n\nNCT07307053\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nPHASE1, PHASE2\n2026-01-01\n2031-01-31\n600\n2025-12-13\n\n\nNCT04746924\nBeiGene\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon-small Cell Lung Cancer, NSCLC\nPHASE3\n2021-06-08\n2026-03-31\n662\n2025-06-23\n\n\nNCT07098338\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small Cell Lung Cancer\nPHASE2\n2025-08-07\n2029-04-06\n278\n2025-09-25\n\n\nNCT06532539\nShandong Cancer Hospital and Institute\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nPHASE2\n2024-06-13\n2026-05\n30\n2024-07-29\n\n\nNCT06864598\nPeking University Peopleâ€™s Hospital\nðŸŸ¢ No Change\nENROLLING_BY_INVITATION\nGraft-versus-host Disease (GVHD)\nN/A\n2025-01-09\n2026-10-31\n100\n2025-03-04\n\n\nNCT03661047\nMassachusetts General Hospital\nðŸŸ¢ No Change\nWITHDRAWN\nColon Cancer\nPHASE2\n2019-11-30\n2021-11-30\n0\n2021-11-10\n\n\nNCT04866017\nBeiGene\nðŸŸ¢ No Change\nTERMINATED\nNon Small Cell Lung Cancer\nPHASE3\n2021-06-17\n2023-10-17\n63\n2024-10-09\n\n\nNCT05127824\nJodi Maranchie\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Renal Cell\nPHASE2\n2023-07-06\n2026-12\n42\n2025-04-30\n\n\nNCT04303169\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-09-24\n146\n2025-10-23\n\n\nNCT05329766\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGastrointestinal Tract Malignancies\nPHASE2\n2022-06-10\n2027-06\n332\n2026-01-27\n\n\nNCT04323202\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nCOMPLETED\nBasal Cell Carcinoma of the Head and Neck\nPHASE1\n2020-08-04\n2025-06-25\n13\n2025-10-23\n\n\nNCT07221253\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBiliary Tract Cancer\nPHASE3\n2025-12-04\n2029-07-04\n1100\n2026-01-07\n\n\nNCT05676931\nGilead Sciences\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Non-Small Cell Lung Cancer\nPHASE2\n2023-02-21\n2027-12\n400\n2025-09-29\n\n\nNCT06790706\nHospices Civils de Lyon\nðŸŸ¢ No Change\nRECRUITING\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor\nPHASE2\n2025-10-01\n2031-06\n154\n2025-10-01\n\n\nNCT04543617\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nEsophageal Squamous Cell Carcinoma\nPHASE3\n2020-09-28\n2027-03-31\n760\n2026-01-16\n\n\nNCT04305041\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-08-25\n100\n2025-08-28\n\n\nNCT06996782\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced or Metastatic Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2025-11-24\n2029-02-23\n152\n2026-01-13\n\n\nNCT05665595\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE3\n2023-01-19\n2025-09-26\n1594\n2025-10-03\n\n\nNCT06868277\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Non-Small Cell Lung\nPHASE3\n2025-04-10\n2030-12-02\n830\n2026-01-12\n\n\nNCT06692738\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-small Cell Lung Cancer\nPHASE3\n2024-11-18\n2029-10-08\n880\n2026-01-20\n\n\nNCT04774484\nFrancesc Marti\nðŸŸ¢ No Change\nWITHDRAWN\nEnd Stage Renal Disease\nNA\n2023-01\n2026-06-30\n0\n2023-02-10\n\n\nNCT04256421\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nSmall Cell Lung Cancer\nPHASE3\n2020-02-04\n2025-07-31\n490\n2026-01-09\n\n\nNCT06989112\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Cancer\nPHASE3\n2025-03-27\n2031-02-19\n600\n2026-01-14\n\n\nNCT05816460\nUniversity College Dublin\nðŸŸ¢ No Change\nUNKNOWN\nInsomnia, Cancer\nNA\n2023-05-22\n2024-06-10\n308\n2023-05-19\n\n\nNCT06627647\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-squamous Non-small Cell Lung Cancer\nPHASE3\n2024-11-27\n2030-03-25\n878\n2025-12-19\n\n\nNCT04305054\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1, PHASE2\n2020-07-01\n2026-04-20\n315\n2025-08-28\n\n\nNCT04294810\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nNon-Small Cell Lung Cancer\nPHASE3\n2020-03-04\n2025-12-30\n620\n2026-01-29\n\n\nNCT03198546\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT04585815\nPfizer\nðŸŸ¢ No Change\nTERMINATED\nCarcinoma, Non-Small-Cell Lung\nPHASE1, PHASE2\n2020-11-10\n2024-10-29\n34\n2025-12-18\n\n\nNCT02443155\nNovo Nordisk A/S\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes, Diabetes Mellitus, Type 1\nPHASE2\n2015-11-10\n2019-02-27\n308\n2021-03-10\n\n\n\nView Full Change History"
  },
  {
    "objectID": "index.html#monitoring-status",
    "href": "index.html#monitoring-status",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "This page monitors specific clinical trials and highlights any updates in their status or key fields.\nDownload Status Summary (CSV)\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT04818619\nAssiut University\nðŸŸ¢ No Change\nUNKNOWN\nChronic Myeloid Leukemia\nN/A\n2021-04\n2022-12\n65\n2021-03-25\n\n\nNCT04150965\nMultiple Myeloma Research Consortium\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nPHASE1, PHASE2\n2020-07-10\n2024-08-30\n14\n2025-02-12\n\n\nNCT05607563\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumor\nPHASE1\n2022-11-21\n2023-12\n54\n2023-02-07\n\n\nNCT05394168\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced/Metastatic Solid Tumors\nPHASE1\n2022-12-09\n2025-03-04\n12\n2024-03-28\n\n\nNCT07171307\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nConjunctivitis, Allergic\nN/A\n2026-01-01\n2026-09\n60\n2025-09-15\n\n\nNCT04995523\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small-Cell Lung Carcinoma\nPHASE1, PHASE2\n2021-09-14\n2028-03-16\n210\n2025-11-21\n\n\nNCT03119428\nOncoMed Pharmaceuticals, Inc.\nðŸŸ¢ No Change\nTERMINATED\nLocally Advanced Cancer, Metastatic Cancer\nPHASE1\n2017-05-02\n2019-05-15\n33\n2020-08-10\n\n\nNCT04500678\nUniversity of Hawaii\nðŸŸ¢ No Change\nUNKNOWN\nHIV/AIDS\nPHASE2, PHASE3\n2019-02-01\n2022-12-31\n38\n2020-08-04\n\n\nNCT05483400\nUniversity Medical Center Groningen\nðŸŸ¢ No Change\nRECRUITING\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\nPHASE2\n2023-10-18\n2027-09\n97\n2025-03-28\n\n\nNCT05390528\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors, Lymphoma, Metastatic Tumors\nPHASE1, PHASE2\n2022-06-20\n2024-12-30\n30\n2023-08-07\n\n\nNCT06250036\nRoyal Marsden NHS Foundation Trust\nðŸŸ¢ No Change\nRECRUITING\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer\nPHASE2\n2025-02-20\n2031-09-01\n50\n2025-08-19\n\n\nNCT05653284\nAkeso\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignant Tumors\nPHASE1\n2023-02-09\n2024-05-30\n19\n2024-08-11\n\n\nNCT05102214\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2022-05-03\n2024-02\n150\n2023-08-07\n\n\nNCT05023109\nShanghai Zhongshan Hospital\nðŸŸ¢ No Change\nUNKNOWN\nBiliary Tract Carcinoma\nPHASE2\n2021-02-01\n2024-12-01\n45\n2023-08-12\n\n\nNCT05130177\nDiwakar Davar\nðŸŸ¢ No Change\nRECRUITING\nMelanoma\nPHASE2\n2022-03-16\n2031-01\n26\n2025-05-02\n\n\nNCT04047862\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced and Metastatic Solid Tumors\nPHASE1\n2019-08-15\n2024-08-07\n446\n2025-08-04\n\n\nNCT05537051\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumours\nPHASE1\n2023-10-30\n2025-12-31\n30\n2023-02-07\n\n\nNCT05019677\nFudan University\nðŸŸ¢ No Change\nWITHDRAWN\nIntrahepatic Cholangiocarcinoma\nPHASE2\n2021-09-01\n2024-12-01\n0\n2022-03-22\n\n\nNCT05061628\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors\nPHASE1\n2021-04-21\n2024-09-30\n176\n2021-09-21\n\n\nNCT04656535\nYale University\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nEARLY_PHASE1\n2021-04-21\n2026-12-31\n46\n2026-01-06\n\n\nNCT06773507\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPHASE1\n2025-05-12\n2027-06\n80\n2025-07-07\n\n\nNCT06349980\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Hepatocellular\nPHASE2\n2024-08-05\n2027-02-10\n117\n2024-12-15\n\n\nNCT05706207\nHuabo Biopharm Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nPHASE1\n2021-12-21\n2023-09-30\n36\n2023-01-20\n\n\nNCT05060432\niTeos Belgium SA\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nPHASE1, PHASE2\n2021-09-06\n2025-07\n153\n2024-06-19\n\n\nNCT06713798\nGustave Roussy, Cancer Campus, Grand Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\nPHASE2\n2025-07\n2030-01\n115\n2025-06-23\n\n\nNCT05394337\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nMetastatic Malignancy\nPHASE1, PHASE2\n2023-02-23\n2025-12-31\n10\n2025-10-07\n\n\nNCT05253105\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nWITHDRAWN\nPreviously Treated, Advanced, Malignancies\nPHASE1\n2022-03-15\n2027-01\n0\n2022-05-24\n\n\nNCT04270942\nProvention Bio, a Sanofi Company\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes Mellitus, Type 1\nPHASE2\n2020-02-26\n2024-01-22\n6\n2025-01-20\n\n\nNCT05294952\nAssiut University\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nPre-Eclampsia\nPHASE4\n2025-01-01\n2025-11-04\n82\n2024-02-01\n\n\nNCT06754501\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nCancer\nPHASE2\n2025-04-11\n2029-07-01\n35\n2025-10-01\n\n\nNCT05757492\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nPHASE1\n2023-04-26\n2024-07-31\n22\n2025-04-30\n\n\nNCT04952597\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLimited Stage Small Cell Lung Cancer\nPHASE2\n2021-07-15\n2023-07-26\n126\n2024-10-23\n\n\nNCT05805501\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRenal Cell Carcinoma\nPHASE2\n2023-04-21\n2026-07-31\n199\n2025-11-12\n\n\nNCT03447678\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\nðŸŸ¢ No Change\nUNKNOWN\nNon Small Cell Lung Cancer (NSCLC)\nPHASE2\n2018-05-23\n2022-05-31\n65\n2021-06-08\n\n\nNCT04672369\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-06-06\n2023-06-01\n42\n2023-06-18\n\n\nNCT04672356\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-01-25\n2023-06-01\n19\n2023-06-18\n\n\nNCT05009069\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRectal Neoplasms, Rectal Cancer\nPHASE2\n2022-03-18\n2026-11-06\n58\n2026-01-16\n\n\nNCT04353830\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignancies\nPHASE1\n2020-05-22\n2022-05-11\n34\n2023-02-28\n\n\nNCT07337447\nHospices Civils de Lyon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCarcinoma, Neuroendocrine\nPHASE2\n2026-04\n2030-04\n122\n2026-01-07\n\n\nNCT04354246\nCompugen Ltd\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC\nPHASE1\n2020-03-31\n2025-12-30\n110\n2025-05-18\n\n\nNCT04933227\nHoffmann-La Roche\nðŸŸ¢ No Change\nTERMINATED\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\nPHASE2\n2021-08-06\n2023-11-17\n29\n2024-11-11\n\n\nNCT05414032\nUniversity Health Network, Toronto\nðŸŸ¢ No Change\nRECRUITING\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\nPHASE2\n2023-07-12\n2026-07\n200\n2025-03-25\n\n\nNCT06003621\nOmico\nðŸŸ¢ No Change\nRECRUITING\nSolid Tumor, Adult\nPHASE2\n2023-12-15\n2028-11-01\n96\n2024-11-13\n\n\nNCT05568095\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nPHASE3\n2022-11-21\n2026-06\n1040\n2026-01-30\n\n\nNCT06777628\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\nðŸŸ¢ No Change\nRECRUITING\nLiver Cancer, Adult\nN/A\n2024-09-15\n2028-10-15\n100\n2025-01-14\n\n\nNCT06773481\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHO Grade IV\nPHASE1\n2025-04-07\n2026-12\n40\n2025-07-07\n\n\nNCT03708224\nAlain Algazi\nðŸŸ¢ No Change\nRECRUITING\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nPHASE2\n2019-03-08\n2028-06-30\n55\n2025-01-24\n\n\nNCT03652402\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nCOMPLETED\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nN/A\n2018-11-27\n2021-10-28\n558\n2024-06-04\n\n\nNCT03486119\nYonsei University\nðŸŸ¢ No Change\nCOMPLETED\nNon -Small Cell Lung Cancer\nN/A\n2018-02-05\n2020-07-07\n60\n2020-10-14\n\n\nNCT05120375\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nSolid Tumor\nPHASE1\n2022-02-17\n2023-04-07\n5\n2023-10-08\n\n\nNCT05327530\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nLocally Advanced or Metastatic Urothelial Carcinoma\nPHASE2\n2022-08-17\n2026-06-25\n256\n2026-01-23\n\n\nNCT04570839\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nPHASE1, PHASE2\n2020-08-31\n2024-05-15\n48\n2024-07-17\n\n\nNCT05520294\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nN/A\n2022-09-01\n2024-08-31\n90\n2024-04-15\n\n\nNCT05417321\nShanghai Huaota Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor, NSCLC\nPHASE1, PHASE2\n2022-08-25\n2025-08-01\n80\n2025-01-02\n\n\nNCT06328036\nNational Cancer Institute (NCI)\nðŸŸ¢ No Change\nWITHDRAWN\nRecurrent Glioblastoma, IDH-Wildtype\nPHASE2\n2025-04-30\n2025-07-01\n0\n2024-12-27\n\n\nNCT04465643\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nðŸŸ¢ No Change\nCOMPLETED\nNerve Sheath Tumors\nPHASE1\n2021-06-08\n2025-07-30\n13\n2025-10-02\n\n\nNCT04262856\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2020-05-28\n2025-07-09\n151\n2025-08-25\n\n\nNCT04736173\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2021-02-08\n2027-05\n169\n2025-12-09\n\n\nNCT05126537\nSoutheast University, China\nðŸŸ¢ No Change\nUNKNOWN\n28 Day Mortality\nN/A\n2022-01-01\n2022-12-31\n100\n2022-11-25\n\n\nNCT05289492\niTeos Therapeutics\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma\nPHASE1\n2022-05-01\n2023-11-29\n16\n2024-10-23\n\n\nNCT07115043\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma\nPHASE1, PHASE2\n2025-07-29\n2029-10-02\n60\n2025-12-18\n\n\nNCT05743504\nNational Taiwan University Hospital\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced Esophageal Squamous Cell Carcinoma\nPHASE1, PHASE2\n2023-09-18\n2025-11-30\n32\n2024-01-31\n\n\nNCT05073484\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor\nPHASE1\n2021-10-29\n2023-03-30\n13\n2023-10-09\n\n\nNCT07376512\nCentre Georges Francois Leclerc\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nN/A\n2026-03-01\n2030-03-01\n378\n2026-01-22\n\n\nNCT05904886\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nHepatocellular Carcinoma\nPHASE3\n2023-09-14\n2026-09-01\n687\n2025-12-30\n\n\nNCT03739710\nGlaxoSmithKline\nðŸŸ¢ No Change\nCOMPLETED\nNeoplasms\nPHASE2\n2019-01-24\n2024-05-02\n175\n2025-06-13\n\n\nNCT04791839\nWashington University School of Medicine\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\nPHASE2\n2021-08-04\n2030-06-30\n30\n2025-11-04\n\n\nNCT05020912\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nBasal Cell Carcinoma\nPHASE2\n2021-12-13\n2027-12\n28\n2025-11-25\n\n\nNCT06334406\nCentre Hospitalier Universitaire de Besancon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nBladder Cancer\nN/A\n2024-04-02\n2026-04-02\n33\n2024-03-19\n\n\nNCT07343310\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\nPHASE1\n2024-08-27\n2025-04-14\n9\n2026-01-15\n\n\nNCT03342417\nExcellaBio LLC\nðŸŸ¢ No Change\nTERMINATED\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nPHASE2\n2018-02-14\n2019-05-29\n5\n2021-11-05\n\n\nNCT04682665\nUniversity of Leeds\nðŸŸ¢ No Change\nCOMPLETED\nColon Cancer Liver Metastasis\nN/A\n2021-09-16\n2024-07-31\n81\n2024-12-03\n\n\nNCT05123482\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer\nPHASE1, PHASE2\n2021-10-18\n2027-09-29\n460\n2025-12-02\n\n\nNCT07161414\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1\n2025-11-25\n2029-07-24\n40\n2025-12-18\n\n\nNCT07015164\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nHIV\nN/A\n2025-06-10\n2026-09-11\n80\n2025-06-03\n\n\nNCT05702229\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer\nPHASE2\n2023-01-16\n2027-09-28\n240\n2025-11-14\n\n\nNCT07213882\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\n2025-10-02\n\n\nNCT03628677\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Unspecified, Adult\nPHASE1\n2018-09-12\n2025-01-23\n75\n2025-02-03\n\n\nNCT06897436\nMedical University of Lublin\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nEndometriosis\nN/A\n2025-05-01\n2029-12-31\n60\n2025-03-24\n\n\nNCT05633927\nHospitales Universitarios Virgen del RocÃ­o\nðŸŸ¢ No Change\nCOMPLETED\nSARS-CoV-2 RNA Vaccines, HIV Infection\nN/A\n2021-04-01\n2022-12-01\n48\n2024-10-09\n\n\nNCT04836507\nCurocell Inc.\nðŸŸ¢ No Change\nRECRUITING\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)\nPHASE1, PHASE2\n2021-03-02\n2028-02\n91\n2021-04-29\n\n\nNCT05775159\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Biliary Tract Cancer\nPHASE2\n2023-04-24\n2027-10-28\n294\n2025-11-12\n\n\nNCT06338657\nUniversity of Southern California\nðŸŸ¢ No Change\nTERMINATED\nHead and Neck Squamous Cell Carcinoma\nPHASE1\n2024-04-01\n2025-09-09\n1\n2025-09-09\n\n\nNCT06860815\nCity of Hope Medical Center\nðŸŸ¢ No Change\nRECRUITING\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver\nPHASE2\n2026-04-01\n2027-01-30\n11\n2026-01-27\n\n\nNCT04624828\nIstituto Clinico Humanitas\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\nNA\n2020-10-19\n2026-07\n40\n2025-04-22\n\n\nNCT05574335\nNational Institute of Allergy and Infectious Diseases (NIAID)\nðŸŸ¢ No Change\nTERMINATED\nType 1 Diabetes Mellitus\nPHASE1, PHASE2\n2023-04-26\n2025-10-20\n8\n2026-01-05\n\n\nNCT06302556\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nLung Transplant Rejection\nN/A\n2024-04\n2026-02\n280\n2024-03-06\n\n\nNCT04761198\nMereo BioPharma\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\nPHASE1, PHASE2\n2021-03-23\n2023-10-30\n76\n2025-03-07\n\n\nNCT04693234\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nCervical Cancer\nPHASE2\n2021-02-15\n2023-08-31\n178\n2025-04-09\n\n\nNCT03563716\nGenentech, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon-small Cell Lung Cancer\nPHASE2\n2018-08-10\n2025-11-24\n135\n2025-12-30\n\n\nNCT07324642\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nHealthy Volunteers\nPHASE1\n2025-05-26\n2025-08-25\n24\n2025-12-24\n\n\nNCT05809895\nNovartis Pharmaceuticals\nðŸŸ¢ No Change\nWITHDRAWN\nTriple Negative Breast Cancer\nPHASE2\n2023-09-15\n2029-07-18\n0\n2023-07-21\n\n\nNCT04732494\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nEsophageal Squamous Cell Carcinoma\nPHASE2\n2021-03-31\n2023-12-26\n125\n2024-12-23\n\n\nNCT05645692\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nUrothelial Cancer\nPHASE2\n2023-04-13\n2026-12-31\n204\n2026-01-28\n\n\nNCT04457778\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nMetastatic Solid Tumors\nPHASE1\n2020-07-10\n2023-06-23\n58\n2023-12-07\n\n\nNCT03772899\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1\n2019-03-27\n2026-08\n20\n2025-03-26\n\n\nNCT04374877\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer\nPHASE1\n2020-04-22\n2025-06-05\n145\n2025-11-06\n\n\nNCT06346197\nCentre Leon Berard\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\nPHASE3\n2025-12-08\n2028-05-15\n132\n2025-12-19\n\n\nNCT05780073\nFundaciÃ³ Institut Germans Trias i Pujol\nðŸŸ¢ No Change\nCOMPLETED\nHIV Infection Primary\nPHASE2\n2023-10-16\n2025-04-01\n60\n2025-09-16\n\n\nNCT03667716\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer\nPHASE1\n2018-09-06\n2024-01-30\n121\n2025-01-15\n\n\nNCT06784947\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV\nPHASE2\n2025-03-25\n2028-05\n13\n2025-10-01\n\n\nNCT05014815\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV\nPHASE2\n2021-11-16\n2024-09-04\n272\n2025-08-28\n\n\nNCT07307053\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nPHASE1, PHASE2\n2026-01-01\n2031-01-31\n600\n2025-12-13\n\n\nNCT04746924\nBeiGene\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon-small Cell Lung Cancer, NSCLC\nPHASE3\n2021-06-08\n2026-03-31\n662\n2025-06-23\n\n\nNCT07098338\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small Cell Lung Cancer\nPHASE2\n2025-08-07\n2029-04-06\n278\n2025-09-25\n\n\nNCT06532539\nShandong Cancer Hospital and Institute\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nPHASE2\n2024-06-13\n2026-05\n30\n2024-07-29\n\n\nNCT06864598\nPeking University Peopleâ€™s Hospital\nðŸŸ¢ No Change\nENROLLING_BY_INVITATION\nGraft-versus-host Disease (GVHD)\nN/A\n2025-01-09\n2026-10-31\n100\n2025-03-04\n\n\nNCT03661047\nMassachusetts General Hospital\nðŸŸ¢ No Change\nWITHDRAWN\nColon Cancer\nPHASE2\n2019-11-30\n2021-11-30\n0\n2021-11-10\n\n\nNCT04866017\nBeiGene\nðŸŸ¢ No Change\nTERMINATED\nNon Small Cell Lung Cancer\nPHASE3\n2021-06-17\n2023-10-17\n63\n2024-10-09\n\n\nNCT05127824\nJodi Maranchie\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Renal Cell\nPHASE2\n2023-07-06\n2026-12\n42\n2025-04-30\n\n\nNCT04303169\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-09-24\n146\n2025-10-23\n\n\nNCT05329766\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGastrointestinal Tract Malignancies\nPHASE2\n2022-06-10\n2027-06\n332\n2026-01-27\n\n\nNCT04323202\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nCOMPLETED\nBasal Cell Carcinoma of the Head and Neck\nPHASE1\n2020-08-04\n2025-06-25\n13\n2025-10-23\n\n\nNCT07221253\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBiliary Tract Cancer\nPHASE3\n2025-12-04\n2029-07-04\n1100\n2026-01-07\n\n\nNCT05676931\nGilead Sciences\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Non-Small Cell Lung Cancer\nPHASE2\n2023-02-21\n2027-12\n400\n2025-09-29\n\n\nNCT06790706\nHospices Civils de Lyon\nðŸŸ¢ No Change\nRECRUITING\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor\nPHASE2\n2025-10-01\n2031-06\n154\n2025-10-01\n\n\nNCT04543617\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nEsophageal Squamous Cell Carcinoma\nPHASE3\n2020-09-28\n2027-03-31\n760\n2026-01-16\n\n\nNCT04305041\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-08-25\n100\n2025-08-28\n\n\nNCT06996782\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced or Metastatic Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2025-11-24\n2029-02-23\n152\n2026-01-13\n\n\nNCT05665595\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE3\n2023-01-19\n2025-09-26\n1594\n2025-10-03\n\n\nNCT06868277\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Non-Small Cell Lung\nPHASE3\n2025-04-10\n2030-12-02\n830\n2026-01-12\n\n\nNCT06692738\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-small Cell Lung Cancer\nPHASE3\n2024-11-18\n2029-10-08\n880\n2026-01-20\n\n\nNCT04774484\nFrancesc Marti\nðŸŸ¢ No Change\nWITHDRAWN\nEnd Stage Renal Disease\nNA\n2023-01\n2026-06-30\n0\n2023-02-10\n\n\nNCT04256421\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nSmall Cell Lung Cancer\nPHASE3\n2020-02-04\n2025-07-31\n490\n2026-01-09\n\n\nNCT06989112\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Cancer\nPHASE3\n2025-03-27\n2031-02-19\n600\n2026-01-14\n\n\nNCT05816460\nUniversity College Dublin\nðŸŸ¢ No Change\nUNKNOWN\nInsomnia, Cancer\nNA\n2023-05-22\n2024-06-10\n308\n2023-05-19\n\n\nNCT06627647\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-squamous Non-small Cell Lung Cancer\nPHASE3\n2024-11-27\n2030-03-25\n878\n2025-12-19\n\n\nNCT04305054\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1, PHASE2\n2020-07-01\n2026-04-20\n315\n2025-08-28\n\n\nNCT04294810\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nNon-Small Cell Lung Cancer\nPHASE3\n2020-03-04\n2025-12-30\n620\n2026-01-29\n\n\nNCT03198546\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT04585815\nPfizer\nðŸŸ¢ No Change\nTERMINATED\nCarcinoma, Non-Small-Cell Lung\nPHASE1, PHASE2\n2020-11-10\n2024-10-29\n34\n2025-12-18\n\n\nNCT02443155\nNovo Nordisk A/S\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes, Diabetes Mellitus, Type 1\nPHASE2\n2015-11-10\n2019-02-27\n308\n2021-03-10\n\n\n\nView Full Change History"
  },
  {
    "objectID": "full_data.html",
    "href": "full_data.html",
    "title": "Full Snapshot Data",
    "section": "",
    "text": "This page displays the consolidated raw data from all monitored trial snapshots. This includes all fields from ClinicalTrials.gov in a flattened format.\nDownload Full Snapshots (CSV)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nannotationSection_annotationModule_unpostedAnnotation_unpostedEvents\nannotationSection_annotationModule_unpostedAnnotation_unpostedResponsibleParty\nderivedSection_conditionBrowseModule_ancestors\nderivedSection_conditionBrowseModule_meshes\nderivedSection_interventionBrowseModule_ancestors\nderivedSection_interventionBrowseModule_meshes\nderivedSection_miscInfoModule_removedCountries\nderivedSection_miscInfoModule_submissionTracking_estimatedResultsFirstSubmitDate\nderivedSection_miscInfoModule_submissionTracking_firstMcpInfo_postDateStruct_date\nderivedSection_miscInfoModule_submissionTracking_firstMcpInfo_postDateStruct_type\nderivedSection_miscInfoModule_submissionTracking_submissionInfos\nderivedSection_miscInfoModule_versionHolder\ndocumentSection_largeDocumentModule_largeDocs\nhasResults\nprotocolSection_armsInterventionsModule_armGroups\nprotocolSection_armsInterventionsModule_interventions\nprotocolSection_conditionsModule_conditions\nprotocolSection_conditionsModule_keywords\nprotocolSection_contactsLocationsModule_centralContacts\nprotocolSection_contactsLocationsModule_locations\nprotocolSection_contactsLocationsModule_overallOfficials\nprotocolSection_descriptionModule_briefSummary\nprotocolSection_descriptionModule_detailedDescription\nprotocolSection_designModule_bioSpec_description\nprotocolSection_designModule_bioSpec_retention\nprotocolSection_designModule_designInfo_allocation\nprotocolSection_designModule_designInfo_interventionModel\nprotocolSection_designModule_designInfo_interventionModelDescription\nprotocolSection_designModule_designInfo_maskingInfo_masking\nprotocolSection_designModule_designInfo_maskingInfo_maskingDescription\nprotocolSection_designModule_designInfo_maskingInfo_whoMasked\nprotocolSection_designModule_designInfo_observationalModel\nprotocolSection_designModule_designInfo_primaryPurpose\nprotocolSection_designModule_designInfo_timePerspective\nprotocolSection_designModule_enrollmentInfo_count\nprotocolSection_designModule_enrollmentInfo_type\nprotocolSection_designModule_patientRegistry\nprotocolSection_designModule_phases\nprotocolSection_designModule_studyType\nprotocolSection_designModule_targetDuration\nprotocolSection_eligibilityModule_eligibilityCriteria\nprotocolSection_eligibilityModule_genderBased\nprotocolSection_eligibilityModule_genderDescription\nprotocolSection_eligibilityModule_healthyVolunteers\nprotocolSection_eligibilityModule_maximumAge\nprotocolSection_eligibilityModule_minimumAge\nprotocolSection_eligibilityModule_samplingMethod\nprotocolSection_eligibilityModule_sex\nprotocolSection_eligibilityModule_stdAges\nprotocolSection_eligibilityModule_studyPopulation\nprotocolSection_identificationModule_acronym\nprotocolSection_identificationModule_briefTitle\nprotocolSection_identificationModule_nctId\nprotocolSection_identificationModule_nctIdAliases\nprotocolSection_identificationModule_officialTitle\nprotocolSection_identificationModule_orgStudyIdInfo_id\nprotocolSection_identificationModule_organization_class\nprotocolSection_identificationModule_organization_fullName\nprotocolSection_identificationModule_secondaryIdInfos\nprotocolSection_ipdSharingStatementModule_accessCriteria\nprotocolSection_ipdSharingStatementModule_description\nprotocolSection_ipdSharingStatementModule_infoTypes\nprotocolSection_ipdSharingStatementModule_ipdSharing\nprotocolSection_ipdSharingStatementModule_timeFrame\nprotocolSection_ipdSharingStatementModule_url\nprotocolSection_outcomesModule_otherOutcomes\nprotocolSection_outcomesModule_primaryOutcomes\nprotocolSection_outcomesModule_secondaryOutcomes\nprotocolSection_oversightModule_isFdaRegulatedDevice\nprotocolSection_oversightModule_isFdaRegulatedDrug\nprotocolSection_oversightModule_isUsExport\nprotocolSection_oversightModule_oversightHasDmc\nprotocolSection_referencesModule_references\nprotocolSection_referencesModule_seeAlsoLinks\nprotocolSection_sponsorCollaboratorsModule_collaborators\nprotocolSection_sponsorCollaboratorsModule_leadSponsor_class\nprotocolSection_sponsorCollaboratorsModule_leadSponsor_name\nprotocolSection_sponsorCollaboratorsModule_responsibleParty_investigatorAffiliation\nprotocolSection_sponsorCollaboratorsModule_responsibleParty_investigatorFullName\nprotocolSection_sponsorCollaboratorsModule_responsibleParty_investigatorTitle\nprotocolSection_sponsorCollaboratorsModule_responsibleParty_type\nprotocolSection_statusModule_completionDateStruct_date\nprotocolSection_statusModule_completionDateStruct_type\nprotocolSection_statusModule_dispFirstPostDateStruct_date\nprotocolSection_statusModule_dispFirstPostDateStruct_type\nprotocolSection_statusModule_dispFirstSubmitDate\nprotocolSection_statusModule_dispFirstSubmitQcDate\nprotocolSection_statusModule_expandedAccessInfo_hasExpandedAccess\nprotocolSection_statusModule_lastKnownStatus\nprotocolSection_statusModule_lastUpdatePostDateStruct_date\nprotocolSection_statusModule_lastUpdatePostDateStruct_type\nprotocolSection_statusModule_lastUpdateSubmitDate\nprotocolSection_statusModule_overallStatus\nprotocolSection_statusModule_primaryCompletionDateStruct_date\nprotocolSection_statusModule_primaryCompletionDateStruct_type\nprotocolSection_statusModule_resultsFirstPostDateStruct_date\nprotocolSection_statusModule_resultsFirstPostDateStruct_type\nprotocolSection_statusModule_resultsFirstSubmitDate\nprotocolSection_statusModule_resultsFirstSubmitQcDate\nprotocolSection_statusModule_startDateStruct_date\nprotocolSection_statusModule_startDateStruct_type\nprotocolSection_statusModule_statusVerifiedDate\nprotocolSection_statusModule_studyFirstPostDateStruct_date\nprotocolSection_statusModule_studyFirstPostDateStruct_type\nprotocolSection_statusModule_studyFirstSubmitDate\nprotocolSection_statusModule_studyFirstSubmitQcDate\nprotocolSection_statusModule_whyStopped\nresultsSection_adverseEventsModule_description\nresultsSection_adverseEventsModule_eventGroups\nresultsSection_adverseEventsModule_frequencyThreshold\nresultsSection_adverseEventsModule_otherEvents\nresultsSection_adverseEventsModule_seriousEvents\nresultsSection_adverseEventsModule_timeFrame\nresultsSection_baselineCharacteristicsModule_denoms\nresultsSection_baselineCharacteristicsModule_groups\nresultsSection_baselineCharacteristicsModule_measures\nresultsSection_baselineCharacteristicsModule_populationDescription\nresultsSection_moreInfoModule_certainAgreement_otherDetails\nresultsSection_moreInfoModule_certainAgreement_piSponsorEmployee\nresultsSection_moreInfoModule_certainAgreement_restrictionType\nresultsSection_moreInfoModule_certainAgreement_restrictiveAgreement\nresultsSection_moreInfoModule_limitationsAndCaveats_description\nresultsSection_moreInfoModule_pointOfContact_email\nresultsSection_moreInfoModule_pointOfContact_organization\nresultsSection_moreInfoModule_pointOfContact_phone\nresultsSection_moreInfoModule_pointOfContact_phoneExt\nresultsSection_moreInfoModule_pointOfContact_title\nresultsSection_outcomeMeasuresModule_outcomeMeasures\nresultsSection_participantFlowModule_groups\nresultsSection_participantFlowModule_periods\nresultsSection_participantFlowModule_preAssignmentDetails\nresultsSection_participantFlowModule_recruitmentDetails\n\n\n\n\n\n\n[{â€œidâ€: â€œD007951â€, â€œtermâ€: â€œLeukemia, Myeloidâ€}, {â€œidâ€: â€œD007938â€, â€œtermâ€: â€œLeukemiaâ€}, {â€œidâ€: â€œD009â€¦\n[{â€œidâ€: â€œD015464â€, â€œtermâ€: â€œLeukemia, Myelogenous, Chronic, BCR-ABL Positiveâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œchronic myeloid leukemia patientsâ€, â€œinterventionNamesâ€: [â€œDiagnostic Test: flow cytometâ€¦\n[{â€œtypeâ€: â€œDIAGNOSTIC_TESTâ€, â€œnameâ€: â€œflow cytometry testâ€, â€œdescriptionâ€: â€œBlood samples will be stâ€¦\nChronic Myeloid Leukemia\n\n[{â€œnameâ€: â€œOla Abdelkarem, M.B.B.Châ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ00201066088250â€, â€œemailâ€: â€œolaabdâ€¦\n\n\nTo expresse TIGIT in NK Cells in Patients with Chronic Myeloid Leukemia\nChronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. Itâ€™s a type of cancer â€¦\n\n\n\n\n\n\n\n\nCASE_CONTROL\n\nCROSS_SECTIONAL\n65\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nTrue\n\n\nNON_PROBABILITY_SAMPLE\nALL\nCHILD, ADULT, OLDER_ADULT\nthe participants will be divided into 2 groups , 40 CML patients and 25 healthy individuals .\n\nTIGIT in Patients With Chronic Myeloid Leukemia\nNCT04818619\n\nExpression of TIGIT in NK Cells in Patients With Chronic Myeloid Leukemia\nchronic myeloid leukemia\nOTHER\nAssiut University\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œTIGIT expression frequency on NK cellsâ€, â€œdescriptionâ€: â€œIn this study, we will assay â€¦\n\nFalse\nFalse\n\n\n[{â€œpmidâ€: â€œ10403855â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œFaderl S, Talpaz M, Estrov Z, Oâ€™Brien S, Kuâ€¦\n\n\nOTHER\nAssiut University\nAssiut University\nOla Abdelkarem Hasan\nClinical pathologist\nPRINCIPAL_INVESTIGATOR\n2022-12\nESTIMATED\n\n\n\n\nFalse\nNOT_YET_RECRUITING\n2021-03-29\nACTUAL\n2021-03-25\nUNKNOWN\n2022-04\nESTIMATED\n\n\n\n\n2021-04\nESTIMATED\n2021-03\n2021-03-26\nACTUAL\n2021-03-24\n2021-03-24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* CML patients\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Healthy individuals\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nExclusion Criteria:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients who have â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD054219â€, â€œtermâ€: â€œNeoplasms, Plasma Cellâ€}, {â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplasms by Histolâ€¦\n[{â€œidâ€: â€œD009101â€, â€œtermâ€: â€œMultiple Myelomaâ€}, {â€œidâ€: â€œD012008â€, â€œtermâ€: â€œRecurrenceâ€}]\n[{â€œidâ€: â€œD011246â€, â€œtermâ€: â€œPregnadienetriolsâ€}, {â€œidâ€: â€œD011245â€, â€œtermâ€: â€œPregnadienesâ€}, {â€œidâ€: â€œâ€¦\n[{â€œidâ€: â€œC546027â€, â€œtermâ€: â€œelotuzumabâ€}, {â€œidâ€: â€œC467566â€, â€œtermâ€: â€œpomalidomideâ€}, {â€œidâ€: â€œD003907â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A - Elotuzumabâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œPatients receive Elotuâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œElotuzumab, pomalidomide, dexamethasoneâ€, â€œdescriptionâ€: â€œStudy Patients â€¦\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nMultiple Myeloma, Relapsed, Refractory, MM, Multiple Myeloma Research Consortium, Multiple Myeloma Râ€¦\n\n[{â€œfacilityâ€: â€œEmory Universityâ€, â€œcityâ€: â€œAtlantaâ€, â€œstateâ€: â€œGeorgiaâ€, â€œzipâ€: â€œ30322â€, â€œcountryâ€: â€¦\n[{â€œnameâ€: â€œMadhav V. Dhodapkar, M.D.â€, â€œaffiliationâ€: â€œMedical Monitorâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nThis a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have râ€¦\nThis study will enroll 104 patients to one of three treatment arms. The study is open to patients reâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\nThe trial is designed for patients with functionally high-risk MM (early relapse after initial theraâ€¦\nNONE\n\n\n\nTREATMENT\n\n14\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nImmuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT\nNCT04150965\n\nA Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) andâ€¦\nMyCheckpoint (MMRC-089)\nNETWORK\nMultiple Myeloma Research Consortium\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œOverall Response Rateâ€, â€œdescriptionâ€: â€œThe overall response rate of the drug combinatâ€¦\n\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ39187595â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œRichard S, Lesokhin AM, Paul B, Kaufman JL, Piâ€¦\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œEmory Universityâ€, â€œclassâ€: â€œOTHERâ€¦\nNETWORK\nMultiple Myeloma Research Consortium\n\n\n\nSPONSOR\n2024-08-30\nACTUAL\n\n\n\n\nFalse\n\n2025-02-14\nACTUAL\n2025-02-12\nTERMINATED\n2024-08-30\nACTUAL\n\n\n\n\n2020-07-10\nACTUAL\n2025-02\n2019-11-05\nACTUAL\n2019-11-01\n2019-11-01\nPharmaceutical support has been discontinued.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. 18 years of age or greater.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Willing and able to provide informed consent\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPM1009 120 mg monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPM1009 120 mgâ€, â€œintâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPM1009 injectionâ€, â€œdescriptionâ€: â€œParticipants receive PM1009 intravenouâ€¦\nAdvanced Tumor\nPM1009, TIGIT, PVRIG\n[{â€œnameâ€: â€œXuelian Xingâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+86 021 32120207â€, â€œemailâ€: â€œxing.xl@biotheusâ€¦\n[{â€œfacilityâ€: â€œShanghai Orient Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œShanghaiâ€, â€œcountryâ€: â€œChâ€¦\n[{â€œnameâ€: â€œYe Guoâ€, â€œaffiliationâ€: â€œShanghai Orient Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nThe study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary effiâ€¦\nThis is a single-arm, open-label, Phase I study contains dose escalation stage and dose expansion stâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nPatients sequentially receive PM1009 120 mg, 300 mg, 600 mg, 1200 mg, intravenously, Q2W\nNONE\n\n\n\nTREATMENT\n\n54\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours\nNCT05607563\n\nA Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetic Characteristics and Preliminarâ€¦\nPM1009-A001M-ST-R\nINDUSTRY\nBiotheus Inc.\n\nNCI is committed to sharing data in accordance with NIH policy.\nThe data will be published or presented for publications (poster, abstract, articles or papers) or mâ€¦\n\nYES\nafter the trial completed\n\n[{â€œmeasureâ€: â€œT-lymphocyte phenotypesâ€, â€œdescriptionâ€: â€œT-lymphocyte phenotypes in peripheral bloodâ€â€¦\n[{â€œmeasureâ€: â€œDose Limited Toxicityï¼ˆDLTï¼‰â€, â€œdescriptionâ€: â€œOccurrence of DLT after receiving PM1009 â€¦\n[{â€œmeasureâ€: â€œRecommended Phase II Dose (RP2D)â€, â€œdescriptionâ€: â€œTo determine the RP2D of PM1009 injâ€¦\nFalse\nFalse\n\nFalse\n\n\n\nINDUSTRY\nBiotheus Inc.\n\n\n\nSPONSOR\n2023-12\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2023-02-08\nACTUAL\n2023-02-07\nUNKNOWN\n2023-11\nESTIMATED\n\n\n\n\n2022-11-21\nACTUAL\n2022-11\n2022-11-07\nACTUAL\n2022-10-19\n2022-11-04\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients participate in the study voluntarily and sign informed consentï¼›\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Maâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHLX53â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œan anti-TIGIT Fc fusion proteinâ€, â€œinterâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œHLX53â€, â€œdescriptionâ€: â€œThere are 5 preset dose groups, namely 30mgâ€¦\nAdvanced/Metastatic Solid Tumors\n\n\n[{â€œfacilityâ€: â€œFudan University Shanghai Cancer Centerâ€, â€œcityâ€: â€œShanghaiâ€, â€œcountryâ€: â€œChinaâ€, â€œgeâ€¦\n[{â€œnameâ€: â€œJian Zhangâ€, â€œaffiliationâ€: â€œFudan Universityâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nThis phase I, first-in-human, open-label clinical study will evaluate the safety, tolerability, pharâ€¦\nThis study is an open-label phase I clinical study to evaluate the safety, tolerability , PK/PD and â€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n12\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors\nNCT05394168\n\nA Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Pâ€¦\nHLX53-FIH101\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œAdverse eventâ€, â€œdescriptionâ€: â€œIncidence and severity of adverse events graded accordâ€¦\n[{â€œmeasureâ€: â€œCmaxâ€, â€œdescriptionâ€: â€œPeak concentration of HLX53â€, â€œtimeFrameâ€: â€œFrom baseline to 30â€¦\nFalse\nFalse\n\nTrue\n\n\n\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\nSPONSOR\n2025-03-04\nESTIMATED\n\n\n\n\nFalse\n\n2024-04-01\nACTUAL\n2024-03-28\nACTIVE_NOT_RECRUITING\n2024-12-04\nESTIMATED\n\n\n\n\n2022-12-09\nACTUAL\n2024-03\n2022-05-27\nACTUAL\n2022-04-29\n2022-05-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Voluntary participation in clinical studies, full understanding of the trial,â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD003231â€, â€œtermâ€: â€œConjunctivitisâ€}, {â€œidâ€: â€œD003229â€, â€œtermâ€: â€œConjunctival Diseasesâ€}, {â€œâ€¦\n[{â€œidâ€: â€œD003233â€, â€œtermâ€: â€œConjunctivitis, Allergicâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œConjunctivitis Allergic with allergen-specific immunotherapy (AIT)â€, â€œdescriptionâ€: â€œTheâ€¦\n\nConjunctivitis, Allergic\nconjunctivitis allergic, TIGIT, Tregs, PDL-1\n[{â€œnameâ€: â€œMarÃ­a del CarmÃ©n JimÃ©nez MartÃ­nezâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ5554421700â€, â€œemailâ€: â€œmâ€¦\n[{â€œfacilityâ€: â€œInstituto de OftalmologÃ­a FAP Conde de Valenciana, IAP Sede Centroâ€, â€œcityâ€: â€œMexico â€¦\n\nThis study aims to evaluate the effector function and expression of TIGIT and PD-1 on Tregs, as wellâ€¦\nAllergic conjunctivitis is a prevalent ocular condition affecting approximately 10-20% of the globalâ€¦\nBlood and tear samples will be collected from patients with and without desensitization therapy, as â€¦\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCOHORT\n\nCROSS_SECTIONAL\n60\nESTIMATED\nTrue\n\nOBSERVATIONAL\n1 Day\nInclusion Criteria:\n\n\nTrue\n30 Years\n5 Years\nNON_PROBABILITY_SAMPLE\nALL\nCHILD, ADULT\nThe study subjects are patients recruited from the outpatient clinic of â€œClinical Immunologyâ€ at Insâ€¦\nINMUNOREG\nTreg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therâ€¦\nNCT07171307\n\nStudy of the Effector Function of Regulatory T Cells and the Th2/Treg in Patients With Allergic Conjâ€¦\nCEI-2024/06/16\nOTHER\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\n[{â€œidâ€: â€œCI-032-2024â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œResearch Committeeâ€}, {â€œidâ€: â€œCB-031-2024â€, â€œtypeâ€¦\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œTo evaluate the effector function and the expression of TIGIT and PD-1 molecules on reâ€¦\n[{â€œmeasureâ€: â€œConcentration of IgE and IgG4 antibodies in serum and tearsâ€, â€œdescriptionâ€: â€œSerum anâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ32900655â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œKucuksezer UC, Ozdemir C, Cevhertas L, Ogulâ€¦\n\n\nOTHER\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nMarÃ­a C. JimÃ©nez MartÃ­nez\nHead of the Immunology Department, Research Unit\nPRINCIPAL_INVESTIGATOR\n2026-09\nESTIMATED\n\n\n\n\nFalse\n\n2025-09-17\nACTUAL\n2025-09-15\nNOT_YET_RECRUITING\n2026-09\nESTIMATED\n\n\n\n\n2026-01-01\nESTIMATED\n2025-09\n2025-09-12\nACTUAL\n2025-09-01\n2025-09-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Subjects aged between 5 and 30 years, of either sex.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Subjects with a confirâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Dâ€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Canceâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAZD2936â€, â€œdescriptionâ€: â€œAnti-TIGIT/Anti-PD-1 Bispecific Antibodyâ€, â€œarmâ€¦\nNon-Small-Cell Lung Carcinoma\nTIGIT, Anti-TIGIT, PD-1, Anti-PD-1, NSCLC, Non-small Cell Lung Cancer, Advanced, Metastatic, Solid Tâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œWITHDRAWNâ€, â€œcityâ€: â€œOrangeâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€â€¦\n\nThis is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antiâ€¦\nThis is a first-time-in-human (FTIH), open-label, multicenter, multi-part, dose-escalation and dose-â€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nThe study includes 5 parts: Part A: Dose escalation; B & C & E: Dose expansion non-randomized; D: â€¦\nNONE\n\n\n\nTREATMENT\n\n210\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n130 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARTEMIDE-01\nA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastaâ€¦\nNCT04995523\n\nPhase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokineticâ€¦\nD7020C00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2023-508262-15-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œEU CT Numberâ€}, {â€œidâ€: â€œ2021-000857-23â€,â€¦\nWhen a request has been approved AstraZeneca will provide access to the de-identified individual patâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagroup-dt.pharmacm.com/DT/Home\n\n[{â€œmeasureâ€: â€œPercentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), â€¦\n[{â€œmeasureâ€: â€œORRâ€, â€œdescriptionâ€: â€œPercentage of participants with a confirmed CR or PR according tâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2028-03-16\nESTIMATED\n\n\n\n\n\n\n2025-11-24\nACTUAL\n2025-11-21\nRECRUITING\n2026-08-18\nESTIMATED\n\n\n\n\n2021-09-14\nACTUAL\n2025-11\n2021-08-09\nACTUAL\n2021-07-16\n2021-07-29\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Written informed consent\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Aged 18 or above\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Part A and Part B: Unresectableâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009385â€, â€œtermâ€: â€œNeoplastic Processesâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œâ€¦\n[{â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Metastasisâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œOMP-313M32â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œIntravenous (in the vein) infusionsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOMP-313M32â€, â€œdescriptionâ€: â€œOMP-313M32 is a monoclonal antibody which biâ€¦\nLocally Advanced Cancer, Metastatic Cancer\n\n\n[{â€œfacilityâ€: â€œScottsdaleâ€, â€œcityâ€: â€œScottsdaleâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85258â€, â€œcountryâ€: â€œUnâ€¦\n[{â€œnameâ€: â€œJohn Lewicki, PhDâ€, â€œaffiliationâ€: â€œMereo BioPharmaâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to evaluate the safety and tolerability of OMP-31M32 as a single agent â€¦\nThis is an open-label, Phase 1a/b dose escalation study of OMP-31M32 administered as a single agent â€¦\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n33\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors\nNCT03119428\n\nA Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Admiâ€¦\n313M32-001\nINDUSTRY\nMereo BioPharma\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œIncidence of dose limiting toxicities (DLTs)â€, â€œdescriptionâ€: â€œThe Maximum tolerated dâ€¦\n[{â€œmeasureâ€: â€œPharmacokinetic Outcome Measures (AUC) - Phase 1aâ€, â€œdescriptionâ€: â€œArea under the plaâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ34844977â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œMettu NB, Ulahannan SV, Bendell JC, Garrido-Laâ€¦\n\n\nINDUSTRY\nOncoMed Pharmaceuticals, Inc.\n\n\n\nSPONSOR\n2019-05-15\nACTUAL\n\n\n\n\nFalse\n\n2020-08-11\nACTUAL\n2020-08-10\nTERMINATED\n2019-05-15\nACTUAL\n\n\n\n\n2017-05-02\nACTUAL\n2020-08\n2017-04-18\nACTUAL\n2017-03-29\n2017-04-17\nSponsor decision\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologic documentation of locally advanced, recurrent or metastatic solid â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD015658â€, â€œtermâ€: â€œHIV Infectionsâ€}, {â€œidâ€: â€œD000086982â€, â€œtermâ€: â€œBlood-Borne Infectionsâ€}â€¦\n[{â€œidâ€: â€œD000163â€, â€œtermâ€: â€œAcquired Immunodeficiency Syndromeâ€}]\n[{â€œidâ€: â€œD001645â€, â€œtermâ€: â€œBiguanidesâ€}, {â€œidâ€: â€œD006146â€, â€œtermâ€: â€œGuanidinesâ€}, {â€œidâ€: â€œD000578â€,â€¦\n[{â€œidâ€: â€œD008687â€, â€œtermâ€: â€œMetforminâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œMetforminâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œMetformin 500 mg Extended Release (Eâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œMetforminâ€, â€œdescriptionâ€: â€œMetformin 500 mg Extended Release (ER) qd incâ€¦\nHIV/AIDS\n\n[{â€œnameâ€: â€œCecilia M Shikuma, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ808 692-1328â€, â€œemailâ€: â€œshikuma@hawâ€¦\n[{â€œfacilityâ€: â€œJohn A. Burns School of Medicine, University of Hawaii - Manoaâ€, â€œstatusâ€: â€œRECRUITINâ€¦\n[{â€œnameâ€: â€œCecilia M Shikuma, MDâ€, â€œaffiliationâ€: â€œUniversity of Hawaiiâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIâ€¦\nNon-diabetic, aviremic HIV-infected individuals on antiretroviral therapy (ART) will be randomized tâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\nMetformin vs Observation\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nDIAGNOSTIC\n\n38\nESTIMATED\n\nPHASE2, PHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n40 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nImpact of Metformin on Immuno-virologic Parameters in HIV\nNCT04500678\n\nA 72 Week, Randomized, Open-label vs Observation Study to Assess the Potential Immuno-virologic Beneâ€¦\nH046\nOTHER\nUniversity of Hawaii\n\nDe-identified dataset will be provided upon request to legitimate researchers\nDataset will be available to other researchers upon request once the primary manuscript is written\nSTUDY_PROTOCOL, SAP, ICF\nYES\nAfter the study analyses are completed and primary manuscript is published, and for a duration of atâ€¦\n\n[{â€œmeasureâ€: â€œSafety and Tolerability: # of grade 2 or greater adverse events in each armâ€, â€œdescripâ€¦\n[{â€œmeasureâ€: â€œCD4 T cell PD1+TIGIT+â€, â€œdescriptionâ€: â€œComparison of change over time in percentage oâ€¦\n[{â€œmeasureâ€: â€œCD8 T cell PD1+TIGIT+â€, â€œdescriptionâ€: â€œComparison of change over time in percentage oâ€¦\nFalse\nTrue\nFalse\nFalse\n\n\n[{â€œnameâ€: â€œMerck Sharp & Dohme LLCâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nUniversity of Hawaii\nUniversity of Hawaii\nCecilia Shikuma\nProfessor, Medicine\nPRINCIPAL_INVESTIGATOR\n2022-12-31\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2020-08-05\nACTUAL\n2020-08-04\nUNKNOWN\n2022-02-01\nESTIMATED\n\n\n\n\n2019-02-01\nACTUAL\n2020-08\n2020-08-05\nACTUAL\n2020-07-31\n2020-08-04\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* HIV+\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* On suppressive ART stable for &gt; 1 year\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Plasma HIV RNA &lt; 50 copies/â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siteâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œD01â€¦\n[{â€œidâ€: â€œD006258â€, â€œtermâ€: â€œHead and Neck Neoplasmsâ€}, {â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œLocalized Head and Neck Squamous Cell Cancerâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œtâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTiragolumab and atezolizumabâ€, â€œdescriptionâ€: â€œthree weekly tiragolumab 1â€¦\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\natezolizumab, tiragolumab\n[{â€œnameâ€: â€œDerk JA de Groot, Md PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+31503612821â€, â€œemailâ€: â€œd.j.a.deâ€¦\n[{â€œfacilityâ€: â€œUniversity Medical Center Groningenâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œGroningenâ€, â€œzâ€¦\n[{â€œnameâ€: â€œDerk JA de Groot, MD PhDâ€, â€œaffiliationâ€: â€œUniversity Medical Center Groningenâ€, â€œroleâ€: â€¦\nIn this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and â€¦\nRationale:\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\nSimon 2 stage design with 4 cohorts.\nNONE\n\n\n\nTREATMENT\n\n97\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nTIRACAN\nOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors\nNCT05483400\n\nOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors: TIRACAN\n10389\nOTHER\nUniversity Medical Center Groningen\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œPathologic response in cohort 1â€, â€œdescriptionâ€: â€œpTR is defined as the presence of tuâ€¦\n[{â€œmeasureâ€: â€œClinical safetyâ€, â€œdescriptionâ€: â€œIncidence, nature and severity of adverse events, inâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n\nOTHER\nUniversity Medical Center Groningen\n\n\n\nSPONSOR\n2027-09\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-30\nACTUAL\n2025-03-28\nRECRUITING\n2025-09\nESTIMATED\n\n\n\n\n2023-10-18\nACTUAL\n2025-03\n2022-08-02\nACTUAL\n2022-07-26\n2022-08-01\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTumor immunotherapy has demonstrated that therapies focused on enhancing T cell responseâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Tumor lesion(s) of which a histological biopsy can be safely obtained accordiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplasms by Histologic Typeâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, â€¦\n[{â€œidâ€: â€œD008223â€, â€œtermâ€: â€œLymphomaâ€}, {â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Metastasisâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œExperimental Group(phase Ia)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPhase 1a uses accâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHLX301â€, â€œdescriptionâ€: â€œHLX301 will be administered as a single intravenâ€¦\nAdvanced Tumors, Lymphoma, Metastatic Tumors\n\n\n[{â€œfacilityâ€: â€œJilin Provincial Cancer Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œChangchunâ€, â€œstatâ€¦\n\nA Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, iâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nHLX301\nA Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGITÃ—PDL1 Bispeâ€¦\nNCT05390528\n\nA Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics andâ€¦\nHLX301-002\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œPhase 1a: The incidence, nature, and severity of adverse events according to the Natioâ€¦\n\nFalse\nFalse\n\nFalse\n\n\n\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\nSPONSOR\n2024-12-30\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2023-08-08\nACTUAL\n2023-08-07\nUNKNOWN\n2023-09-01\nESTIMATED\n\n\n\n\n2022-06-20\nACTUAL\n2023-04\n2022-05-25\nACTUAL\n2022-04-25\n2022-05-21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubjects who meet each of the following criteria are eligible for inclusion:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSingle agent zimberelimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œSingle agent zimbereâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œSingle agent zimberelimabâ€, â€œdescriptionâ€: â€œSingle agent zimberelimab (PDâ€¦\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-juncâ€¦\ndMMR, MMRd, MSI-H, gastric adenocarcinoma, GEJ adenocarcinoma, Gastroesophageal-junction adenocarcinâ€¦\n[{â€œnameâ€: â€œProject Managerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ02086613279â€, â€œemailâ€: â€œZODIAC@rmh.nhs.ukâ€â€¦\n[{â€œfacilityâ€: â€œAddenbrookeâ€™s Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œCambridgeâ€, â€œstateâ€: â€œCambrâ€¦\n[{â€œnameâ€: â€œNaureen Starlingâ€, â€œaffiliationâ€: â€œThe Royal Marsden NHSFT UKâ€, â€œroleâ€: â€œPRINCIPAL_INVESTâ€¦\nA phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectabâ€¦\nPrimary objective The primary objective of the trial is to evaluate the efficacy of zimberelimab +/-â€¦\n\n\nRANDOMIZED\nPARALLEL\nA UK multicentre, prospective, randomised open label phase II proof of concept study with screen selâ€¦\nNONE\n\n\n\nTREATMENT\n\n50\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion criteria\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nZODIAC\nZimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer\nNCT06250036\n\nA Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunâ€¦\nCCR5924\nOTHER\nRoyal Marsden NHS Foundation Trust\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œExploratory - Translational analyses to exploring response to immunotherapy. To reviewâ€¦\n[{â€œmeasureâ€: â€œEfficacy of zimberelimab +/- domvanalimab in patients with resectable MMRd/MSI-H gastrâ€¦\n[{â€œmeasureâ€: â€œEfficacy of zimberelimab +/- domvanalimab in patients with resectable MMRd/MSI-H gastrâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nRoyal Marsden NHS Foundation Trust\n\n\n\nSPONSOR\n2031-09-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-08-21\nACTUAL\n2025-08-19\nRECRUITING\n2027-03-20\nESTIMATED\n\n\n\n\n2025-02-20\nACTUAL\n2025-08\n2024-02-08\nACTUAL\n2023-12-11\n2024-01-31\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age: â‰¥18 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed gastric or gastro-oesophageal junctiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAK130â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œEach subject will receive a single dose â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAK130â€, â€œdescriptionâ€: â€œIV infusion, specified dose on specified days.â€, â€¦\nAdvanced Malignant Tumors\n\n\n[{â€œfacilityâ€: â€œThe Cancer Hospital Affiliated to Shandong First Medical Universityâ€, â€œcityâ€: â€œJinanâ€â€¦\n[{â€œnameâ€: â€œJinming Yuâ€, â€œaffiliationâ€: â€œThe Cancer Hospital Affiliated to Shandong First Medical Uniâ€¦\nA Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n19\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of AK130 in Patients With Advanced Malignant Tumors\nNCT05653284\n\nA Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AK13â€¦\nAK130-101\nINDUSTRY\nAkeso\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œIncidence and severity of participants with adverse events (AEs)â€, â€œtimeFrameâ€: â€œFrom â€¦\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œtimeFrameâ€: â€œUp to approximately 2 yearsâ€}, {â€œmeasureâ€¦\nFalse\nFalse\n\n\n\n\n\nINDUSTRY\nAkeso\n\n\n\nSPONSOR\n2024-05-30\nACTUAL\n\n\n\n\nFalse\n\n2024-08-13\nACTUAL\n2024-08-11\nCOMPLETED\n2023-12-12\nACTUAL\n\n\n\n\n2023-02-09\nACTUAL\n2024-08\n2022-12-16\nACTUAL\n2022-11-25\n2022-12-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Written and signed informed consent and any locally required authorization oâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPhase 1a dose-escalation stageâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPhase 1a uses tâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHLX301â€, â€œdescriptionâ€: â€œA Recombinant Humanized Anti-PDL1 and Anti-TIGITâ€¦\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œBlacktown Hospitalâ€, â€œstatusâ€: â€œNOT_YET_RECRUITINGâ€, â€œcityâ€: â€œBlacktownâ€, â€œstateâ€: â€œNâ€¦\n\nThis Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinicâ€¦\nUp to 150 patients will be included in this study. Up to 30 DLT evaluable patients will be enrolled â€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n150\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nHLX301 (TIGITÃ—PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors\nNCT05102214\n\nA Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, iâ€¦\nHLX301-001\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\n\nUNDECIDED\n\n\n[{â€œmeasureâ€: â€œExploratory biomarkers: To evaluate the correlation between biomarker expression levelâ€¦\n[{â€œmeasureâ€: â€œPhase 1a: Safety assessments in patients receiving the trial drugâ€, â€œdescriptionâ€: â€œinâ€¦\n[{â€œmeasureâ€: â€œPhase 1a: The pharmacokinetic parameters of HLX301: Peak concentration (Cmax, Cmax,ss)â€¦\nFalse\nFalse\n\n\n[{â€œpmidâ€: â€œ35522941â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œMu S, Liang Z, Wang Y, Chu W, Chen YL, Wang Q,â€¦\n\n\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\nSPONSOR\n2024-02\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2023-08-08\nACTUAL\n2023-08-07\nUNKNOWN\n2023-09-15\nESTIMATED\n\n\n\n\n2022-05-03\nACTUAL\n2023-04\n2021-11-01\nACTUAL\n2021-09-29\n2021-10-20\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 1. Patients who meet the following criteria will be enrolled:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Phase 1aâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œGP+PD-1+Tightâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTislelizumab 200mg IV Q3W + Ocipâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œGP+PD-1+Tightâ€, â€œdescriptionâ€: â€œDrug: Tislelizumab Tislelizumab 200mg IV â€¦\nBiliary Tract Carcinoma\n\n\n[{â€œfacilityâ€: â€œZhongshan hospitalâ€, â€œcityâ€: â€œShanghaiâ€, â€œzipâ€: â€œ200032â€, â€œcountryâ€: â€œChinaâ€, â€œgeoPoiâ€¦\n[{â€œnameâ€: â€œJia Fanâ€, â€œaffiliationâ€: â€œShanghai Zhongshan Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}â€¦\nThis is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of GP (Gemcitabâ€¦\nBiliary Tract Carcinoma (BTC) has an insidious onset, invasiveness, high malignancy, and no specificâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n45\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nGP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC\nNCT05023109\n\nA Study to Evaluate GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Tâ€¦\nZSAB-TOP\nOTHER\nShanghai Zhongshan Hospital\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œORR is defined as the proportion of suâ€¦\n[{â€œmeasureâ€: â€œDisease control rate (DCR)â€, â€œdescriptionâ€: â€œDCR is defined as the proportion of subjeâ€¦\nFalse\nFalse\n\nFalse\n\n\n[{â€œnameâ€: â€œJining Medical Universityâ€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œCancer Hospital of Guangxi Medicâ€¦\nOTHER\nShanghai Zhongshan Hospital\n\n\n\nSPONSOR\n2024-12-01\nESTIMATED\n\n\n\n\nFalse\nACTIVE_NOT_RECRUITING\n2023-08-15\nACTUAL\n2023-08-12\nUNKNOWN\n2023-01-18\nACTUAL\n\n\n\n\n2021-02-01\nACTUAL\n2023-08\n2021-08-26\nACTUAL\n2021-08-20\n2021-08-20\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â€¢ Subjects with a histopathological or cytologically diagnosis of BTC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Thâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œZimberelimab plus Domvanalimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTreatment Phaseâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œZimberelimabâ€, â€œdescriptionâ€: â€œZimberelimab is a fully human immunoglobulâ€¦\nMelanoma\n\n[{â€œnameâ€: â€œAmy Rose, RN, BSNâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ412-647-8587â€, â€œemailâ€: â€œkennaj@upmc.eduâ€¦\n[{â€œfacilityâ€: â€œUPMC Hillman Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œPittsburghâ€, â€œstateâ€: â€œâ€¦\n[{â€œnameâ€: â€œDiwakar Davar, MDâ€, â€œaffiliationâ€: â€œUPMC Hillman Cancer Centerâ€, â€œroleâ€: â€œPRINCIPAL_INVESâ€¦\nThe main goal of this study is to establish the proportion of patients with objective response to ziâ€¦\nThis is a single-arm two-stage phase II study of PD-1 inhibitor zimberelimab (AB122) in combination â€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n26\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nZimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma\nNCT05130177\n\nPhase II Study of PD-1 Inhibitor Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in Pâ€¦\nHCC 21-150\nOTHER\nUniversity of Pittsburgh\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œThe proportion of patients with Compleâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) (iRECIST)â€, â€œdescriptionâ€: â€œThe proportion of patients wâ€¦\nFalse\nTrue\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œArcus Biosciences, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nDiwakar Davar\nUniversity of Pittsburgh\nDiwakar Davar\nAssistant Professor of Medicine\nSPONSOR_INVESTIGATOR\n2031-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-05-07\nACTUAL\n2025-05-02\nRECRUITING\n2028-01\nESTIMATED\n\n\n\n\n2022-03-16\nACTUAL\n2025-05\n2021-11-23\nACTUAL\n2021-11-10\n2021-11-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male/female participants who are at least 18 years of age on the day of signiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD006147â€, â€œtermâ€: â€œGuanineâ€}, {â€œidâ€: â€œD007042â€, â€œtermâ€: â€œHypoxanthinesâ€}, {â€œidâ€: â€œD011688â€,â€¦\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œD000068437â€, â€œtermâ€: â€œPemetrexedâ€}, {â€œidâ€: â€œDâ€¦\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œPhase 1: Dose Escalation: Ociperlimab 50 mg + Tislelizumab 200 mgâ€, â€œtypeâ€: â€œEXPERIMENTAâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOciperlimabâ€, â€œdescriptionâ€: â€œAdministered as an intravenous (IV) injectiâ€¦\nLocally Advanced and Metastatic Solid Tumors\nBGB-A1217, Anti-TIGIT antibody, Tislelizumab, anti-PD-1 antibody, Ociperlimab\n\n[{â€œfacilityâ€: â€œMayo Clinic Phoenixâ€, â€œcityâ€: â€œPhoenixâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85254â€, â€œcountryâ€¦\n[{â€œnameâ€: â€œStudy Directorâ€, â€œaffiliationâ€: â€œBeiGeneâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe primary objectives of this study were: to assess the safety and tolerability, to determine the mâ€¦\n\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n446\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors\nNCT04047862\n\nPhase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monocloâ€¦\nBGB-900-105\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œAdvanTIG-105â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œBeiGeneâ€}, {â€œidâ€: â€œCTR20202608â€, â€œtypeâ€: â€œOTHERâ€â€¦\nSee plan description\nBeiGene shares data on completed studies responsibly and provides qualified scientific and medical râ€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\nSee plan description\nhttps://beigene.com/science/clinical-trials/\n\n[{â€œmeasureâ€: â€œPhase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treâ€¦\n[{â€œmeasureâ€: â€œPhase 1: ORR as Per RECIST v.1.1â€, â€œdescriptionâ€: â€œORR was defined as the percentage oâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ37857528â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œFrentzas S, Kao S, Gao R, Zheng H, Rizwan A, Buâ€¦\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2024-08-07\nACTUAL\n\n\n\n\nFalse\n\n2025-08-22\nACTUAL\n2025-08-04\nCOMPLETED\n2024-08-07\nACTUAL\n2025-08-22\nACTUAL\n2025-08-04\n2025-08-04\n2019-08-15\nACTUAL\n2025-08\n2019-08-07\nACTUAL\n2019-08-01\n2019-08-06\n\nAnalysis was performed on safety set.\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPhase 1: Dose Escalation: Ociperlimab 50 mg + Tislelizumab 200 mgâ€, â€œdescâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nAll cause-mortality data was collected from randomization through end of study (up to 5 years). SAEsâ€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ1â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaluâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPhase 1: Dose Escalation: Ociperlimab 50 mg + Tislelizumab 200 mgâ€, â€œdescâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nBaseline analysis included participants from safety analysis set, that is, (i.e.) participants who râ€¦\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene\n+1-877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œPhase 1: Number of Participants With Treatment Emergent Adverse Eventâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPhase 1: Dose Escalation: Ociperlimab 50 mg + Tislelizumab 200 mgâ€, â€œdescâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPhase 1 Key Inclusion Criteria\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Had Eastern Cooperative Oncology Group (â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPM1021 150 mg, 450 mg, 900 mg or 1200 mg monotherapy or in combination with PM8001 (20 mâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPM1021, PM8001â€, â€œdescriptionâ€: â€œParticipants will be administered with Pâ€¦\nAdvanced Solid Tumours\nPM1021, PM8001, monotherapy, combination therapy\n[{â€œnameâ€: â€œVineet Kwatra, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+61 883 592 565â€, â€œemailâ€: â€œvineet.kwatâ€¦\n\n[{â€œnameâ€: â€œVineet Kwatraâ€, â€œaffiliationâ€: â€œCancer Research South Australiaâ€, â€œroleâ€: â€œPRINCIPAL_INVEâ€¦\nThe purpose of this research is to assess the safety, tolerability and effectiveness of PM1021 Monotâ€¦\nThis is a single-arm, open-label, Phase I study including a first-in-human study for PM1021, and theâ€¦\n\n\n\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-Î²) in Patients With Advanced Sâ€¦\nNCT05537051\n\nA Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Effâ€¦\nPM10218001-A001C-ST-R\nINDUSTRY\nBiotheus Inc.\n\nNCI is committed to sharing data in accordance with NIH policy.\nThe data will be published or presented for publications (poster, abstract, articles or papers) or mâ€¦\n\nYES\nafter the trial completed\n\n\n[{â€œmeasureâ€: â€œDLTâ€, â€œdescriptionâ€: â€œThe incidence of DLTs in PM1021 monotherapy and PM1021 combinatiâ€¦\n[{â€œmeasureâ€: â€œRP2Dâ€, â€œdescriptionâ€: â€œTo determine the recommended Phase II Dose (RP2D) of PM1021 monâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nINDUSTRY\nBiotheus Inc.\n\n\n\nSPONSOR\n2025-12-31\nESTIMATED\n\n\n\n\nFalse\nNOT_YET_RECRUITING\n2023-02-08\nACTUAL\n2023-02-07\nUNKNOWN\n2024-10-30\nESTIMATED\n\n\n\n\n2023-10-30\nESTIMATED\n2022-09\n2022-09-13\nACTUAL\n2022-09-08\n2022-09-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female, aged 18-75 years (inclusive) on the day of signing the consenâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD018281â€, â€œtermâ€: â€œCholangiocarcinomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œGP+PD-1+Tightâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œExperimental: Tislelizumab 200mgâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œGP+PD-1+Tightâ€, â€œdescriptionâ€: â€œDrug: Tislelizumab Tislelizumab 200mg IV â€¦\nIntrahepatic Cholangiocarcinoma\n\n\n[{â€œfacilityâ€: â€œZhongshan hospital, Fudan Universityâ€, â€œcityâ€: â€œShanghaiâ€, â€œstateâ€: â€œShanghai Municipâ€¦\n[{â€œnameâ€: â€œJia Fanâ€, â€œaffiliationâ€: â€œShanghai Zhongshan Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}â€¦\nThis is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of GP (Gemcitabâ€¦\nBiliary Tract Carcinoma (BTC) have insidious onset, invasiveness, high malignancy, and no specific sâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nGP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advancedâ€¦\nNCT05019677\n\nA Study to Evaluate GP Chemotherapy in Combination With Tislelizumab(Anti-PD-1) and Ociperlimab(Antiâ€¦\nzs-BTC\nOTHER\nFudan University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œORR is defined as the proportion of suâ€¦\n[{â€œmeasureâ€: â€œDisease control rate (DCR)â€, â€œdescriptionâ€: â€œDCR is defined as the proportion of subjeâ€¦\nFalse\nFalse\n\nFalse\n\n\n\nOTHER\nFudan University\nFudan University\nJia Fan\nProfessor\nPRINCIPAL_INVESTIGATOR\n2024-12-01\nESTIMATED\n\n\n\n\nFalse\n\n2022-04-04\nACTUAL\n2022-03-22\nWITHDRAWN\n2024-12-01\nESTIMATED\n\n\n\n\n2021-09-01\nESTIMATED\n2021-08\n2021-08-25\nACTUAL\n2021-08-18\n2021-08-18\nRepeat registration\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â€¢ Subjects with a histopathological or cytologically diagnosis of BTC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Thâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000656314â€, â€œtermâ€: â€œtoripalimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œJS006 as Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œ1. JS006 as Monotherapy dâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œJS006 as Monotherapyâ€, â€œdescriptionâ€: â€œ1. JS006 as Monotherapy dose-escalâ€¦\nAdvanced Tumors\n\n[{â€œnameâ€: â€œBifeng Liuâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ18967116090â€, â€œemailâ€: â€œbifeng_liu@junshipharmaâ€¦\n[{â€œfacilityâ€: â€œSun Yat-Sen University Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œGuangzhouâ€, â€œâ€¦\n\nThis is an open-label, dose-escalation and dose-expansion phase I clinical study to evaluate the safâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n176\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nThe Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination Withâ€¦\nNCT05061628\n\nA Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recomâ€¦\nJS006-001-I\nOTHER\nShanghai Junshi Bioscience Co., Ltd.\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œPD-L1 expressionâ€, â€œdescriptionâ€: â€œThe relationship between efficacy and potential bioâ€¦\n[{â€œmeasureâ€: â€œTo evaluate the safety and tolerability of JS006 as Monotherapy and in combination witâ€¦\n[{â€œmeasureâ€: â€œPharmacokinetic (PK) profile: JS006â€, â€œdescriptionâ€: â€œJS006 concentrations in individuâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nShanghai Junshi Bioscience Co., Ltd.\n\n\n\nSPONSOR\n2024-09-30\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2021-09-29\nACTUAL\n2021-09-21\nUNKNOWN\n2023-08-14\nESTIMATED\n\n\n\n\n2021-04-21\nACTUAL\n2021-08\n2021-09-29\nACTUAL\n2021-08-19\n2021-09-21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Understanding and signature of the informed consent form voluntarily;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Age â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD001254â€, â€œtermâ€: â€œAstrocytomaâ€}, {â€œidâ€: â€œD005910â€, â€œtermâ€: â€œGliomaâ€}, {â€œidâ€: â€œD018302â€, â€œtâ€¦\n[{â€œidâ€: â€œD005909â€, â€œtermâ€: â€œGlioblastomaâ€}, {â€œidâ€: â€œD012008â€, â€œtermâ€: â€œRecurrenceâ€}]\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œZimberelimab (AB 122) + Domvanalimab (AB 154) Safety Cohort (Cohort A)â€, â€œtypeâ€: â€œEXPERIâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œZimberelimabâ€, â€œdescriptionâ€: â€œZimberelimab (AB122) is a fully human immuâ€¦\nGlioblastoma\nGlioblastoma, Recurrent, PD1, TIGIT, Immunotherapy\n\n[{â€œfacilityâ€: â€œUniversity of California San Franciscoâ€, â€œcityâ€: â€œSan Franciscoâ€, â€œstateâ€: â€œCaliforniâ€¦\n[{â€œnameâ€: â€œSylvia Kurz, MDâ€, â€œaffiliationâ€: â€œProfessor of Neurologyâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATOâ€¦\nThis is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will bâ€¦\nThis is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will bâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\nAfter the initial safety cohort confirms the safety of the dosing schedule an expansion surgical cohâ€¦\nTRIPLE\nMasking will only occur in the surgical cohort B (4 arms) during the first cycle prior to surgery. Tâ€¦\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n46\nESTIMATED\n\nEARLY_PHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAB154 Combined With AB122 for Recurrent Glioblastoma\nNCT04656535\n\nA Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody Aâ€¦\n2000028799\nOTHER\nYale University\n[{â€œidâ€: â€œR01CA266757â€, â€œtypeâ€: â€œNIHâ€, â€œlinkâ€: â€œhttps://reporter.nih.gov/quickSearch/R01CA266757â€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] associated wiâ€¦\n[{â€œmeasureâ€: â€œSingle cell RNA sequencing of tumor and blood after exposure to AB154 with and withoutâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œNational Cancer Institute (NCI)â€, â€œclassâ€: â€œNIHâ€}, {â€œnameâ€: â€œArcus Biosciences, Inc.â€, â€œcâ€¦\nOTHER\nYale University\nYale University\nSylvia Kurz\nAssociate Professor of Neurology\nPRINCIPAL_INVESTIGATOR\n2026-12-31\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-07\nACTUAL\n2026-01-06\nACTIVE_NOT_RECRUITING\n2026-07-30\nESTIMATED\n\n\n\n\n2021-04-21\nACTUAL\n2026-01\n2020-12-07\nACTUAL\n2020-11-18\n2020-11-30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Grade IV glioma (glioblastoma and its variants according to the World Healthâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œD004938â€, â€œtermâ€: â€œEsophageal Neoplasmsâ€}, {â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-â€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œBC008-1A 900mgâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œBiological: BC008-1A 900â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œBC008-1A 900mgâ€, â€œdescriptionâ€: â€œBC008-1A 900mg will be administereâ€¦\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPD-1, TIGIT, Esophageal Cancer, non-small cell lung cancer\n[{â€œnameâ€: â€œJianing Wangâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ86-13802107048â€, â€œemailâ€: â€œwangjianing@buchanâ€¦\n[{â€œfacilityâ€: â€œTianjin Medical University Cancer Institute and Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcâ€¦\n\nThe goal of this study is to learn if BC008-1A given 900mg or 1200mg intravenously once every 3 weekâ€¦\nThis is an open-label clinical study aims to evaluate the safety, pharmacokinetic characteristics anâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n80\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nPhase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors\nNCT06773507\n\nAn Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinâ€¦\nleadingpharm2022010\nINDUSTRY\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œObjective response rate per RECIST1.1â€â€¦\n[{â€œmeasureâ€: â€œDisease control rate (DCR)â€, â€œdescriptionâ€: â€œDefined as the proportion of subjects whoâ€¦\nFalse\nFalse\nFalse\nFalse\n\n\n[{â€œnameâ€: â€œCancer Institute and Hospital, Chinese Academy of Medical Sciencesâ€, â€œclassâ€: â€œOTHERâ€}]\nINDUSTRY\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n\n\n\nSPONSOR\n2027-06\nESTIMATED\n\n\n\n\nFalse\n\n2025-07-09\nACTUAL\n2025-07-07\nRECRUITING\n2026-06\nESTIMATED\n\n\n\n\n2025-05-12\nACTUAL\n2025-07\n2025-01-14\nACTUAL\n2025-01-02\n2025-01-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Cohort 1:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPatients with inoperable, locally advanced or metastatic esophâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000068258â€, â€œtermâ€: â€œBevacizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHLX53(1000mg)+ HLX10+ HLX04â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œHLX53+ HLX10+ HLX0â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHLX53 (1000mg)â€, â€œdescriptionâ€: â€œHLX53 will be administered by IV infusioâ€¦\nCarcinoma, Hepatocellular\n\n[{â€œnameâ€: â€œJia Fan, Drâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ021-64041990â€, â€œemailâ€: â€œfan.jia@zs-hospital.sâ€¦\n[{â€œfacilityâ€: â€œZhongshan Hospital, Fudan Universityâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œShanghaiâ€, â€œcâ€¦\n[{â€œnameâ€: â€œJia Fanâ€, â€œaffiliationâ€: â€œFudan Universityâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}, {â€œnameâ€: â€¦\nThe study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety aâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nQUADRUPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n117\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10â€¦\nNCT06349980\n\nA Randomized, Double-blind, Multi-center, Phase II Study to Evaluate the Anti-tumor Efficacy, Safetyâ€¦\nHLX53-HCC201\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œORRâ€, â€œdescriptionâ€: â€œObjective response rate (ORR) (assessed by the IRRC according toâ€¦\n[{â€œmeasureâ€: â€œORRâ€, â€œdescriptionâ€: â€œObjective response rate (ORR) (assessed by INV according to the â€¦\nFalse\nFalse\nFalse\nFalse\n\n\n\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\nSPONSOR\n2027-02-10\nESTIMATED\n\n\n\n\nFalse\n\n2024-12-18\nACTUAL\n2024-12-15\nRECRUITING\n2027-02-10\nESTIMATED\n\n\n\n\n2024-08-05\nACTUAL\n2024-04\n2024-04-05\nACTUAL\n2024-04-01\n2024-04-01\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Volunteer to participate in clinical research;To fully understand and undersâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm 1â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTreatment with 0.03 mg/kg HB0030 injectiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHB0030 injectionâ€, â€œdescriptionâ€: â€œ0.03 mg/kg intravenously, every 3 weekâ€¦\nAdvanced Solid Tumor\n\n[{â€œnameâ€: â€œhuan zhou, Masterâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+8613665527160â€, â€œemailâ€: â€œzhouhuanbest@â€¦\n[{â€œfacilityâ€: â€œthe First Affiliated Hospital of Bengbu Medical Collegeâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œciâ€¦\n[{â€œnameâ€: â€œhuan zhou, masterâ€, â€œaffiliationâ€: â€œThe First Affiliated Hospital of Bengbu Medical Univeâ€¦\nThis is a phase Ia single-center, open-label, dose escalation study.The objectives of this study areâ€¦\nThe phase Ia study will enroll up to 19-36 subjects with advanced solid tumor who have progressing tâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nSubjects were enrolled from low to high doses. The dose groups were 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, â€¦\nNONE\n\n\n\nTREATMENT\n\n36\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of HB0030 Injection in Patients With Advanced Solid Tumors\nNCT05706207\n\nA Phase Ia,Single Center,Open-label,Dose-escalation Study to Evaluate the Safety and Pharmacokineticâ€¦\nHB0030-01\nINDUSTRY\nHuabo Biopharm Co., Ltd.\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œDose Limiting Toxicity(DLT)â€, â€œdescriptionâ€: â€œ* DLT refers to the following toxicity râ€¦\n[{â€œmeasureâ€: â€œMaximum serum concentration(Cmax)â€, â€œdescriptionâ€: â€œ* Cmax refers to The maximum bloodâ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œThe First Affiliated Hospital of Bengbu Medical Universityâ€, â€œclassâ€: â€œOTHERâ€}]\nINDUSTRY\nHuabo Biopharm Co., Ltd.\n\n\n\nSPONSOR\n2023-09-30\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2023-01-31\nACTUAL\n2023-01-20\nUNKNOWN\n2023-09-30\nESTIMATED\n\n\n\n\n2021-12-21\nACTUAL\n2023-01\n2023-01-31\nACTUAL\n2023-01-06\n2023-01-20\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female Age â‰¥ 18 years.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients with histologically or cytologicallâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD012142â€, â€œtermâ€: â€œRespiratory Tract Neoplasmsâ€}, {â€œidâ€: â€œD013899â€, â€œtermâ€: â€œThoracic Neoplâ€¦\n[{â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplasmsâ€}, {â€œidâ€: â€œD006258â€, â€œtermâ€: â€œHead and Neck Neoplasmsâ€}, â€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œC000719628â€, â€œtermâ€: â€œdostarlimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPart 1A - EOS-448 + pembrolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipantsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œEOS-448â€, â€œdescriptionâ€: â€œAnti-TIGIT monoclonal antibodyâ€, â€œarmGroupLabelâ€¦\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nEOS884448, GSK4428859A, TIGIT, Anti-TIGIT, EOS-448, pembrolizumab, dostarlimab, inupadenant, A2A Recâ€¦\n\n[{â€œfacilityâ€: â€œUniversity of California San Diegoâ€, â€œcityâ€: â€œSan Diegoâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€¦\n[{â€œnameâ€: â€œIteos Clinical Trialsâ€, â€œaffiliationâ€: â€œiTeos Belgium SAâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2â€¦\nThe combinations evaluated will be:\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n153\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nTIG-006\nStudy of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanceâ€¦\nNCT05060432\n\nA Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Câ€¦\nTIG-006\nINDUSTRY\niTeos Therapeutics\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œPercentage of participants with DLT and Adverse Eventsâ€, â€œtimeFrameâ€: â€œFrom first studâ€¦\n[{â€œmeasureâ€: â€œDuration of Response (DOR)â€, â€œtimeFrameâ€: â€œUntil disease progression or death - Approxâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œGlaxoSmithKlineâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œiTeos Therapeuticsâ€, â€œclassâ€: â€œINDUSTRYâ€¦\nINDUSTRY\niTeos Belgium SA\n\n\n\nSPONSOR\n2025-07\nESTIMATED\n\n\n\n\nFalse\n\n2024-06-21\nACTUAL\n2024-06-19\nACTIVE_NOT_RECRUITING\n2024-07\nESTIMATED\n\n\n\n\n2021-09-06\nACTUAL\n2024-06\n2021-09-29\nACTUAL\n2021-09-06\n2021-09-27\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* EOS-448 combined with pembrolizumab, an anti-PD-1 antibody\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Provide a signed written informed consent for the trial\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Have measurable disâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD012142â€, â€œtermâ€: â€œRespiratory Tract Neoplasmsâ€}, {â€œidâ€: â€œD013899â€, â€œtermâ€: â€œThoracic Neoplâ€¦\n[{â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplasmsâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA1 : the patients naÃ¯ve from systemic treatment - atezolizumab + tiragolumabâ€, â€œtypeâ€: â€œâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumab 1200 mg IVâ€, â€œdescriptionâ€: â€œatezolizumab (intravenous 1200mâ€¦\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\n\n[{â€œnameâ€: â€œAntoine ITALIANO, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+33 1 42 11 42 11â€, â€œemailâ€: â€œantoineâ€¦\n[{â€œfacilityâ€: â€œCentre Hospitalier Cote Basqueâ€, â€œcityâ€: â€œBayonneâ€, â€œzipâ€: â€œ64109â€, â€œcountryâ€: â€œFrancâ€¦\n\nThis study encompasses multicenter open-label, phase II trials.\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n115\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nINDIGO\nTargeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures\nNCT06713798\n\nTargeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures\n2023-503218-56-00\nOTHER\nGustave Roussy, Cancer Campus, Grand Paris\n[{â€œidâ€: â€œ2022/3418â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œCSET numberâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œBest overall response (BOR) rateâ€, â€œdescriptionâ€: â€œBest overall response (BOR) rate deâ€¦\n\nFalse\nFalse\nTrue\nTrue\n\n\n[{â€œnameâ€: â€œRoche Global Developmentâ€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nGustave Roussy, Cancer Campus, Grand Paris\n\n\n\nSPONSOR\n2030-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-06-24\nACTUAL\n2025-06-23\nNOT_YET_RECRUITING\n2028-01\nESTIMATED\n\n\n\n\n2025-07\nESTIMATED\n2025-06\n2024-12-03\nACTUAL\n2024-11-27\n2024-11-27\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPatients will be dispatched into 2 â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed TLS-positive advanced or metastatic NSCLC.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* NSCLC sâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAtezolizumab will be administeredâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œGiven by vein (IV)â€, â€œarmGroupLabelsâ€: [â€œAâ€¦\nMetastatic Malignancy\n\n[{â€œnameâ€: â€œPadmanee Sharma, MD, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ713-792-2830â€, â€œemailâ€: â€œPadSharmâ€¦\n[{â€œfacilityâ€: â€œM D Anderson Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œHoustonâ€, â€œstateâ€: â€œTexâ€¦\n[{â€œnameâ€: â€œPadmanee Sharma, MD, PhDâ€, â€œaffiliationâ€: â€œM.D.Â Anderson Cancer Centerâ€, â€œroleâ€: â€œPRINCIPâ€¦\nTo learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when â€¦\nPrimary Safety Objective:\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nSINGLE\n\nPARTICIPANT\n\nTREATMENT\n\n10\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nNeoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urotheâ€¦\nNCT05394337\n\nNeoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urotheâ€¦\n2021-0928\nOTHER\nM.D.Â Anderson Cancer Center\n[{â€œidâ€: â€œNCI-2022-04565â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œNCI-CTRP Clinical Trials Reporting Registryâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œTo evaluate relapse-free survival (RFS)â€, â€œtimeFrameâ€: â€œThrough study completion, an aâ€¦\n\nFalse\nTrue\nFalse\nTrue\n\n[{â€œlabelâ€: â€œMD Anderson Cancer Centerâ€, â€œurlâ€: â€œhttp://www.mdanderson.orgâ€}]\n\nOTHER\nM.D.Â Anderson Cancer Center\n\n\n\nSPONSOR\n2025-12-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-09\nACTUAL\n2025-10-07\nRECRUITING\n2025-12-31\nESTIMATED\n\n\n\n\n2023-02-23\nACTUAL\n2025-10\n2022-05-27\nACTUAL\n2022-05-23\n2022-05-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ€¢To evaluate the safety and tolerability oftiragolumab and atezolizumab iâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Signed Informed Consent Form\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Age &gt;18 years at time of signing Informed Câ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}]\n\n[{â€œidâ€: â€œC000656314â€, â€œtermâ€: â€œtoripalimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTAB006 60mg and Torpalimab 240mg repeat dose every 21 days up to 2 yearsâ€, â€œtypeâ€: â€œEXPEâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTAB006â€, â€œdescriptionâ€: â€œRecombinant humanized, IgG4Îº (immunoglobulin gamâ€¦\nPreviously Treated, Advanced, Malignancies\nimmunotherapy, advance malignancies, monoclonal antibody, phase 1 trial\n\n\n[{â€œnameâ€: â€œSheng Yao, PhDâ€, â€œaffiliationâ€: â€œTopAlliance Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€â€¦\nThe primary objective is to assess the safety and tolerability of TAB006 as monotherapy and in combiâ€¦\nOVERVIEW This is a Phase 1, multi-center, open-label, dose-escalation study of TAB006 in combinationâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies\nNCT05253105\n\nA Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and â€¦\nTAB006-01\nOTHER\nShanghai Junshi Bioscience Co., Ltd.\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œTIGIT receptor occupancy (RO) in peripheral blood mononuclear cells (PBMC) and tumorâ€,â€¦\n[{â€œmeasureâ€: â€œTo assess the safety and tolerability of multiple doses of TAB006 in combination with â€¦\n[{â€œmeasureâ€: â€œMaximum Observed Concentration (Cmax)â€, â€œtimeFrameâ€: â€œfrom first treatment visit thru â€¦\nFalse\nTrue\n\nFalse\n\n\n[{â€œnameâ€: â€œTopAlliance Biosciences, Inc.â€, â€œclassâ€: â€œUNKNOWNâ€}, {â€œnameâ€: â€œCTI Clinical Trial and Conâ€¦\nOTHER\nShanghai Junshi Bioscience Co., Ltd.\n\n\n\nSPONSOR\n2027-01\nESTIMATED\n\n\n\n\nFalse\n\n2022-05-31\nACTUAL\n2022-05-24\nWITHDRAWN\n2026-09\nESTIMATED\n\n\n\n\n2022-03-15\nESTIMATED\n2022-02\n2022-02-23\nACTUAL\n2022-01-17\n2022-02-15\ntransfer the study to another sponser\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 1. Able to understand and willing to sign the Informed Consent Form;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 2. Mâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD003920â€, â€œtermâ€: â€œDiabetes Mellitusâ€}, {â€œidâ€: â€œD044882â€, â€œtermâ€: â€œGlucose Metabolism Disorâ€¦\n[{â€œidâ€: â€œD003922â€, â€œtermâ€: â€œDiabetes Mellitus, Type 1â€}]\n\n[{â€œidâ€: â€œC502540â€, â€œtermâ€: â€œteplizumabâ€}]\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œTeplizumab treatedâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAdministration of teplizumaâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œteplizumab 1 mg/mLâ€, â€œdescriptionâ€: â€œSolution for infusion administered aâ€¦\nDiabetes Mellitus, Type 1\nRecent-onset type 1 diabetes, Teplizumab, T1D, Stage 3, Type 1 diabetes, New onset type 1 diabetes\n\n[{â€œfacilityâ€: â€œBarbara Davis Center for Diabetes Site Number : 04â€, â€œcityâ€: â€œAuroraâ€, â€œstateâ€: â€œColoâ€¦\n[{â€œnameâ€: â€œClinical Sciences & Operationsâ€, â€œaffiliationâ€: â€œSanofiâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861â€¦\nThe study was a single-arm, multicenter, open-label clinical trial. All participants received a 12-dâ€¦\n\n\n\nSINGLE_GROUP\nSingle-arm, multicenter, open-label clinical trial\nNONE\n\n\n\nTREATMENT\n\n6\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n\n\nALL\nCHILD, ADULT, OLDER_ADULT\n\n\nAt-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)\nNCT04270942\n\nAn Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop â€¦\nPRV-031-002\nINDUSTRY\nSanofi\n[{â€œidâ€: â€œSFY18115â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œSanofi Identifierâ€}]\n\nQualified researchers may request access to patient level data and related study documents includingâ€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergâ€¦\n[{â€œmeasureâ€: â€œSerum Concentration Immediately Prior to Administration of the Next Dose (Ctrough) of â€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nProvention Bio, a Sanofi Company\n\n\n\nSPONSOR\n2024-01-22\nACTUAL\n\n\n\n\nFalse\n\n2025-02-12\nACTUAL\n2025-01-20\nCOMPLETED\n2024-01-22\nACTUAL\n2025-02-12\nACTUAL\n2025-01-20\n2025-01-20\n2020-02-26\nACTUAL\n2025-01\n2020-02-17\nACTUAL\n2020-02-10\n2020-02-12\n\nThe safety analysis set included all participants who received at least 1 dose of teplizumab.\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œTeplizumabâ€, â€œdescriptionâ€: â€œParticipants received teplizumab 9 mg/m\\^2 â€¦\n5.0\n[{â€œtermâ€: â€œLeukopeniaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œâ€¦\n[{â€œtermâ€: â€œCompleted Suicideâ€, â€œorganSystemâ€: â€œPsychiatric disordersâ€, â€œsourceVocabularyâ€: â€œMedDra 2â€¦\nFrom the first dose of study drug administration (Day 1) up to approximately 78 weeks\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ6â€}]}]\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œTeplizumabâ€, â€œdescriptionâ€: â€œParticipants received teplizumab 9 mg/m\\^2 â€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe safety analysis set included all participants who received at least 1 dose of teplizumab.\nThe Sponsor supports publication of clinical trial results but may request that investigators temporâ€¦\nFalse\nOTHER\nTrue\n\nContact-US@sanofi.com\nSanofi aventis recherche & dÃ©veloppement\n800-633-1610\n#6\nTrial Transparency Team\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œNumber of Participants With Treatment-emergent Adverse Events (TEAEs)â€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œTeplizumabâ€, â€œdescriptionâ€: â€œParticipants received teplizumab 9 milligramâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nA total of 6 participants from the TN-10 study (NCT01030861) who developed clinical (stage 3) type 1â€¦\nThe study was conducted in the United States from 26-Feb-2020 to 22-Jan-2024.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Previous participant in the TN-10 study\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Participant had received a diagnoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD046110â€, â€œtermâ€: â€œHypertension, Pregnancy-Inducedâ€}, {â€œidâ€: â€œD011248â€, â€œtermâ€: â€œPregnancy â€¦\n[{â€œidâ€: â€œD011225â€, â€œtermâ€: â€œPre-Eclampsiaâ€}]\n[{â€œidâ€: â€œD016133â€, â€œtermâ€: â€œPolymerase Chain Reactionâ€}, {â€œidâ€: â€œD021141â€, â€œtermâ€: â€œNucleic Acid Ampâ€¦\n[{â€œidâ€: â€œD060888â€, â€œtermâ€: â€œReal-Time Polymerase Chain Reactionâ€}, {â€œidâ€: â€œD004797â€, â€œtermâ€: â€œEnzymeâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œpreeclampsiapregnant womenâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œInclusion criteria...\n[{â€œtypeâ€: â€œGENETICâ€, â€œnameâ€: â€œreal time PCRâ€, â€œdescriptionâ€: â€œdiagnostic testâ€, â€œarmGroupLabelsâ€: [â€œâ€¦\nPre-Eclampsia\ncoinhibtory receptor\n\n\n\nPreeclampsia is a form of hypertensive pregnancy disorder with multiorgan involvement. It is charactâ€¦\nT lymphocytes, as well as their regulatory subpopulations could possibly possess a part in PE . The â€¦\n\n\nRANDOMIZED\nPARALLEL\npreeclasmpsia pregnant women and normal pregnant women\nNONE\n\n\n\nPREVENTION\n\n82\nESTIMATED\n\nPHASE4\nINTERVENTIONAL\n\nInclusion Criteria:\nTrue\nfemale\nFalse\n\n\n\nFEMALE\nCHILD, ADULT, OLDER_ADULT\n\nasd\nco Ihibtory Receptor in Preeclampsia\nNCT05294952\n\nLevels of Co-inhibitory Receptors (TIM-3,LAG-3 and TIGIT)in Preeclampsia Patients\nzisdas\nOTHER\nAssiut University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œearly detection of preeclampsiaâ€, â€œdescriptionâ€: â€œdetection levels of co inhibtory recâ€¦\n\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nAssiut University\nAssiut University\nZeinab Ibrahim Sayed\nreal time PCR\nPRINCIPAL_INVESTIGATOR\n2025-11-04\nESTIMATED\n\n\n\n\nFalse\n\n2024-02-05\nACTUAL\n2024-02-01\nNOT_YET_RECRUITING\n2025-02-03\nESTIMATED\n\n\n\n\n2025-01-01\nESTIMATED\n2024-02\n2022-03-24\nACTUAL\n2022-03-04\n2022-03-22\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* total of 41 women in third trimester pregnancy complicated with PE showing:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment with Atezolizumab + Tiragolumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€:â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œGiven by veinâ€, â€œarmGroupLabelsâ€: [â€œTreatmâ€¦\nCancer\n\n[{â€œnameâ€: â€œRyan Huey, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ(713) 792-2828â€, â€œemailâ€: â€œrwhuey@mdandersonâ€¦\n[{â€œfacilityâ€: â€œThe University of Texas M. D. Anderson Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€â€¦\n[{â€œnameâ€: â€œRyan Huey, MDâ€, â€œaffiliationâ€: â€œM.D.Â Anderson Cancer Centerâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nThe goal of this clinical research study is to learn if the combination of atezolizumab and tiragoluâ€¦\nPrimary Objectives:\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n35\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition Witâ€¦\nNCT06754501\n\nA Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition Witâ€¦\n2024-0210\nOTHER\nM.D.Â Anderson Cancer Center\n[{â€œidâ€: â€œNCI-2024-10697â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œClinical Trials Reporting Program (CTRP)â€}]\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œSafety and Adverse Events (AEs)â€, â€œdescriptionâ€: â€œIncidence of Adverse Events, Graded â€¦\n\nFalse\nTrue\nFalse\nTrue\n\n[{â€œlabelâ€: â€œMD Anderson Cancer Center Websiteâ€, â€œurlâ€: â€œhttp://www.mdanderson.orgâ€}]\n[{â€œnameâ€: â€œGenentech, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œStrategic Allianceâ€, â€œclassâ€: â€œUNKNOWNâ€â€¦\nOTHER\nM.D.Â Anderson Cancer Center\n\n\n\nSPONSOR\n2029-07-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-07\nACTUAL\n2025-10-01\nRECRUITING\n2027-07-01\nESTIMATED\n\n\n\n\n2025-04-11\nACTUAL\n2025-08\n2024-12-31\nACTUAL\n2024-12-30\n2024-12-30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTo assess the anti-tumor activity of tiragolumab and atezolizumab in patients wâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ— Patients must have histopathological confirmed unresected, locally advanced, â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, â€¦\n\n[{â€œidâ€: â€œC000656314â€, â€œtermâ€: â€œtoripalimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDose Optimization Phase - Arm Aâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œAdvanced â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œCHS-006 (anti-TIGIT)â€, â€œdescriptionâ€: â€œArm A participants will receive CHâ€¦\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nTIGIT inhibitor, PD-1 inhibitor, Advanced Solid Tumor\n\n[{â€œfacilityâ€: â€œUniversity of Florida Health Cancer Centerâ€, â€œcityâ€: â€œOrlandoâ€, â€œstateâ€: â€œFloridaâ€, â€œâ€¦\n\nThis phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preâ€¦\nThe Dose Optimization phase will enroll participants with advanced/metastatic solid tumors (except pâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\nThis is a Phase 1, open-label, multiple-phase, multiple phase study. Participants within the advanceâ€¦\nNONE\n\n\n\nTREATMENT\n\n22\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advancedâ€¦\nNCT05757492\n\nA Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, andâ€¦\nCHS-006-01\nINDUSTRY\nCoherus Oncology, Inc.\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œAssessment of the number of participants with treatment-emergent adverse events (TEAEsâ€¦\n[{â€œmeasureâ€: â€œDescription of the PK profile of CHS-006 in combination with toripalimabâ€, â€œdescriptioâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œMedpace, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œShanghai Junshi Bioscience Co., Ltd.â€, â€œcâ€¦\nINDUSTRY\nCoherus Oncology, Inc.\n\n\n\nSPONSOR\n2024-07-31\nACTUAL\n\n\n\n\nFalse\n\n2025-05-01\nACTUAL\n2025-04-30\nTERMINATED\n2024-07-31\nACTUAL\n\n\n\n\n2023-04-26\nACTUAL\n2025-04\n2023-03-07\nACTUAL\n2023-01-02\n2023-02-23\nThe study was terminated for strategic reasons (not for safety concerns)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Males and females, â‰¥18 years old;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histopathologically or cytologically confâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD003131â€, â€œtermâ€: â€œCombined Modality Therapyâ€}, {â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, â€¦\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œD059248â€, â€œtermâ€: â€œChemoradiotherapyâ€}]\n\n\n2024-08-09\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œArm A: Ociperlimab + Tislelizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œOciperlimab â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOciperlimabâ€, â€œdescriptionâ€: â€œOciperlimab 900 milligrams (mg) administereâ€¦\nLimited Stage Small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œTennessee Cancer Specialistâ€, â€œcityâ€: â€œKnoxvilleâ€, â€œstateâ€: â€œTennesseeâ€, â€œzipâ€: â€œ3790â€¦\n[{â€œnameâ€: â€œBeiGeneâ€, â€œaffiliationâ€: â€œStudy Directorâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumabâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n126\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limitedâ€¦\nNCT04952597\n\nA Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy â€¦\nAdvanTIG-204\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œCTR20211531â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œChinaDrugTrialsâ€}, {â€œidâ€: â€œBGB-A317-A1217-204â€, â€œâ€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œProgression Free Survival (PFS)â€, â€œdescriptionâ€: â€œDefined as the time from the date ofâ€¦\n[{â€œmeasureâ€: â€œComplete Response Rate (CR)â€, â€œdescriptionâ€: â€œdefined as the percentage of participantâ€¦\nFalse\nTrue\n\n\n[{â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œYouling Gong, Qingsong Pang, Rong Yu, Zhengfei Zhu, Jiangqiong â€¦\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2023-07-26\nACTUAL\n\n\n\n\nFalse\n\n2024-10-26\nACTUAL\n2024-10-23\nCOMPLETED\n2023-07-26\nACTUAL\n2024-09-19\nACTUAL\n2024-07-16\n2024-08-16\n2021-07-15\nACTUAL\n2024-10\n2021-07-07\nACTUAL\n2021-06-28\n2021-06-28\n\nAll-cause mortality is reported for all randomized participants. Serious and other adverse events inâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œArm A: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œOciperlimab plus tislâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\nAll-cause mortality and adverse events (AEs): From the first dose of study drug(s) to 30 days after â€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ41â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œArm A: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œOciperlimab plus tislâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Intent-To-Treat (ITT) Analysis Set includes all randomized patients.\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene\n+1-877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œProgression Free Survival (PFS)â€, â€œdescriptionâ€: â€œDefined as the timeâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œArm A: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œOciperlimab plus tislâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\n\nParticipants were enrolled in multiple study centers in China, South Korea, and the United States.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participant has pathologically (histologically or cytologically) proven dâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD002292â€, â€œtermâ€: â€œCarcinoma, Renal Cellâ€}]\n[{â€œidâ€: â€œD001549â€, â€œtermâ€: â€œBenzamidesâ€}, {â€œidâ€: â€œD000577â€, â€œtermâ€: â€œAmidesâ€}, {â€œidâ€: â€œD009930â€, â€œteâ€¦\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD0â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A (Tobemstomig + Axitinib)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants wiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTobemstomigâ€, â€œdescriptionâ€: â€œParticipants will receive IV tobemstomig Q3â€¦\nRenal Cell Carcinoma\n\n\n[{â€œfacilityâ€: â€œUniversity of Alabama at Birminghamâ€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabamaâ€, â€œzipâ€â€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-LaRocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone orâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n199\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locâ€¦\nNCT05805501\n\nA Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in â€¦\nBO43936\nINDUSTRY\nHoffmann-La Roche\n\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œIncidence and Severity of Adverse Events (AEs)â€, â€œtimeFrameâ€: â€œUp to a maximum of 2 yeâ€¦\n\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2026-07-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-13\nACTUAL\n2025-11-12\nACTIVE_NOT_RECRUITING\n2026-07-31\nESTIMATED\n\n\n\n\n2023-04-21\nACTUAL\n2025-11\n2023-04-10\nACTUAL\n2023-03-28\n2023-03-28\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Iâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œtypeâ€: â€œRELEASEâ€, â€œdateâ€: â€œ2023-03-21â€}, {â€œtypeâ€: â€œRESETâ€, â€œdateâ€: â€œ2024-01-03â€}]\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\n\n2023-03-21\n\n\n[{â€œreleaseDateâ€: â€œ2023-03-21â€, â€œresetDateâ€: â€œ2024-01-03â€}]\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPembrolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œsubjects with PD-L1 low (PD-L1Loâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œhumanized antibody used in cancer immunotâ€¦\nNon Small Cell Lung Cancer (NSCLC)\n\n\n[{â€œfacilityâ€: â€œNational Cancer Instituteâ€, â€œcityâ€: â€œMilanâ€, â€œzipâ€: â€œ20133â€, â€œcountryâ€: â€œItalyâ€, â€œgeoâ€¦\n[{â€œnameâ€: â€œMarina Chiara Garassino, MDâ€, â€œaffiliationâ€: â€œNational Cancer Institute (NCI)â€, â€œroleâ€: â€œâ€¦\nThis is a prospective, monocentric, open label, phase II trial of intravenous (IV) Pembrolizumab monâ€¦\nApproximately 65 subjects with PD-L1 low (PD-L1Lo), EGFR wt, EML4/ALK fusion negative NSCLC will be â€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n65\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nPEOPLE\nPembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.\nNCT03447678\n\nPhase II Study to Test Pembrolizumab (MK-3475) in First Line Treatment of Advanced NSCLC Patients Wiâ€¦\nINT 178-17\nOTHER\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œImmune biomarkersâ€, â€œdescriptionâ€: â€œtumor infiltrating lymphocytes in patients whose tâ€¦\n[{â€œmeasureâ€: â€œImmune biomarkers distribution between pre and post Pembrolizumab treatmentâ€, â€œdescripâ€¦\nFalse\nFalse\n\nFalse\n[{â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œKorman A, Chen B, Wang C, Wu L, Cardarelli P, Selby M. Activityâ€¦\n\n\nOTHER\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\n\n\n\nSPONSOR\n2022-05-31\nESTIMATED\n\n\n\n\nFalse\nACTIVE_NOT_RECRUITING\n2021-06-09\nACTUAL\n2021-06-08\nUNKNOWN\n2022-05-31\nESTIMATED\n\n\n\n\n2018-05-23\nACTUAL\n2021-06\n2018-02-27\nACTUAL\n2018-02-13\n2018-02-26\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Have a confirmed diagnosis of NSCLC in stage IIIB/ IV. Do not have an EGFR sâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000632826â€, â€œtermâ€: â€œsintilimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œIBI939 in combination with Sintilimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œBâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œIBI939â€, â€œdescriptionâ€: â€œIBI939 injectionâ€, â€œarmGroupLabelsâ€: [â€œIBIâ€¦\nAdvanced Lung Cancer\n\n\n[{â€œfacilityâ€: â€œJilin Province Cancer Hospitalâ€, â€œcityâ€: â€œJilinâ€, â€œcountryâ€: â€œChinaâ€, â€œgeoPointâ€: {â€œlâ€¦\n[{â€œnameâ€: â€œYing Chengâ€, â€œaffiliationâ€: â€œJilin Province Cancer Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nThis study is an open-label, phase I clinical study to evaluate the efficacy, tolerability and safetâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n42\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced â€¦\nNCT04672369\n\nAn Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 inâ€¦\nCIBI939A102(Ib)\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate(ORR)â€, â€œdescriptionâ€: â€œProportion of subjects with complete reâ€¦\n[{â€œmeasureâ€: â€œadverse eventâ€, â€œtimeFrameâ€: â€œ3 monthsâ€}, {â€œmeasureâ€: â€œProgression-free survival(PFS)â€â€¦\nFalse\nFalse\n\nFalse\n\n\n\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\nSPONSOR\n2023-06-01\nACTUAL\n\n\n\n\nFalse\n\n2023-06-22\nACTUAL\n2023-06-18\nCOMPLETED\n2023-01-01\nACTUAL\n\n\n\n\n2021-06-06\nACTUAL\n2023-06\n2020-12-17\nACTUAL\n2020-12-13\n2020-12-16\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Signed the Informed Consent Form;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Male or female â‰¥ 18 andâ‰¤75 years of ageâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000632826â€, â€œtermâ€: â€œsintilimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPhase Ia: IBI939 in combination with Sintilimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€:â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œIBI939â€, â€œdescriptionâ€: â€œIBI939 injectionâ€, â€œarmGroupLabelsâ€: [â€œPhaâ€¦\nAdvanced Lung Cancer\n\n\n[{â€œfacilityâ€: â€œJilin Province Cancer Hospitalâ€, â€œcityâ€: â€œJilinâ€, â€œcountryâ€: â€œChinaâ€, â€œgeoPointâ€: {â€œlâ€¦\n[{â€œnameâ€: â€œYing Chengâ€, â€œaffiliationâ€: â€œJilin Province Cancer Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nThis study is an open-label, phase I clinical study to evaluate the efficacy, tolerability and safetâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n19\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab â€¦\nNCT04672356\n\nAn Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 inâ€¦\nCIBI939A102(Ia)\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œAdverse Eventsâ€, â€œtimeFrameâ€: â€œ3 monthsâ€}, {â€œmeasureâ€: â€œRecommended Phase II Dose(RP2Dâ€¦\n[{â€œmeasureâ€: â€œObjective response rate(ORR)â€, â€œdescriptionâ€: â€œProportion of subjects with complete reâ€¦\nFalse\nFalse\n\nFalse\n\n\n\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\nSPONSOR\n2023-06-01\nACTUAL\n\n\n\n\nFalse\n\n2023-06-22\nACTUAL\n2023-06-18\nCOMPLETED\n2023-01-01\nACTUAL\n\n\n\n\n2021-01-25\nACTUAL\n2023-06\n2020-12-17\nACTUAL\n2020-12-13\n2020-12-16\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Signed the Informed Consent Form;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Male or female â‰¥ 18 andâ‰¤75 years of ageâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD015179â€, â€œtermâ€: â€œColorectal Neoplasmsâ€}, {â€œidâ€: â€œD007414â€, â€œtermâ€: â€œIntestinal Neoplasmsâ€â€¦\n[{â€œidâ€: â€œD012004â€, â€œtermâ€: â€œRectal Neoplasmsâ€}]\n[{â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, {â€œidâ€: â€œD003841â€, â€œtermâ€: â€œDeoxycytidineâ€}, {â€œidâ€: â€œD003â€¦\n[{â€œidâ€: â€œD011878â€, â€œtermâ€: â€œRadiotherapyâ€}, {â€œidâ€: â€œD000069287â€, â€œtermâ€: â€œCapecitabineâ€}, {â€œidâ€: â€œD0â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezolizumab + Tiragolumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œWeeks 1-5: Radiotheâ€¦\n[{â€œtypeâ€: â€œRADIATIONâ€, â€œnameâ€: â€œRadiotherapyâ€, â€œdescriptionâ€: â€œWeeks 1-5: 45-50.4Gy in 25-28 fractioâ€¦\nRectal Neoplasms, Rectal Cancer\n\n\n[{â€œfacilityâ€: â€œBeijing Cancer Hospitalâ€, â€œcityâ€: â€œBeijingâ€, â€œzipâ€: â€œ100142â€, â€œcountryâ€: â€œChinaâ€, â€œgeâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the efficacy and safety of atezolizumab plus tiragolumab or atezolizumab alâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n58\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Partiâ€¦\nNCT05009069\n\nA Phase II, Randomized, Open Label, Parallel-group Study of Atezolizumab With or Without Tiragolumabâ€¦\nML43050\nINDUSTRY\nHoffmann-La Roche\n\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œPercentage of Participants With Pathological Complete Response (pCR)â€, â€œtimeFrameâ€: â€œAâ€¦\n[{â€œmeasureâ€: â€œPercentage of Participants With R0 Resectionâ€, â€œtimeFrameâ€: â€œAt Week 16, Day 1â€}, {â€œmeâ€¦\nFalse\nTrue\nTrue\n\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2026-11-06\nESTIMATED\n2024-10-15\nACTUAL\n2024-11-12\n\nFalse\n\n2026-01-22\nACTUAL\n2026-01-16\nACTIVE_NOT_RECRUITING\n2023-11-21\nACTUAL\n\n\n\n\n2022-03-18\nACTUAL\n2026-01\n2021-08-17\nACTUAL\n2021-08-10\n2021-08-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically confirmed diagnosis of adenocarcinoma of the â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPhase Ia Dose-Escalation Stage:IBI939â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œIBI939â€, â€œdescriptionâ€: â€œSeveral dose levels will be evaluated for IBI939â€¦\nAdvanced Malignancies\n\n\n[{â€œfacilityâ€: â€œPeking University Cancer Hospital & Instituteâ€, â€œcityâ€: â€œBeijingâ€, â€œcountryâ€: â€œChinaâ€â€¦\n\nThis is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacoâ€¦\n\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n34\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Iâ€¦\nNCT04353830\n\nA Phase 1a, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Initial Effiâ€¦\nCIBI939A101\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œNumber of subjects with AEs and SAEsâ€, â€œdescriptionâ€: â€œTo evaluate the safety and toleâ€¦\n[{â€œmeasureâ€: â€œPharmacokinetics: AUCâ€, â€œdescriptionâ€: â€œThe area under the curve (AUC) of serum concenâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\nSPONSOR\n2022-05-11\nACTUAL\n\n\n\n\nFalse\n\n2023-03-01\nACTUAL\n2023-02-28\nCOMPLETED\n2022-05-11\nACTUAL\n\n\n\n\n2020-05-22\nACTUAL\n2023-02\n2020-04-20\nACTUAL\n2020-04-17\n2020-04-17\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Able to understand and willing to sign the ICF.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Adults 18 years of age orâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD018278â€, â€œtermâ€: â€œCarcinoma, Neuroendocrineâ€}]\n[{â€œidâ€: â€œD019984â€, â€œtermâ€: â€œQuality Indicators, Health Careâ€}, {â€œidâ€: â€œD011787â€, â€œtermâ€: â€œQuality ofâ€¦\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€: â€œD059039â€, â€œtermâ€: â€œStandard of Careâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œExperimental arm (EA) 61 patients prospectively enrolled to receive the experimental treâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œFOLFIRI + Zimberelimab + Domvanalimabâ€, â€œdescriptionâ€: â€œFOLFIRI every 14 â€¦\nCarcinoma, Neuroendocrine\nCarcinoma, Neuroendocrine, gastro-enteropancreatic or unknown origin, GEP/UK NEC\n[{â€œnameâ€: â€œThomas WALTER, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ4 72 11 73 98â€, â€œphoneExtâ€: â€œ+33â€, â€œemaiâ€¦\n[{â€œfacilityâ€: â€œCHU Amiens Picardieâ€, â€œcityâ€: â€œAmiensâ€, â€œcountryâ€: â€œFranceâ€, â€œcontactsâ€: [{â€œnameâ€: â€œVâ€¦\n[{â€œnameâ€: â€œThomas WALTER, MDâ€, â€œaffiliationâ€: â€œHospices Civils de Lyonâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nBackground Neuroendocrine carcinomas (NECs) of gastro-entero-pancreatic (GEP) or unknown (UK) originâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n122\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nREWENEC 01\nTrial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Secâ€¦\nNCT07337447\n\nPRODIGE 113 (FFCD 2314) - REWENEC 01 STUDY Randomized Trial of FOLFIRI + Zimberelimab + Domvanalimabâ€¦\n69HCL24_0759\nOTHER\nHospices Civils de Lyon\n[{â€œidâ€: â€œ2024-519922-19-00â€, â€œtypeâ€: â€œCTISâ€}]\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œOverall survival (%) between FOLFIRI and FOLFIRI+Zimberelimab+Domvanalimabâ€, â€œdescriptâ€¦\n[{â€œmeasureâ€: â€œProgression free survival (PFS)â€, â€œdescriptionâ€: â€œTime from randomization to disease pâ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œFederation Francophone de Cancerologie Digestiveâ€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nHospices Civils de Lyon\n\n\n\nSPONSOR\n2030-04\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-13\nACTUAL\n2026-01-07\nNOT_YET_RECRUITING\n2029-04\nESTIMATED\n\n\n\n\n2026-04\nESTIMATED\n2026-01\n2026-01-13\nACTUAL\n2025-12-08\n2026-01-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Man or woman aged â‰¥ 18 years old,\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Poorly differentiated neuroendocrine carcâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004701â€, â€œtermâ€: â€œEndocrine Gland Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Sitâ€¦\n[{â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€}, {â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplasmsâ€}, {â€œidâ€:â€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCOM902 monotherapy dose escalation.â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œMonotherapâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDose escalation: COM902 monotherapy.â€, â€œdescriptionâ€: â€œCOM902 monotherapyâ€¦\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, â€¦\nTIGIT antibody, PVRIG antibody, COM701, Low Fc-effector function, Pembrolizumab\n\n[{â€œfacilityâ€: â€œFlorida Cancer Specialistsâ€, â€œcityâ€: â€œSarasotaâ€, â€œstateâ€: â€œFloridaâ€, â€œzipâ€: â€œ34230â€, â€¦\n[{â€œnameâ€: â€œCOM902 Study Director COM902 Study Directorâ€, â€œaffiliationâ€: â€œCompugen Ltdâ€, â€œroleâ€: â€œSTUâ€¦\nPhase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, toleâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n110\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCOM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies\nNCT04354246\n\nA Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies\nCPG-02-101\nINDUSTRY\nCompugen Ltd\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œEvaluation of the preliminary antitumor activity of COM902 as monotherapy and in combiâ€¦\n[{â€œmeasureâ€: â€œThe safety and tolerability of COM902 monotherapy and in combination with COM701.â€, â€œdâ€¦\n[{â€œmeasureâ€: â€œTo characterize immunogenicity of COM902 monotherapy and in combination with COM701.â€,â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nCompugen Ltd\n\n\n\nSPONSOR\n2025-12-30\nESTIMATED\n\n\n\n\nFalse\n\n2025-05-22\nACTUAL\n2025-05-18\nACTIVE_NOT_RECRUITING\n2025-12-30\nESTIMATED\n\n\n\n\n2020-03-31\nACTUAL\n2025-05\n2020-04-21\nACTUAL\n2020-04-15\n2020-04-16\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Subjects with histologically/cytologically confirmed advanced malignancy â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplasmsâ€}]\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezo + Tira + XELOXâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAtezolizumab plus tiragolâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œAtezolizumab 1200 mg will be administered â€¦\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\n\n\n[{â€œfacilityâ€: â€œBeijing Cancer Hospitalâ€, â€œcityâ€: â€œBeijingâ€, â€œzipâ€: â€œ100142â€, â€œcountryâ€: â€œChinaâ€, â€œgeâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study is designed to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combiâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n29\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st â€¦\nNCT04933227\n\nA Phase II, Single-Arm Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab andâ€¦\nML42913\nINDUSTRY\nHoffmann-La Roche\n\n\nQualified researchers may request access to individual patient level data through the clinical studyâ€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) in the Full Analysis Set (FAS) Populationâ€, â€œtimeFrameâ€:â€¦\n[{â€œmeasureâ€: â€œDuration of Response (DOR) in Responders of the FAS Populationâ€, â€œtimeFrameâ€: â€œThe timâ€¦\nFalse\nTrue\nTrue\n\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2023-11-17\nACTUAL\n2024-03-12\nACTUAL\n2024-11-11\n\nFalse\n\n2024-11-14\nACTUAL\n2024-11-11\nTERMINATED\n2023-11-17\nACTUAL\n\n\n\n\n2021-08-06\nACTUAL\n2024-11\n2021-06-21\nACTUAL\n2021-06-17\n2021-06-17\nSponsorâ€™s decision to terminate the study after Stage 1; will not proceed with Stage 2.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed (by enrolling center) gastric cancer or adenocarcinoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œMRD positive Cohort - Arm A (treatment)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDose fâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œAZD2936â€, â€œdescriptionâ€: â€œAZD2936 is a monovalent, bispecific, humaâ€¦\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\n\n[{â€œnameâ€: â€œLillian Siu, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ416-946-4501â€, â€œphoneExtâ€: â€œ2911â€, â€œemailâ€â€¦\n[{â€œfacilityâ€: â€œPrincess Margaret Cancer Centreâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œTorontoâ€, â€œcountryâ€¦\n[{â€œnameâ€: â€œLillian Siu, MDâ€, â€œaffiliationâ€: â€œPrincess Margaret Cancer Centreâ€, â€œroleâ€: â€œPRINCIPAL_INâ€¦\nThis is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residuaâ€¦\nThis is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residuaâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n200\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria for All Parts\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nMERIDIAN\nMolecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC\nNCT05414032\n\nResidual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC\nMERIDIAN\nOTHER\nUniversity Health Network, Toronto\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œPredictive value (in terms of predicting radiological recurrence of disease or death) â€¦\n[{â€œmeasureâ€: â€œEfficacy (in terms of ctDNA clearance) of AZD2936 compared to observation (Standard ofâ€¦\n[{â€œmeasureâ€: â€œEfficacy (in terms of delaying or preventing radiological recurrence of disease or deaâ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œAstraZenecaâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œNeoGenomics Laboratories, Inc.â€, â€œclassâ€: â€œâ€¦\nOTHER\nUniversity Health Network, Toronto\n\n\n\nSPONSOR\n2026-07\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-30\nACTUAL\n2025-03-25\nRECRUITING\n2026-07\nESTIMATED\n\n\n\n\n2023-07-12\nACTUAL\n2025-03\n2022-06-10\nACTUAL\n2022-05-26\n2022-06-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Age â‰¥ 18 years at the time of screening or age of consent accorâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTiragolumab and atezolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œ96 patients will â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œTiragolumabâ€, â€œdescriptionâ€: â€œ600mg IV every 21 days from Cycle 1 Dâ€¦\nSolid Tumor, Adult\n\n[{â€œnameâ€: â€œSimone Jacobyâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+61 2 8052 4300â€, â€œemailâ€: â€œmost-tap@georgeiâ€¦\n[{â€œfacilityâ€: â€œBorder Medical Oncology Research Unitâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œAlburyâ€, â€œstâ€¦\n[{â€œnameâ€: â€œDavid Thomas, PHD, FRACPâ€, â€œaffiliationâ€: â€œOmico; UNSW Sydneyâ€, â€œroleâ€: â€œPRINCIPAL_INVESTâ€¦\nThis phase II study will explore the effect of 2 monoclonal antibodies, tiragolumab and atezolizumabâ€¦\nPatients who are enrolled in the MoST or CaSP cancer screening programs, and whose tumour is assesseâ€¦\n\n\n\nSINGLE_GROUP\nProspective, multicentre, single-arm, open-label, phase II signal-seeking trial\nNONE\n\n\n\nTREATMENT\n\n96\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nMoST-TAP\nTiragolumab and Atezolizumab in Advanced Pan-cancer Patients\nNCT06003621\n\nA Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients â€¦\nML43743\nOTHER\nOmico\n\n\nSubject to further IRB review and protocol amendment\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œProgression Free Survival (PFS) rate at 6 Monthsâ€, â€œdescriptionâ€: â€œThe primary outcomeâ€¦\n[{â€œmeasureâ€: â€œObjective tumour response rate (OTRR) as per iRECIST or RANO criteriaâ€, â€œdescriptionâ€:â€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œHoffmann-La Rocheâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œThe George Institute for Global Healtâ€¦\nOTHER\nOmico\n\n\n\nSPONSOR\n2028-11-01\nESTIMATED\n\n\n\n\nFalse\n\n2024-11-15\nACTUAL\n2024-11-13\nRECRUITING\n2026-05-01\nESTIMATED\n\n\n\n\n2023-12-15\nACTUAL\n2024-06\n2023-08-22\nACTUAL\n2023-08-07\n2023-08-15\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Provision of written informed consent.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Aged â‰¥18 years old.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n3. Histologicaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œC562730â€, â€œtermâ€: â€œAdenocarcinoma Of Esophagusâ€}, {â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplaâ€¦\n[{â€œidâ€: â€œD003841â€, â€œtermâ€: â€œDeoxycytidineâ€}, {â€œidâ€: â€œD003562â€, â€œtermâ€: â€œCytidineâ€}, {â€œidâ€: â€œD011741â€â€¦\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€: â€œD000069287â€, â€œtermâ€: â€œCapecitabineâ€}, {â€œidâ€: â€¦\nGreece\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDomvanalimab + Zimberelimab + FOLFOX/CAPOX (PI Choice)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œIntravenous (IV) Aqueous Solutionâ€, â€œarmGrâ€¦\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nDomvanalimab, Zimberelimab, Nivolumab, Advanced upper gastrointestinal tract adenocarcinoma, Gastroeâ€¦\n\n[{â€œfacilityâ€: â€œGenesis Cancer Center and Blood Institute - Hot Springsâ€, â€œcityâ€: â€œHot Springsâ€, â€œstaâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciencesâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n1040\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSTAR-221\nA Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, fâ€¦\nNCT05568095\n\nA Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy â€¦\nSTAR-221\nINDUSTRY\nArcus Biosciences, Inc.\n[{â€œidâ€: â€œjRCT2051220179â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œJapan Registry of Clinical Trialsâ€}, {â€œidâ€:â€¦\n\nArcus will provide access to individual de-identified participant data and related study documents ...\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n\n[{â€œmeasureâ€: â€œOverall survivalâ€, â€œtimeFrameâ€: â€œFrom date of randomization until date of death from aâ€¦\n[{â€œmeasureâ€: â€œProgression-free survival (PFS)â€, â€œtimeFrameâ€: â€œFrom date of randomization to date of â€¦\nFalse\nTrue\n\nTrue\n\n[{â€œlabelâ€: â€œSTAR-221 Public Websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=STAR-221â€}]\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œTaiho Pharmaceutical Co., Ltd.â€, â€œclassâ€¦\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2026-06\nESTIMATED\n\n\n\n\nFalse\n\n2026-02-02\nACTUAL\n2026-01-30\nACTIVE_NOT_RECRUITING\n2026-06\nESTIMATED\n\n\n\n\n2022-11-21\nACTUAL\n2025-04\n2022-10-05\nACTUAL\n2022-10-03\n2022-10-03\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Capable of giving signed informed consent which is in compliance with theâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}]\n[{â€œidâ€: â€œD043924â€, â€œtermâ€: â€œAngiogenesis Modulating Agentsâ€}, {â€œidâ€: â€œD006133â€, â€œtermâ€: â€œGrowth Subsâ€¦\n[{â€œidâ€: â€œD020533â€, â€œtermâ€: â€œAngiogenesis Inhibitorsâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHCC patientsâ€, â€œdescriptionâ€: â€œPatients with advanced HCC undergoing immunotherapyâ€, â€œinâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œImmunochemotherapy combined with antiangiogenicâ€, â€œdescriptionâ€: â€œImmunocâ€¦\nLiver Cancer, Adult\nimmunophenotype, HCC patients, immunotherapy\n[{â€œnameâ€: â€œLaura Gramantieri, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0512142579â€, â€œemailâ€: â€œlaura.gramantâ€¦\n[{â€œfacilityâ€: â€œIRCCS-Azienda Ospedaliero-Universitaria di Bolognaâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€¦\n[{â€œnameâ€: â€œLaura Gramantieriâ€, â€œaffiliationâ€: â€œIRCCS Azienda Ospedaliero-Universitaria di Bolognaâ€, â€¦\nThe study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay toâ€¦\n* To assess the accuracy of biomarkers from an immunophenotypic test (CD8+, PD1+, PD-L1+, CTLA4+, LAâ€¦\nperipheral blood mononuclear cells separated by Ficoll gradient\nSAMPLES_WITHOUT_DNA\n\n\n\n\n\n\nCASE_ONLY\n\nPROSPECTIVE\n100\nESTIMATED\nTrue\n\nOBSERVATIONAL\n3 Years\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\npatients with advanced hepatocellular carcinoma\nImmunecheck\nImmunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma\nNCT06777628\n\nImmunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in â€¦\nImmunecheck\nOTHER\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œTo find predictive biomarkers of response to immunotherapy in HCCâ€, â€œdescriptionâ€: â€œSeâ€¦\n[{â€œmeasureâ€: â€œTo compare the transcriptomic signatures of PBMC of responders and non-respondersâ€, â€œdâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\n\n\n\nSPONSOR\n2028-10-15\nESTIMATED\n\n\n\n\nFalse\n\n2025-01-16\nACTUAL\n2025-01-14\nRECRUITING\n2026-10-15\nESTIMATED\n\n\n\n\n2024-09-15\nACTUAL\n2024-09\n2025-01-16\nACTUAL\n2024-11-28\n2025-01-14\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* age â‰¥ 18 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* diagnosis of HCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* execution of laboratory tests and subsequâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018302â€, â€œtermâ€: â€œNeoplasms, Neuroepithelialâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermalâ€¦\n[{â€œidâ€: â€œD005910â€, â€œtermâ€: â€œGliomaâ€}, {â€œidâ€: â€œD005909â€, â€œtermâ€: â€œGlioblastomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œBC008-1A 900mgâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œBiological: BC008-1Aâ€]},â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œBC008-1Aâ€, â€œdescriptionâ€: â€œBiological: 900 mg BC008-1A will be intrâ€¦\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHOâ€¦\nglioma, PD-1, TIGIT, bispecific antibody, glioblastoma\n[{â€œnameâ€: â€œJianing Wangâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ86-13802107048â€, â€œemailâ€: â€œwangjianing@buchanâ€¦\n[{â€œfacilityâ€: â€œBeijing Tiantan Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œBeijingâ€, â€œstateâ€: â€œBeijiâ€¦\n\nThe purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmâ€¦\nBC008-1A is an innovative bispecific antibody targeting TIGIT and PD-1, which is developed by Sichuaâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n40\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nBC008-1A Injection for Recurrent CNS WHO G4 Glioma\nNCT06773481\n\nA Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of BC008-1A Injection in Suâ€¦\nBC0081A-103\nINDUSTRY\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œSafetyâ€, â€œdescriptionâ€: â€œAssesing the type, frequency, severity, and duration of adverâ€¦\n[{â€œmeasureâ€: â€œobjective response rate (ORR)â€, â€œdescriptionâ€: â€œDefined as the proportion of patients â€¦\nFalse\nFalse\nFalse\nFalse\n\n\n[{â€œnameâ€: â€œBeijing Tiantan Hospitalâ€, â€œclassâ€: â€œOTHERâ€}]\nINDUSTRY\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n\n\n\nSPONSOR\n2026-12\nESTIMATED\n\n\n\n\nFalse\n\n2025-07-09\nACTUAL\n2025-07-07\nRECRUITING\n2026-06\nESTIMATED\n\n\n\n\n2025-04-07\nACTUAL\n2025-07\n2025-01-14\nACTUAL\n2025-01-02\n2025-01-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Voluntarily sign the informed consent form;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Recurrent CNS WHO grade 4 gliâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009375â€, â€œtermâ€: â€œNeoplasms, Glandular and Epithelialâ€}, {â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplaâ€¦\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD002294â€, â€œâ€¦\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC502936â€, â€œtermâ€: â€œtocilizumabâ€}, {â€œidâ€: â€œC00â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezolizumab Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants will recâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œGiven intravenously (IV)â€, â€œarmGroupâ€¦\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nCancer, Non-Virally Associated Squamous Cell Carcinoma, Head and Neck\n[{â€œnameâ€: â€œUCSF HDFCCC Cancer Immunotherapy Program (CIP)â€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ(877) 827-3â€¦\n[{â€œfacilityâ€: â€œUniversity of San Francisco, Californiaâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œSan Franciâ€¦\n[{â€œnameâ€: â€œAlain Algazi, MDâ€, â€œaffiliationâ€: â€œUniversity of California, San Franciscoâ€, â€œroleâ€: â€œPRIâ€¦\nTo determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulaâ€¦\nPRIMARY OBJECTIVES:\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n55\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nPreoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck\nNCT03708224\n\nA Phase II Study of Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head â€¦\n177018\nOTHER\nUniversity of California, San Francisco\n[{â€œidâ€: â€œNCI-2018-01992â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œClinical Trials Reporting Program (CTRP)â€}, {â€œâ€¦\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œProportion of subjects with a &gt;= 40% increase in the cluster of differentiation 3 (CD3â€¦\n[{â€œmeasureâ€: â€œChanges in immune parameters using mass cytometry (CyTOF), histology and gene expressiâ€¦\nFalse\nTrue\nFalse\nTrue\n[{â€œpmidâ€: â€œ36931243â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œRahim MK, Okholm TLH, Jones KB, McCarthy EE, Lâ€¦\n\n[{â€œnameâ€: â€œGenentech, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œAmerican Head and Neck Societyâ€, â€œclassâ€¦\nOTHER\nAlain Algazi\nUniversity of California, San Francisco\nAlain Algazi\nAssociate Professor\nSPONSOR_INVESTIGATOR\n2028-06-30\nESTIMATED\n\n\n\n\nFalse\n\n2025-01-28\nACTUAL\n2025-01-24\nRECRUITING\n2028-06-30\nESTIMATED\n\n\n\n\n2019-03-08\nACTUAL\n2024-11\n2018-10-17\nACTUAL\n2018-10-12\n2018-10-12\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nI. To determine the effect of neoadjuvant atezolizumab alone or in combination â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Patients must have clinically suspected SCCHN that is amenable to surgical râ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD012919â€, â€œtermâ€: â€œSocial Behaviorâ€}, {â€œidâ€: â€œD001519â€, â€œtermâ€: â€œBehaviorâ€}]\n[{â€œidâ€: â€œD012059â€, â€œtermâ€: â€œRejection, Psychologyâ€}]\n[{â€œidâ€: â€œD017582â€, â€œtermâ€: â€œRenal Replacement Therapyâ€}, {â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, â€¦\n[{â€œidâ€: â€œD016030â€, â€œtermâ€: â€œKidney Transplantationâ€}, {â€œidâ€: â€œD020869â€, â€œtermâ€: â€œGene Expression Proâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œkidney transplantationâ€, â€œdescriptionâ€: â€œsamples additional to the sâ€¦\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nKidney, Allogenic transplantation, Cohort study, Rejection, Biomarkers, Response to treatment, Integâ€¦\n\n[{â€œfacilityâ€: â€œHÃ´pital du Kremlin BicÃªtreâ€, â€œcityâ€: â€œLe Kremlin-BicÃªtreâ€, â€œstateâ€: â€œParisâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œAlexandre Loupy, Prâ€, â€œaffiliationâ€: â€œInstitut National de la SantÃ© Et de la Recherche MÃ©â€¦\nMain objective: To design a precision risk stratification system that predicts individual risk of reâ€¦\nAllograft rejection is still a major threat to allografts with thousands of allografts failing everyâ€¦\nblood samples, kidney biopsy samples for these analysis : Transcriptomics analysis Characteristics oâ€¦\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n558\nACTUAL\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n100 Years\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nNew kidney transplants patients\nEU-TRAIN\nPrecision Risk Stratification in Kidney Transplant Patients - EU-TRAIN\nNCT03652402\n\nThe EUropean TRAnsplantation and INnovation Consortium for Risk Stratification in Kidney Transplant â€¦\nK170203J\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n[{â€œidâ€: â€œIDRCB 2018-A00733-52â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œAssistance Publique HÃ´pitaux de Parisâ€}]\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œCapacity of non-invasive biomarkers and intragraft gene expression profiles combined tâ€¦\n[{â€œmeasureâ€: â€œCorrelation of blood biomarkers concentration with allograft rejection (rejection asseâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ31165086â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œMontero N, Farouk S, Gandolfini I, Crespo E, Jaâ€¦\n[{â€œlabelâ€: â€œSecure Distribution of Factor Analysis of Mixed Data (FAMD) and Its Application to Persoâ€¦\n\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\nSPONSOR\n2021-10-28\nACTUAL\n\n\n\n\nFalse\n\n2024-06-05\nACTUAL\n2024-06-04\nCOMPLETED\n2021-10-28\nACTUAL\n\n\n\n\n2018-11-27\nACTUAL\n2024-06\n2018-08-29\nACTUAL\n2018-07-16\n2018-08-27\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Men and women, Age â‰¥ 18 years old at the time of transplantation.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œnivolumabâ€, â€œdescriptionâ€: â€œSubjects will be treated with 3mg/kg in nivoâ€¦\nNon -Small Cell Lung Cancer\nNon -small cell lung cancer\n\n[{â€œfacilityâ€: â€œDepartment of Oncology, Yonsei University College of Medicineâ€, â€œcityâ€: â€œSeoulâ€, â€œstaâ€¦\n\nThe study aimed to elucidate predictive immune related biomarker to the responsiveness to the PD-1 bâ€¦\nNon-small cell lung cancer (NSCLC) is the leading cause of cancer related mortality worldwide. Immunâ€¦\n\n\n\n\n\n\n\n\nOTHER\n\nPROSPECTIVE\n60\nACTUAL\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n20 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nThe sample size is not based on statistical consideration. This is pilot study designed to explore bâ€¦\n\nA Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy â€¦\nNCT03486119\n\nA Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy â€¦\n4-2017-0788\nOTHER\nYonsei University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œMDSC markersâ€, â€œdescriptionâ€: â€œCD11b, Gr11b,â€, â€œtimeFrameâ€: â€œchange from baseline blooâ€¦\n[{â€œmeasureâ€: â€œORR(Objective response rate)â€, â€œtimeFrameâ€: â€œevery 6 months up to 5years.â€}, {â€œmeasureâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ33302114â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œKim CG, Hong MH, Kim KH, Seo IH, Ahn BC, Pyo Kâ€¦\n\n\nOTHER\nYonsei University\n\n\n\nSPONSOR\n2020-07-07\nACTUAL\n\n\n\n\nFalse\n\n2020-10-19\nACTUAL\n2020-10-14\nCOMPLETED\n2020-07-07\nACTUAL\n\n\n\n\n2018-02-05\nACTUAL\n2020-10\n2018-04-03\nACTUAL\n2018-03-07\n2018-04-02\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Ageâ‰¥ 18 years old.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed advanced NSCLC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Metastatic or â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA/ Accelerated titrationâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œ1mg of BAT6021â€, â€œintâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œBAT6021â€, â€œdescriptionâ€: â€œâ…£ infusionsâ€, â€œarmGroupLabelsâ€: [â€œA/ Accelerateâ€¦\nSolid Tumor\n\n\n[{â€œfacilityâ€: â€œGuangdong Provincial Peopleâ€™s Hospitalâ€, â€œcityâ€: â€œGuangzhouâ€, â€œstateâ€: â€œGuangdongâ€, â€œâ€¦\n[{â€œnameâ€: â€œYilong Wu, M.D, Ph.Dâ€, â€œaffiliationâ€: â€œGuangdong Provincial Peopleâ€™s Hospitalâ€, â€œroleâ€: â€œâ€¦\nMain purpose:\nThis study design for center, openness, dose escalation, and expand the research of phase I clinicalâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n5\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAssessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China\nNCT05120375\n\nA Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Prelâ€¦\nBAT-6021-001-CR\nINDUSTRY\nBio-Thera Solutions\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œDose-limiting toxicity(DLT)â€, â€œdescriptionâ€: â€œDose-limiting toxicity (DLT) is defined â€¦\n[{â€œmeasureâ€: â€œPharmacokinetics (PK)â€, â€œdescriptionâ€: â€œCmaxâ€, â€œtimeFrameâ€: â€œevery cycle until cycle 6â€¦\nFalse\nFalse\n\n\n\n\n\nINDUSTRY\nBio-Thera Solutions\n\n\n\nSPONSOR\n2023-04-07\nACTUAL\n\n\n\n\nFalse\n\n2023-10-11\nACTUAL\n2023-10-08\nTERMINATED\n2023-04-07\nACTUAL\n\n\n\n\n2022-02-17\nACTUAL\n2023-10\n2021-11-15\nACTUAL\n2021-11-03\n2021-11-03\nBased on the disclosed global research data on the same target drugs, the company has carefully consâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* To evaluate the safety and tolerability of BAT6021 injection in the treatment of loâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Age: â‰¥18 years old, gender: male or female;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. The expected survival was assâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD009375â€, â€œtermâ€: â€œNeoplasms, Glandular and Epithelâ€¦\n[{â€œidâ€: â€œD002295â€, â€œtermâ€: â€œCarcinoma, Transitional Cellâ€}, {â€œidâ€: â€œD001749â€, â€œtermâ€: â€œUrinary Bladdâ€¦\n\n[{â€œidâ€: â€œC000609138â€, â€œtermâ€: â€œavelumabâ€}, {â€œidâ€: â€œC000608132â€, â€œtermâ€: â€œsacituzumab govitecanâ€}, {â€œâ€¦\nDenmark\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œGroup A: Avelumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: Avelumabâ€]}, {â€œâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAvelumabâ€, â€œdescriptionâ€: â€œParticipants will receive avelumab intravenousâ€¦\nLocally Advanced or Metastatic Urothelial Carcinoma\nAvelumab, Avelumab in combination, Bladder cancer, M6223 (anti-TIGIT antibody), PD-L1, Sacituzumab gâ€¦\n\n[{â€œfacilityâ€: â€œBeacon Cancer Careâ€, â€œcityâ€: â€œCoeur dâ€™Aleneâ€, â€œstateâ€: â€œIdahoâ€, â€œzipâ€: â€œ83814â€, â€œcounâ€¦\n[{â€œnameâ€: â€œMedical Responsibleâ€, â€œaffiliationâ€: â€œMerck Healthcare KGaA, Darmstadt, Germany, an affilâ€¦\nThe purpose of this study is to assess the safety and efficacy of avelumab in combination with otherâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n256\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanceâ€¦\nNCT05327530\n\nA Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB001071â€¦\nMS100070_0119\nINDUSTRY\nEMD Serono\n[{â€œidâ€: â€œ2021-003669-36â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œ2023-510139-12-00â€, â€œtypeâ€: â€œCTISâ€}]\nQualified scientific and medical researchers can request the data. Such requests must be submitted iâ€¦\nWe are committed to enhancing public health through responsible sharing of clinical trial data. Follâ€¦\nSTUDY_PROTOCOL, SAP, CSR, ANALYTIC_CODE\nYES\nWithin six months after the approval of a new product or a new indication for an approved product inâ€¦\nhttp://bit.ly/IPD21\n\n[{â€œmeasureâ€: â€œProgression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œtimeFrameâ€: â€œTime from randomization of study drug until deatâ€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ39929671â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œNaing A, McKean M, Tolcher A, Victor A, Hu P, â€¦\n[{â€œlabelâ€: â€œTrial Awareness and Transparency websiteâ€, â€œurlâ€: â€œhttps://clinicaltrials.emdgroup.com/eâ€¦\n[{â€œnameâ€: â€œMerck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeuticsâ€, â€œclassâ€: â€œUNKNOWNâ€â€¦\nINDUSTRY\nEMD Serono Research & Development Institute, Inc.\n\n\n\nSPONSOR\n2026-06-25\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-26\nACTUAL\n2026-01-23\nACTIVE_NOT_RECRUITING\n2025-06-20\nACTUAL\n\n\n\n\n2022-08-17\nACTUAL\n2026-01\n2022-04-14\nACTUAL\n2022-04-05\n2022-04-13\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants with histologically confirmed, unresectable locally advanced or â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014594â€, â€œtermâ€: â€œUterine Neoplasmsâ€}, {â€œidâ€: â€œD005833â€, â€œtermâ€: â€œGenital Neoplasms, Femalâ€¦\n[{â€œidâ€: â€œD016889â€, â€œtermâ€: â€œEndometrial Neoplasmsâ€}, {â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€},â€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDose Escalation Cohorts.â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œUp to 5 sequential doâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œCOM701 in combination with BMS-986207 and nivolumab.â€, â€œdescriptionâ€: â€œStâ€¦\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nTIGIT, PVRIG, checkpoint inhibitor, Immune checkpoint, Immuno-oncology, CD226, CD112, CD155, Solid tâ€¦\n\n[{â€œfacilityâ€: â€œUniversity of Chicago Medical Centerâ€, â€œcityâ€: â€œChicagoâ€, â€œstateâ€: â€œIllinoisâ€, â€œzipâ€:â€¦\n[{â€œnameâ€: â€œLead COM701 ClinInfoâ€, â€œaffiliationâ€: â€œCompugen Ltdâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the â€¦\nThis phase 1/2 study evaluates the safety/tolerability, pharmacokinetics and preliminary antitumor aâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nSequential dose escalation, followed by an expansion cohort upon determination of the recommended doâ€¦\nNONE\n\n\n\nTREATMENT\n\n48\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCOM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.\nNCT04570839\n\nA Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 iâ€¦\nCPG-03-101.\nINDUSTRY\nCompugen Ltd\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œThe proportion of subjects with adverse events on the study.â€, â€œdescriptionâ€: â€œThe proâ€¦\n[{â€œmeasureâ€: â€œThe objective response rate of subjects enrolled in cohorts 1-4.â€, â€œdescriptionâ€: â€œObjâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nCompugen Ltd\n\n\n\nSPONSOR\n2024-05-15\nACTUAL\n\n\n\n\nFalse\n\n2024-07-18\nACTUAL\n2024-07-17\nCOMPLETED\n2024-05-15\nACTUAL\n\n\n\n\n2020-08-31\nACTUAL\n2024-07\n2020-09-30\nACTUAL\n2020-09-18\n2020-09-25\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically confirmed, locally advanced or metastaticâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œChronic Cannabinoid Usersâ€, â€œdescriptionâ€: â€œIb or II Melanoma patients who are chronic câ€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œHigh-performance liquid chromatography-tandem mass spectrometry assaysâ€,â€¦\nMelanoma\n\n\n[{â€œfacilityâ€: â€œUniversity of Colorado Denverâ€, â€œcityâ€: â€œAuroraâ€, â€œstateâ€: â€œColoradoâ€, â€œzipâ€: â€œ80045â€â€¦\n[{â€œnameâ€: â€œCamille Stewart, MDâ€, â€œaffiliationâ€: â€œUniversity of Colorado, Denverâ€, â€œroleâ€: â€œPRINCIPALâ€¦\nThe goal of this proposal is to determine how cannabinoid use affects the tumor immune microenvironmâ€¦\nSpecific Aim 1.Assess how systemic cannabinoids remodel tumor infiltrating lymphocytes (TILs) withinâ€¦\nParaffin Tissue Blocks Whole Blood\nSAMPLES_WITHOUT_DNA\n\n\n\n\n\n\nOTHER\n\nPROSPECTIVE\n90\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\n\n100 Years\n21 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nDescription of Population to be Enrolled:\n\nEvaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocyteâ€¦\nNCT05520294\n\nEvaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocyteâ€¦\n22-1132\nOTHER\nUniversity of Colorado, Denver\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œGrade of TIL in melanoma biopsyâ€, â€œdescriptionâ€: â€œHematoxylin and eosin slide assessmeâ€¦\n\nFalse\nFalse\n\nFalse\n\n\n[{â€œnameâ€: â€œCancer League of Coloradoâ€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nUniversity of Colorado, Denver\n\n\n\nSPONSOR\n2024-08-31\nESTIMATED\n\n\n\n\nFalse\n\n2024-04-17\nACTUAL\n2024-04-15\nACTIVE_NOT_RECRUITING\n2024-08-31\nESTIMATED\n\n\n\n\n2022-09-01\nACTUAL\n2024-04\n2022-08-29\nACTUAL\n2022-08-25\n2022-08-25\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Biopsy proven melanoma, any stage\n\n\n\n\n\n\n\n\nPatients who are either chronic cannabis/cannabinoid userâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Biopsy obtained within 4 weeks of antiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHB0036â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œHB0036 IV every 3 weeks (q3w)â€, â€œintervâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHB0036â€, â€œdescriptionâ€: â€œPatients will be assigned to dose regimens in thâ€¦\nAdvanced Solid Tumor, NSCLC\n\n[{â€œnameâ€: â€œJingjing Wang, Masterâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ021-51320053â€, â€œphoneExtâ€: â€œ6029â€, â€œâ€¦\n[{â€œfacilityâ€: â€œHorizon Oncologyâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œLafayetteâ€, â€œstateâ€: â€œIndianaâ€, â€œâ€¦\n[{â€œnameâ€: â€œYang Yang, MD/PHDâ€, â€œaffiliationâ€: â€œShanghai Huaota Biopharmaceutical Co., Ltd.â€, â€œroleâ€:â€¦\nIt is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacoâ€¦\nThis is a phase â… /â…¡, multicenter, open-label, first-in-human study in patients with advanced solid tâ€¦\n\n\n\nSEQUENTIAL\nA single-subject cohort will be enrolled at the protocol starting dose of HB0036 every 3 weeks (Q3W)â€¦\nNONE\n\n\n\nTREATMENT\n\n80\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors\nNCT05417321\n\nA Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamiâ€¦\nHB0036-01\nINDUSTRY\nShanghai Huaota Biopharmaceutical Co., Ltd.\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œORR assessment in dose-escalation phaseâ€, â€œdescriptionâ€: â€œOverall response rate (ORR) â€¦\n[{â€œmeasureâ€: â€œSafety and tolerabilityâ€, â€œdescriptionâ€: â€œNumber of participants with a Dose Limiting â€¦\n[{â€œmeasureâ€: â€œAUCâ€, â€œdescriptionâ€: â€œArea Under concentration-time Curve (AUC)â€, â€œtimeFrameâ€: â€œUp to â€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nShanghai Huaota Biopharmaceutical Co., Ltd.\n\n\n\nSPONSOR\n2025-08-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-01-03\nACTUAL\n2025-01-02\nRECRUITING\n2025-08-01\nESTIMATED\n\n\n\n\n2022-08-25\nACTUAL\n2025-01\n2022-06-14\nACTUAL\n2022-05-30\n2022-06-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPatients must meet all the following criteria to be eligible for participation iâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD001254â€, â€œtermâ€: â€œAstrocytomaâ€}, {â€œidâ€: â€œD005910â€, â€œtermâ€: â€œGliomaâ€}, {â€œidâ€: â€œD018302â€, â€œtâ€¦\n[{â€œidâ€: â€œD005909â€, â€œtermâ€: â€œGlioblastomaâ€}]\n[{â€œidâ€: â€œD019411â€, â€œtermâ€: â€œClinical Laboratory Techniquesâ€}, {â€œidâ€: â€œD019937â€, â€œtermâ€: â€œDiagnostic â€¦\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œD013048â€, â€œtermâ€: â€œSpecimen Handlingâ€}, {â€œidâ€â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œGROUP A (neoadjuvant atezolizumab, tiragolumab)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€:â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œGiven IVâ€, â€œarmGroupLabelsâ€: [â€œGROUPâ€¦\nRecurrent Glioblastoma, IDH-Wildtype\n\n\n\n[{â€œnameâ€: â€œMegan Manticaâ€, â€œaffiliationâ€: â€œUniversity of Pittsburgh Cancer Institute LAOâ€, â€œroleâ€: â€œâ€¦\nThis phase II trial compares the safety, side effects and effectiveness of atezolizumab with tiragolâ€¦\nPRIMARY OBJECTIVE:\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nTesting the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Paâ€¦\nNCT06328036\n\nPhase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients With Recurrent Glioblastoma\nNCI-2024-02185\nNIH\nNational Cancer Institute (NCI)\n[{â€œidâ€: â€œNCI-2024-02185â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTRP (Clinical Trial Reporting Program)â€}, â€¦\n\nNCI is committed to sharing data in accordance with NIH policy. For more details on how clinical triâ€¦\n\nYES\n\nhttps://grants.nih.gov/policy/sharing.htm\n[{â€œmeasureâ€: â€œTumor response signatures including for T-cells, interferon and cell cycleâ€, â€œdescriptâ€¦\n[{â€œmeasureâ€: â€œProgression free survival (PFS)â€, â€œdescriptionâ€: â€œWill be assessed and compared betweeâ€¦\n[{â€œmeasureâ€: â€œTumor infiltrating T lymphocyte densityâ€, â€œdescriptionâ€: â€œWill be assessed and compareâ€¦\nFalse\nTrue\nFalse\nFalse\n\n\n\nNIH\nNational Cancer Institute (NCI)\n\n\n\nSPONSOR\n2025-07-01\nESTIMATED\n\n\n\n\nFalse\n\n2024-12-30\nACTUAL\n2024-12-27\nWITHDRAWN\n2025-07-01\nESTIMATED\n\n\n\n\n2025-04-30\nESTIMATED\n2024-12\n2024-03-25\nACTUAL\n2024-03-22\n2024-03-22\nOther - Protocol moved to Disapproved\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nI. To evaluate the impact of combination atezolizumab plus tiragolumab on progreâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients must have histologically confirmed IDH wildtype World Health Organizâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009380â€, â€œtermâ€: â€œNeoplasms, Nerve Tissueâ€}, {â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplasms by Histoâ€¦\n[{â€œidâ€: â€œD018317â€, â€œtermâ€: â€œNerve Sheath Neoplasmsâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}, {â€œidâ€: â€œD000074324â€, â€œtermâ€: â€œIpilimumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œImmunotherapy with Nivolumab and Ipilimumabâ€, â€œtypeâ€: â€œOTHERâ€, â€œdescriptionâ€: â€œNivolumabâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œNivolumabâ€, â€œdescriptionâ€: â€œNivolumab 4.5 mg/kg Q3W x 2â€, â€œarmGroupLabelsâ€¦\nNerve Sheath Tumors\n\n\n[{â€œfacilityâ€: â€œJohns Hopkins Medical Institutionâ€, â€œcityâ€: â€œBaltimoreâ€, â€œstateâ€: â€œMarylandâ€, â€œzipâ€: â€¦\n[{â€œnameâ€: â€œJaishri Blakeley, MDâ€, â€œaffiliationâ€: â€œJohns Hopkins Universityâ€, â€œroleâ€: â€œPRINCIPAL_INVEâ€¦\nThe purpose of the study is to evaluate safety and feasibility of neoadjuvant nivolumab plus ipilimuâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n13\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n100 Years\n12 Years\n\nALL\nCHILD, ADULT, OLDER_ADULT\n\n\nNeoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor\nNCT04465643\n\nNeoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor\nJ20112\nOTHER\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\n[{â€œidâ€: â€œIRB00215437â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œJohns Hopkins Universityâ€}, {â€œidâ€: â€œW81XWH-22-1-0â€¦\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œProportion of participants who had meaâ€¦\n[{â€œmeasureâ€: â€œSafety of combination nivolumab and ipilimumab as assessed by number of participants wâ€¦\n[{â€œmeasureâ€: â€œSafety as assessed by number of treatment-emergent adverse events in patients on combiâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œCongressionally Directed Medical Râ€¦\nOTHER\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\n\n\n\nSPONSOR\n2025-07-30\nACTUAL\n\n\n\n\nFalse\n\n2025-10-08\nACTUAL\n2025-10-02\nCOMPLETED\n2025-07-30\nACTUAL\n\n\n\n\n2021-06-08\nACTUAL\n2025-10\n2020-07-10\nACTUAL\n2020-07-07\n2020-07-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed diagnosis of atypical neurofibromatous neoplasms of â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplaâ€¦\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm 1 (zimberelimab monotherapy)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œDomvanalimab is a humanized monoclonal antâ€¦\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Canâ€¦\nNon Small Cell Lung Cancer, Lung Cancer, NSCLC\n\n[{â€œfacilityâ€: â€œUniversity of Alabama at Birminghamâ€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabamaâ€, â€œzipâ€â€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB12â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n151\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARC-7\nStudy to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Noâ€¦\nNCT04262856\n\nA Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With â€¦\nARC-7 (AB154CSP0002)\nINDUSTRY\nArcus Biosciences, Inc.\n\n\nArcus will provide access to individual de-identified participant data and related study documents (â€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œORR as assessed by RECIST v1.1â€, â€œtimeâ€¦\n[{â€œmeasureâ€: â€œDuration of response (DoR)â€, â€œdescriptionâ€: â€œDoR as assessed by RECIST v1.1â€, â€œtimeFraâ€¦\nFalse\nTrue\n\n\n\n[{â€œlabelâ€: â€œARC-7 - Public websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=ARC-7â€}]\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2025-07-09\nACTUAL\n\n\n\n\nFalse\n\n2025-08-26\nACTUAL\n2025-08-25\nCOMPLETED\n2025-06-05\nACTUAL\n\n\n\n\n2020-05-28\nACTUAL\n2024-08\n2020-02-10\nACTUAL\n2020-01-23\n2020-02-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female participants; age â‰¥ 18 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed, treatâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplaâ€¦\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD01â€¦\nBangladesh, Belarus, Brazil, Egypt, France, India, Peru, Russia, Serbia, Slovakia, Ukraine\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A - Study Part 1 (Platinum-based Chemotherapy)â€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescrâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œDomvanalimab is a humanized monoclonal antâ€¦\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Canâ€¦\nDomvanalimab, Zimberelimab, Non Small Cell Lung Cancer, Lung Cancer, NSCLC\n\n[{â€œfacilityâ€: â€œHope and Healing Cancer Serviceâ€, â€œcityâ€: â€œHinsdaleâ€, â€œstateâ€: â€œIllinoisâ€, â€œzipâ€: â€œ60â€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in frontâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n169\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARC-10\nStudy Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer\nNCT04736173\n\nOfficial Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, â€¦\nARC-10\nINDUSTRY\nArcus Biosciences, Inc.\n[{â€œidâ€: â€œ2020-003562-39â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œPHRR210222-003371â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nArcus will provide access to individual de-identified participant data and related study documents (â€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n\n[{â€œmeasureâ€: â€œProgression-free Survival (PFS)â€, â€œtimeFrameâ€: â€œFrom randomization until death from anâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œtimeFrameâ€: â€œFrom randomization until death from any cause (uâ€¦\nFalse\nTrue\n\nTrue\n\n[{â€œlabelâ€: â€œARC-10 - Public Websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=ARC-10â€}]\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2027-05\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-15\nACTUAL\n2025-12-09\nACTIVE_NOT_RECRUITING\n2027-05\nESTIMATED\n\n\n\n\n2021-02-08\nACTUAL\n2025-04\n2021-02-03\nACTUAL\n2021-01-29\n2021-01-29\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed, treatment naÃ¯ve, locally advanced or metastaticâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHealth volunteersâ€, â€œdescriptionâ€: â€œHealth volunteers as control groupâ€, â€œinterventionNaâ€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œno interventionâ€, â€œdescriptionâ€: â€œprospective and observational study wiâ€¦\n28 Day Mortality\nsepsis immunosuppression Treg\n[{â€œnameâ€: â€œSongqiao Liu, MD. PhD.â€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ086-2583262550â€, â€œemailâ€: â€œliusongqâ€¦\n[{â€œfacilityâ€: â€œZhongda Hospital, Southeast Universityâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œNanjingâ€, â€œâ€¦\n[{â€œnameâ€: â€œQingxiang Liu, MD.â€, â€œaffiliationâ€: â€œZhongda Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}â€¦\nthere is high mortality rate of sepsis, 36% in 90-days of sepsis in China, and there is no effectiveâ€¦\n1. peripheral blood Treg cells and their surface PD-1ã€CTLA-4 and TIGIT levels in sepsis patients werâ€¦\nVenous blood was extracted according to time points and stored\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nOTHER\n\nPROSPECTIVE\n100\nESTIMATED\nTrue\n\nOBSERVATIONAL\n28 Days\nInclusion Criteria:\n\n\nTrue\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\npatients diagnosed with sepsis\n\nCo-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis\nNCT05126537\n\nAn Observational Study on the Relationship Between Expression of Co-inhibitory Molecules on Treg andâ€¦\n2020ZDSYLL041-Y01\nOTHER\nSoutheast University, China\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œ28 day mortalityâ€, â€œdescriptionâ€: â€œall patients followed up to 28 daysâ€, â€œtimeFrameâ€: â€¦\n\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nSoutheast University, China\nSoutheast University, China\nSongqiao Liu\nChief\nPRINCIPAL_INVESTIGATOR\n2022-12-31\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2022-11-30\nACTUAL\n2022-11-25\nUNKNOWN\n2022-12-31\nESTIMATED\n\n\n\n\n2022-01-01\nACTUAL\n2022-11\n2021-11-19\nACTUAL\n2021-11-08\n2021-11-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* sepsis 3.0 diagnositic criteria are met. older than 18 years old. total coursâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD054219â€, â€œtermâ€: â€œNeoplasms, Plasma Cellâ€}, {â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplasms by Histolâ€¦\n[{â€œidâ€: â€œD009101â€, â€œtermâ€: â€œMultiple Myelomaâ€}]\n[{â€œidâ€: â€œD011246â€, â€œtermâ€: â€œPregnadienetriolsâ€}, {â€œidâ€: â€œD011245â€, â€œtermâ€: â€œPregnadienesâ€}, {â€œidâ€: â€œâ€¦\n[{â€œidâ€: â€œC000624220â€, â€œtermâ€: â€œiberdomideâ€}, {â€œidâ€: â€œD003907â€, â€œtermâ€: â€œDexamethasoneâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA: Participants will receive EOS884448â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œEOS8844â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œEOS884448â€, â€œdescriptionâ€: â€œEOS884448 will be administered in arm A,B andâ€¦\nMultiple Myeloma\nMultiple Myeloma, EOS884448, GSK4428859A, TIGIT, Anti-TIGIT, iberdomide, CELMoD, CC-220, EOS-448, Beâ€¦\n\n[{â€œfacilityâ€: â€œBanner MD Andersonâ€, â€œcityâ€: â€œGilbertâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85234â€, â€œcountryâ€â€¦\n[{â€œnameâ€: â€œIteos Clinical Trialsâ€, â€œaffiliationâ€: â€œiTeos Belgium SAâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, anâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n16\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Novel Regimens in Relapsed or Refractory Multiple Myeloma\nNCT05289492\n\nStudy of EOS884448 Alone, and in Combination with Iberdomide with or Without Dexamethasone, in Partiâ€¦\nTIG-007\nINDUSTRY\niTeos Therapeutics\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œNumber of participants with any adverse events (AEs) and serious adverse events (SAEs)â€¦\n[{â€œmeasureâ€: â€œProgression-free-survival (PFS)â€, â€œtimeFrameâ€: â€œUntil disease progression or death - Aâ€¦\nFalse\nTrue\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œGlaxoSmithKlineâ€, â€œclassâ€: â€œINDUSTâ€¦\nINDUSTRY\niTeos Therapeutics\n\n\n\nSPONSOR\n2023-11-29\nACTUAL\n\n\n\n\nFalse\n\n2024-10-26\nACTUAL\n2024-10-23\nTERMINATED\n2023-11-29\nACTUAL\n\n\n\n\n2022-05-01\nACTUAL\n2024-10\n2022-03-21\nACTUAL\n2022-03-11\n2022-03-18\nCompany operational decision. Decision to stop study is not due to safety or efficacy concerns\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* All participants must have a documented diagnosis of relapse/refractory Multiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€},â€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œModule 1â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAZD6750 administered intravenously (Iâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAZD6750â€, â€œdescriptionâ€: â€œAZD6750- CD8 guided IL-2â€, â€œarmGroupLabelsâ€: [â€œâ€¦\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Câ€¦\n\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œGrand Rapidsâ€, â€œstateâ€: â€œMichiganâ€, â€¦\n\nA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Soâ€¦\nA Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokineticsâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\nModule 1 consists of treatment with AZD6750 administered as a single agent to enroll participants wiâ€¦\nNONE\n\n\n\nTREATMENT\n\n60\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Soâ€¦\nNCT07115043\n\nA Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokineticsâ€¦\nD7350C00001\nINDUSTRY\nAstraZeneca\n\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œSafety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)â€, â€œdescriptioâ€¦\n[{â€œmeasureâ€: â€œPharmacodynamic- Part 1A & Part 2A (dose escalation) and Part B (dose expansion)â€, â€œdeâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-10-02\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-19\nACTUAL\n2025-12-18\nRECRUITING\n2029-10-02\nESTIMATED\n\n\n\n\n2025-07-29\nACTUAL\n2025-12\n2025-08-11\nACTUAL\n2025-07-16\n2025-08-04\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participant â‰¥ 18 year\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* ECOG PS of 0 to 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Provision of â€˜archivalâ€™ tumor speâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD043823â€, â€œtermâ€: â€œTaxoidsâ€}, {â€œidâ€: â€œD043822â€, â€œtermâ€: â€œCyclodecanesâ€}, {â€œidâ€: â€œD003516â€, â€¦\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œImmunotherapy with CCRT before surgeryâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTiragolâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTiragolumabâ€, â€œdescriptionâ€: â€œNeoadjuvant Tiragolumab, Atezolizumab, Paclâ€¦\nLocally Advanced Esophageal Squamous Cell Carcinoma\n\n[{â€œnameâ€: â€œChia-Hsien Cheng, câ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+886-2-2352-2846â€, â€œemailâ€: â€œjasonchenâ€¦\n[{â€œfacilityâ€: â€œNational Taiwan University Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œTaipeiâ€, â€œzipâ€â€¦\n[{â€œnameâ€: â€œChia-Hsien Cheng, Chengâ€, â€œaffiliationâ€: â€œEmployeeâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nThe prognosis of ESCC is poor with a five-year overall survival rate of 10 to 30 %. Randomized cliniâ€¦\nEsophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancy worldwide. The prognoâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n32\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n20 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nImmunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients\nNCT05743504\n\nA Phase Ib/II Trial of Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapyâ€¦\n202111099MIPC\nOTHER\nNational Taiwan University Hospital\n[{â€œidâ€: â€œML43431â€, â€œtypeâ€: â€œOTHER_GRANTâ€, â€œdomainâ€: â€œF. Hoffmann-La Roche Ltdâ€}]\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œPathological complete response rateâ€, â€œdescriptionâ€: â€œPathological complete response râ€¦\n[{â€œmeasureâ€: â€œSide effect evaluationâ€, â€œdescriptionâ€: â€œmajor morbidity rate after completion of protâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n\nOTHER\nNational Taiwan University Hospital\n\n\n\nSPONSOR\n2025-11-30\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2024-02-02\nACTUAL\n2024-01-31\nUNKNOWN\n2025-05-31\nESTIMATED\n\n\n\n\n2023-09-18\nACTUAL\n2023-09\n2023-02-24\nACTUAL\n2023-01-30\n2023-02-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically proved squamous cell carcinoma of esophagus\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Locally advancâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004333â€, â€œtermâ€: â€œDrug Administration Routesâ€}, {â€œidâ€: â€œD004358â€, â€œtermâ€: â€œDrug Therapyâ€},â€¦\n[{â€œidâ€: â€œD007267â€, â€œtermâ€: â€œInjectionsâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œ10 mg of BAT6021â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œBAT6021 100mg/vialï¼Œ10mg â…£ infâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œBAT6021â€, â€œdescriptionâ€: â€œâ…£ infusionsâ€, â€œarmGroupLabelsâ€: [â€œ10 mg of BAT6â€¦\nAdvanced Solid Tumor\n\n\n[{â€œfacilityâ€: â€œLiverpool Hospitalâ€, â€œcityâ€: â€œLiverpoolâ€, â€œstateâ€: â€œNew South Walesâ€, â€œcountryâ€: â€œAusâ€¦\n[{â€œnameâ€: â€œAbhijit Pal, M.D, Ph.Dâ€, â€œaffiliationâ€: â€œMedical Oncologist at cancer Therapy, Liverpool â€¦\nThis first-in-human open-label, multi center, dose-escalation and expansion study is designed to evaâ€¦\nAnti-PD-1 and anti-PD-L1 antibodies targeting the immuno-inhibitory PD-1 pathway (thus activating T â€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n13\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAssessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients\nNCT05073484\n\nA Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Prelâ€¦\nBAT-6021-002-CR\nINDUSTRY\nBio-Thera Solutions\n\n\nno plan to share IPD\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œDose-limiting toxicity(DLT)â€, â€œdescriptionâ€: â€œDLT is defined as one of the following aâ€¦\n[{â€œmeasureâ€: â€œPharmacokinetics (PK)â€, â€œdescriptionâ€: â€œCmaxâ€, â€œtimeFrameâ€: â€œevery cycle until cycle 6â€¦\nFalse\nFalse\nFalse\nFalse\n\n\n\nINDUSTRY\nBio-Thera Solutions\n\n\n\nSPONSOR\n2023-03-30\nACTUAL\n\n\n\n\nFalse\n\n2023-10-11\nACTUAL\n2023-10-09\nTERMINATED\n2023-03-30\nACTUAL\n\n\n\n\n2021-10-29\nACTUAL\n2023-10\n2021-10-11\nACTUAL\n2021-09-09\n2021-09-28\nBased on the disclosed global research data on the same target drugs, the company has carefully consâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Able to give voluntary informed consent and understand the study and are wilâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAdvanced NSCLC or Melanoma - Anti-PD-(L)1 Therapyâ€, â€œdescriptionâ€: â€œThis cohort includesâ€¦\n\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nstandard treatment with anti-PD-(L)1 monotherapy or combination therapy\n[{â€œnameâ€: â€œCourÃ¨che CK KADERBHAI, Doctorâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ03 80 73 75 28â€, â€œphoneExtâ€:â€¦\n[{â€œfacilityâ€: â€œCHU BesanÃ§on - Service Dermatologieâ€, â€œcityâ€: â€œBesanÃ§onâ€, â€œzipâ€: â€œ25000â€, â€œcountryâ€: â€¦\n[{â€œnameâ€: â€œJessica JG GOBBO, Clinical Research Scientistâ€, â€œaffiliationâ€: â€œCentre Georges FranÃ§ois Lâ€¦\nThe objective of this prospective multicenter study is to evaluate whether the analysis of immunologâ€¦\nImmune checkpoint inhibitors (anti-PD-1/PD-L1) have become standard treatment for patients with advaâ€¦\n\n\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n378\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nPatients with non-small cell lung cancer (NSCLC) or melanoma, locally advanced or metastatic, and unâ€¦\nEVpredict\nPredicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis\nNCT07376512\n\nPredicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis\n2025-A01783-46\nOTHER\nCentre Georges Francois Leclerc\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œTarget protein levels in plasma-derived extracellular vesicles (EVs) measured by multiâ€¦\n\nFalse\nFalse\n\nFalse\n\n\n\nOTHER\nCentre Georges Francois Leclerc\n\n\n\nSPONSOR\n2030-03-01\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-29\nACTUAL\n2026-01-22\nNOT_YET_RECRUITING\n2029-03-01\nESTIMATED\n\n\n\n\n2026-03-01\nESTIMATED\n2026-01\n2026-01-29\nACTUAL\n2026-01-22\n2026-01-22\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age â‰¥18 years.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed diagnosis of non-small cell lung caâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œD000068258â€, â€œtermâ€: â€œBevacizumabâ€}, {â€œidâ€: â€œâ€¦\nMorocco\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezolizumab + Bevacizumab + Tiragolumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAtezoâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œAtezolizumab will be administered by intraâ€¦\nHepatocellular Carcinoma\n\n\n[{â€œfacilityâ€: â€œGenesis Cancer Centerâ€, â€œcityâ€: â€œHot Springsâ€, â€œstateâ€: â€œArkansasâ€, â€œzipâ€: â€œ71913â€, â€œâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monocloâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nQUADRUPLE\nThe study has been unblinded as of amendment version 5.\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n687\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSKYSCRAPER-14\nA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Uâ€¦\nNCT05904886\n\nA Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating Atezolizumab and Bevacizuâ€¦\nCO44668\nINDUSTRY\nHoffmann-La Roche\n[{â€œidâ€: â€œ2023-503422-39-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œEU CT Numberâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œInvestigator-assessed Progression-free Survival (PFS) According to Response Evaluationâ€¦\n[{â€œmeasureâ€: â€œInvestigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1â€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ38861301â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œBadhrinarayanan S, Cotter C, Zhu H, Lin YC, Kuâ€¦\n\n[{â€œnameâ€: â€œChugai Pharmaceuticalâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2026-09-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-31\nACTUAL\n2025-12-30\nACTIVE_NOT_RECRUITING\n2025-05-08\nACTUAL\n\n\n\n\n2023-09-14\nACTUAL\n2025-12\n2023-06-15\nACTUAL\n2023-05-23\n2023-06-14\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}â€¦\n[{â€œidâ€: â€œD043823â€, â€œtermâ€: â€œTaxoidsâ€}, {â€œidâ€: â€œD043822â€, â€œtermâ€: â€œCyclodecanesâ€}, {â€œidâ€: â€œD003516â€, â€¦\n[{â€œidâ€: â€œD000077143â€, â€œtermâ€: â€œDocetaxelâ€}, {â€œidâ€: â€œD000074324â€, â€œtermâ€: â€œIpilimumabâ€}, {â€œidâ€: â€œC000â€¦\nAustralia, Denmark\n\n2025-05-22\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProt_SAPâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: true, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Prâ€¦\nTrue\n[{â€œlabelâ€: â€œPart 1: Participants receiving feladilimab and ipilimumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œintâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDocetaxelâ€, â€œdescriptionâ€: â€œDocetaxel will be administered.â€, â€œarmGroupLaâ€¦\nNeoplasms\nNon-small cell lung cancer, Inducible t-cell co-stimulator (ICOS), Docetaxel, Standard of care, Immuâ€¦\n\n[{â€œfacilityâ€: â€œGSK Investigational Siteâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€: â€œ9002â€¦\n[{â€œnameâ€: â€œGSK Clinical Trialsâ€, â€œaffiliationâ€: â€œGlaxoSmithKlineâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will compare the clinical activity of novel regimens (in combination or as single agents)â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\nThe study will be open-label.\n\n\nTREATMENT\n\n175\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nPlatform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lâ€¦\nNCT03739710\n\nA Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimenâ€¦\n205801\nINDUSTRY\nGlaxoSmithKline\n[{â€œidâ€: â€œ2018-001316-29â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\nAccess is provided after a research proposal is submitted and has received approval from the Indepenâ€¦\nIPD for this study will be made available via the Clinical Study Data Request site.\nSTUDY_PROTOCOL, SAP, ICF, CSR\nYES\nIPD will be made available within 6 months of publishing the results of the primary endpoints, key sâ€¦\nhttp://clinicalstudydatarequest.com\n\n[{â€œmeasureâ€: â€œNumber of Participants Randomized Across Sub-studiesâ€, â€œdescriptionâ€: â€œNumber of Partiâ€¦\n\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œiTeos Belgium SAâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nGlaxoSmithKline\n\n\n\nSPONSOR\n2024-05-02\nACTUAL\n\n\n\n\nFalse\n\n2025-06-15\nACTUAL\n2025-06-13\nCOMPLETED\n2024-05-02\nACTUAL\n2025-06-15\nACTUAL\n2025-05-02\n2025-06-13\n2019-01-24\nACTUAL\n2025-06\n2018-11-14\nACTUAL\n2018-11-09\n2018-11-09\n\nAdverse event(s) of special interest [AESIs] and Serious Adverse Event(s) [SAEs] assessed as relâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œAll Screened Participantsâ€, â€œdescriptionâ€: â€œParticipants with Non-Small Câ€¦\n0.0\n\n\nScreening (-28 to 0 days)\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ256â€}]}]\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œAll Screened Participantsâ€, â€œdescriptionâ€: â€œParticipants with Non-Small Câ€¦\n[{â€œtitleâ€: â€œAge, Customizedâ€, â€œparamTypeâ€: â€œCOUNT_OF_PARTICIPANTSâ€, â€œunitOfMeasureâ€: â€œParticipantsâ€,â€¦\n\nGSK agreements may vary with individual investigators, but will not prohibit any investigator from pâ€¦\nFalse\nOTHER\nTrue\n\nGSKClinicalSupportHD@gsk.com\nGlaxoSmithKline\n866-435-7343\n\nGSK Response Center\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œNumber of Participants Randomized Across Sub-studiesâ€, â€œdescriptionâ€:â€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œAll Screened Participantsâ€, â€œdescriptionâ€: â€œParticipants with Non-Small Câ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œcommentâ€: â€œAll participants who wereâ€¦\nA total of 256 participants started the overall study which includes all who were screened prior to â€¦\nThis master record includes data of screened participants for its sub-studies, 205801-001 (NCT055538â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants capable of giving signed informed consent/assent.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or femaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCohort A: Zimberelimab + Domvanalimab + Etrumadenantâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œZimberelimabâ€, â€œdescriptionâ€: â€œZimberelimab will be supplied by Arcus Bioâ€¦\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œWashington University School of Medicineâ€, â€œcityâ€: â€œSt Louisâ€, â€œstateâ€: â€œMissouriâ€, â€œâ€¦\n[{â€œnameâ€: â€œDaniel Morgensztern, M.D.â€, â€œaffiliationâ€: â€œWashington University School of Medicineâ€, â€œrâ€¦\nSince anti-PD1, anti-TIGIT, and A2R antagonists have complementary mechanisms of action, and the latâ€¦\n\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n30\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSafety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenanâ€¦\nNCT04791839\n\nA Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanâ€¦\n202104122\nOTHER\nWashington University School of Medicine\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œ* Defined as the proportion of patientâ€¦\n[{â€œmeasureâ€: â€œNumber of study treatment related adverse eventsâ€, â€œdescriptionâ€: â€œ\\- Adverse events â€¦\nFalse\nTrue\nFalse\nTrue\n\n[{â€œlabelâ€: â€œAlvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University Schooâ€¦\n[{â€œnameâ€: â€œArcus Biosciences, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nWashington University School of Medicine\n\n\n\nSPONSOR\n2030-06-30\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-05\nACTUAL\n2025-11-04\nACTIVE_NOT_RECRUITING\n2026-04-30\nESTIMATED\n\n\n\n\n2021-08-04\nACTUAL\n2025-11\n2021-03-10\nACTUAL\n2021-03-05\n2021-03-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed metastatic squamous or non-squamous non-small cell lâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD009375â€, â€œtermâ€: â€œNeoplasms, Glandular and Epithelâ€¦\n[{â€œidâ€: â€œD002280â€, â€œtermâ€: â€œCarcinoma, Basal Cellâ€}]\n[{â€œidâ€: â€œD007982â€, â€œtermâ€: â€œLevulinic Acidsâ€}, {â€œidâ€: â€œD007651â€, â€œtermâ€: â€œKeto Acidsâ€}, {â€œidâ€: â€œD002â€¦\n[{â€œidâ€: â€œD000622â€, â€œtermâ€: â€œAminolevulinic Acidâ€}, {â€œidâ€: â€œC008848â€, â€œtermâ€: â€œ1-phenyl-3,3-dimethyltâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPhotodynamic therapy (PDT)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œEach participant wiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œALAâ€, â€œdescriptionâ€: â€œAt first visit, ALA applied to one BCC lesionâ€, â€œarâ€¦\nBasal Cell Carcinoma\n\n[{â€œnameâ€: â€œEdward V Maytin, MD, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ216-444-5139â€, â€œemailâ€: â€œmaytine@â€¦\n[{â€œfacilityâ€: â€œCleveland Clinic, Case Comprehensive Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€¦\n[{â€œnameâ€: â€œEdward V Maytin, MD, PhDâ€, â€œaffiliationâ€: â€œCleveland Clinic, Case Comprehensive Cancer Ceâ€¦\nThe purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) â€¦\nPDT is a technique that works by combining a photosensitizing topical agent and an intense light to â€¦\n\n\n\nSINGLE_GROUP\nEach participant will serve as their own control - one tumor will be PDT-treated and other left as uâ€¦\nNONE\n\n\n\nTREATMENT\n\n28\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAlteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy\nNCT05020912\n\nAlteration of the Immune Microenvironment in Basal Cell Carcinoma (BCC) Following Photodynamic Theraâ€¦\nCASE2621\nOTHER\nCase Comprehensive Cancer Center\n\n\nAll IPD that underlie results in publication\nSTUDY_PROTOCOL, SAP, ICF, CSR\nYES\n\n\n\n[{â€œmeasureâ€: â€œTime to maximum expression of immune checkpoint moleculesâ€, â€œdescriptionâ€: â€œTime (daysâ€¦\n[{â€œmeasureâ€: â€œProportion of tumor-activated CD8+ T-cells after PDTâ€, â€œdescriptionâ€: â€œDifference in Câ€¦\nFalse\nTrue\n\nFalse\n\n\n\nOTHER\nCase Comprehensive Cancer Center\n\n\n\nSPONSOR\n2027-12\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-26\nACTUAL\n2025-11-25\nRECRUITING\n2027-09\nESTIMATED\n\n\n\n\n2021-12-13\nACTUAL\n2025-11\n2021-08-25\nACTUAL\n2021-08-19\n2021-08-19\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Adults scheduled to undergo Mohs surgery within the Dermatologic Surgery unitâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014571â€, â€œtermâ€: â€œUrologic Neoplasmsâ€}, {â€œidâ€: â€œD014565â€, â€œtermâ€: â€œUrogenital Neoplasmsâ€},â€¦\n[{â€œidâ€: â€œD001749â€, â€œtermâ€: â€œUrinary Bladder Neoplasmsâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCohort Aâ€, â€œdescriptionâ€: â€œPatients treated with intravesical instillations for non-invaâ€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œBiological samplesâ€, â€œdescriptionâ€: â€œBlood samples will be collected at â€¦\nBladder Cancer\n\n[{â€œnameâ€: â€œJihane Boustani, MD, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+33 3 70 63 23 02â€, â€œemailâ€: â€œjboâ€¦\n\n\nThe main objective of this study is to evaluate the induction of Th1 anti-TERT responses by treatmenâ€¦\n\n\n\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n33\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nPROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nPatients treated for a bladder cancer\nimmunoBLAD\nAntitumor T Cell Responses in Patients With Bladder Cancer\nNCT06334406\n\nStudy of Antitumor T Cell Immune Responses in Patients With Bladder Cancer\n098 DRC 210 ER03 012\nOTHER\nCentre Hospitalier Universitaire de Besancon\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œTumor antigen specific T-cell responsesâ€, â€œdescriptionâ€: â€œIncrease in the post-treatmeâ€¦\n[{â€œmeasureâ€: â€œMonitoring of T cells in the bloodâ€, â€œdescriptionâ€: â€œFlow cytometry analysis using T câ€¦\nFalse\nFalse\n\n\n\n\n\nOTHER\nCentre Hospitalier Universitaire de Besancon\n\n\n\nSPONSOR\n2026-04-02\nESTIMATED\n\n\n\n\nFalse\n\n2024-03-28\nACTUAL\n2024-03-19\nNOT_YET_RECRUITING\n2026-04-02\nESTIMATED\n\n\n\n\n2024-04-02\nESTIMATED\n2024-03\n2024-03-28\nACTUAL\n2024-02-28\n2024-03-19\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients undergoing transurethral resection of the bladder (TURBT) for a tumoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD011129â€, â€œtermâ€: â€œPolyradiculoneuropathyâ€}, {â€œidâ€: â€œD020274â€, â€œtermâ€: â€œAutoimmune Diseasesâ€¦\n[{â€œidâ€: â€œD020277â€, â€œtermâ€: â€œPolyradiculoneuropathy, Chronic Inflammatory Demyelinatingâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œKINE-101 120mgâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œSubjects received a single intrâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œKINE-101â€, â€œdescriptionâ€: â€œKINE-101 injection, 12.5 mg/mL, administered oâ€¦\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\n\n\n[{â€œfacilityâ€: â€œKangbuk Samsung Hospitalâ€, â€œcityâ€: â€œSeoulâ€, â€œstateâ€: â€œSeoulâ€, â€œzipâ€: â€œ03181â€, â€œcountrâ€¦\n[{â€œnameâ€: â€œHanna Parkâ€, â€œaffiliationâ€: â€œKine Sciences Co., Ltd.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a multicenter, open-label, single-dose, dose-escalation study evaluating the safety and toleâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nSequential dose escalation in single experimental arm with cohorts receiving 120 mg, 240 mg, or 360 â€¦\nNONE\n\n\n\nTREATMENT\n\n9\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n19 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP\nNCT07343310\n\nMulti-Center, Open-label, Single Dosing, Dose-Ascending, Phase 1 Study to Evaluate the Safety and Toâ€¦\nCIDP101-CR1-001P\nINDUSTRY\nKine Sciences Co., Ltd.\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œChange From Baseline in Inflammatory Neuropathy Cause and Treatment (INCAT) Disabilityâ€¦\n[{â€œmeasureâ€: â€œIncidence of Adverse Events (AEs)â€, â€œdescriptionâ€: â€œIncidence, severity, and relationsâ€¦\n\nFalse\nFalse\n\n\n\n\n\nINDUSTRY\nKine Sciences Co., Ltd.\n\n\n\nSPONSOR\n2025-04-14\nACTUAL\n\n\n\n\nFalse\n\n2026-01-20\nACTUAL\n2026-01-15\nCOMPLETED\n2025-04-14\nACTUAL\n\n\n\n\n2024-08-27\nACTUAL\n2026-01\n2026-01-15\nACTUAL\n2025-12-10\n2026-01-06\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Adults aged â‰¥19 years at informed consent.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Diagnosed with CIDP and refractoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004701â€, â€œtermâ€: â€œEndocrine Gland Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Sitâ€¦\n[{â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€}, {â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplasmsâ€}, {â€œiâ€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}, {â€œidâ€: â€œD000074324â€, â€œtermâ€: â€œIpilimumabâ€}]\n\n2022-01-25\n\n\n[{â€œreleaseDateâ€: â€œ2022-01-25â€, â€œresetDateâ€: â€œ2022-02-16â€, â€œmcpReleaseNâ€: 10}]\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œNeoadjuvant Breast Cancerâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œNewly diagnosed patiâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œNivolumabâ€, â€œdescriptionâ€: â€œNivolumab 240 mg administered by IV infâ€¦\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nbreast cancer, ovarian cancer, gastric cancer\n\n[{â€œfacilityâ€: â€œHoffman Oncologyâ€, â€œcityâ€: â€œThe Bronxâ€, â€œstateâ€: â€œNew Yorkâ€, â€œzipâ€: â€œ10469â€, â€œcountryâ€¦\n[{â€œnameâ€: â€œAnthony Hoffman, MDâ€, â€œaffiliationâ€: â€œExcellaBio LLCâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nSafety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with â€¦\nOpen-Label, Non-Randomization and Safety Run-In: Part 1 of the study is a Phase 2 clinical trial in â€¦\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\nOpen-Label, Non-Randomization Phase 2 clinical trial with Safety Run-In (3 parts): Part 1 in 20 newlâ€¦\nNONE\n\n\n\nTREATMENT\n\n5\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria: Patients must meet all inclusion criteria before enrollment:\nTrue\nPart 1. Neoadjuvant Breast (Females â‰¥18 years of age)\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCombination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients\nNCT03342417\n\nPhase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Unâ€¦\nCA209-929\nINDUSTRY\nExcellaBio LLC\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œPart 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Tumor Genomics and Biomarâ€¦\n[{â€œmeasureâ€: â€œNumber of participants with treatment-related adverse events as assessed by CTCAE v4.0â€¦\n[{â€œmeasureâ€: â€œPart 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - BCTâ€, â€œdescriptionâ€: â€œChaâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nExcellaBio LLC\n\n\n\nSPONSOR\n2019-05-29\nACTUAL\n\n\n\n\nFalse\n\n2021-11-09\nACTUAL\n2021-11-05\nTERMINATED\n2019-05-29\nACTUAL\n\n\n\n\n2018-02-14\nACTUAL\n2021-11\n2017-11-17\nACTUAL\n2017-10-20\n2017-11-09\nSlow patient accrual\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFor Part 1 of the â€¦\n\nPart 2. Platinum-resistant refractory ovarianâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD015179â€, â€œtermâ€: â€œColorectal Neoplasmsâ€}, {â€œidâ€: â€œD007414â€, â€œtermâ€: â€œIntestinal Neoplasmsâ€â€¦\n[{â€œidâ€: â€œD003110â€, â€œtermâ€: â€œColonic Neoplasmsâ€}]\n\n[{â€œidâ€: â€œC035276â€, â€œtermâ€: â€œeicosapentaenoic acid ethyl esterâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œExperimentalâ€, â€œdescriptionâ€: â€œPatients randomized to the experimental arm of the EMT2 tâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œIcosapent Ethyl Oral Capsuleâ€, â€œdescriptionâ€: â€œSoft gelatin capsules contâ€¦\nColon Cancer Liver Metastasis\nColon Cancer, Liver Metastases, Microbiome\n\n[{â€œfacilityâ€: â€œSt Jamesâ€™s University Hospitalâ€, â€œcityâ€: â€œLeedsâ€, â€œcountryâ€: â€œUnited Kingdomâ€, â€œgeoPoâ€¦\n[{â€œnameâ€: â€œMark Hullâ€, â€œaffiliationâ€: â€œUniversity of Leedsâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nA significant proportion of patients who undergo liver surgery to remove bowel cancer that has spreaâ€¦\nDespite advance in the diagnosis and treatment of colorectal cancer (CRC), it remains the second mosâ€¦\nWhole blood, serum, stool, urine, tumour tissue (colorectal cancer liver metastases).\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n81\nACTUAL\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nAny participant who has already been enrolled in the EMT2 trial is eligible for inclusion in the bioâ€¦\n\nPrebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases\nNCT04682665\n\nBiospecimen Collection for:Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancerâ€¦\n20/YH/0306\nOTHER\nUniversity of Leeds\n[{â€œidâ€: â€œ1R01CA243454-01A1â€, â€œtypeâ€: â€œNIHâ€, â€œlinkâ€: â€œhttps://reporter.nih.gov/quickSearch/1R01CA2434â€¦\n\nAnonymised individual patient experimental data may be shared depending on experimental outcomes\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œAbundance of individual bacterial taxa in the gut microbiome (eg. Bifidobacterium, Lacâ€¦\n\nFalse\nTrue\nTrue\nTrue\n\n\n[{â€œnameâ€: â€œNational Cancer Institute (NCI)â€, â€œclassâ€: â€œNIHâ€}, {â€œnameâ€: â€œMassachusetts General Hospitâ€¦\nOTHER\nUniversity of Leeds\nUniversity of Leeds\nMark A Hull, PhD FRCP\nProfessor of Gastroenterology\nPRINCIPAL_INVESTIGATOR\n2024-07-31\nACTUAL\n\n\n\n\nFalse\n\n2024-12-04\nACTUAL\n2024-12-03\nCOMPLETED\n2024-07-31\nACTUAL\n\n\n\n\n2021-09-16\nACTUAL\n2024-12\n2020-12-24\nACTUAL\n2020-12-02\n2020-12-18\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Only individuals who have already been enrolled in the EMT2 trial are eligiblâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siteâ€}, {â€œidâ€: â€œD001941â€, â€œtermâ€: â€œBreast Diseasesâ€}, {â€œidâ€â€¦\n[{â€œidâ€: â€œD001943â€, â€œtermâ€: â€œBreast Neoplasmsâ€}, {â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€}, {â€œidâ€¦\n\n[{â€œidâ€: â€œC000722772â€, â€œtermâ€: â€œAZD5305â€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSub-Study 1 AZD8205 Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œSub-Study 1 haâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAZD8205â€, â€œdescriptionâ€: â€œAZD8205 is an antibody drug conjugate that has â€¦\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell â€¦\nFirst In Human, antibody drug conjugate, cancer, solid tumour, Phase I, Phase IIa\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œDuarteâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€¦\n\nThis research study is studying a new compound, AZD8205, as a possible treatment for advanced or metâ€¦\nThis study is a Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Sâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\nThe study consists a master protocol with sub studies each evaluating the safety and tolerability ofâ€¦\nNONE\n\n\n\nTREATMENT\n\n460\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solâ€¦\nNCT05123482\n\nA Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD820â€¦\nD6900C00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2022-502759-70-01â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTIS (EU)â€}, {â€œidâ€: â€œ2021-000736-66â€, â€œtâ€¦\nWhen a request has been approved AstraZeneca will provide access to the deidentified individual patiâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagroup-dt.pharmacm.com/DT/Home\n\n[{â€œmeasureâ€: â€œThe number of patients with adverse eventsâ€, â€œdescriptionâ€: â€œNumber of patients with aâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œThe percentage of patients with a confâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ39392424â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œHuang Y, Tan HY, Yuan J, Mu R, Yang J, Ball K,â€¦\n[{â€œlabelâ€: â€œFirst in Human Study to Evaluate AZD8205â€, â€œurlâ€: â€œhttps://www.breastcancerstudylocatorâ€¦.\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2027-09-29\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-08\nACTUAL\n2025-12-02\nRECRUITING\n2027-09-29\nESTIMATED\n\n\n\n\n2021-10-18\nACTUAL\n2025-11\n2021-11-17\nACTUAL\n2021-10-13\n2021-11-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age â‰¥ 18 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Relapsed/metastatic solid tumors treated with prior adeqâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Dominant Lewy Bodyâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPart 1 (dose finding): Cohort A - SC Rilvegostomig Dose Level 1 (DL1) and rHuâ€, â€œtypeâ€: â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œIV Rilvegostomigâ€, â€œdescriptionâ€: â€œRilvegostomig administered IV.â€, â€œarmGâ€¦\nAdvanced Solid Tumors\nRecombinant Human Hyaluronidase, Immunooncology monotherapy, T cell Immunoglobulin and Immunoreceptoâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œHuntersvilleâ€, â€œstateâ€: â€œNorth Carolâ€¦\n\nThe purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposuâ€¦\nThis is a Phase I, open-label, multicenter, multi-part, dose finding and dose confirmation study to â€¦\n\n\nRANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n40\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARTEMIDE-subQ\nA Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Particâ€¦\nNCT07161414\n\nA Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokineticsâ€¦\nD702EC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2025-521614-26-00â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œEU CT Numberâ€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\n\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œArea under the Concentration-time Curve During One Dosing Interval (AUCtau)â€, â€œdescripâ€¦\n[{â€œmeasureâ€: â€œNumber of participants with adverse events (AEs)â€, â€œdescriptionâ€: â€œTo assess safety anâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œParexelâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-07-24\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-24\nACTUAL\n2025-12-18\nRECRUITING\n2027-07-19\nESTIMATED\n\n\n\n\n2025-11-25\nACTUAL\n2025-12\n2025-09-08\nACTUAL\n2025-09-03\n2025-09-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented advanced (metastatic and/or unreseâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œidentification of clinical and immunological parametersâ€, â€œdescriptionâ€: â€œIdentificationâ€¦\n\nHIV\nHIV, antiretroviral treatment, viral reservoir, persistent viremia\n[{â€œnameâ€: â€œJade GHOSN, professorâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0140258000â€, â€œemailâ€: â€œjade.ghosn@apâ€¦\n[{â€œfacilityâ€: â€œHÃ´pital Bichat, service des Maladies Infectieuses et Tropicalesâ€, â€œcityâ€: â€œParisâ€, â€œsâ€¦\n\nLow-level HIV replication in a patient on effective antiretroviral therapy is a relatively frequent â€¦\nThe aim of antiretroviral (ARV) treatment is to inhibit viral replication in order to achieve an undâ€¦\n\n\n\n\n\n\n\n\nCASE_CONTROL\n\nCROSS_SECTIONAL\n80\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nPLHIV with persistent low plasma viral load on ARV therapy :\n\n\nFalse\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nAdults living with HIV-1, under antiretroviral therapy (ART) for at least 2 years, recruited from a â€¦\nViPer\nRole of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia inâ€¦\nNCT07015164\n\nRole of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia inâ€¦\nAPHP240349\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œQuantification of HIV-1 cellular reservoir parameters using molecular techniquesâ€, â€œdeâ€¦\n[{â€œmeasureâ€: â€œGenetic diversity of HIV-1 proviruses integrated in cellular genomesâ€, â€œdescriptionâ€: â€¦\nFalse\nFalse\n\nFalse\n\n\n\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\nSPONSOR\n2026-09-11\nESTIMATED\n\n\n\n\nFalse\n\n2025-06-11\nACTUAL\n2025-06-03\nNOT_YET_RECRUITING\n2026-09-10\nESTIMATED\n\n\n\n\n2025-06-10\nESTIMATED\n2025-05\n2025-06-11\nACTUAL\n2025-06-03\n2025-06-03\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* PLHIV &gt; 18 years of age\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* On ARV trâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplasmsâ€}]\n[{â€œidâ€: â€œD014498â€, â€œtermâ€: â€œUracilâ€}, {â€œidâ€: â€œD011744â€, â€œtermâ€: â€œPyrimidinonesâ€}, {â€œidâ€: â€œD011743â€, â€¦\n[{â€œidâ€: â€œC410216â€, â€œtermâ€: â€œFolfox protocolâ€}, {â€œidâ€: â€œC519688â€, â€œtermâ€: â€œXELOXâ€}, {â€œidâ€: â€œD005472â€,â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSubstudy 1â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œVolrustomig plus XELOX (oxaliplatinâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œan anti PD-1 and anti-TIGIT bispecific anâ€¦\nGastric Cancer\nLocally advanced, Metatstatic, Gastric adenocarcinoma, GEJ adenocarcinoma, GEMINI-Gastric\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCaliforniaâ€,â€¦\n\nThis is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safeâ€¦\nApproximately 240 participants will be assigned across 6 substudies, with approximately 40 evaluableâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n240\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nNovel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastrâ€¦\nNCT05702229\n\nAn Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerabiliâ€¦\nD7986C00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2022-002840-29â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\nWhen a request has been approved AstraZeneca will provide access to the deidentified individual patiâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\n\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagroup-dt.pharmacm.com/DT/Home\n\n[{â€œmeasureâ€: â€œORR (per RECIST 1.1 as assessed by Investigator)â€, â€œdescriptionâ€: â€œthe proportion of pâ€¦\n[{â€œmeasureâ€: â€œPFS per RECIST 1.1 as assessed by the Investigatorâ€, â€œdescriptionâ€: â€œthe time from theâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2027-09-28\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-17\nACTUAL\n2025-11-14\nRECRUITING\n2026-07-03\nESTIMATED\n\n\n\n\n2023-01-16\nACTUAL\n2025-11\n2023-01-27\nACTUAL\n2022-12-07\n2023-01-18\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 18 years or older at the time of signing the ICF.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Body weight &gt; 35 kg.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Pâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD016399â€, â€œtermâ€: â€œLymphoma, T-Cellâ€}, {â€œidâ€: â€œD008228â€, â€œtermâ€: â€œLymphoma, Non-Hodgkinâ€}, â€¦\n[{â€œidâ€: â€œD016410â€, â€œtermâ€: â€œLymphoma, T-Cell, Cutaneousâ€}, {â€œidâ€: â€œD009182â€, â€œtermâ€: â€œMycosis Fungoiâ€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œsingle agent DT-7012â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: DT-7012â€]}]\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDT-7012â€, â€œdescriptionâ€: â€œThis study use the Bayesian one-stage time-to-eâ€¦\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nCutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome\n[{â€œnameâ€: â€œCaroline RAM WOLFF, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+33142499961â€, â€œphoneExtâ€: â€œ+33â€, â€œâ€¦\n\n\nCutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lymphomas characterized by a primary â€¦\n\n\n\n\nSINGLE_GROUP\nSingle arm, open-label, multicenter prospective phase 1 dose-escalation study\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nEARLY_PHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nCITY\nA Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Doâ€¦\nNCT07213882\n\nA Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Doâ€¦\nAPHP240605\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\n\nUNDECIDED\n\n\n[{â€œmeasureâ€: â€œPercentage of of positive cells within the infiltrate by immunohistochemistryâ€, â€œdescrâ€¦\n[{â€œmeasureâ€: â€œDose limiting toxicity (DLT) defined by any treatment-emergent adverse event (TEAE) noâ€¦\n[{â€œmeasureâ€: â€œIncidence of Adverse eventsâ€, â€œdescriptionâ€: â€œAdverse Events (AEs), Serious Adverse Evâ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œDomain Therapeutics SAâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\nSPONSOR\n2028-08-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-09\nACTUAL\n2025-10-02\nNOT_YET_RECRUITING\n2028-08-01\nESTIMATED\n\n\n\n\n2026-01-01\nESTIMATED\n2025-10\n2025-10-09\nACTUAL\n2025-10-02\n2025-10-02\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Adult Patients (â‰¥18 years) with no upper age limit\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Confirmed diagnosis ofâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDomvanalimab Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œVarying Doses of domvâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œDomvanalimabis a fully human immunoglobuliâ€¦\nSolid Tumor, Unspecified, Adult\n\n\n[{â€œfacilityâ€: â€œThe Angeles Clinic and Research Instituteâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCalifornâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerabiliâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nDose Escalation Design\nNONE\n\n\n\nTREATMENT\n\n75\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies\nNCT03628677\n\nA Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapyâ€¦\nAB154CSP0001\nINDUSTRY\nArcus Biosciences, Inc.\n\n\nArcus will provide access to individual de-identified participant data and related study documents ...\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n[{â€œmeasureâ€: â€œDomvanalimab Receptor Occupancyâ€, â€œdescriptionâ€: â€œReceptor Occupancy May be Summarizedâ€¦\n[{â€œmeasureâ€: â€œNumber of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by Câ€¦\n[{â€œmeasureâ€: â€œAB154 Peak Plasma Concentration (Cmax)â€, â€œdescriptionâ€: â€œPeak Plasma Concentration (Cmâ€¦\nFalse\nTrue\n\nFalse\n\n[{â€œlabelâ€: â€œAB154CSP0001 - Public Websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=AB154CSP00â€¦\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2025-01-23\nACTUAL\n\n\n\n\nFalse\n\n2025-02-04\nACTUAL\n2025-02-03\nCOMPLETED\n2025-01-23\nACTUAL\n\n\n\n\n2018-09-12\nACTUAL\n2024-05\n2018-08-14\nACTUAL\n2018-07-26\n2018-08-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Capable of giving signed informed consent\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female participants â‰¥ 18 â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005831â€, â€œtermâ€: â€œGenital Diseases, Femaleâ€}, {â€œidâ€: â€œD052776â€, â€œtermâ€: â€œFemale Urogenitalâ€¦\n[{â€œidâ€: â€œD004715â€, â€œtermâ€: â€œEndometriosisâ€}, {â€œidâ€: â€œD003884â€, â€œtermâ€: â€œDermoid Cystâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œstudy groupâ€, â€œdescriptionâ€: â€œpre-menopausal adult women with clinically and/or ultrasouâ€¦\n\nEndometriosis\nendometriosis, dermoid cyst, immune system\n[{â€œnameâ€: â€œMarek Gogacz, professorâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œmarekgogacz@umlub.plâ€, â€œemailâ€: â€œmâ€¦\n\n[{â€œnameâ€: â€œJarogniew Åuszczki, professorâ€, â€œaffiliationâ€: â€œUNIWERSYTET MEDYCZNY W LUBLINIEâ€, â€œroleâ€:â€¦\nThe EUmetriosis project aims to address the most important unmet needs of endometriosis sufferers toâ€¦\nEUmetriosis will generate new knowledge in the field of endometriosis, its drivers and consequences,â€¦\nperipheral blood, menstrual effluent/blood\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCASE_CONTROL\n\nOTHER\n60\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nTrue\n40 Years\n18 Years\nNON_PROBABILITY_SAMPLE\nFEMALE\nADULT\nThe University Clinical Hospital No.4 and No.1, 1 Military Clinical Hospital in Lublin SPZOZ\nEUmetriosis\nCharacterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients\nNCT06897436\n\nâ€œEUmetriosis: Transforming Endometriosis Care in Europe: an Integrated Approach to Enhance Understanâ€¦\n101157146\nOTHER\nMedical University of Lublin\n[{â€œidâ€: â€œProject 101157146-EUmetriosisâ€, â€œtypeâ€: â€œOTHER_GRANTâ€, â€œdomainâ€: â€œEuropean Unionâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œAlterations in immune system cell phenotype and activity associated with endometriosisâ€¦\n\nFalse\nFalse\nFalse\nFalse\n\n[{â€œlabelâ€: â€œCORDIS belongs to the Research and Innovation community platform of the European Commissâ€¦\n[{â€œnameâ€: â€œEuropean Commissionâ€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nMedical University of Lublin\nMedical University of Lublin\nIwona Wertel\nprofessor\nPRINCIPAL_INVESTIGATOR\n2029-12-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-27\nACTUAL\n2025-03-24\nNOT_YET_RECRUITING\n2029-12-31\nESTIMATED\n\n\n\n\n2025-05-01\nESTIMATED\n2025-01\n2025-03-27\nACTUAL\n2025-03-14\n2025-03-24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Women with a clinical and/or ultrasound diagnosis of endometriosis who are caâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000086982â€, â€œtermâ€: â€œBlood-Borne Infectionsâ€}, {â€œidâ€: â€œD003141â€, â€œtermâ€: â€œCommunicable Disâ€¦\n[{â€œidâ€: â€œD015658â€, â€œtermâ€: â€œHIV Infectionsâ€}]\n[{â€œidâ€: â€œD014765â€, â€œtermâ€: â€œViral Vaccinesâ€}, {â€œidâ€: â€œD014612â€, â€œtermâ€: â€œVaccinesâ€}, {â€œidâ€: â€œD001688â€¦\n[{â€œidâ€: â€œD000086663â€, â€œtermâ€: â€œCOVID-19 Vaccinesâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œNon-immunological responderâ€, â€œdescriptionâ€: â€œPatients who start ART with \\&lt;350 CD4+ T â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œSARS-CoV-2 Vaccineâ€, â€œdescriptionâ€: â€œAnalyse humoral and cellular râ€¦\nSARS-CoV-2 RNA Vaccines, HIV Infection\n\n\n[{â€œfacilityâ€: â€œVirgen del Rocio University Hospitalâ€, â€œcityâ€: â€œSevilleâ€, â€œzipâ€: â€œ41013â€, â€œcountryâ€: â€¦\n\nProspective, non-equality, cohort study, where investigators propose to analyze humoral and cellularâ€¦\n\n\n\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n48\nACTUAL\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nPROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nThe study was designed as a cohort study comparing the immune response after vaccination of HIV-infeâ€¦\n\nHumoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed\nNCT05633927\n\nProspective Study to Evaluate the Persistence and Characteristics of Humoral and Cellular Immunity Aâ€¦\nCoVa-VIH-2021\nOTHER\nHospitales Universitarios Virgen del RocÃ­o\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œAntibodiesâ€, â€œdescriptionâ€: â€œAnalyse the percentage of subjects with SARS-CoV-2-specifâ€¦\n\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ37006309â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œLopez-Cortes LF, Saborido-Alconchel A, Trujilloâ€¦\n[{â€œlabelâ€: â€œRelated Infoâ€, â€œurlâ€: â€œhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1129753/fâ€¦\n\nOTHER\nHospitales Universitarios Virgen del RocÃ­o\nHospitales Universitarios Virgen del RocÃ­o\nLuis F. Lopez-Cortes\nPrincipal Investigator\nPRINCIPAL_INVESTIGATOR\n2022-12-01\nACTUAL\n\n\n\n\nFalse\n\n2024-10-15\nACTUAL\n2024-10-09\nCOMPLETED\n2022-03-31\nACTUAL\n\n\n\n\n2021-04-01\nACTUAL\n2024-10\n2022-12-01\nACTUAL\n2022-11-21\n2022-11-21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. HIV-infected subjects over 18 years old and â‰¤200 CD4/Î¼l who have completed vâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD016393â€, â€œtermâ€: â€œLymphoma, B-Cellâ€}, {â€œidâ€: â€œD008228â€, â€œtermâ€: â€œLymphoma, Non-Hodgkinâ€}, â€¦\n[{â€œidâ€: â€œD016403â€, â€œtermâ€: â€œLymphoma, Large B-Cell, Diffuseâ€}]\n[{â€œidâ€: â€œD010752â€, â€œtermâ€: â€œPhosphoramide Mustardsâ€}, {â€œidâ€: â€œD009588â€, â€œtermâ€: â€œNitrogen Mustard Coâ€¦\n[{â€œidâ€: â€œC024352â€, â€œtermâ€: â€œfludarabineâ€}, {â€œidâ€: â€œD003520â€, â€œtermâ€: â€œCyclophosphamideâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCRC01â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œA conditioning chemotherapy regimen of fâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œCRC01â€, â€œdescriptionâ€: â€œA single infusion of chimeric antigen recepâ€¦\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBâ€¦\nCRC01, anti-CD19 CAR-T, CAR-T, CAR T cells, Chimeric antigen receptor, PD-1 knock down, TIGIT knock â€¦\n[{â€œnameâ€: â€œBom-I Kwon, BScâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+82428633698â€, â€œemailâ€: â€œbikwon@curocellbtâ€¦\n[{â€œfacilityâ€: â€œSamsung Medical Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œSeoulâ€, â€œzipâ€: â€œ06351â€, â€œcoâ€¦\n\nThis is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patiâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n91\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n19 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients\nNCT04836507\n\nAn Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy â€¦\nCRC01-01\nINDUSTRY\nCurocell Inc.\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œPhase 1 Study: Maximum Tolerated Dose (MTD) which will be the Recommended Phase 2 Doseâ€¦\n[{â€œmeasureâ€: â€œTime to response (TTR)â€, â€œtimeFrameâ€: â€œ5 yearsâ€}, {â€œmeasureâ€: â€œDuration of overall resâ€¦\nFalse\nFalse\n\nTrue\n[{â€œpmidâ€: â€œ34628052â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œLee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Huppereâ€¦\n\n\nINDUSTRY\nCurocell Inc.\n\n\n\nSPONSOR\n2028-02\nESTIMATED\n\n\n\n\nFalse\n\n2021-05-03\nACTUAL\n2021-04-29\nRECRUITING\n2023-05\nESTIMATED\n\n\n\n\n2021-03-02\nACTUAL\n2021-04\n2021-04-08\nACTUAL\n2021-04-05\n2021-04-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. â‰¥ 19 years of age and provided written informed consent\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Histologically coâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}, {â€œidâ€: â€œD001661â€, â€œtermâ€: â€œBiliary Tract Neâ€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000068258â€, â€œtermâ€: â€œBevacizumabâ€}, {â€œidâ€: â€œC531958â€, â€œtermâ€: â€œlenvatinibâ€}, {â€œidâ€: â€œD0000â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCohort 1Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œVolrustomig monotherapyâ€, â€œinterventâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œVolrustomigâ€, â€œdescriptionâ€: â€œCTLA-4/Anti-PD-1 Bispecific Antibodyâ€, â€œarmâ€¦\nHepatocellular Carcinoma, Biliary Tract Cancer\nHepatobiliary cancer, Hepatocellular carcinoma, Biliary tract cancer, GEMINI-Hepatobiliary, MEDI5752â€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabamaâ€, â€œziâ€¦\n\nGEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulatoâ€¦\nThis Phase II, open-label, uncontrolled, multicentre study evaluating the preliminary efficacy and sâ€¦\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n294\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participâ€¦\nNCT05775159\n\nA Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safetâ€¦\nD7987C00001\nINDUSTRY\nAstraZeneca\n\nWhen a request has been approved AstraZeneca will provide access to the de-identified individual patâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagroup-dt.pharmacm.com/DT/Home\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œORR is defined as the proportion of paâ€¦\n[{â€œmeasureâ€: â€œDuration Of Response (DOR)â€, â€œdescriptionâ€: â€œDoR is defined as the time from the date â€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2027-10-28\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-13\nACTUAL\n2025-11-12\nRECRUITING\n2026-10-27\nESTIMATED\n\n\n\n\n2023-04-24\nACTUAL\n2025-11\n2023-03-20\nACTUAL\n2023-03-02\n2023-03-17\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age â‰¥18 years at the time of signing the ICF.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Provision of a signed and datâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002294â€, â€œtermâ€: â€œCarcinoma, Squamous Cellâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD000077195â€, â€œtermâ€: â€œSquamous Cell Carcinoma of Head and Neckâ€}]\n[{â€œidâ€: â€œD019411â€, â€œtermâ€: â€œClinical Laboratory Techniquesâ€}, {â€œidâ€: â€œD019937â€, â€œtermâ€: â€œDiagnostic â€¦\n[{â€œidâ€: â€œD013048â€, â€œtermâ€: â€œSpecimen Handlingâ€}, {â€œidâ€: â€œD009682â€, â€œtermâ€: â€œMagnetic Resonance Spectâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment (FID-007)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients receive FID-007 Iâ€¦\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œBiospecimen Collectionâ€, â€œdescriptionâ€: â€œUndergo blood sample collecâ€¦\nHead and Neck Squamous Cell Carcinoma\n\n\n[{â€œfacilityâ€: â€œLos Angeles General Medical Centerâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzâ€¦\n[{â€œnameâ€: â€œJacob Thomas, MDâ€, â€œaffiliationâ€: â€œUniversity of Southern Californiaâ€, â€œroleâ€: â€œPRINCIPALâ€¦\nThis phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) aâ€¦\nPRIMARY OBJECTIVE:\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n1\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nFID-007 Followed by Standard of Care Surgery in Head and Neck Cancer\nNCT06338657\n\nA Window of Opportunity Study of Taxanes in Head and Neck Cancer\n7H-23-5\nOTHER\nUniversity of Southern California\n[{â€œidâ€: â€œNCI-2024-01367â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTRP (Clinical Trial Reporting Program)â€}, â€¦\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œEvaluate the phenotypical and functional changes of different T cell subsets within thâ€¦\n[{â€œmeasureâ€: â€œIncidence of adverse events (AEs)â€, â€œdescriptionâ€: â€œA summary table at subject level fâ€¦\nFalse\nTrue\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œNational Cancer Institute (NCI)â€, â€œclassâ€: â€œNIHâ€}]\nOTHER\nUniversity of Southern California\n\n\n\nSPONSOR\n2025-09-09\nACTUAL\n\n\n\n\n\n\n2025-09-16\nACTUAL\n2025-09-09\nTERMINATED\n2025-09-03\nACTUAL\n\n\n\n\n2024-04-01\nACTUAL\n2025-09\n2024-03-29\nACTUAL\n2024-03-14\n2024-03-22\nSlow accrual\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nI. To describe the phenotypical and functional changes of different T cell subseâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients must have histopathologically / cytologically confirmed diagnosis ofâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siteâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œD00â€¦\n[{â€œidâ€: â€œD001943â€, â€œtermâ€: â€œBreast Neoplasmsâ€}]\n[{â€œidâ€: â€œD003581â€, â€œtermâ€: â€œCytodiagnosisâ€}, {â€œidâ€: â€œD003584â€, â€œtermâ€: â€œCytological Techniquesâ€}, {â€œâ€¦\n[{â€œidâ€: â€œD001706â€, â€œtermâ€: â€œBiopsyâ€}, {â€œidâ€: â€œD013048â€, â€œtermâ€: â€œSpecimen Handlingâ€}, {â€œidâ€: â€œC00062â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment (cemiplimab, Y90 SIR-Spheres, TARE)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œâ€¦\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œBiopsyâ€, â€œdescriptionâ€: â€œUndergo tumor biopsyâ€, â€œarmGroupLabelsâ€: [â€œâ€¦\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liâ€¦\n\n\n[{â€œfacilityâ€: â€œCity of Hope Medical Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œDuarteâ€, â€œstateâ€: â€œCalâ€¦\n[{â€œnameâ€: â€œJonathan Kesslerâ€, â€œaffiliationâ€: â€œCity of Hope Medical Centerâ€, â€œroleâ€: â€œPRINCIPAL_INVESâ€¦\nThis phase II trial tests how well cemiplimab and transarterial radioembolization (TARE) with yttriuâ€¦\nPRIMARY OBJECTIVE:\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n11\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Diâ€¦\nNCT06860815\n\nPilot Study of Cemiplimab and Hepatic Radioembolization in Patients With Liver Dominant Metastatic Bâ€¦\n23768\nOTHER\nCity of Hope Medical Center\n[{â€œidâ€: â€œNCI-2025-00340â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTRP (Clinical Trial Reporting Program)â€}, â€¦\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œCD8+ T cell infiltration in tumor microenvironment (TME): baselineâ€, â€œdescriptionâ€: â€œWâ€¦\n[{â€œmeasureâ€: â€œIncidence of adverse eventsâ€, â€œdescriptionâ€: â€œWill be assessed and graded using Nationâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œNational Cancer Institute (NCI)â€, â€œclassâ€: â€œNIHâ€}]\nOTHER\nCity of Hope Medical Center\n\n\n\nSPONSOR\n2027-01-30\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-28\nACTUAL\n2026-01-27\nRECRUITING\n2027-01-30\nESTIMATED\n\n\n\n\n2026-04-01\nESTIMATED\n2026-01\n2025-03-06\nACTUAL\n2025-02-04\n2025-02-28\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nI. To describe the effect of cemiplimab and yttrium Y90 resin microspheres (90Y â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Documented informed consent of the participant and/or legally authorized reprâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, {â€œidâ€: â€œD006727â€, â€œtermâ€: â€œHormone Antagonistsâ€}, {â€œidâ€:â€¦\n[{â€œidâ€: â€œD011878â€, â€œtermâ€: â€œRadiotherapyâ€}, {â€œidâ€: â€œD000726â€, â€œtermâ€: â€œAndrogen Antagonistsâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œStereotactic body radiation treatment (SBRT)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œRâ€¦\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œRadiotherapyâ€, â€œdescriptionâ€: â€œRT treatment Schedule as for clinicalâ€¦\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\n\n\n[{â€œfacilityâ€: â€œHumanitas Research Hospitalâ€, â€œcityâ€: â€œRozzanoâ€, â€œstateâ€: â€œMilanoâ€, â€œzipâ€: â€œ20089â€, â€œâ€¦\n\nAt the moment there is a lack of data in the setting of oligometastatic PC in particular regarding tâ€¦\nProstate cancer (PC) represents the second most common cancer in men worldwide, managed with surgeryâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nOTHER\n\n40\nESTIMATED\n\n\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nMALE\nADULT, OLDER_ADULT\n\nIOSCAR\nImmune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated Wâ€¦\nNCT04624828\n\nPilot Study of Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patâ€¦\n2683\nOTHER\nIstituto Clinico Humanitas\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œimmune evaluationâ€, â€œdescriptionâ€: â€œAnalysis of the immunitary background performed beâ€¦\n[{â€œmeasureâ€: â€œProgression free survivalâ€, â€œdescriptionâ€: â€œEvaluation of Progression free survival (Pâ€¦\nFalse\nFalse\nFalse\nFalse\n\n\n[{â€œnameâ€: â€œIpsenâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nIstituto Clinico Humanitas\n\n\n\nSPONSOR\n2026-07\nESTIMATED\n\n\n\n\nFalse\n\n2025-04-24\nACTUAL\n2025-04-22\nACTIVE_NOT_RECRUITING\n2026-07\nESTIMATED\n\n\n\n\n2020-10-19\nACTUAL\n2025-04\n2020-11-12\nACTUAL\n2020-11-02\n2020-11-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age â‰¥ 18years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Written informed consent according to ICH/GCP regulations befâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD003920â€, â€œtermâ€: â€œDiabetes Mellitusâ€}, {â€œidâ€: â€œD044882â€, â€œtermâ€: â€œGlucose Metabolism Disorâ€¦\n[{â€œidâ€: â€œD003922â€, â€œtermâ€: â€œDiabetes Mellitus, Type 1â€}]\n\n[{â€œidâ€: â€œC544394â€, â€œtermâ€: â€œsiplizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAdults with T1D 0.08 mg/kg SQ doseâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œCohort 1 Grâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œSiplizumabâ€, â€œdescriptionâ€: â€œWeekly siplizumab doses for a total of 12 weâ€¦\nType 1 Diabetes Mellitus\ndiabetic, Type 1 diabetes, T1DM, siplizumab\n\n[{â€œfacilityâ€: â€œUniversity of Colorado School of Medicine: Barbara Davis Center for Diabetesâ€, â€œcityâ€â€¦\n[{â€œnameâ€: â€œStephen Gitelman, M.D.â€, â€œaffiliationâ€: â€œUniversity of California San Francisco, School oâ€¦\nThis is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n8\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n45 Years\n8 Years\n\nALL\nCHILD, ADULT\n\nDESIGNATE\nSiplizumab in T1DM\nNCT05574335\n\nA T Cell Phenotype Signature Driven Dose Finding Study With Siplizumab in Type 1 Diabetes Mellitus (â€¦\nDAIT ITN095AI\nNIH\nNational Institute of Allergy and Infectious Diseases (NIAID)\n\nOpen access.\nImmunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic dâ€¦\n\nYES\nOn average, within 24 months after database lock for the trial.\nhttps://www.immport.org/home\n\n[{â€œmeasureâ€: â€œNumber of Participants with a T cell phenotype signature responseâ€, â€œdescriptionâ€: â€œEvâ€¦\n[{â€œmeasureâ€: â€œFrequency of Adverse Events (AEs) in all siplizumab dosing armsâ€, â€œdescriptionâ€: â€œAE wâ€¦\nFalse\nTrue\n\nTrue\n\n[{â€œlabelâ€: â€œImmune Tolerance Network (ITN)â€, â€œurlâ€: â€œhttps://www.immunetolerance.org/â€}, {â€œlabelâ€: â€œâ€¦\n\nNIH\nNational Institute of Allergy and Infectious Diseases (NIAID)\n\n\n\nSPONSOR\n2025-10-20\nACTUAL\n\n\n\n\nFalse\n\n2026-01-06\nACTUAL\n2026-01-05\nTERMINATED\n2025-05-14\nACTUAL\n\n\n\n\n2023-04-26\nACTUAL\n2026-01\n2022-10-10\nACTUAL\n2022-09-19\n2022-10-06\nPrior to termination the DESIGNATE study was an on enrollment hold due to greater than anticipated lâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Ability to provide informed consent (parental permission and informed assentâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œLung re-transplant cohortâ€, â€œdescriptionâ€: â€œThis cohort includes consecutive participantâ€¦\n[{â€œtypeâ€: â€œDIAGNOSTIC_TESTâ€, â€œnameâ€: â€œImmune checkpoints analysisâ€, â€œdescriptionâ€: â€œThe researcher wâ€¦\nLung Transplant Rejection\nLung transplantation, Immune checkpoint, Acute rejection, Chronic rejection, Chronic lung allograft â€¦\n[{â€œnameâ€: â€œMario Nosotti, Medicineâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ3393924679â€, â€œemailâ€: â€œmario.nosotâ€¦\n[{â€œfacilityâ€: â€œFondazione IRCCS CÃ  Granda, Ospedale Maggiore Policlinicoâ€, â€œcityâ€: â€œMilanâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œMario Nosotti, Medicineâ€, â€œaffiliationâ€: â€œUniversity of Milan, Italyâ€, â€œroleâ€: â€œPRINCIPALâ€¦\nThe goal of this observational study is to learn about rejection in lung transplantation.\nLung transplantation is the less common solid organ transplant performed; it is the treatment of choâ€¦\nLung tissue, bronchoalveolar lavage\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCOHORT\n\nOTHER\n280\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n70 Years\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nCohort 1: Participants who received lung re-transplantation for chronic lung allograft dysfunction.\nILTRA\nThe Role of Immune Checkpoints in Lung Transplant (ILTRA)\nNCT06302556\n\nThe Role of Immune Checkpoints in Lung Transplant: the Pathways of Rejection and the Immunomodulatorâ€¦\n2022XJ9W4F\nOTHER\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\n[{â€œidâ€: â€œG53D2300526 0006â€, â€œtypeâ€: â€œOTHER_GRANTâ€, â€œdomainâ€: â€œMinistry of University and Research. Nâ€¦\nAccess to IPD can be requested by qualified researchers engaging in independent scientific research,â€¦\nThe anonymized data collected will be recorded on a database available online by other researchers uâ€¦\nSTUDY_PROTOCOL\nYES\nData requests can be submitted starting 9 months after closing of recruitment and the data will be mâ€¦\n\n\n[{â€œmeasureâ€: â€œLung-tissue immune-checkpoint profile and bronchoalveolar immune-cells mRNA signature â€¦\n\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ36703976â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œRighi I, Vaira V, Morlacchi LC, Croci GA, Râ€¦\n\n[{â€œnameâ€: â€œUniversity of Milanâ€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œUniversity of Padovaâ€, â€œclassâ€: â€œOTHERâ€¦\nOTHER\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\n\n\n\nSPONSOR\n2026-02\nESTIMATED\n\n\n\n\nFalse\n\n2024-03-08\nACTUAL\n2024-03-06\nNOT_YET_RECRUITING\n2026-01\nESTIMATED\n\n\n\n\n2024-04\nESTIMATED\n2024-02\n2024-03-08\nACTUAL\n2024-02-28\n2024-03-06\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe main â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Lung transplant patients\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nExclusion Criteria:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Hyperimmunized patients\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Hiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009385â€, â€œtermâ€: â€œNeoplastic Processesâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œâ€¦\n[{â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Metastasisâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n2025-02-24\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œCohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naiveâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œEtigilimabâ€, â€œdescriptionâ€: â€œIV infusion of IV etigilimab every 2 weeksâ€,â€¦\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\netigilimab, nivolumab, anti-TIGIT antibody, MPH313, Opdivo, ACTIVATE\n\n[{â€œfacilityâ€: â€œMereo Investigator Siteâ€, â€œcityâ€: â€œPhoenixâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85054â€, â€œcouâ€¦\n\nThis is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, toleâ€¦\nThis is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, toleâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\nBasket study\nNONE\n\n\n\nBASIC_SCIENCE\n\n76\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors\nNCT04761198\n\nA Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combâ€¦\nMPH313-1-02\nINDUSTRY\nMereo BioPharma\n[{â€œidâ€: â€œ2020-004222-37â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) as Assessed Based on Response Evaluation Criteria in Solâ€¦\n[{â€œmeasureâ€: â€œNumber of Participants WithTreatment-emergent Adverse Events (TEAEs), Any Adverse Evenâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œICON Clinical Researchâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nMereo BioPharma\n\n\n\nSPONSOR\n2023-10-30\nACTUAL\n2025-03-17\nACTUAL\n2024-10-28\n\nFalse\n\n2025-03-17\nACTUAL\n2025-03-07\nCOMPLETED\n2023-10-30\nACTUAL\n2025-03-17\nACTUAL\n2025-01-31\n2025-03-07\n2021-03-23\nACTUAL\n2025-03\n2021-02-18\nACTUAL\n2021-02-12\n2021-02-17\n\nSafety Analysis Set included all participants who received any amount of study drug.\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œCohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naiveâ€, â€œdescriptionâ€: â€œParâ€¦\n5.0\n[{â€œtermâ€: â€œNauseaâ€, â€œorganSystemâ€: â€œGastrointestinal disordersâ€, â€œsourceVocabularyâ€: â€œMedDRA 26.0â€, â€¦\n[{â€œtermâ€: â€œPneumoniaâ€, â€œorganSystemâ€: â€œInfections and infestationsâ€, â€œsourceVocabularyâ€: â€œMedDRA 26â€¦.\nFrom first dose of study drug until 100 days after the last dose of study drug or the initiation of â€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ11â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œCohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naiveâ€, â€œdescriptionâ€: â€œParâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nSafety Analysis Set included all participants who received any amount of study drug.\nAll PIs must seek written permission from the sponsor before publication of any trial results.\nFalse\nOTHER\nTrue\n\nenquiries@mereobiopharma.com\nMereo BioPharma\nPlease Email\n\nMereo BioPharma\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œObjective Response Rate (ORR) as Assessed Based on Response Evaluatioâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œCohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naiveâ€, â€œdescriptionâ€: â€œParâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nCohort D (Recurrent advanced and/or metastatic gastric or gastroesophageal junction adenocarcinoma) â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histological or cytological diagnosis of a relevant tumor type as per the stuâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014594â€, â€œtermâ€: â€œUterine Neoplasmsâ€}, {â€œidâ€: â€œD005833â€, â€œtermâ€: â€œGenital Neoplasms, Femalâ€¦\n[{â€œidâ€: â€œD002583â€, â€œtermâ€: â€œUterine Cervical Neoplasmsâ€}]\n\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}]\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œCohort 1: Ociperlimab + Tislelizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTislelizuâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œTislelizumabâ€, â€œdescriptionâ€: â€œ200 mg administered intravenously onâ€¦\nCervical Cancer\n\n\n[{â€œfacilityâ€: â€œ\"Mhat uni hospital\" oodâ€, â€œcityâ€: â€œPanagyurishteâ€, â€œzipâ€: â€œ4500â€, â€œcountryâ€: â€œBulgaâ€¦\n[{â€œnameâ€: â€œStudy Directorâ€, â€œaffiliationâ€: â€œBeiGeneâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study tested how well and how safely the drug tislelizumab, given either alone or with another â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n178\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\nTrue\n\nFalse\n\n18 Years\n\nFEMALE\nADULT, OLDER_ADULT\n\n\nAdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIâ€¦\nNCT04693234\n\nPhase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-Aâ€¦\nBGB-A317-A1217-202\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œ2020-004657-77â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œAdvanTIG-202â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œCohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (Iâ€¦\n[{â€œmeasureâ€: â€œCohort 2: Objective Response Rate (ORR) Assessed by an Independent Review Committee inâ€¦\nFalse\nFalse\nFalse\nFalse\n[{â€œpmidâ€: â€œ40411966â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œLee JY, Boonyapipat S, Yuan G, Kim HS, Lee â€¦\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2023-08-31\nACTUAL\n\n\n\n\nFalse\n\n2025-04-27\nACTUAL\n2025-04-09\nCOMPLETED\n2022-06-16\nACTUAL\n2025-04-27\nACTUAL\n2024-08-22\n2025-04-09\n2021-02-15\nACTUAL\n2025-04\n2021-01-05\nACTUAL\n2020-12-22\n2020-12-30\n\n\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œCohort 1: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nAll-cause mortality: From randomization through the end of study; up to 24.5 months. Adverse events:â€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ138â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œCohort 1: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Safety Analysis Set is defined as all participants who received &gt;= 1 dose of any study drug forâ€¦\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene\n+1-877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œCohort 1: Objective Response Rate (ORR) Assessed by an Independent Reâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œCohort 1: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nThe study was composed of an initial screening phase (up to 28 days), a treatment phase, an end of tâ€¦\nParticipants were enrolled in multiple study centers in China, South Korea, and Europe.The first parâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically or cytologically confirmed squamous cell carcinoma, adenosquaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\nBrazil, Poland, Romania\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProt_SAPâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: true, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Prâ€¦\nTrue\n[{â€œlabelâ€: â€œPlacebo + Atezolizumabâ€, â€œtypeâ€: â€œPLACEBO_COMPARATORâ€, â€œdescriptionâ€: â€œParticipants willâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œAtezolizumab at a fixed dose of 1200 mg wiâ€¦\nNon-small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œArizona Oncology Associates, PC - HALâ€, â€œcityâ€: â€œTempeâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nTREATMENT\n\n135\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-NaÃ¯ve Patients With Locally â€¦\nNCT03563716\n\nA Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, Inâ€¦\nGO40290\nINDUSTRY\nGenentech, Inc.\n[{â€œidâ€: â€œ2018-000280-81â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œ2023-508083-30-00â€, â€œtypeâ€: â€œCTISâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œORR, defined as a complete response (Câ€¦\n[{â€œmeasureâ€: â€œDuration of Objective Response (DOR)â€, â€œdescriptionâ€: â€œDOR, defined as the time from tâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ38418879â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œGuan X, Hu R, Choi Y, Srivats S, Nabet BY, Silâ€¦\n\n\nINDUSTRY\nGenentech, Inc.\n\n\n\nSPONSOR\n2025-11-24\nACTUAL\n\n\n\n\nFalse\n\n2026-01-20\nACTUAL\n2025-12-30\nCOMPLETED\n2019-06-30\nACTUAL\n2020-07-09\nACTUAL\n2020-06-19\n2020-06-19\n2018-08-10\nACTUAL\n2025-12\n2018-06-20\nACTUAL\n2018-04-17\n2018-06-19\n\nThe safety population included all participants who received at least one dose of study medication.\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œParticipants received atezolizumâ€¦\n5.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAtrial fibrillationâ€, â€œorganSystemâ€: â€œCardiac disordersâ€, â€œsourceVocabularyâ€: â€œMedDRA 22â€¦.\nUp to primary completion date (approximately 11 months)\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ68â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œParticipants received atezolizumâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\n\nThe Study being conducted under this Agreement is part of the Overall Study. Investigator is free toâ€¦\nFalse\nOTHER\nTrue\n\ngenentech@druginfo.com\nHoffmann-La Roche\n800 821-8590\n\nMedical Communications\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œORR, defined as a comâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œParticipants received atezolizumâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nEligible patients with previously untreated, locally advanced unresectable or metastatic PD-L1-selecâ€¦\nParticipants were recruited at study sites in 6 countries.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* ECOG Performance Status of 0 or 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documenteâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œKINE-101â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: KINE-101â€]}, {â€œlabelâ€: â€œâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œKINE-101â€, â€œdescriptionâ€: â€œKINE-101 injection, 12.5 mg/mL, intravenous inâ€¦\nHealthy Volunteers\n\n\n[{â€œfacilityâ€: â€œChungbuk National University Hospitalâ€, â€œcityâ€: â€œCheongju-siâ€, â€œstateâ€: â€œNorth Chungcâ€¦\n[{â€œnameâ€: â€œHanna Parkâ€, â€œaffiliationâ€: â€œKine Sciences Co., Ltd.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a randomized, single-center, single-blind, placebo-controlled, dose-escalation Phase 1 cliniâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nSINGLE\n\nPARTICIPANT\n\nTREATMENT\n\n24\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nTrue\n55 Years\n19 Years\n\nALL\nADULT\n\n\nA Phase 1 MAD Study of KINE-101 in Healthy Volunteers\nNCT07324642\n\nA Randomized, Single-center, Single-blind, Placebo-controlled, Dose Escalation Phase 1 Clinical Triaâ€¦\nCIDP101-CR1-002P\nINDUSTRY\nKine Sciences Co., Ltd.\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œChange from baseline in serum biomarkers following KINE-101 administrationâ€, â€œdescriptâ€¦\n[{â€œmeasureâ€: â€œIncidence of Treatment-Emergent Adverse Eventsâ€, â€œdescriptionâ€: â€œNumber and percentageâ€¦\n[{â€œmeasureâ€: â€œMaximum plasma concentration (Cmax)â€, â€œdescriptionâ€: â€œMaximum plasma concentration (Cmâ€¦\nFalse\nFalse\n\nFalse\n\n\n[{â€œnameâ€: â€œChungbuk National University Hospitalâ€, â€œclassâ€: â€œOTHERâ€}]\nINDUSTRY\nKine Sciences Co., Ltd.\n\n\n\nSPONSOR\n2025-08-25\nACTUAL\n\n\n\n\nFalse\n\n2026-01-07\nACTUAL\n2025-12-24\nCOMPLETED\n2025-08-25\nACTUAL\n\n\n\n\n2025-05-26\nACTUAL\n2025-12\n2026-01-07\nACTUAL\n2025-12-09\n2025-12-24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Healthy male or female adults aged 19 to 55 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Body weight â‰¥ 50.0 kg andâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD001943â€, â€œtermâ€: â€œBreast Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siteâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD064726â€, â€œtermâ€: â€œTriple Negative Breast Neoplasmsâ€}]\n[{â€œidâ€: â€œD043823â€, â€œtermâ€: â€œTaxoidsâ€}, {â€œidâ€: â€œD043822â€, â€œtermâ€: â€œCyclodecanesâ€}, {â€œidâ€: â€œD003516â€, â€¦\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œD017239â€, â€œtermâ€: â€œPaclitaxelâ€}, {â€œidâ€: â€œC520â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A: ociperlimab+tislelizumab+chemotherapy (PD-L1 CPS â‰¥ 10)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOciperlimabâ€, â€œdescriptionâ€: â€œ900 mg intravenously (IV) every 3 weeks (Q3â€¦\nTriple Negative Breast Cancer\nTNBC, Triple Negative Breast Cancer, PD-L1, Ociperlimab, Tislelizumab, WCD118 (BGB-A1217), VDT482 (Bâ€¦\n\n\n[{â€œnameâ€: â€œNovartis Pharmaceuticalsâ€, â€œaffiliationâ€: â€œNovartis Pharmaceuticalsâ€, â€œroleâ€: â€œSTUDY_DIREâ€¦\nThe primary scientific question of interest of this study is whether the combination of ociperlimab,â€¦\nThis is a randomized, double-blind, placebo-controlled, multicenter, Phase II study evaluating the eâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\nParticipants will be randomized to Arms A, B and C in a double-blind manner Participants will be enrâ€¦\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nAdvanTIG-211\nPhase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab anâ€¦\nNCT05809895\n\nAdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Evaluating the Efficacyâ€¦\nCWCD118B12201\nINDUSTRY\nNovartis\n[{â€œidâ€: â€œ2022-503099-99-00â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œEU CTIS numberâ€}]\n\nNovartis is committed to sharing with qualified external researchers, access to patient-level data aâ€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œProgression-free Survival (PFS) based on investigator assessment using RECIST 1.1 critâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS) based on investigator assessment using RECIST 1.1 criteria in Arâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nNovartis Pharmaceuticals\n\n\n\nSPONSOR\n2029-07-18\nESTIMATED\n\n\n\n\nFalse\n\n2023-07-24\nACTUAL\n2023-07-21\nWITHDRAWN\n2029-07-17\nESTIMATED\n\n\n\n\n2023-09-15\nESTIMATED\n2023-07\n2023-04-12\nACTUAL\n2023-03-30\n2023-03-30\nBusiness decision, not driven by safety concerns; no new safety signals have been observed in the ocâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participant has histologically confirmed diagnosis of advanced (loco-regiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002294â€, â€œtermâ€: â€œCarcinoma, Squamous Cellâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD000077277â€, â€œtermâ€: â€œEsophageal Squamous Cell Carcinomaâ€}]\n\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}]\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œArm A: Tislelizumab plus Ociperlimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipaâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œTislelizumabâ€, â€œdescriptionâ€: â€œTislelizumab is a monoclonal antibodâ€¦\nEsophageal Squamous Cell Carcinoma\n\n\n[{â€œfacilityâ€: â€œAnhui Provincial Cancer Hospitalâ€, â€œcityâ€: â€œHefeiâ€, â€œstateâ€: â€œAnhuiâ€, â€œzipâ€: â€œ230088â€â€¦\n[{â€œnameâ€: â€œStudy Directorâ€, â€œaffiliationâ€: â€œBeiGeneâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nA study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n125\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nAdvanTIG-203\nAnti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonalâ€¦\nNCT04732494\n\nA Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Moâ€¦\nBGB-A317-A1217-203\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œ2020-004658-32â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œCTR20213241/CTR20210243â€, â€œtypeâ€: â€œOTHEâ€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) Assessed by the Investigatorâ€, â€œdescriptionâ€: â€œObjectiveâ€¦\n[{â€œmeasureâ€: â€œOverall Survivalâ€, â€œdescriptionâ€: â€œOverall survival (OS) is defined as the time from tâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2023-12-26\nACTUAL\n\n\n\n\nFalse\n\n2025-01-31\nACTUAL\n2024-12-23\nCOMPLETED\n2023-02-01\nACTUAL\n2025-01-31\nACTUAL\n2024-12-23\n2024-12-23\n2021-03-31\nACTUAL\n2024-12\n2021-02-01\nACTUAL\n2021-01-25\n2021-01-28\n\n\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œArm A: Tislelizumab Plus Ociperlimabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\nAll-cause mortality is reported from randomization through the end of study; up to 30 months. AEs arâ€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ62â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œArm A: Tislelizumab Plus Ociperlimabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n[{â€œtitleâ€: â€œAge, Categoricalâ€, â€œparamTypeâ€: â€œCOUNT_OF_PARTICIPANTSâ€, â€œunitOfMeasureâ€: â€œParticipantsâ€â€¦\n\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene, Ltd.\n1 877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œObjective Response Rate (ORR) Assessed by the Investigatorâ€, â€œdescripâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œArm A: Tislelizumab Plus Ociperlimabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nParticipants were randomized equally to one of two treatment groups. Randomization was stratified byâ€¦\nThe study was conducted at 52 study centers in 7 countries/regions in Chinese mainland, Chinese Taiwâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically confirmed diagnosis of esophageal squamous cell carcinomaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm Aâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œParticipants will receive intravenoâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œParticipants will receive 1200 mg IV atezoâ€¦\nUrothelial Cancer\n\n\n[{â€œfacilityâ€: â€œCleveland Clinicâ€, â€œcityâ€: â€œClevelandâ€, â€œstateâ€: â€œOhioâ€, â€œzipâ€: â€œ44106â€, â€œcountryâ€: â€œâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-LaRocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the safety of tobemstomig alone or in combination with tiragolumab comparedâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n204\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-Lâ€¦\nNCT05645692\n\nA Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combinaâ€¦\nBO44157\nINDUSTRY\nHoffmann-La Roche\n\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œIncidence and Severity of Adverse Eventsâ€, â€œtimeFrameâ€: â€œUp to approximately 30 monthsâ€¦\n\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2026-12-31\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-30\nACTUAL\n2026-01-28\nACTIVE_NOT_RECRUITING\n2026-12-31\nESTIMATED\n\n\n\n\n2023-04-13\nACTUAL\n2026-01\n2022-12-09\nACTUAL\n2022-11-28\n2022-12-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of â‰¤ 2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histoloâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œtypeâ€: â€œRELEASEâ€, â€œdateâ€: â€œ2025-12-11â€}, {â€œtypeâ€: â€œRESETâ€, â€œdateâ€: â€œ2025-12-31â€}]\nEMD Serono Research & Development Institute, Inc.\n\n\n\n[{â€œidâ€: â€œC000723824â€, â€œtermâ€: â€œbintrafusp alfa protein, humanâ€}]\nGermany\n2025-12-11\n\n\n[{â€œreleaseDateâ€: â€œ2025-12-11â€, â€œresetDateâ€: â€œ2025-12-31â€}, {â€œreleaseDateâ€: â€œ2026-01-23â€}]\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPart 1A: M6223 Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: M6223â€â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œM6223â€, â€œdescriptionâ€: â€œParticipants will receive an intravenous (IV) infâ€¦\nMetastatic Solid Tumors\nM6223, Bintrafusp alfa, Metastatic Solid Tumors\n\n[{â€œfacilityâ€: â€œSarah Cannon Research Instituteâ€, â€œcityâ€: â€œNashvilleâ€, â€œstateâ€: â€œTennesseeâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œMedical Responsibleâ€, â€œaffiliationâ€: â€œMerck Healthcare KGaA, Darmstadt, Germany, an affilâ€¦\nThe main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), immuâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n58\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nFirst in Human Study of M6223\nNCT04457778\n\nPhase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Toleraâ€¦\nMS201430_0001\nINDUSTRY\nEMD Serono\n\n\nWe are committed to enhancing public health through responsible sharing of clinical trial data. Follâ€¦\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œPart 1A and 1B: Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observatiâ€¦\n[{â€œmeasureâ€: â€œPart 1A and Part 1B: Area Under the Serum Concentration-Time Curve From Time Zero to tâ€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ39929671â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œNaing A, McKean M, Tolcher A, Victor A, Hu P, â€¦\n[{â€œlabelâ€: â€œTrial Awareness and Transparency websiteâ€, â€œurlâ€: â€œhttps://clinicaltrials.emdgroup.com/eâ€¦\n[{â€œnameâ€: â€œMerck KGaA, Darmstadt, Germanyâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nEMD Serono Research & Development Institute, Inc.\n\n\n\nSPONSOR\n2023-06-23\nACTUAL\n\n\n\n\nFalse\n\n2023-12-08\nACTUAL\n2023-12-07\nCOMPLETED\n2023-06-23\nACTUAL\n\n\n\n\n2020-07-10\nACTUAL\n2023-11\n2020-07-07\nACTUAL\n2020-06-30\n2020-06-30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants have histologically or cytologically proven locally advanced or â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œStudy Interventionâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œFecal Microbial Transplantaâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œFecal Microbial Transplantationâ€, â€œdescriptionâ€: â€œAll patients in this trâ€¦\nMelanoma\n\n\n[{â€œfacilityâ€: â€œLondon Regional Cancer Programâ€, â€œcityâ€: â€œLondonâ€, â€œstateâ€: â€œOntarioâ€, â€œzipâ€: â€œN6A 5Wâ€¦\n[{â€œnameâ€: â€œJohn Lenehan, MDâ€, â€œaffiliationâ€: â€œLondon Regional Cancer Programâ€, â€œroleâ€: â€œPRINCIPAL_INâ€¦\nImmunotherapy has helped many cancer patients in the last 5 years by enhancing a patientâ€™s immune syâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n20\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n19 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nFecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)\nNCT03772899\n\nFecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)\nMIMic\nOTHER\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œTo evaluate the safety of combining Fecal Microbial Transplantation (FMT) using intestâ€¦\n[{â€œmeasureâ€: â€œAssess Objective Response Rateâ€, â€œdescriptionâ€: â€œTo evaluate whether combination of FMâ€¦\nFalse\nFalse\nFalse\nTrue\n[{â€œpmidâ€: â€œ37414899â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œRouty B, Lenehan JG, Miller WH Jr, Jamal R, Meâ€¦\n\n\nOTHER\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\n\n\n\nSPONSOR\n2026-08\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-28\nACTUAL\n2025-03-26\nACTIVE_NOT_RECRUITING\n2021-09-14\nACTUAL\n\n\n\n\n2019-03-27\nACTUAL\n2025-03\n2018-12-11\nACTUAL\n2018-11-16\n2018-12-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients must be 18-years old or older\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients must have a confirmed diagnâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD002292â€, â€œtermâ€: â€œCarcinoma, Renal Cellâ€}, {â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocelâ€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œC000656314â€, â€œtermâ€: â€œtoripalimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPart A Monotherapy Dose Escalationâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œThe Part A â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œCHS-388â€, â€œdescriptionâ€: â€œCHS-388 is a fully human IgG1 antibody against â€¦\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lungâ€¦\nmetastatic solid tumors, advanced solid tumors, Phase 1, CHS-388, IL-27, safety, efficacy, immunotheâ€¦\n\n[{â€œfacilityâ€: â€œCity of Hopeâ€, â€œcityâ€: â€œDuarteâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€: â€œ91010â€, â€œcountryâ€: â€œUâ€¦\n[{â€œnameâ€: â€œKoho Iizuka, MDâ€, â€œaffiliationâ€: â€œCoherus BioSciencesâ€, â€œroleâ€: â€œSTUDY_CHAIRâ€}]\nThis is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a â€¦\nThis is a Phase 1/1b, open-label, first-in-human (FIH), dose-escalation and expansion study of CHS-3â€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n145\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nPart A and Part B Abbreviated Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors\nNCT04374877\n\nA Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors\nSRF388-101\nINDUSTRY\nCoherus Oncology, Inc.\n[{â€œidâ€: â€œKEYNOTE-C16â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMerck Sharp & Dohme LLCâ€}, {â€œidâ€: â€œMK-3475-C16â€, â€¦\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œ[Part A] Dose Limiting Toxicity (DLT)â€, â€œdescriptionâ€: â€œEvaluation of DLT of CHS-388 aâ€¦\n[{â€œmeasureâ€: â€œ[Part A, Part B] Safety Analysis: Summary of adverse events (AEs) and based on treatmeâ€¦\nFalse\nTrue\n\nFalse\n\n\n[{â€œnameâ€: â€œMerck Sharp & Dohme LLCâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nCoherus Oncology, Inc.\n\n\n\nSPONSOR\n2025-06-05\nACTUAL\n\n\n\n\nFalse\n\n2025-11-10\nACTUAL\n2025-11-06\nCOMPLETED\n2025-05-28\nACTUAL\n\n\n\n\n2020-04-22\nACTUAL\n2025-11\n2020-05-05\nACTUAL\n2020-04-30\n2020-04-30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â‰¥ 18 years of age\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Locally advanced or metastaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplasmsâ€}, {â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Metastasisâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œC000720935â€, â€œtermâ€: â€œbalstilimabâ€}, {â€œidâ€: â€œC410216â€, â€œtermâ€: â€œFolfox protocolâ€}, {â€œidâ€: â€œâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œExperimental armâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients treated with Botensiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œBalstilimabâ€, â€œdescriptionâ€: â€œBalstilimab: 240mg, IV, Q2W, until disease â€¦\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\n\n[{â€œnameâ€: â€œChristelle DE LA FOUCHARDIERE, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ04 91 22 35 03â€, â€œemailâ€â€¦\n[{â€œfacilityâ€: â€œCentre LÃ©on BÃ©rardâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œLyonâ€, â€œcountryâ€: â€œFranceâ€, â€œcoâ€¦\n\nCIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the surâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n132\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nCIME\nCombination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomâ€¦\nNCT06346197\n\nA Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patieâ€¦\nET23-185\nOTHER\nCentre Leon Berard\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œGene expression and genomic profile descriptionâ€, â€œdescriptionâ€: â€œRNA Sequencingâ€, â€œtiâ€¦\n[{â€œmeasureâ€: â€œSurvival of patientsâ€, â€œdescriptionâ€: â€œComparison of survival of patients under Botensâ€¦\n[{â€œmeasureâ€: â€œProgression free survivalâ€, â€œtimeFrameâ€: â€œAt least 2 yearsâ€}, {â€œmeasureâ€: â€œObjective râ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œAgenus Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nCentre Leon Berard\n\n\n\nSPONSOR\n2028-05-15\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-26\nACTUAL\n2025-12-19\nRECRUITING\n2028-05-15\nESTIMATED\n\n\n\n\n2025-12-08\nACTUAL\n2025-12\n2024-04-03\nACTUAL\n2024-03-08\n2024-03-28\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female patient â‰¥18 years of age at time of informed consent form signâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD013844â€, â€œtermâ€: â€œThiazolesâ€}, {â€œidâ€: â€œD013457â€, â€œtermâ€: â€œSulfur Compoundsâ€}, {â€œidâ€: â€œD009â€¦\n[{â€œidâ€: â€œD000069439â€, â€œtermâ€: â€œDasatinibâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDasatinibâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDasatinib 70 mg/daily, orally adminiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDasatinib 70 mgâ€, â€œdescriptionâ€: â€œCommercially available tablets containiâ€¦\nHIV Infection Primary\nSAMHD1 phosphorylation, T-cell activation, Dasatinib, Suppressive combined Anti Retroviral Treatment\n\n[{â€œfacilityâ€: â€œHospital Universitari Germans Trias i Pujolâ€, â€œcityâ€: â€œBadalonaâ€, â€œstateâ€: â€œBarcelonaâ€¦\n[{â€œnameâ€: â€œJosÃ© MoltÃ³, MD, PhDâ€, â€œaffiliationâ€: â€œFundaciÃ³ Lluita contra les Infeccions - Hospital Unâ€¦\nThe goal of this clinical trial is to evaluate the safety, tolerability and Impact of low dose Dasatâ€¦\nThis is a Phase II, single-center, randomized, double-blind, placebo-controlled clinical trial in Peâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nQUADRUPLE\nDasatinib capsules re-capsulated with identical appearance with Placebo\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n60\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSafety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antireâ€¦\nNCT05780073\n\nSafety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antireâ€¦\nBCN04-Dasa\nOTHER\nFundaciÃ³ Institut Germans Trias i Pujol\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œChanges in the contributors to the reservoir repertoireâ€, â€œdescriptionâ€: â€œMeasured by â€¦\n[{â€œmeasureâ€: â€œGrade 3 or 4 treatment-related adverse events or laboratory abnormalities during the sâ€¦\n[{â€œmeasureâ€: â€œProviral reactivation capacity upon in-vitro T-cell activation: Proportion of intracelâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œSpanish Clinical Research Network - SCReNâ€, â€œclassâ€: â€œNETWORKâ€}, {â€œnameâ€: â€œIrsiCaixaâ€, â€œcâ€¦\nOTHER\nFundaciÃ³ Institut Germans Trias i Pujol\n\n\n\nSPONSOR\n2025-04-01\nACTUAL\n\n\n\n\nFalse\n\n2025-09-22\nACTUAL\n2025-09-16\nCOMPLETED\n2025-04-01\nACTUAL\n\n\n\n\n2023-10-16\nACTUAL\n2025-09\n2023-03-22\nACTUAL\n2023-02-27\n2023-03-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 1. Males and females aged at least 18 years on the day of screening.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 2. Câ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004701â€, â€œtermâ€: â€œEndocrine Gland Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Sitâ€¦\n[{â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€}, {â€œidâ€: â€œD001943â€, â€œtermâ€: â€œBreast Neoplasmsâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œP1a Arm A (Monotherapy Dose Escalation).â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œCOM70â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œCOM701â€, â€œdescriptionâ€: â€œCOM701 monotherapy.â€, â€œarmGroupLabelsâ€: [â€œP1a Arâ€¦\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Tâ€¦\nPVRIG, advanced cancer, checkpoint inhibitor, DNAM (DNAX Accessory molecule 1), PD-1 inhibitor, CD11â€¦\n\n[{â€œfacilityâ€: â€œUniversity of California Los Angeles (UCLA).â€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCalifâ€¦\n[{â€œnameâ€: â€œCOM701 Study Directorâ€, â€œaffiliationâ€: â€œCompugen USA, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the saâ€¦\nThis Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary clinicaâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n121\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCOM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.\nNCT03667716\n\nA Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjecâ€¦\nCPG-01-001\nINDUSTRY\nCompugen Ltd\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œIncidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Tâ€¦\n[{â€œmeasureâ€: â€œIncidence of subjects with Anti-COM701 antibody.â€, â€œdescriptionâ€: â€œImmunogenicity of Câ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nCompugen Ltd\n\n\n\nSPONSOR\n2024-01-30\nACTUAL\n\n\n\n\nFalse\n\n2025-01-17\nACTUAL\n2025-01-15\nCOMPLETED\n2024-01-30\nACTUAL\n\n\n\n\n2018-09-06\nACTUAL\n2025-01\n2018-09-12\nACTUAL\n2018-09-10\n2018-09-11\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Subject has Eastern Cooperative Oncology Group (ECOG) performance status â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002526â€, â€œtermâ€: â€œCerebellar Diseasesâ€}, {â€œidâ€: â€œD001927â€, â€œtermâ€: â€œBrain Diseasesâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD013132â€, â€œtermâ€: â€œSpinocerebellar Degenerationsâ€}, {â€œidâ€: â€œD015179â€, â€œtermâ€: â€œColorectal Nâ€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment with Biopsyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients in Cohort A wilâ€¦\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œPre-Treatment Biopsyâ€, â€œdescriptionâ€: â€œThe pre-treatment biopsy shouâ€¦\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal â€¦\nimmunotherapy, microsatellite stable colorectal cancer, tiragolumab, metastatic colorectal cancer, aâ€¦\n\n[{â€œfacilityâ€: â€œUniverstiy of Colorado Hospitalâ€, â€œcityâ€: â€œAuroraâ€, â€œstateâ€: â€œColoradoâ€, â€œzipâ€: â€œ8004â€¦\n[{â€œnameâ€: â€œHannah Robinson, MDâ€, â€œaffiliationâ€: â€œUniversity of Colorado, Denverâ€, â€œroleâ€: â€œPRINCIPALâ€¦\nThe goal of this study is to learn if a new combination treatment is effective for patients with micâ€¦\nThis is a phase II study investigating the efficacy and safety of a triple-combination immunotherapyâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n13\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nTrial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatâ€¦\nNCT06784947\n\nA Phase II Trial of Tiragolumab in Combination With Atezolizumab and Bevacizumab in Patients With Prâ€¦\n24-0547.cc\nOTHER\nUniversity of Colorado, Denver\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œDisease Control Rate (DCR)â€, â€œdescriptionâ€: â€œThe disease control rate (DCR) is definedâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œThe primary outcome of this trial is oâ€¦\n[{â€œmeasureâ€: â€œProgression Free Survival (PFS)â€, â€œdescriptionâ€: â€œProgression free survival (PFS) measâ€¦\nFalse\nTrue\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œGenentech, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nUniversity of Colorado, Denver\n\n\n\nSPONSOR\n2028-05\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-02\nACTUAL\n2025-10-01\nACTIVE_NOT_RECRUITING\n2025-09-18\nACTUAL\n\n\n\n\n2025-03-25\nACTUAL\n2025-10\n2025-01-20\nACTUAL\n2025-01-08\n2025-01-16\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Able to sign the consent form.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Stated willingness and ability to comply wâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Meâ€¦\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD01â€¦\nPoland, Turkey (TÃ¼rkiye)\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œArm A (O+T+C)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDuring the induction phase, partâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOciperlimabâ€, â€œdescriptionâ€: â€œ900 mg intravenously (IV) once every 3 weekâ€¦\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung â€¦\nmetastatic, Lung Cancer, Non-Squamous, Ociperlimab, Tislelizumab, Anti-PD-1, BGB-A317, BGB-A1217, Anâ€¦\n\n[{â€œfacilityâ€: â€œValkyrie Clinical Trialsâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€: â€œ9006â€¦\n\nThis study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nTREATMENT\n\n272\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nOciperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Câ€¦\nNCT05014815\n\nAdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherâ€¦\nAdvanTIG-205\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œ2021-001075-17â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œCTR20212782â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€â€¦\nSee plan description\nBeiGene shares data on completed studies responsibly and provides qualified scientific and medical râ€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\nSee plan description\n\n\n[{â€œmeasureâ€: â€œProgression-free Survival (PFS)â€, â€œdescriptionâ€: â€œPFS was defined as the time from ranâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œObjective response rate is defined as â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2024-09-04\nACTUAL\n\n\n\n\nFalse\n\n2025-09-16\nACTUAL\n2025-08-28\nCOMPLETED\n2024-09-04\nACTUAL\n2025-09-16\nACTUAL\n2025-08-28\n2025-08-28\n2021-11-16\nACTUAL\n2025-08\n2021-08-20\nACTUAL\n2021-08-16\n2021-08-16\n\nAll-cause mortality is reported for all randomized participants. Serious and other adverse events arâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œArm A (O+T+C)â€, â€œdescriptionâ€: â€œOciperlimab (900 mg IV), tislelizumab (20â€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nAll-cause mortality is reported from randomization up to study completion date cut-off date of 04 Seâ€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ136â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œArm A (O+T+C)â€, â€œdescriptionâ€: â€œOciperlimab (900 mg IV), tislelizumab (20â€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Intent-to-Treat Analysis Set is defined as all randomized participants\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene\n1 877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œProgression-free Survival (PFS)â€, â€œdescriptionâ€: â€œPFS was defined as â€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œArm A (O+T+C)â€, â€œdescriptionâ€: â€œOciperlimab (900 mg IV), tislelizumab (20â€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nEligible participants were randomized in a 1:1 ratio to receive either ociperlimab or placebo treatmâ€¦\nThis study was conducted at 75 study centers in 8 countries (China, South Korea, United States of Amâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Participants had histologically or cytologically confirmed locally advanâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œBL-B01D1 Armâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants receive BL-B01D1 injâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œBL-B01D1â€, â€œdescriptionâ€: â€œBL-B01D1 is a first-in-class novel ADC consistâ€¦\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nRare Tumors, Platform Trial, Precision Medicine, Immunotherapy, Targeted Therapy, Cell and gene therâ€¦\n[{â€œnameâ€: â€œNing Li, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ86-010-87788713â€, â€œemailâ€: â€œlining@cicams.ac.câ€¦\n\n[{â€œnameâ€: â€œNing Li, MDâ€, â€œaffiliationâ€: â€œCancer Hospital of CICAMSâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€¦\nThe goal of this Phase I/II observational and interventional platform study is to evaluate the safetâ€¦\nThis is an open-label, non-randomized, multi-arm, single-center Phase I/II platform study (PLATFORM2â€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n600\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nRare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)\nNCT07307053\n\nAn Open-Label, Single-Arm, Phase I/II Platform Trial of Innovative Therapies and Technologies Primarâ€¦\nPLATFORM2\nOTHER\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œAssessed by BICR and Investigator per â€¦\n[{â€œmeasureâ€: â€œProgression-Free Survival (PFS)â€, â€œdescriptionâ€: â€œAssessed by BICR and Investigator.â€,â€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\n\n\n\nSPONSOR\n2031-01-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-29\nACTUAL\n2025-12-13\nNOT_YET_RECRUITING\n2029-01-31\nESTIMATED\n\n\n\n\n2026-01-01\nESTIMATED\n2025-12\n2025-12-29\nACTUAL\n2025-12-12\n2025-12-13\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Subjects must meet all of the following inclusion criteria:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Male or femaleâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Meâ€¦\n\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\nMexico\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A: Tislelizumab plus Ociperlimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipaâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTislelizumabâ€, â€œdescriptionâ€: â€œTislelizumab is a monoclonal antibody formâ€¦\nNon-small Cell Lung Cancer, NSCLC\nLocally Advanced, Unresectable, Metastatic, Tislelizumab, BGB-A317, Ociperlimab, BGB-A1217, Pembroliâ€¦\n\n[{â€œfacilityâ€: â€œProvidence Medical Foundation St Jude Heritage Healthcareâ€, â€œcityâ€: â€œFullertonâ€, â€œstaâ€¦\n\nThe purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compaâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n662\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Luâ€¦\nNCT04746924\n\nA Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination Witâ€¦\nAdvanTIG-302\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œBGB-A317-A1217-302â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œBeiGeneâ€}, {â€œidâ€: â€œCTR20211476/CTR20211464â€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œdescriptionâ€: â€œOS will be defined as the time from the date oâ€¦\n[{â€œmeasureâ€: â€œProgression-free Survival (PFS) As Assessed By Investigatorsâ€, â€œdescriptionâ€: â€œPFS wilâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2026-03-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-06-24\nACTUAL\n2025-06-23\nACTIVE_NOT_RECRUITING\n2025-05-30\nACTUAL\n\n\n\n\n2021-06-08\nACTUAL\n2025-06\n2021-02-10\nACTUAL\n2021-02-05\n2021-02-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically or cytologically documented locally advanced or recurrentâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000096662â€, â€œtermâ€: â€œRamucirumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSub-study 1, investigate rilvegostomigÂ± ramucirumab in 1L non-AGA NSCLC with PD-L1 â‰¥50%â€â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œRilvegostomig will be administered as IV â€¦\nNon-Small Cell Lung Cancer\nNon-Small Cell Lung Cancer(NSCLC), Antibody-Drug Conjugates (ADCs), T-cell immunoreceptor with Ig anâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œNOT_YET_RECRUITINGâ€, â€œcityâ€: â€œSanta Monicaâ€, â€œstateâ€: â€œCalâ€¦\n\nThis is a Phase II, multi-center, open-label platform study evaluating novel combination treatment oâ€¦\nThe master protocol will include 3 sub-studies, each focused on a specific disease population.\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n278\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria for All Sub-studies:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nLIBRA\nA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)\nNCT07098338\n\nAn Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmaâ€¦\nD6187C00001\nINDUSTRY\nAstraZeneca\n\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œNumber of participants with adverse events (AE) and serious adverse events (SAE)â€, â€œdeâ€¦\n[{â€œmeasureâ€: â€œBest Overall Response(BOR)â€, â€œdescriptionâ€: â€œBOR is the best response a participant haâ€¦\nFalse\nTrue\n\nFalse\n\n\n[{â€œnameâ€: â€œDaiichi Sankyoâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-04-06\nESTIMATED\n\n\n\n\nFalse\n\n2025-09-30\nACTUAL\n2025-09-25\nRECRUITING\n2027-03-21\nESTIMATED\n\n\n\n\n2025-08-07\nACTUAL\n2025-09\n2025-08-01\nACTUAL\n2025-07-04\n2025-07-25\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Suâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participant must be â‰¥ 18 years of age at the time of signâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014594â€, â€œtermâ€: â€œUterine Neoplasmsâ€}, {â€œidâ€: â€œD005833â€, â€œtermâ€: â€œGenital Neoplasms, Femalâ€¦\n[{â€œidâ€: â€œD016889â€, â€œtermâ€: â€œEndometrial Neoplasmsâ€}, {â€œidâ€: â€œD009364â€, â€œtermâ€: â€œNeoplasm Recurrence,â€¦\n[{â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}]\n[{â€œidâ€: â€œC111043â€, â€œtermâ€: â€œTP protocolâ€}, {â€œidâ€: â€œD011878â€, â€œtermâ€: â€œRadiotherapyâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment Armâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œChemotherapyï¼šTP (Paclitaxel and â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPaclitaxel and Cisplatinâ€, â€œdescriptionâ€: â€œPaclitaxel and Cisplatin Pacliâ€¦\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nImmunotherapy, Cadonilimab, Paclitaxel, Cisplatin, Radiation Therapy, Combined Modality Therapy, Cliâ€¦\n[{â€œnameâ€: â€œJing Liuâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+86 13065077425â€, â€œemailâ€: â€œ13065077425@126.comâ€}â€¦\n[{â€œfacilityâ€: â€œShandong Cancer Hospital Affiliated to Shandong First Medical Universityâ€, â€œstatusâ€: â€¦\n[{â€œnameâ€: â€œPeng Xieâ€, â€œaffiliationâ€: â€œShandong Cancer Hospital and Instituteâ€, â€œroleâ€: â€œPRINCIPAL_INâ€¦\nThe goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combinationâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n80 Years\n18 Years\n\nFEMALE\nADULT, OLDER_ADULT\n\n\nCadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma\nNCT06532539\n\nA Phase II, Single-arm, Multicenter Clinical Trial of Definitive Treatment With Cadonilimab, Paclitaâ€¦\nSDZLEC2024-160-01\nOTHER\nShandong Cancer Hospital and Institute\n\n\n\nSTUDY_PROTOCOL\nYES\n\n\n[{â€œmeasureâ€: â€œBiomarkerâ€, â€œdescriptionâ€: â€œCD8A, PD-1, PD-L1, CD68, panCK, CD56, CD155, TIGIT, TMB, Mâ€¦\n[{â€œmeasureâ€: â€œProgression-Free Survivalâ€, â€œdescriptionâ€: â€œProgression-Free Survival (PFS) will be asâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rateâ€, â€œdescriptionâ€: â€œORR refers to the proportion of patients whoâ€¦\nFalse\nFalse\n\n\n\n\n\nOTHER\nShandong Cancer Hospital and Institute\nShandong Cancer Hospital and Institute\nPeng Xie\nDirector\nPRINCIPAL_INVESTIGATOR\n2026-05\nESTIMATED\n\n\n\n\nFalse\n\n2024-08-01\nACTUAL\n2024-07-29\nRECRUITING\n2025-05\nESTIMATED\n\n\n\n\n2024-06-13\nACTUAL\n2024-06\n2024-08-01\nACTUAL\n2024-07-22\n2024-07-29\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. A written informed consent form must be signed before the implementation of â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD007154â€, â€œtermâ€: â€œImmune System Diseasesâ€}]\n[{â€œidâ€: â€œD006086â€, â€œtermâ€: â€œGraft vs Host Diseaseâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n\n\nGraft-versus-host Disease (GVHD)\nallogeneic hematopoietic stem cell transplantation, Graft-versus-host disease, CD8 regulatory precurâ€¦\n\n[{â€œfacilityâ€: â€œNo.Â 11 Xizhimen South Street, Xicheng District, Beijing, Chinaâ€, â€œcityâ€: â€œBeijingâ€, â€œâ€¦\n\nAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective treatment for aâ€¦\n\n\n\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n100\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nTrue\n60 Years\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT\nAbout 100 patients to be recruited for allogeneic hematopoietic stem cell transplantation in the Depâ€¦\n\nThe Application of Novel Identified CD8 Regulatory Precursors in Inducing Immune Tolerance After Allâ€¦\nNCT06864598\n\nThe Application of Novel Identified CD8 Regulatory Precursors in Inducing Immune Tolerance After Allâ€¦\n2025PHB050-001\nOTHER\nPeking University Peopleâ€™s Hospital\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œProportion of CD8 Trp subgroupsâ€, â€œdescriptionâ€: â€œHealthy donor samples will be collecâ€¦\n[{â€œmeasureâ€: â€œT-cell functionâ€, â€œdescriptionâ€: â€œHealthy donor samples will be collected at the onsetâ€¦\nFalse\nFalse\nFalse\nFalse\n\n\n\nOTHER\nPeking University Peopleâ€™s Hospital\nPeking University Peopleâ€™s Hospital\nXiao-Jun Huang\nPrincipal Investigator\nPRINCIPAL_INVESTIGATOR\n2026-10-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-07\nACTUAL\n2025-03-04\nENROLLING_BY_INVITATION\n2026-02-01\nESTIMATED\n\n\n\n\n2025-01-09\nACTUAL\n2025-02\n2025-03-07\nACTUAL\n2025-02-21\n2025-03-04\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Patients proposed for allogeneic haematopoietic stem cell transplantation;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD007414â€, â€œtermâ€: â€œIntestinal Neoplasmsâ€}, {â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neopâ€¦\n[{â€œidâ€: â€œD003110â€, â€œtermâ€: â€œColonic Neoplasmsâ€}, {â€œidâ€: â€œD011127â€, â€œtermâ€: â€œPolypsâ€}, {â€œidâ€: â€œD01517â€¦\n[{â€œidâ€: â€œD004042â€, â€œtermâ€: â€œDietary Fats, Unsaturatedâ€}, {â€œidâ€: â€œD004041â€, â€œtermâ€: â€œDietary Fatsâ€}, â€¦\n[{â€œidâ€: â€œC035276â€, â€œtermâ€: â€œeicosapentaenoic acid ethyl esterâ€}, {â€œidâ€: â€œD015525â€, â€œtermâ€: â€œFatty Acâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œOmega-3 treatmentâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œDaily 4-gram marine omeâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAMR101 (VASCEPA, icosapent ethyl)â€, â€œdescriptionâ€: â€œOral administration, â€¦\nColon Cancer\nNutrition, Omega-3 fatty acid, Fish oil, Tumor microenvironment, Immune response, Gut microbiota, Poâ€¦\n\n[{â€œfacilityâ€: â€œMassachusetts General Hospitalâ€, â€œcityâ€: â€œBostonâ€, â€œstateâ€: â€œMassachusettsâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œAndrew T. Chan, MD, MPHâ€, â€œaffiliationâ€: â€œMassachusetts General Hospitalâ€, â€œroleâ€: â€œPRINCâ€¦\nThis is a prospective, double-blind, placebo-controlled, randomized clinical trial to assess the effâ€¦\nThis research study is evaluating the effect of AMR101, as a chemopreventive agent to reduce risk ofâ€¦\n\n\nRANDOMIZED\nPARALLEL\nDouble-blind, placebo-controlled, stratified, randomized clinical trial\nQUADRUPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nOMICC\nOMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer\nNCT03661047\nNCT03419455\nOMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer\n18-097\nOTHER\nMassachusetts General Hospital\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œThe change in the marine omega-3 polyunsaturated fatty acid (MO3PUFA) composition in câ€¦\n[{â€œmeasureâ€: â€œThe change in Tumor CD8+ T cells in the tumor tissue between pre- and post- AMR101 treâ€¦\nFalse\nTrue\nFalse\nTrue\n[{â€œpmidâ€: â€œ30834441â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œHang D, Kvaerner AS, Ma W, Hu Y, Tabung FK, Naâ€¦\n\n[{â€œnameâ€: â€œHarvard School of Public Health (HSPH)â€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nMassachusetts General Hospital\nMassachusetts General Hospital\nAndrew T. Chan, MD, MPH\nPrinicipal Investigator\nPRINCIPAL_INVESTIGATOR\n2021-11-30\nESTIMATED\n\n\n\n\nFalse\n\n2021-11-17\nACTUAL\n2021-11-10\nWITHDRAWN\n2021-11-30\nESTIMATED\n\n\n\n\n2019-11-30\nACTUAL\n2021-11\n2018-09-07\nACTUAL\n2018-08-31\n2018-09-06\nStudy will be closed due to zero enrollment in over 2 years.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParticipants must meet the following criteria on screening examination to be eliâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, {â€œidâ€: â€œD003131â€, â€œtermâ€: â€œCombined Modality Therapyâ€}]\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œC000613593â€, â€œtermâ€: â€œdurvalumabâ€}, {â€œidâ€: â€œDâ€¦\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œOciperlimab + Tislelizumab + cCRTâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipantsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTislelizumabâ€, â€œdescriptionâ€: â€œ200 mg intravenously every three weeksâ€, â€œâ€¦\nNon Small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œXCancer/Centeral Care Centerâ€, â€œcityâ€: â€œBolivarâ€, â€œstateâ€: â€œMissouriâ€, â€œzipâ€: â€œ65613â€â€¦\n\nThe purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination withâ€¦\nThe study initiated with Protocol Amendment 1.0 (PA 1; dated on 16 April 2021). In April 2022 Protocâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n63\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiothâ€¦\nNCT04866017\n\nA Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A3â€¦\nBGB-A317-A1217-301\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œ2020-004656-14â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œAdvanTIG-301â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œProgression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)â€â€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œdescriptionâ€: â€œDefined as the time from the date of randomizaâ€¦\nFalse\nTrue\nTrue\nTrue\n\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2023-10-17\nACTUAL\n\n\n\n\nFalse\n\n2024-10-31\nACTUAL\n2024-10-09\nTERMINATED\n2023-10-17\nACTUAL\n2024-10-31\nACTUAL\n2024-10-09\n2024-10-09\n2021-06-17\nACTUAL\n2024-10\n2021-04-29\nACTUAL\n2020-10-28\n2021-04-26\nThis decision was conducted by the sponsor and not driven by safety concerns as no new safety signalâ€¦\nAll-cause mortality is reported for all randomized participants. Serious and other adverse events inâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œOciperlimab + Tislelizumab + cCRTâ€, â€œdescriptionâ€: â€œParticipants enrolledâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\n[{â€œtermâ€: â€œStomatitisâ€, â€œorganSystemâ€: â€œGastrointestinal disordersâ€, â€œsourceVocabularyâ€: â€œmeddra 26â€¦.\nFrom first dose to 30 days after the last dose or initiation of a new anticancer therapy, whichever â€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ22â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œOciperlimab + Tislelizumab + cCRTâ€, â€œdescriptionâ€: â€œParticipants enrolledâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Intent-to-Treat (ITT) Analysis Set is defined as all randomized participants.\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\nSince no participants were enrolled under PA 2, no analyses of the primary or secondary endpoints weâ€¦\nclinicaltrials@beigene.com\nBeiGene\n1-877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œProgression-Free Survival (PFS) as Assessed by the Independent Reviewâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œOciperlimab + Tislelizumab + cCRTâ€, â€œdescriptionâ€: â€œParticipants enrolledâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nThis study was initiated under Protocol Amendment (PA) 1. PA 2 was subsequently implemented; howeverâ€¦\nParticipants were enrolled in multiple study centers in Taiwan, China, Spain , United States, and Auâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Age â‰¥ 18 years on the day of signing the informed consent form (or the lâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD002292â€, â€œtermâ€: â€œCarcinoma, Renal Cellâ€}]\n\n[{â€œidâ€: â€œC558660â€, â€œtermâ€: â€œcabozantinibâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHLA-A2 postiveâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œThe study will include 21 partiâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œAutologous alpha-DC1/TBVA vaccineâ€, â€œdescriptionâ€: â€œDendritic cellsâ€¦\nCarcinoma, Renal Cell\nClear Cell Renal Cell Carcinoma\n[{â€œnameâ€: â€œMorgan Pokora, RNâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ412-623-4886â€, â€œemailâ€: â€œpokoraml3@upmcâ€¦.\n[{â€œfacilityâ€: â€œUPMC Department of Urologyâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œPittsburghâ€, â€œstateâ€: â€œâ€¦\n[{â€œnameâ€: â€œJodi Maranchie, MDâ€, â€œaffiliationâ€: â€œUPMC Department of Urologyâ€, â€œroleâ€: â€œPRINCIPAL_INVEâ€¦\nThe purpose of this study is to estimate the probability of immune response for the combination treaâ€¦\nParticipants with newly diagnosed, non-metastatic, histologically confirmed, clear cell renal cell câ€¦\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n42\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAutologous Dendritic Cell Vaccine in Kidney Cancer\nNCT05127824\n\nA Phase 2a Study to Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Veâ€¦\nHCC 19-126\nOTHER\nUniversity of Pittsburgh\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œTo assess the impact of treatment on formation of tertiary lymphoid structures in pre-â€¦\n[{â€œmeasureâ€: â€œProbability of immune responseâ€, â€œdescriptionâ€: â€œProportion of HLA-A2+ ccRCC patients â€¦\n[{â€œmeasureâ€: â€œMarkers of vascular normalizationâ€, â€œdescriptionâ€: â€œChange in presence of mature CD31+â€¦\nFalse\nTrue\nFalse\nTrue\n[{â€œpmidâ€: â€œ29487224â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œTannir NM, Pal SK, Atkins MB. Second-Line Tâ€¦\n\n\nOTHER\nJodi Maranchie\nUniversity of Pittsburgh\nJodi Maranchie\nAssociate Professor Urology & Urologic Oncology\nSPONSOR_INVESTIGATOR\n2026-12\nESTIMATED\n\n\n\n\nFalse\n\n2025-05-04\nACTUAL\n2025-04-30\nRECRUITING\n2026-12\nESTIMATED\n\n\n\n\n2023-07-06\nACTUAL\n2025-04\n2021-11-19\nACTUAL\n2021-10-22\n2021-11-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically proven clear cell renal cancer that is non-metastatic and ameâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Doâ€¦\n[{â€œidâ€: â€œD014801â€, â€œtermâ€: â€œVitamin Aâ€}, {â€œidâ€: â€œD012176â€, â€œtermâ€: â€œRetinoidsâ€}, {â€œidâ€: â€œD002338â€, â€œâ€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD014212â€, â€œtermâ€: â€œTretinoinâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPembrolizumab + Vibostolimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPrior to tumor reâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œAdministered via IV infusion at a sâ€¦\nMelanoma\nprogrammed cell death 1 (PD-1, PD1), programmed cell death ligand 1 (PD-L1, PDL1), Coxsackievirus A2â€¦\n\n[{â€œfacilityâ€: â€œThe Angeles Clinic and Research Institute ( Site 3009)â€, â€œcityâ€: â€œLos Angelesâ€, â€œstatâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œMerck Sharp & Dohme LLCâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nSubstudy 02C is part of a larger research study that is testing experimental treatments for melanomaâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n146\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n120 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSubstudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pemâ€¦\nNCT04303169\n\nA Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Withouâ€¦\n3475-02C\nINDUSTRY\nMerck Sharp & Dohme LLC\n[{â€œidâ€: â€œMK-3475-02Câ€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMSDâ€}, {â€œidâ€: â€œKEYMAKER-U02â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nhttps://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf\n\nYES\n\nhttps://externaldatasharing-msd.com/\n\n[{â€œmeasureâ€: â€œPercentage of participants who experience an adverse event (AE)â€, â€œdescriptionâ€: â€œAn Aâ€¦\n[{â€œmeasureâ€: â€œNear pathological complete response (near pCR) rateâ€, â€œdescriptionâ€: â€œNear pCR is defiâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ39775043â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œDummer R, Robert C, Scolyer RA, Taube JM, Tetzlâ€¦\n[{â€œlabelâ€: â€œMerck Clinical Trials Informationâ€, â€œurlâ€: â€œhttps://www.merckclinicaltrials.com/â€}, {â€œlaâ€¦\n\nINDUSTRY\nMerck Sharp & Dohme LLC\n\n\n\nSPONSOR\n2025-09-24\nACTUAL\n\n\n\n\nFalse\n\n2025-10-27\nACTUAL\n2025-10-23\nCOMPLETED\n2025-09-24\nACTUAL\n\n\n\n\n2020-06-26\nACTUAL\n2025-10\n2020-03-10\nACTUAL\n2020-03-09\n2020-03-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has histologically or cytologically confirmed melanoma\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has clinically detecâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œC562730â€, â€œtermâ€: â€œAdenocarcinoma Of Esophagusâ€}, {â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplaâ€¦\n[{â€œidâ€: â€œD014498â€, â€œtermâ€: â€œUracilâ€}, {â€œidâ€: â€œD011744â€, â€œtermâ€: â€œPyrimidinonesâ€}, {â€œidâ€: â€œD011743â€, â€¦\n[{â€œidâ€: â€œC000723779â€, â€œtermâ€: â€œquemliclustatâ€}, {â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€:â€¦\nArgentina\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA1: First Line - Treatment NaÃ¯ve Participantsâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œAdministered as specified in the treatmentâ€¦\nGastrointestinal Tract Malignancies\nDomvanalimab, Quemliclustat, Zimberelimab, Esophageal adenocarcinoma, Gastric adenocarcinoma, Gastriâ€¦\n\n[{â€œfacilityâ€: â€œMayo Clinic - Arizonaâ€, â€œcityâ€: â€œPhoenixâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85054â€, â€œcountâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to evaluate the safety and preliminary clinical activity of treatment câ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n332\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nEDGE-Gastric\nA Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Particiâ€¦\nNCT05329766\n\nA Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advancâ€¦\nARC-21\nINDUSTRY\nArcus Biosciences, Inc.\n[{â€œidâ€: â€œ2021-006291-16â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œ2024-511917-40-00â€, â€œtypeâ€: â€œCTISâ€}]\n\nArcus will provide access to individual de-identified participant data and related study documents (â€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n\n[{â€œmeasureâ€: â€œNumber of Participants with Adverse Events (AEs)â€, â€œtimeFrameâ€: â€œUp to 18 monthsâ€}, {â€œâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) as measured by PD-L1 Expression Levelâ€, â€œtimeFrameâ€: â€œUpâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ41109921â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œJanjigian YY, Oh DY, Pelster M, Wainberg ZA, Pâ€¦\n[{â€œlabelâ€: â€œARC-21 - Public websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=ARC-21â€}]\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2027-06\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-29\nACTUAL\n2026-01-27\nACTIVE_NOT_RECRUITING\n2027-01\nESTIMATED\n\n\n\n\n2022-06-10\nACTUAL\n2025-03\n2022-04-15\nACTUAL\n2022-04-08\n2022-04-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants with histologically confirmed diagnosis of locally advanced â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018070â€, â€œtermâ€: â€œBiological Specimen Banksâ€}, {â€œidâ€: â€œD006268â€, â€œtermâ€: â€œHealth Facilitieâ€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD014015â€, â€œtermâ€: â€œTissue Banksâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPermbrolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants will undergo fine â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œPost Fine-cut CT: 4 doses of pembrolizumaâ€¦\nBasal Cell Carcinoma of the Head and Neck\n\n\n[{â€œfacilityâ€: â€œCleveland Clinic, Case Comprehensive Cancer Centerâ€, â€œcityâ€: â€œClevelandâ€, â€œstateâ€: â€œOâ€¦\n[{â€œnameâ€: â€œJames Isaacs, MDâ€, â€œaffiliationâ€: â€œCleveland Clinic, Case Comprehensive Cancer Centerâ€, â€œâ€¦\nThe purpose of this study is to evaluate anti-PD-1 Neoadjuvant therapy in Basal cell carcinoma to prâ€¦\nThis is a phase 1 study looking at anti-PD-1 Neoadjuvant therapy in Basal cell carcinoma in participâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n13\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nNeoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N\nNCT04323202\n\nA Phase 1B, Single Arm Study of Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cellâ€¦\nCASE10319\nOTHER\nCase Comprehensive Cancer Center\n\n\nIndividual participant data will not be shared but the study team expects to publish the data from tâ€¦\n\nNO\n\n\n[{â€œmeasureâ€: â€œNumber of Tumor Infiltrating Lymphocytes (TILs)â€, â€œdescriptionâ€: â€œNumber of Tumor Infiâ€¦\n[{â€œmeasureâ€: â€œPathologic response as assessed by change in tumor volume (RECIST 1.1)â€, â€œdescriptionâ€â€¦\n[{â€œmeasureâ€: â€œNumber of participants experiencing a grade 3 or higher Adverse Eventâ€, â€œdescriptionâ€:â€¦\nFalse\nTrue\n\nTrue\n\n\n\nOTHER\nCase Comprehensive Cancer Center\n\n\n\nSPONSOR\n2025-06-25\nACTUAL\n\n\n\n\nFalse\n\n2025-10-24\nACTUAL\n2025-10-23\nCOMPLETED\n2024-07-23\nACTUAL\n\n\n\n\n2020-08-04\nACTUAL\n2025-10\n2020-03-26\nACTUAL\n2020-03-20\n2020-03-24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Advanced basal cell carcinoma for the purposes of this study will be defined â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive System Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siâ€¦\n[{â€œidâ€: â€œD001661â€, â€œtermâ€: â€œBiliary Tract Neoplasmsâ€}, {â€œidâ€: â€œD012008â€, â€œtermâ€: â€œRecurrenceâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD006571â€, â€œtermâ€: â€œHeterocyclic Compoundsâ€}, {â€œidâ€: â€œD003841â€, â€œtermâ€: â€œDeoxycytidineâ€}, {â€œâ€¦\n[{â€œidâ€: â€œC000613593â€, â€œtermâ€: â€œdurvalumabâ€}, {â€œidâ€: â€œD000093542â€, â€œtermâ€: â€œGemcitabineâ€}, {â€œidâ€: â€œD0â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œControl Armâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œDurvalumab IV infusion + chemâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œRilvegostomig IV (intravenous) Q3Wâ€, â€œarmâ€¦\nBiliary Tract Cancer\nRilvegostomig, Durvalumab, Biliary Tract Cancer, Bispecific Antibody, PD-L1, TIGIT, Initially Unreseâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œNOT_YET_RECRUITINGâ€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabaâ€¦\n\nThe purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\nOpen label\n\n\nTREATMENT\n\n1100\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nKey inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nAB02\nA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Câ€¦\nNCT07221253\n\nPhase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combiâ€¦\nD702NC00001\nINDUSTRY\nAstraZeneca\n\nWhen a request has been approved AstraZeneca will provide access to the de-identified individual patâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure\n\n[{â€œmeasureâ€: â€œOverall Survival (OS) in the PDL1 â‰¥ 1% populationâ€, â€œdescriptionâ€: â€œOverall Survival iâ€¦\n[{â€œmeasureâ€: â€œOverall Survival in the intent to treat (ITT) populationâ€, â€œdescriptionâ€: â€œOverall Surâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-07-04\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-08\nACTUAL\n2026-01-07\nRECRUITING\n2029-07-04\nESTIMATED\n\n\n\n\n2025-12-04\nACTUAL\n2025-12\n2025-10-27\nACTUAL\n2025-10-01\n2025-10-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed adenocarcinoma of the biliary tract, including iâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD043823â€, â€œtermâ€: â€œTaxoidsâ€}, {â€œidâ€: â€œD043822â€, â€œtermâ€: â€œCyclodecanesâ€}, {â€œidâ€: â€œD003516â€, â€¦\n[{â€œidâ€: â€œC000723779â€, â€œtermâ€: â€œquemliclustatâ€}, {â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€:â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA1: Domvanalimab + Zimberelimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDomvanalimab aâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œAdministered as specified in the treatmentâ€¦\nAdvanced Non-Small Cell Lung Cancer\nAdvanced Non-Small Cell Lung Cancer, Domvanalimab, Zimberelimab, Quemliclustat, Anti-TIGIT antibody,â€¦\n\n[{â€œfacilityâ€: â€œUniversity of Alabama at Birmingham (UAB)â€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabamaâ€,â€¦\n[{â€œnameâ€: â€œGilead Study Directorâ€, â€œaffiliationâ€: â€œGilead Sciencesâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combâ€¦\nThe study includes multiple substudy arms (Substudy A, B, C), which will evaluate immunotherapy-baseâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n400\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nEDGE-Lung\nStudy With Various Immunotherapy Treatments in Participants With Lung Cancer\nNCT05676931\n\nA Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participantsâ€¦\nEDGE-Lung\nINDUSTRY\nGilead Sciences\n[{â€œidâ€: â€œ2022-502916-35-01â€, â€œtypeâ€: â€œCTISâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œtimeFrameâ€: â€œFrom date of first dose until the date of death â€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œArcus Biosciences, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nGilead Sciences\n\n\n\nSPONSOR\n2027-12\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-02\nACTUAL\n2025-09-29\nACTIVE_NOT_RECRUITING\n2027-12\nESTIMATED\n\n\n\n\n2023-02-21\nACTUAL\n2025-09\n2023-01-09\nACTUAL\n2022-12-09\n2023-01-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented Stage IV metastatic, NSCLC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Easteâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014328â€, â€œtermâ€: â€œTrophoblastic Neoplasmsâ€}, {â€œidâ€: â€œD009373â€, â€œtermâ€: â€œNeoplasms, Germ Ceâ€¦\n[{â€œidâ€: â€œD031901â€, â€œtermâ€: â€œGestational Trophoblastic Diseaseâ€}, {â€œidâ€: â€œD013945â€, â€œtermâ€: â€œThymomaâ€â€¦\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCohort 1: Peritoneal mesotheliomasâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients wiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDOMVANALIMAB + ZIMBERELIMABâ€, â€œdescriptionâ€: â€œPatients will be treated wiâ€¦\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Tâ€¦\nRare cancers, Immunotherapy, Peritoneal mesothelioma, Gestational Trophoblastic Tumors, Thymomas andâ€¦\n[{â€œnameâ€: â€œBenoit YOU, Prof; MD/PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0478864385â€, â€œphoneExtâ€: â€œ+33â€, â€œâ€¦\n[{â€œfacilityâ€: â€œInstitut de Cancerologie de lâ€™Ouest , medical oncology departmentâ€, â€œstatusâ€: â€œNOT_YEâ€¦\n\nImmune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, â€¦\n\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n154\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nIMMUNORARE5\nIMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospitâ€¦\nNCT06790706\n\nIMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospitâ€¦\n69HCL24_0656\nOTHER\nHospices Civils de Lyon\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œProgression-free survival rate (cohort 1, 3 and 5)â€, â€œdescriptionâ€: â€œProportion of patâ€¦\n[{â€œmeasureâ€: â€œOverall response rate (cohorts 1, 3, 4 and 5)â€, â€œdescriptionâ€: â€œOverall response rate â€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nHospices Civils de Lyon\n\n\n\nSPONSOR\n2031-06\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-06\nACTUAL\n2025-10-01\nRECRUITING\n2028-11\nESTIMATED\n\n\n\n\n2025-10-01\nACTUAL\n2025-10\n2025-01-24\nACTUAL\n2025-01-16\n2025-01-22\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nGeneral inclusion criteria for all cohorts\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically proven advanced soâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002294â€, â€œtermâ€: â€œCarcinoma, Squamous Cellâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD000077277â€, â€œtermâ€: â€œEsophageal Squamous Cell Carcinomaâ€}]\n\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}]\nBrazil, Czechia\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A: Tiragolumab + Atezolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipantsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTiragolumabâ€, â€œdescriptionâ€: â€œTiragolumab at a fixed dose of 600 milligraâ€¦\nEsophageal Squamous Cell Carcinoma\n\n\n[{â€œfacilityâ€: â€œFlorida Cancer Specialists - Fort Myers (Broadway)â€, â€œcityâ€: â€œFort Myersâ€, â€œstateâ€: â€œâ€¦\n[{â€œnameâ€: â€œClinical Trialâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab coâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nQUADRUPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n760\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSKYSCRAPER-07\nA Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squâ€¦\nNCT04543617\n\nA Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiraâ€¦\nYO42137\nINDUSTRY\nHoffmann-La Roche\n[{â€œidâ€: â€œ2020-001178-31â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œArm A vs Arm C: Investigator-Assessed Progression-Free Survival (PFS)â€, â€œtimeFrameâ€: â€œâ€¦\n[{â€œmeasureâ€: â€œArm B vs Arm C: Investigator-Assessed PFSâ€, â€œtimeFrameâ€: â€œFrom randomization to the fiâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2027-03-31\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-20\nACTUAL\n2026-01-16\nACTIVE_NOT_RECRUITING\n2027-03-31\nESTIMATED\n\n\n\n\n2020-09-28\nACTUAL\n2026-01\n2020-09-10\nACTUAL\n2020-09-03\n2020-09-03\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Doâ€¦\n[{â€œidâ€: â€œD014801â€, â€œtermâ€: â€œVitamin Aâ€}, {â€œidâ€: â€œD012176â€, â€œtermâ€: â€œRetinoidsâ€}, {â€œidâ€: â€œD002338â€, â€œâ€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œC531958â€, â€œtermâ€: â€œlenvatinibâ€}, {â€œidâ€: â€œD01421â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPembrolizumab + Quavonlimab + Vibostolimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œAdministered via IV infusion at a sâ€¦\nMelanoma\nreceptor tyrosine kinase inhibitor, programmed cell death 1 (PD-1, PD1), programmed cell death liganâ€¦\n\n[{â€œfacilityâ€: â€œThe Angeles Clinic and Research Institute ( Site 1009)â€, â€œcityâ€: â€œLos Angelesâ€, â€œstatâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œMerck Sharp & Dohme LLCâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nSubstudy 02A is part of a larger research study that is testing experimental treatments for melanomaâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n100\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n120 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSubstudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Parâ€¦\nNCT04305041\n\nA Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Withouâ€¦\n3475-02A\nINDUSTRY\nMerck Sharp & Dohme LLC\n[{â€œidâ€: â€œMK-3475-02Aâ€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMSDâ€}, {â€œidâ€: â€œKEYMAKER-U02â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nhttps://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf\n\nYES\n\nhttps://externaldatasharing-msd.com/\n\n[{â€œmeasureâ€: â€œPercentage of participants who experience an adverse event (AE)â€, â€œdescriptionâ€: â€œAn Aâ€¦\n[{â€œmeasureâ€: â€œDuration of Response (DOR) per RECIST 1.1â€, â€œdescriptionâ€: â€œFor participants in the anâ€¦\nFalse\nTrue\n\nFalse\n\n[{â€œlabelâ€: â€œMerck Clinical Trials Informationâ€, â€œurlâ€: â€œhttps://www.merckclinicaltrials.com/â€}, {â€œlaâ€¦\n\nINDUSTRY\nMerck Sharp & Dohme LLC\n\n\n\nSPONSOR\n2025-08-25\nACTUAL\n\n\n\n\nFalse\n\n2025-08-29\nACTUAL\n2025-08-28\nCOMPLETED\n2025-08-25\nACTUAL\n\n\n\n\n2020-06-26\nACTUAL\n2025-08\n2020-03-12\nACTUAL\n2020-03-09\n2020-03-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has histologically or cytologically confirmed melanoma\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has unresectable Staâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD017606â€, â€œtermâ€: â€œChlorine Compoundsâ€}, {â€œidâ€: â€œD007287â€, â€œtermâ€: â€œInorganic Chemicalsâ€}, â€¦\n[{â€œidâ€: â€œD002945â€, â€œtermâ€: â€œCisplatinâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD00006843â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSub study 2 Part A: Safety run-inâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipantsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œRilvegostomig will be administered as an â€¦\nAdvanced or Metastatic Non-small Cell Lung Cancer\nCheckpoint inhibitor (CPI), Platinum-based chemotherapy, T-cell immunoreceptor with lg and Immunorecâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œPhoenixâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€:â€¦\n\nThe purpose of this study is to assess the safety and efficacy of multiple study interventions incluâ€¦\nThis is a multicentre, open-label study to evaluate the safety and efficacy of various combinations â€¦\n\n\nRANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n152\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nALTAIR\nA Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nNCT06996782\n\nA Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants Wâ€¦\nD702KC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2024-519786-22â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œEU CT numberâ€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\n\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œPart A and Part B: Number of participants with adverse events (AEs) and serious adversâ€¦\n[{â€œmeasureâ€: â€œPart A: Objective response (OR)â€, â€œdescriptionâ€: â€œThe OR is defined as a BOR of confirâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-02-23\nESTIMATED\n\n\n\n\n\n\n2026-01-14\nACTUAL\n2026-01-13\nRECRUITING\n2029-02-23\nESTIMATED\n\n\n\n\n2025-11-24\nACTUAL\n2026-01\n2025-05-30\nACTUAL\n2025-05-05\n2025-05-21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants with confirmed squamous or non-squamous NSCLC with a current Staâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Doâ€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\n\n\n2025-03-25\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProt_SAPâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: true, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Prâ€¦\nTrue\n[{â€œlabelâ€: â€œPembrolizumab/Vibostolimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants receivâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œPembrolizumab/Vibostolimabâ€, â€œdescriptionâ€: â€œCo-formulation of pembâ€¦\nMelanoma\nProgrammed Cell Death-1 (PD1, PD-1), T-cell immunoreceptor with immunoglobulin and immunoreceptor tyâ€¦\n\n[{â€œfacilityâ€: â€œMoores Cancer Center ( Site 0116)â€, â€œcityâ€: â€œLa Jollaâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€:â€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œMerck Sharp & Dohme LLCâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with resâ€¦\nWith Amendment 4, participants will discontinue treatment with pembrolizumab/vibostolimab.\n\n\nRANDOMIZED\nPARALLEL\n\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nTREATMENT\n\n1594\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n12 Years\n\nALL\nCHILD, ADULT, OLDER_ADULT\n\n\nA Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risâ€¦\nNCT05665595\n\nA Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684â€¦\n7684A-010\nINDUSTRY\nMerck Sharp & Dohme LLC\n[{â€œidâ€: â€œMK-7684A-010â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMSDâ€}, {â€œidâ€: â€œKEYVIBE-010â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nhttps://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf\n\nYES\n\nhttps://externaldatasharing-msd.com/\n\n[{â€œmeasureâ€: â€œRecurrence-Free Survival (RFS)â€, â€œdescriptionâ€: â€œRFS is defined as the time from randoâ€¦\n[{â€œmeasureâ€: â€œNumber of Participants Who Experienced at Least One Adverse Event (AE)â€, â€œdescriptionâ€â€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ39230120â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œShapira-Frommer R, Niu J, Perets R, Peters S, â€¦\n[{â€œlabelâ€: â€œMerck Clinical Trials Informationâ€, â€œurlâ€: â€œhttps://www.merckclinicaltrials.com/â€}, {â€œlaâ€¦\n\nINDUSTRY\nMerck Sharp & Dohme LLC\n\n\n\nSPONSOR\n2025-09-26\nACTUAL\n\n\n\n\nFalse\n\n2025-10-15\nACTUAL\n2025-10-03\nCOMPLETED\n2024-03-06\nACTUAL\n2025-04-06\nACTUAL\n2025-02-07\n2025-03-19\n2023-01-19\nACTUAL\n2025-10\n2022-12-27\nACTUAL\n2022-12-16\n2022-12-16\n\nAll-cause mortality: all participants randomized by the primary completion data cut-off. AEs: all paâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPembrolizumab/Vibostolimabâ€, â€œdescriptionâ€: â€œParticipants received pembroâ€¦\n5.0\n[{â€œtermâ€: â€œHyperthyroidismâ€, â€œorganSystemâ€: â€œEndocrine disordersâ€, â€œsourceVocabularyâ€: â€œMedDRA 26.1â€â€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nUp to approximately 13 months\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ701â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPembrolizumab/Vibostolimabâ€, â€œdescriptionâ€: â€œParticipants received pembroâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nPer protocol, analysis population consisted of all participants randomized by the primary completionâ€¦\nIf publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscâ€¦\nFalse\nOTHER\nTrue\n\nClinicalTrialsDisclosure@msd.com\nMerck Sharp & Dohme LLC\n1-800-672-6372\n\nSenior Vice President, Global Clinical Development\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œRecurrence-Free Survival (RFS)â€, â€œdescriptionâ€: â€œRFS is defined as thâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPembrolizumab/Vibostolimabâ€, â€œdescriptionâ€: â€œParticipants received pembroâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nProtocol-specified final analysis for the following results, including the participant flow, was perâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe protâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has surgically resected and histologically or pathologically confirmed diagnoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDrug: rilvegostomigâ€, â€œinterventionNamesâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œAdministered intravenously (IV) on â€¦\nCarcinoma, Non-Small Cell Lung\nARTEMIDE-Lung04, Rilvegostomig (AZD2936), Non-small cell lung cancer (NSCLC), Bi-specific antibody, â€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œBay Pinesâ€, â€œstateâ€: â€œFloridaâ€, â€œzipâ€¦\n\nThe purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pâ€¦\nThis is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the effiâ€¦\n\n\nRANDOMIZED\nPARALLEL\nParticipants will be randomized in a 1:1 ratio to one of the following intervention arms:\nQUADRUPLE\nDouble blind masking\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n830\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARTEMIDELung04\nA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of Pâ€¦\nNCT06868277\n\nA Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Mâ€¦\nD702GC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2024-517780-24-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTIS (EU)â€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual participant-level data from AstraZâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œdescriptionâ€: â€œOS is defined as the time from randomization uâ€¦\n[{â€œmeasureâ€: â€œLandmark Overall Survival (OS) ratesâ€, â€œdescriptionâ€: â€œOS is defined as the time from â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2030-12-02\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-13\nACTUAL\n2026-01-12\nRECRUITING\n2030-01-17\nESTIMATED\n\n\n\n\n2025-04-10\nACTUAL\n2026-01\n2025-03-10\nACTUAL\n2025-03-07\n2025-03-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nArm A : Râ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented NSCLC (non small lung cancer), incâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD0172â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œRilvegostomig in combination with carbopâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œAdministered intravenously (IV) on Day 1 â€¦\nNon-small Cell Lung Cancer\nARTEMIDE-Lung02, Rilvegostomig (AZD2936), Non-small cell lung cancer (NSCLC), Bi-specific antibody, â€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œNOT_YET_RECRUITINGâ€, â€œcityâ€: â€œTucsonâ€, â€œstateâ€: â€œArizonaâ€,â€¦\n\nThe purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination â€¦\nThis is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the effiâ€¦\n\n\nRANDOMIZED\nPARALLEL\nArm A: Rilvegostomig in combination with carboplatin and paclitaxel or nab-paclitaxel followed by riâ€¦\nQUADRUPLE\nDouble-blind masking\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n880\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatmenâ€¦\nNCT06692738\n\nA Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab iâ€¦\nD702BC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2024-514281-39-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTIS (EU)â€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the European Federaâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œOverall survival (OS)â€, â€œdescriptionâ€: â€œOS is defined as the time from randomization uâ€¦\n[{â€œmeasureâ€: â€œLandmark overall survival (OS) ratesâ€, â€œdescriptionâ€: â€œOS is defined as the time from â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-10-08\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-21\nACTUAL\n2026-01-20\nRECRUITING\n2029-02-05\nESTIMATED\n\n\n\n\n2024-11-18\nACTUAL\n2026-01\n2024-11-18\nACTUAL\n2024-10-04\n2024-11-14\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented squamous NSCLC.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Stage IV mNSCLC â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD051436â€, â€œtermâ€: â€œRenal Insufficiency, Chronicâ€}, {â€œidâ€: â€œD051437â€, â€œtermâ€: â€œRenal Insuffiâ€¦\n[{â€œidâ€: â€œD007676â€, â€œtermâ€: â€œKidney Failure, Chronicâ€}, {â€œidâ€: â€œD009043â€, â€œtermâ€: â€œMotor Activityâ€}, â€¦\n[{â€œidâ€: â€œD064797â€, â€œtermâ€: â€œPhysical Conditioning, Humanâ€}, {â€œidâ€: â€œD015444â€, â€œtermâ€: â€œExerciseâ€}, {â€¦\n[{â€œidâ€: â€œD000072696â€, â€œtermâ€: â€œHigh-Intensity Interval Trainingâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAll subjects will be in one armâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œBoth Lean and â€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œHigh Intensity Interval Trainingâ€, â€œdescriptionâ€: â€œAfter the acclimatizaâ€¦\nEnd Stage Renal Disease\nhigh intensity, interval training, exercise, obesity, inflammation, Treg\n\n[{â€œfacilityâ€: â€œUniversity of Kentucky Transplant Centerâ€, â€œcityâ€: â€œLexingtonâ€, â€œstateâ€: â€œKentuckyâ€, â€¦\n[{â€œnameâ€: â€œFrancesc Marti, PhDâ€, â€œaffiliationâ€: â€œUniversity of Kentucky, College of Medicine / Transâ€¦\nRegulatory T cells (Tregs) are a small population of T cells compromising of 1% to 5% of the total Tâ€¦\nTregs have been studied in clinical practice for different therapeutic applications. In the past sevâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n0\nACTUAL\n\n\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nTrue\n65 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nHigh-Intensity Interval Training and Regulatory T Cells\nNCT04774484\n\nImpact of High-Intensity Interval Training on Regulatory T Cells\n0001\nOTHER\nUniversity of Kentucky\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œChange from baseline Serum IL10 at 12 weeks post HIIT interventionâ€, â€œdescriptionâ€: â€œCâ€¦\n[{â€œmeasureâ€: â€œChange from baseline concentration of circulating Regulatory T cells (Tregs) in blood â€¦\n[{â€œmeasureâ€: â€œChange from baseline Serum Interleukin-6 (IL6) at 12 weeks post HIIT interventionâ€, â€œdâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nFrancesc Marti\nUniversity of Kentucky\nFrancesc Marti\nAssociate Professor\nSPONSOR_INVESTIGATOR\n2026-06-30\nESTIMATED\n\n\n\n\nFalse\n\n2023-02-14\nACTUAL\n2023-02-10\nWITHDRAWN\n2026-06-30\nESTIMATED\n\n\n\n\n2023-01\nESTIMATED\n2023-02\n2021-03-01\nACTUAL\n2020-10-11\n2021-02-24\nFunding was not available.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age between 18 and 65 years old.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* BMI between 18.5 and 25 or above 30. Ratioâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD055752â€, â€œtermâ€: â€œSmall Cell Lung Carcinomaâ€}]\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œâ€¦\nFrance\n\n2025-09-15\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œPlacebo + Atezolizumab + CEâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œParticipants â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTiragolumabâ€, â€œdescriptionâ€: â€œTiragolumab 600 milligrams (mg) administereâ€¦\nSmall Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œRocky Mountain Cancer Centers - Lone Treeâ€, â€œcityâ€: â€œLone Treeâ€, â€œstateâ€: â€œColoradoâ€,â€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposideâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n490\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSKYSCRAPER-02\nA Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With â€¦\nNCT04256421\n\nA Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin andâ€¦\nGO41767\nINDUSTRY\nHoffmann-La Roche\n[{â€œidâ€: â€œ2019-003301-97â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œInvestigator-Assessed Progression Free Survival (PFS) in the Primary Analysis Set (PASâ€¦\n[{â€œmeasureâ€: â€œPFS in the FASâ€, â€œdescriptionâ€: â€œPFS was defined as the time from randomization to theâ€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ37976444â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œRudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee Jâ€¦\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2025-07-31\nACTUAL\n2025-10-22\nACTUAL\n2023-09-01\n\nFalse\n\n2026-01-28\nACTUAL\n2026-01-09\nCOMPLETED\n2022-09-06\nACTUAL\n2025-10-22\nACTUAL\n2025-08-26\n2025-10-07\n2020-02-04\nACTUAL\n2026-01\n2020-02-05\nACTUAL\n2020-01-31\n2020-02-03\n\nAll-cause mortality- FAS: All randomized participants, whether or not the participant received the aâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œDuring induction treatment partiâ€¦\n5.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nUp to approximately 24 months\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ247â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œDuring induction treatment partiâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nFull analysis set (FAS): All randomized participants, whether or not the participant received the asâ€¦\nThe Study being conducted under this Agreement is part of the Overall Study. Investigator is free toâ€¦\nFalse\nOTHER\nTrue\n\ngenentech@druginfo.com\nHoffmann-La Roche\n800 821-8590\n\nMedical Communications\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œInvestigator-Assessed Progression Free Survival (PFS) in the Primary â€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œDuring induction treatment partiâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nParticipants were randomized to receive Placebo + Atezolizumab (P+A) or Tiragolumab + Atezolizumab (â€¦\nA total of 490 participants with extensive stage small cell lung cancer (SCLC) took part at 139 centâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically confirmed extensive-stage small cell lung canâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005833â€, â€œtermâ€: â€œGenital Neoplasms, Femaleâ€}, {â€œidâ€: â€œD014565â€, â€œtermâ€: â€œUrogenital Neoplâ€¦\n[{â€œidâ€: â€œD016889â€, â€œtermâ€: â€œEndometrial Neoplasmsâ€}, {â€œidâ€: â€œD014594â€, â€œtermâ€: â€œUterine Neoplasmsâ€},â€¦\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000614160â€, â€œtermâ€: â€œtrastuzumab deruxtecanâ€}, {â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€},â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A: T-DXd + Rilvegostomigâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œT-DXd IV Q3W plusâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTrastuzumab deruxtecanâ€, â€œdescriptionâ€: â€œExperimental therapy by intravenâ€¦\nEndometrial Cancer\nEndometrial Cancer, Uterine Cancer, Endometrial Carcinoma, Human epidermal growth factor receptor 2 â€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œWITHDRAWNâ€, â€œcityâ€: â€œTucsonâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œâ€¦\n\nDESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/â€¦\n\n\n\nRANDOMIZED\nPARALLEL\nParticipants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent ECâ€¦\nNONE\nThis is an open-label, Sponsor-blinded study. To maintain the integrity of the study, Sponsor personâ€¦\n\n\nTREATMENT\n\n600\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\n* Key Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nFEMALE\nADULT, OLDER_ADULT\n\nDE-01\nDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumâ€¦\nNCT06989112\n\nDESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase IIâ€¦\nD781DC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2023-508056-19-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTIS (EU)â€}, {â€œidâ€: â€œGOG-3098â€, â€œtypeâ€: â€¦\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œProgression-free survival (PFS), as assessed by BICRâ€, â€œdescriptionâ€: â€œDefined as timeâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œdescriptionâ€: â€œDefined as the time from randomization until tâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œDaiichi Sankyo Co., Ltd.â€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œGynecologic Oncology Group (GOâ€¦\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2031-02-19\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-15\nACTUAL\n2026-01-14\nRECRUITING\n2029-01-19\nESTIMATED\n\n\n\n\n2025-03-27\nACTUAL\n2026-01\n2025-05-25\nACTUAL\n2025-03-11\n2025-05-15\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants must be â‰¥ 18 years of age at the time of screening. Otheâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD020919â€, â€œtermâ€: â€œSleep Disorders, Intrinsicâ€}, {â€œidâ€: â€œD020920â€, â€œtermâ€: â€œDyssomniasâ€}, {â€¦\n[{â€œidâ€: â€œD007319â€, â€œtermâ€: â€œSleep Initiation and Maintenance Disordersâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDigital Cognitive Behavioural Therapy for Insomnia (dCBT-I)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdâ€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œDigital Cognitive Behavioural Therapy for Insomnia (dCBT-I)â€, â€œdescriptiâ€¦\nInsomnia, Cancer\nCancer, Insomnia, Sleep, Survivorship, Quality of life, Anxiety, Depression, Fatigue, Hot Flushes\n[{â€œnameâ€: â€œDonal Brennan, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+353879577510â€, â€œemailâ€: â€œdonal.brennanâ€¦\n[{â€œfacilityâ€: â€œUniversity College Dublinâ€, â€œcityâ€: â€œDublinâ€, â€œzipâ€: â€œD04V1W8â€, â€œcountryâ€: â€œIrelandâ€,â€¦\n[{â€œnameâ€: â€œDonal Brennan, PhDâ€, â€œaffiliationâ€: â€œUniversity College Dublinâ€, â€œroleâ€: â€œPRINCIPAL_INVESâ€¦\nThis study will recruit women over the age of 18 with a current or prior cancer diagnosis who have câ€¦\nWomen who are eligible and provide informed consent will be enrolled into this 2-armed, parallel groâ€¦\n\n\nRANDOMIZED\nPARALLEL\n2-armed, parallel group open label randomised controlled trial. Participants will be randomised 1:1 â€¦\nNONE\n\n\n\nTREATMENT\n\n308\nESTIMATED\n\n\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nFEMALE\nADULT, OLDER_ADULT\n\nSACS\nThe Sleepio After Cancer Study\nNCT05816460\n\nThe Sleepio After Cancer Study (SACS). Digital CBT for Insomnia in Women Cancer Patients - A Randomiâ€¦\nWHI22BRE\nOTHER\nUniversity College Dublin\n[{â€œidâ€: â€œWHI22BREâ€, â€œtypeâ€: â€œOTHER_GRANTâ€, â€œdomainâ€: â€œIrish Cancer Society, Womenâ€™s Health Initiativâ€¦\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œImmune cell countâ€, â€œdescriptionâ€: â€œWe will collect a blood sample from a cohort of paâ€¦\n[{â€œmeasureâ€: â€œMean continuous change in the intervention group compared to the control arm as measurâ€¦\n[{â€œmeasureâ€: â€œSleep related Quality of life as measured by Glasgow Sleep Impact Index (GSII)â€, â€œdescâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ41170811â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œCai Z, Tang Y, Liu C, Li H, Zhao G, Zhao Z, Zhâ€¦\n\n[{â€œnameâ€: â€œIrish Cancer Societyâ€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œBig Health Ltd.â€, â€œclassâ€: â€œUNKNOWNâ€}â€¦\nOTHER\nUniversity College Dublin\n\n\n\nSPONSOR\n2024-06-10\nESTIMATED\n\n\n\n\nFalse\nNOT_YET_RECRUITING\n2023-05-23\nACTUAL\n2023-05-19\nUNKNOWN\n2024-06-10\nESTIMATED\n\n\n\n\n2023-05-22\nESTIMATED\n2023-05\n2023-04-18\nACTUAL\n2023-03-13\n2023-04-14\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Women\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Aged 18 and over\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Sleep Condition Indicator (SCI) score of 16 or lesâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD0029â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œRilvegostomig in combination with platinâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œAdministered as one intravenously (IV) onâ€¦\nNon-squamous Non-small Cell Lung Cancer\nARTEMIDE-Lung03, Rilvegostomig (AZD2936), Non-squamous non-small cell lung cancer (NSCLC), Bi-specifâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œMobileâ€, â€œstateâ€: â€œAlabamaâ€, â€œzipâ€: â€¦\n\nThe purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pâ€¦\nThis is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the effiâ€¦\n\n\nRANDOMIZED\nPARALLEL\nArm A: Rilvegostomig in combination with platinum-based doublet chemotherapy followed by rilvegostomâ€¦\nQUADRUPLE\nDouble-blind masking\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n878\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatmenâ€¦\nNCT06627647\n\nA Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab iâ€¦\nD702FC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2024-515008-38-00â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œCTIS IDâ€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œOverall survival (OS)â€, â€œdescriptionâ€: â€œOS is defined as the time from randomization uâ€¦\n[{â€œmeasureâ€: â€œLandmark overall survival (OS) ratesâ€, â€œdescriptionâ€: â€œOS is defined as the time from â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2030-03-25\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-22\nACTUAL\n2025-12-19\nRECRUITING\n2029-05-10\nESTIMATED\n\n\n\n\n2024-11-27\nACTUAL\n2025-12\n2024-10-04\nACTUAL\n2024-10-03\n2024-10-03\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented non-squamous NSCLC.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Stage IV mNSâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Doâ€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œC531958â€, â€œtermâ€: â€œlenvatinibâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPembrolizumab + Vibostolimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants willâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œAdministered via IV infusion at a sâ€¦\nMelanoma\nprogrammed cell death 1 (PD-1, PD1), programmed cell death ligand 1 (PD-L1, PDL1), T cell immunoreceâ€¦\n\n[{â€œfacilityâ€: â€œThe Angeles Clinic and Research Institute ( Site 2009)â€, â€œcityâ€: â€œLos Angelesâ€, â€œstatâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œMerck Sharp & Dohme LLCâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nSubstudy 02B is part of a larger research study where researchers are looking for new ways to treat â€¦\nWith Amendment 6, all arms are closed to enrollment. Participants in arms 2 (pembrolizumab), 3 (cofoâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n315\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n120 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSubstudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pemâ€¦\nNCT04305054\n\nA Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Withouâ€¦\n3475-02B\nINDUSTRY\nMerck Sharp & Dohme LLC\n[{â€œidâ€: â€œMK-3475-02Bâ€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMSDâ€}, {â€œidâ€: â€œKEYMAKER-U02â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nhttps://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf\n\nYES\n\nhttps://externaldatasharing-msd.com/\n\n[{â€œmeasureâ€: â€œPercentage of participants who experience a dose-limiting toxicity (DLT): Safety lead-â€¦\n[{â€œmeasureâ€: â€œDuration of Response (DOR) per RECIST 1.1â€, â€œdescriptionâ€: â€œFor participants in the anâ€¦\nFalse\nTrue\n\nFalse\n\n[{â€œlabelâ€: â€œMerck Clinical Trials Informationâ€, â€œurlâ€: â€œhttps://www.merckclinicaltrials.com/â€}, {â€œlaâ€¦\n\nINDUSTRY\nMerck Sharp & Dohme LLC\n\n\n\nSPONSOR\n2026-04-20\nESTIMATED\n\n\n\n\nFalse\n\n2025-08-29\nACTUAL\n2025-08-28\nACTIVE_NOT_RECRUITING\n2026-04-20\nESTIMATED\n\n\n\n\n2020-07-01\nACTUAL\n2025-08\n2020-03-12\nACTUAL\n2020-03-09\n2020-03-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has histologically or cytologically confirmed melanoma\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has unresectable Staâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\nArgentina, Denmark, France\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTiragolumab + Atezolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants will râ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œAtezolizumab 1200 milligrams (mg) administâ€¦\nNon-Small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œRocky Mountain Cancer Center - Denverâ€, â€œcityâ€: â€œDenverâ€, â€œstateâ€: â€œColoradoâ€, â€œzipâ€:â€¦\n[{â€œnameâ€: â€œClinical Trialâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab comâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n620\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSKYSCRAPER-01\nA Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atâ€¦\nNCT04294810\n\nA Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antiâ€¦\nGO41717\nINDUSTRY\nHoffmann-La Roche\n[{â€œidâ€: â€œ2019-002925-31â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œ2022-502482-17-00â€, â€œtypeâ€: â€œCTISâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œInvestigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Setâ€, â€œtâ€¦\n[{â€œmeasureâ€: â€œInvestigator-Assessed PFS in the Secondary Analysis Setâ€, â€œtimeFrameâ€: â€œFrom randomizaâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2025-12-30\nACTUAL\n\n\n\n\nFalse\n\n2026-01-30\nACTUAL\n2026-01-29\nCOMPLETED\n2025-12-30\nACTUAL\n\n\n\n\n2020-03-04\nACTUAL\n2026-01\n2020-03-04\nACTUAL\n2020-03-02\n2020-03-02\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}, {â€œidâ€: â€œC537340â€, â€œtermâ€: â€œSimpson-Golabi-Bâ€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCAR-T cell therapy groupâ€, â€œtypeâ€: â€œOTHERâ€, â€œdescriptionâ€: â€œAppropriate patients who couâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œGPC3 and/or TGFÎ² targeting CAR-T cellsâ€, â€œdescriptionâ€: â€œEngineerinâ€¦\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Canâ€¦\nHepatocellular carcinoma, immunotherapy, CAR-T cell therapy, GPC3 or TGFÎ² targeting, Phase I clinicaâ€¦\n[{â€œnameâ€: â€œZhenfeng Zhang, MD,PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0086-020-34153532â€, â€œemailâ€: â€œzhangâ€¦\n[{â€œfacilityâ€: â€œThe First Affiliated Hospital of Sun Yat-sen Universityâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œciâ€¦\n[{â€œnameâ€: â€œZhenfeng Zhang, MD,PhDâ€, â€œaffiliationâ€: â€œSecond Affiliated Hospital of Guangzhou Medical â€¦\nThe third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFÎ² (GPâ€¦\n1. Choose appropriate patients with advanced hepatocellular carcinoma,with written consent for this â€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression\nNCT03198546\n\nCAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial\nZZCART-003\nOTHER\nSecond Affiliated Hospital of Guangzhou Medical University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œNumber of Patients with Dose Limiting Toxicityâ€, â€œdescriptionâ€: â€œA dose limiting toxicâ€¦\n[{â€œmeasureâ€: â€œPercent of Patients with best response as either complete remission or partial remissiâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ28123387â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œJiang Z, Jiang X, Chen S, Lai Y, Wei X, Li B, Lâ€¦\n\n[{â€œnameâ€: â€œHunan Zhaotai Yongren Medical Innovation Co.Â Ltd.â€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œGuangdonâ€¦\nOTHER\nSecond Affiliated Hospital of Guangzhou Medical University\n\n\n\nSPONSOR\n2036-08-01\nESTIMATED\n\n\n\n\nFalse\n\n2024-06-25\nACTUAL\n2024-06-22\nRECRUITING\n2029-08-01\nESTIMATED\n\n\n\n\n2017-07-01\nACTUAL\n2024-06\n2017-06-26\nACTUAL\n2017-06-21\n2017-06-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. patients with advanced HCC,which express GPC3 protein.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Life expectancy &gt;â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD012142â€, â€œtermâ€: â€œRespiratory Tract Neoplasmsâ€}, {â€œidâ€: â€œD013899â€, â€œtermâ€: â€œThoracic Neoplâ€¦\n[{â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplasmsâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}]\n[{â€œidâ€: â€œD058851â€, â€œtermâ€: â€œGPI-Linked Proteinsâ€}, {â€œidâ€: â€œD008562â€, â€œtermâ€: â€œMembrane Glycoproteinsâ€¦\n[{â€œidâ€: â€œD000090204â€, â€œtermâ€: â€œMesothelinâ€}, {â€œidâ€: â€œD006162â€, â€œtermâ€: â€œGuanylate Cyclaseâ€}, {â€œidâ€: â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCAR-T cell therapy groupâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients will receiveâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œCAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3,â€¦\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nLung Cancer, CAR-T Cell Therapy, PSCA, MUC1, HER2, Mesothelin, Lewis-Y, GPC3, AXL, EGFR, B7-H3, Clauâ€¦\n[{â€œnameâ€: â€œZhenfeng Zhang, MD,PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0086-020-34153532â€, â€œemailâ€: â€œzhangâ€¦\n[{â€œfacilityâ€: â€œThe First Affiliated Hospital of Sun Yat-sen Universityâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œciâ€¦\n[{â€œnameâ€: â€œZhenfeng Zhang, MD,PhDâ€, â€œaffiliationâ€: â€œSecond Affiliated Hospital of Guangzhou Medical â€¦\nThe third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, â€¦\n1. Choose appropriate patients with advanced lung or other cancers,with written consent for this stuâ€¦\n\n\n\nSINGLE_GROUP\nUse engineered CAR-T cells to kill cancer cells with certain targets.\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nGPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFÎ²/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Againâ€¦\nNCT03198052\n\nCAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFÎ², HER2, Lewis-Y,â€¦\nZZCART-002\nOTHER\nSecond Affiliated Hospital of Guangzhou Medical University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œNumber of Patients with Dose Limiting Toxicityâ€, â€œdescriptionâ€: â€œA dose limiting toxicâ€¦\n[{â€œmeasureâ€: â€œPercent of Patients with best response as either complete remission or partial remissiâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ28405515â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œWei X, Lai Y, Li J, Qin L, Xu Y, Zhao R, Li B, â€¦\n\n[{â€œnameâ€: â€œHunan Zhaotai Yongren Medical Innovation Co.Â Ltd.â€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œGuangdonâ€¦\nOTHER\nSecond Affiliated Hospital of Guangzhou Medical University\n\n\n\nSPONSOR\n2036-08-01\nESTIMATED\n\n\n\n\nFalse\n\n2024-06-25\nACTUAL\n2024-06-22\nRECRUITING\n2026-08-01\nESTIMATED\n\n\n\n\n2017-07-01\nACTUAL\n2024-06\n2017-06-23\nACTUAL\n2017-06-22\n2017-06-22\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Patients with advanced cancer that expresses GPC3/Mesothelin/Claudin18.2/GUâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplaâ€¦\n[{â€œidâ€: â€œD001549â€, â€œtermâ€: â€œBenzamidesâ€}, {â€œidâ€: â€œD000577â€, â€œtermâ€: â€œAmidesâ€}, {â€œidâ€: â€œD009930â€, â€œteâ€¦\n[{â€œidâ€: â€œC000601108â€, â€œtermâ€: â€œencorafenibâ€}, {â€œidâ€: â€œC581313â€, â€œtermâ€: â€œbinimetinibâ€}, {â€œidâ€: â€œD000â€¦\nCanada, United Kingdom\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œSub-Study Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œSasanlimab will be administered suâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œSasanlimab Prefilled syringeâ€, â€œdescriptionâ€: â€œprefilled syringeâ€, â€œarmGrâ€¦\nCarcinoma, Non-Small-Cell Lung\nNon-Small-Cell Lung Carcinoma, NSCLC, non small cell lung cancer, non-small cell lung cancer, BRAF mâ€¦\n\n[{â€œfacilityâ€: â€œCity of Hope Investigational Drug Services (IDS)â€, â€œcityâ€: â€œDuarteâ€, â€œstateâ€: â€œCalifoâ€¦\n[{â€œnameâ€: â€œPfizer CT.gov Call Centerâ€, â€œaffiliationâ€: â€œPfizerâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nPhase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study.\nLandscape 1011 is a clinical research study for people with advanced (stage 3b or 4) non-small cell â€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n34\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria Umbrella Phase 1b & 2:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Nâ€¦\nNCT04585815\n\nA Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Mâ€¦\nB8011011\nINDUSTRY\nPfizer\n[{â€œidâ€: â€œ2020-002829-28â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\n\nPfizer will provide access to individual de-identified participant data and related study documents â€¦\n\nYES\n\nhttps://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests\n\n[{â€œmeasureâ€: â€œPhase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLTâ€¦\n[{â€œmeasureâ€: â€œPhase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded Accorâ€¦\nFalse\nTrue\n\nFalse\n\n[{â€œlabelâ€: â€œTo obtain contact information for a study center near you, click here.â€, â€œurlâ€: â€œhttps:/â€¦\n\nINDUSTRY\nPfizer\n\n\n\nSPONSOR\n2024-10-29\nACTUAL\n\n\n\n\nFalse\n\n2026-01-09\nACTUAL\n2025-12-18\nTERMINATED\n2023-05-17\nACTUAL\n2023-06-22\nACTUAL\n2023-05-30\n2023-05-30\n2020-11-10\nACTUAL\n2025-12\n2020-10-14\nACTUAL\n2020-09-30\n2020-10-09\nStudy was terminated due to portfolio re-prioritization and strategic considerations. The decision wâ€¦\nSame event may appear as both non-serious adverse event (non-SAE) and SAE but are distinct events. Aâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (â€¦\n5.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œChest painâ€, â€œorganSystemâ€: â€œGeneral disordersâ€, â€œsourceVocabularyâ€: â€œMedDRA v27.1â€, â€œassâ€¦\nFrom the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maâ€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ4â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaluâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (â€¦\n[{â€œtitleâ€: â€œAge, Categoricalâ€, â€œparamTypeâ€: â€œCOUNT_OF_PARTICIPANTSâ€, â€œunitOfMeasureâ€: â€œParticipantsâ€â€¦\nFull analysis set included all participants who received at least 1 dose of study drug. Participantsâ€¦\nPfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator wiâ€¦\nFalse\nOTHER\nTrue\nDue to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 waâ€¦\nClinicalTrials.gov_Inquiries@pfizer.com\nPfizer Inc.\n1-800-718-1021\n\nPfizer ClinicalTrials.gov Call Center\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œPhase 1b of Sub-Study A: Percentage of Participants With Dose-Limitinâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (â€¦\n[{â€œtitleâ€: â€œSub-study A- Treatment Phaseâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroâ€¦\n57 participants signed informed consent and 34 participants were enrolled in the study. Of these 34 â€¦\nSub-study A (SSA) was planned to be conducted in 2 parts: Phase 1b and Phase 2. Due to a business deâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSasanlimab (a PD-1â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically confirmed locally advaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD044882â€, â€œtermâ€: â€œGlucose Metabolism Disordersâ€}, {â€œidâ€: â€œD008659â€, â€œtermâ€: â€œMetabolic Disâ€¦\n[{â€œidâ€: â€œD003920â€, â€œtermâ€: â€œDiabetes Mellitusâ€}, {â€œidâ€: â€œD003922â€, â€œtermâ€: â€œDiabetes Mellitus, Type â€¦\n[{â€œidâ€: â€œD052216â€, â€œtermâ€: â€œGlucagon-Like Peptide 1â€}, {â€œidâ€: â€œD004763â€, â€œtermâ€: â€œGlucagon-Like Peptâ€¦\n[{â€œidâ€: â€œD000069450â€, â€œtermâ€: â€œLiraglutideâ€}]\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œNNC0114-0006 + Liraglutideâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: NNC011â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œNNC0114-0006â€, â€œdescriptionâ€: â€œNNC0114-0006 12 mg/kg administered i.v (inâ€¦\nDiabetes, Diabetes Mellitus, Type 1\n\n\n[{â€œfacilityâ€: â€œNovo Nordisk Investigational Siteâ€, â€œcityâ€: â€œLa Jollaâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€:â€¦\n[{â€œnameâ€: â€œGlobal Clinical Registry (GCR, 1452)â€, â€œaffiliationâ€: â€œNovo Nordisk A/Sâ€, â€œroleâ€: â€œSTUDY_â€¦\nThis trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principleâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nTREATMENT\n\n308\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n45 Years\n18 Years\n\nALL\nADULT\n\n\nA Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus â€¦\nNCT02443155\n\nA Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Pâ€¦\nNN9828-4150\nINDUSTRY\nNovo Nordisk A/S\n[{â€œidâ€: â€œ2014-001215-39â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œU1111-1154-7172â€, â€œtypeâ€: â€œOTHERâ€, â€œdomâ€¦\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œArea Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT)â€¦\n[{â€œmeasureâ€: â€œAUC0-2h of C-peptide at Week 54 Relative to Baselineâ€, â€œdescriptionâ€: â€œArea under the â€¦\n\n\n\nFalse\n[{â€œpmidâ€: â€œ33662334â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œvon Herrath M, Bain SC, Bode B, Clausen JO, Copâ€¦\n[{â€œlabelâ€: â€œClinical Trials at Novo Nordiskâ€, â€œurlâ€: â€œhttp://novonordisk-trials.comâ€}]\n\nINDUSTRY\nNovo Nordisk A/S\n\n\n\nSPONSOR\n2019-02-27\nACTUAL\n2019-08-19\nACTUAL\n2019-08-16\n2019-08-16\nFalse\n\n2021-04-09\nACTUAL\n2021-03-10\nCOMPLETED\n2018-08-31\nACTUAL\n2021-01-11\nACTUAL\n2020-12-11\n2020-12-11\n2015-11-10\nACTUAL\n2021-03\n2015-05-13\nESTIMATED\n2015-05-11\n2015-05-11\n\nAll reported adverse events are treatment-emergent. Results are based on the safety analysis set (SAâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œNNC0114-0006 + Liraglutideâ€, â€œdescriptionâ€: â€œParticipants received 12 mg/â€¦\n5.0\n[{â€œtermâ€: â€œAbdominal discomfortâ€, â€œorganSystemâ€: â€œGastrointestinal disordersâ€, â€œsourceVocabularyâ€: â€œâ€¦\n[{â€œtermâ€: â€œAbdominal painâ€, â€œorganSystemâ€: â€œGastrointestinal disordersâ€, â€œsourceVocabularyâ€: â€œMedDRAâ€¦\nWeeks 0-80\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ77â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œNNC0114-0006 + Liraglutide (Experimental)â€, â€œdescriptionâ€: â€œParticipants â€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Full analysis set (FAS) included all randomised participants.\nAt the end of the trial, one or more scientific publications may be prepared collaboratively by the â€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@novonordisk.com\nNovo Nordisk A/S\n(+1) 866-867-7178\n\nClinical Reporting Anchor and Disclosure (1452)\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œArea Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Toleâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œNNC0114-0006 + Liraglutide (Experimental)â€, â€œdescriptionâ€: â€œParticipants â€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nParticipants were randomised in a 1:1:1:1 manner to one of the four treatment groups. One participanâ€¦\nThe trial was conducted at 94 sites in Austria, Belgium, Canada, Denmark, Finland, Ireland, Israel, â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Informed consent obtained before any trial-related activities. Trial-related â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBack to Status Summary"
  },
  {
    "objectID": "full_data.html#consolidated-raw-snapshots",
    "href": "full_data.html#consolidated-raw-snapshots",
    "title": "Full Snapshot Data",
    "section": "",
    "text": "This page displays the consolidated raw data from all monitored trial snapshots. This includes all fields from ClinicalTrials.gov in a flattened format.\nDownload Full Snapshots (CSV)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nannotationSection_annotationModule_unpostedAnnotation_unpostedEvents\nannotationSection_annotationModule_unpostedAnnotation_unpostedResponsibleParty\nderivedSection_conditionBrowseModule_ancestors\nderivedSection_conditionBrowseModule_meshes\nderivedSection_interventionBrowseModule_ancestors\nderivedSection_interventionBrowseModule_meshes\nderivedSection_miscInfoModule_removedCountries\nderivedSection_miscInfoModule_submissionTracking_estimatedResultsFirstSubmitDate\nderivedSection_miscInfoModule_submissionTracking_firstMcpInfo_postDateStruct_date\nderivedSection_miscInfoModule_submissionTracking_firstMcpInfo_postDateStruct_type\nderivedSection_miscInfoModule_submissionTracking_submissionInfos\nderivedSection_miscInfoModule_versionHolder\ndocumentSection_largeDocumentModule_largeDocs\nhasResults\nprotocolSection_armsInterventionsModule_armGroups\nprotocolSection_armsInterventionsModule_interventions\nprotocolSection_conditionsModule_conditions\nprotocolSection_conditionsModule_keywords\nprotocolSection_contactsLocationsModule_centralContacts\nprotocolSection_contactsLocationsModule_locations\nprotocolSection_contactsLocationsModule_overallOfficials\nprotocolSection_descriptionModule_briefSummary\nprotocolSection_descriptionModule_detailedDescription\nprotocolSection_designModule_bioSpec_description\nprotocolSection_designModule_bioSpec_retention\nprotocolSection_designModule_designInfo_allocation\nprotocolSection_designModule_designInfo_interventionModel\nprotocolSection_designModule_designInfo_interventionModelDescription\nprotocolSection_designModule_designInfo_maskingInfo_masking\nprotocolSection_designModule_designInfo_maskingInfo_maskingDescription\nprotocolSection_designModule_designInfo_maskingInfo_whoMasked\nprotocolSection_designModule_designInfo_observationalModel\nprotocolSection_designModule_designInfo_primaryPurpose\nprotocolSection_designModule_designInfo_timePerspective\nprotocolSection_designModule_enrollmentInfo_count\nprotocolSection_designModule_enrollmentInfo_type\nprotocolSection_designModule_patientRegistry\nprotocolSection_designModule_phases\nprotocolSection_designModule_studyType\nprotocolSection_designModule_targetDuration\nprotocolSection_eligibilityModule_eligibilityCriteria\nprotocolSection_eligibilityModule_genderBased\nprotocolSection_eligibilityModule_genderDescription\nprotocolSection_eligibilityModule_healthyVolunteers\nprotocolSection_eligibilityModule_maximumAge\nprotocolSection_eligibilityModule_minimumAge\nprotocolSection_eligibilityModule_samplingMethod\nprotocolSection_eligibilityModule_sex\nprotocolSection_eligibilityModule_stdAges\nprotocolSection_eligibilityModule_studyPopulation\nprotocolSection_identificationModule_acronym\nprotocolSection_identificationModule_briefTitle\nprotocolSection_identificationModule_nctId\nprotocolSection_identificationModule_nctIdAliases\nprotocolSection_identificationModule_officialTitle\nprotocolSection_identificationModule_orgStudyIdInfo_id\nprotocolSection_identificationModule_organization_class\nprotocolSection_identificationModule_organization_fullName\nprotocolSection_identificationModule_secondaryIdInfos\nprotocolSection_ipdSharingStatementModule_accessCriteria\nprotocolSection_ipdSharingStatementModule_description\nprotocolSection_ipdSharingStatementModule_infoTypes\nprotocolSection_ipdSharingStatementModule_ipdSharing\nprotocolSection_ipdSharingStatementModule_timeFrame\nprotocolSection_ipdSharingStatementModule_url\nprotocolSection_outcomesModule_otherOutcomes\nprotocolSection_outcomesModule_primaryOutcomes\nprotocolSection_outcomesModule_secondaryOutcomes\nprotocolSection_oversightModule_isFdaRegulatedDevice\nprotocolSection_oversightModule_isFdaRegulatedDrug\nprotocolSection_oversightModule_isUsExport\nprotocolSection_oversightModule_oversightHasDmc\nprotocolSection_referencesModule_references\nprotocolSection_referencesModule_seeAlsoLinks\nprotocolSection_sponsorCollaboratorsModule_collaborators\nprotocolSection_sponsorCollaboratorsModule_leadSponsor_class\nprotocolSection_sponsorCollaboratorsModule_leadSponsor_name\nprotocolSection_sponsorCollaboratorsModule_responsibleParty_investigatorAffiliation\nprotocolSection_sponsorCollaboratorsModule_responsibleParty_investigatorFullName\nprotocolSection_sponsorCollaboratorsModule_responsibleParty_investigatorTitle\nprotocolSection_sponsorCollaboratorsModule_responsibleParty_type\nprotocolSection_statusModule_completionDateStruct_date\nprotocolSection_statusModule_completionDateStruct_type\nprotocolSection_statusModule_dispFirstPostDateStruct_date\nprotocolSection_statusModule_dispFirstPostDateStruct_type\nprotocolSection_statusModule_dispFirstSubmitDate\nprotocolSection_statusModule_dispFirstSubmitQcDate\nprotocolSection_statusModule_expandedAccessInfo_hasExpandedAccess\nprotocolSection_statusModule_lastKnownStatus\nprotocolSection_statusModule_lastUpdatePostDateStruct_date\nprotocolSection_statusModule_lastUpdatePostDateStruct_type\nprotocolSection_statusModule_lastUpdateSubmitDate\nprotocolSection_statusModule_overallStatus\nprotocolSection_statusModule_primaryCompletionDateStruct_date\nprotocolSection_statusModule_primaryCompletionDateStruct_type\nprotocolSection_statusModule_resultsFirstPostDateStruct_date\nprotocolSection_statusModule_resultsFirstPostDateStruct_type\nprotocolSection_statusModule_resultsFirstSubmitDate\nprotocolSection_statusModule_resultsFirstSubmitQcDate\nprotocolSection_statusModule_startDateStruct_date\nprotocolSection_statusModule_startDateStruct_type\nprotocolSection_statusModule_statusVerifiedDate\nprotocolSection_statusModule_studyFirstPostDateStruct_date\nprotocolSection_statusModule_studyFirstPostDateStruct_type\nprotocolSection_statusModule_studyFirstSubmitDate\nprotocolSection_statusModule_studyFirstSubmitQcDate\nprotocolSection_statusModule_whyStopped\nresultsSection_adverseEventsModule_description\nresultsSection_adverseEventsModule_eventGroups\nresultsSection_adverseEventsModule_frequencyThreshold\nresultsSection_adverseEventsModule_otherEvents\nresultsSection_adverseEventsModule_seriousEvents\nresultsSection_adverseEventsModule_timeFrame\nresultsSection_baselineCharacteristicsModule_denoms\nresultsSection_baselineCharacteristicsModule_groups\nresultsSection_baselineCharacteristicsModule_measures\nresultsSection_baselineCharacteristicsModule_populationDescription\nresultsSection_moreInfoModule_certainAgreement_otherDetails\nresultsSection_moreInfoModule_certainAgreement_piSponsorEmployee\nresultsSection_moreInfoModule_certainAgreement_restrictionType\nresultsSection_moreInfoModule_certainAgreement_restrictiveAgreement\nresultsSection_moreInfoModule_limitationsAndCaveats_description\nresultsSection_moreInfoModule_pointOfContact_email\nresultsSection_moreInfoModule_pointOfContact_organization\nresultsSection_moreInfoModule_pointOfContact_phone\nresultsSection_moreInfoModule_pointOfContact_phoneExt\nresultsSection_moreInfoModule_pointOfContact_title\nresultsSection_outcomeMeasuresModule_outcomeMeasures\nresultsSection_participantFlowModule_groups\nresultsSection_participantFlowModule_periods\nresultsSection_participantFlowModule_preAssignmentDetails\nresultsSection_participantFlowModule_recruitmentDetails\n\n\n\n\n\n\n[{â€œidâ€: â€œD007951â€, â€œtermâ€: â€œLeukemia, Myeloidâ€}, {â€œidâ€: â€œD007938â€, â€œtermâ€: â€œLeukemiaâ€}, {â€œidâ€: â€œD009â€¦\n[{â€œidâ€: â€œD015464â€, â€œtermâ€: â€œLeukemia, Myelogenous, Chronic, BCR-ABL Positiveâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œchronic myeloid leukemia patientsâ€, â€œinterventionNamesâ€: [â€œDiagnostic Test: flow cytometâ€¦\n[{â€œtypeâ€: â€œDIAGNOSTIC_TESTâ€, â€œnameâ€: â€œflow cytometry testâ€, â€œdescriptionâ€: â€œBlood samples will be stâ€¦\nChronic Myeloid Leukemia\n\n[{â€œnameâ€: â€œOla Abdelkarem, M.B.B.Châ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ00201066088250â€, â€œemailâ€: â€œolaabdâ€¦\n\n\nTo expresse TIGIT in NK Cells in Patients with Chronic Myeloid Leukemia\nChronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. Itâ€™s a type of cancer â€¦\n\n\n\n\n\n\n\n\nCASE_CONTROL\n\nCROSS_SECTIONAL\n65\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nTrue\n\n\nNON_PROBABILITY_SAMPLE\nALL\nCHILD, ADULT, OLDER_ADULT\nthe participants will be divided into 2 groups , 40 CML patients and 25 healthy individuals .\n\nTIGIT in Patients With Chronic Myeloid Leukemia\nNCT04818619\n\nExpression of TIGIT in NK Cells in Patients With Chronic Myeloid Leukemia\nchronic myeloid leukemia\nOTHER\nAssiut University\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œTIGIT expression frequency on NK cellsâ€, â€œdescriptionâ€: â€œIn this study, we will assay â€¦\n\nFalse\nFalse\n\n\n[{â€œpmidâ€: â€œ10403855â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œFaderl S, Talpaz M, Estrov Z, Oâ€™Brien S, Kuâ€¦\n\n\nOTHER\nAssiut University\nAssiut University\nOla Abdelkarem Hasan\nClinical pathologist\nPRINCIPAL_INVESTIGATOR\n2022-12\nESTIMATED\n\n\n\n\nFalse\nNOT_YET_RECRUITING\n2021-03-29\nACTUAL\n2021-03-25\nUNKNOWN\n2022-04\nESTIMATED\n\n\n\n\n2021-04\nESTIMATED\n2021-03\n2021-03-26\nACTUAL\n2021-03-24\n2021-03-24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* CML patients\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Healthy individuals\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nExclusion Criteria:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients who have â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD054219â€, â€œtermâ€: â€œNeoplasms, Plasma Cellâ€}, {â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplasms by Histolâ€¦\n[{â€œidâ€: â€œD009101â€, â€œtermâ€: â€œMultiple Myelomaâ€}, {â€œidâ€: â€œD012008â€, â€œtermâ€: â€œRecurrenceâ€}]\n[{â€œidâ€: â€œD011246â€, â€œtermâ€: â€œPregnadienetriolsâ€}, {â€œidâ€: â€œD011245â€, â€œtermâ€: â€œPregnadienesâ€}, {â€œidâ€: â€œâ€¦\n[{â€œidâ€: â€œC546027â€, â€œtermâ€: â€œelotuzumabâ€}, {â€œidâ€: â€œC467566â€, â€œtermâ€: â€œpomalidomideâ€}, {â€œidâ€: â€œD003907â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A - Elotuzumabâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œPatients receive Elotuâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œElotuzumab, pomalidomide, dexamethasoneâ€, â€œdescriptionâ€: â€œStudy Patients â€¦\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nMultiple Myeloma, Relapsed, Refractory, MM, Multiple Myeloma Research Consortium, Multiple Myeloma Râ€¦\n\n[{â€œfacilityâ€: â€œEmory Universityâ€, â€œcityâ€: â€œAtlantaâ€, â€œstateâ€: â€œGeorgiaâ€, â€œzipâ€: â€œ30322â€, â€œcountryâ€: â€¦\n[{â€œnameâ€: â€œMadhav V. Dhodapkar, M.D.â€, â€œaffiliationâ€: â€œMedical Monitorâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nThis a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have râ€¦\nThis study will enroll 104 patients to one of three treatment arms. The study is open to patients reâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\nThe trial is designed for patients with functionally high-risk MM (early relapse after initial theraâ€¦\nNONE\n\n\n\nTREATMENT\n\n14\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nImmuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT\nNCT04150965\n\nA Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) andâ€¦\nMyCheckpoint (MMRC-089)\nNETWORK\nMultiple Myeloma Research Consortium\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œOverall Response Rateâ€, â€œdescriptionâ€: â€œThe overall response rate of the drug combinatâ€¦\n\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ39187595â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œRichard S, Lesokhin AM, Paul B, Kaufman JL, Piâ€¦\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œEmory Universityâ€, â€œclassâ€: â€œOTHERâ€¦\nNETWORK\nMultiple Myeloma Research Consortium\n\n\n\nSPONSOR\n2024-08-30\nACTUAL\n\n\n\n\nFalse\n\n2025-02-14\nACTUAL\n2025-02-12\nTERMINATED\n2024-08-30\nACTUAL\n\n\n\n\n2020-07-10\nACTUAL\n2025-02\n2019-11-05\nACTUAL\n2019-11-01\n2019-11-01\nPharmaceutical support has been discontinued.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. 18 years of age or greater.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Willing and able to provide informed consent\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPM1009 120 mg monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPM1009 120 mgâ€, â€œintâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPM1009 injectionâ€, â€œdescriptionâ€: â€œParticipants receive PM1009 intravenouâ€¦\nAdvanced Tumor\nPM1009, TIGIT, PVRIG\n[{â€œnameâ€: â€œXuelian Xingâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+86 021 32120207â€, â€œemailâ€: â€œxing.xl@biotheusâ€¦\n[{â€œfacilityâ€: â€œShanghai Orient Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œShanghaiâ€, â€œcountryâ€: â€œChâ€¦\n[{â€œnameâ€: â€œYe Guoâ€, â€œaffiliationâ€: â€œShanghai Orient Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nThe study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary effiâ€¦\nThis is a single-arm, open-label, Phase I study contains dose escalation stage and dose expansion stâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nPatients sequentially receive PM1009 120 mg, 300 mg, 600 mg, 1200 mg, intravenously, Q2W\nNONE\n\n\n\nTREATMENT\n\n54\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours\nNCT05607563\n\nA Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetic Characteristics and Preliminarâ€¦\nPM1009-A001M-ST-R\nINDUSTRY\nBiotheus Inc.\n\nNCI is committed to sharing data in accordance with NIH policy.\nThe data will be published or presented for publications (poster, abstract, articles or papers) or mâ€¦\n\nYES\nafter the trial completed\n\n[{â€œmeasureâ€: â€œT-lymphocyte phenotypesâ€, â€œdescriptionâ€: â€œT-lymphocyte phenotypes in peripheral bloodâ€â€¦\n[{â€œmeasureâ€: â€œDose Limited Toxicityï¼ˆDLTï¼‰â€, â€œdescriptionâ€: â€œOccurrence of DLT after receiving PM1009 â€¦\n[{â€œmeasureâ€: â€œRecommended Phase II Dose (RP2D)â€, â€œdescriptionâ€: â€œTo determine the RP2D of PM1009 injâ€¦\nFalse\nFalse\n\nFalse\n\n\n\nINDUSTRY\nBiotheus Inc.\n\n\n\nSPONSOR\n2023-12\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2023-02-08\nACTUAL\n2023-02-07\nUNKNOWN\n2023-11\nESTIMATED\n\n\n\n\n2022-11-21\nACTUAL\n2022-11\n2022-11-07\nACTUAL\n2022-10-19\n2022-11-04\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients participate in the study voluntarily and sign informed consentï¼›\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Maâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHLX53â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œan anti-TIGIT Fc fusion proteinâ€, â€œinterâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œHLX53â€, â€œdescriptionâ€: â€œThere are 5 preset dose groups, namely 30mgâ€¦\nAdvanced/Metastatic Solid Tumors\n\n\n[{â€œfacilityâ€: â€œFudan University Shanghai Cancer Centerâ€, â€œcityâ€: â€œShanghaiâ€, â€œcountryâ€: â€œChinaâ€, â€œgeâ€¦\n[{â€œnameâ€: â€œJian Zhangâ€, â€œaffiliationâ€: â€œFudan Universityâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nThis phase I, first-in-human, open-label clinical study will evaluate the safety, tolerability, pharâ€¦\nThis study is an open-label phase I clinical study to evaluate the safety, tolerability , PK/PD and â€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n12\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors\nNCT05394168\n\nA Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Pâ€¦\nHLX53-FIH101\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œAdverse eventâ€, â€œdescriptionâ€: â€œIncidence and severity of adverse events graded accordâ€¦\n[{â€œmeasureâ€: â€œCmaxâ€, â€œdescriptionâ€: â€œPeak concentration of HLX53â€, â€œtimeFrameâ€: â€œFrom baseline to 30â€¦\nFalse\nFalse\n\nTrue\n\n\n\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\nSPONSOR\n2025-03-04\nESTIMATED\n\n\n\n\nFalse\n\n2024-04-01\nACTUAL\n2024-03-28\nACTIVE_NOT_RECRUITING\n2024-12-04\nESTIMATED\n\n\n\n\n2022-12-09\nACTUAL\n2024-03\n2022-05-27\nACTUAL\n2022-04-29\n2022-05-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Voluntary participation in clinical studies, full understanding of the trial,â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD003231â€, â€œtermâ€: â€œConjunctivitisâ€}, {â€œidâ€: â€œD003229â€, â€œtermâ€: â€œConjunctival Diseasesâ€}, {â€œâ€¦\n[{â€œidâ€: â€œD003233â€, â€œtermâ€: â€œConjunctivitis, Allergicâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œConjunctivitis Allergic with allergen-specific immunotherapy (AIT)â€, â€œdescriptionâ€: â€œTheâ€¦\n\nConjunctivitis, Allergic\nconjunctivitis allergic, TIGIT, Tregs, PDL-1\n[{â€œnameâ€: â€œMarÃ­a del CarmÃ©n JimÃ©nez MartÃ­nezâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ5554421700â€, â€œemailâ€: â€œmâ€¦\n[{â€œfacilityâ€: â€œInstituto de OftalmologÃ­a FAP Conde de Valenciana, IAP Sede Centroâ€, â€œcityâ€: â€œMexico â€¦\n\nThis study aims to evaluate the effector function and expression of TIGIT and PD-1 on Tregs, as wellâ€¦\nAllergic conjunctivitis is a prevalent ocular condition affecting approximately 10-20% of the globalâ€¦\nBlood and tear samples will be collected from patients with and without desensitization therapy, as â€¦\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCOHORT\n\nCROSS_SECTIONAL\n60\nESTIMATED\nTrue\n\nOBSERVATIONAL\n1 Day\nInclusion Criteria:\n\n\nTrue\n30 Years\n5 Years\nNON_PROBABILITY_SAMPLE\nALL\nCHILD, ADULT\nThe study subjects are patients recruited from the outpatient clinic of â€œClinical Immunologyâ€ at Insâ€¦\nINMUNOREG\nTreg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therâ€¦\nNCT07171307\n\nStudy of the Effector Function of Regulatory T Cells and the Th2/Treg in Patients With Allergic Conjâ€¦\nCEI-2024/06/16\nOTHER\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\n[{â€œidâ€: â€œCI-032-2024â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œResearch Committeeâ€}, {â€œidâ€: â€œCB-031-2024â€, â€œtypeâ€¦\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œTo evaluate the effector function and the expression of TIGIT and PD-1 molecules on reâ€¦\n[{â€œmeasureâ€: â€œConcentration of IgE and IgG4 antibodies in serum and tearsâ€, â€œdescriptionâ€: â€œSerum anâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ32900655â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œKucuksezer UC, Ozdemir C, Cevhertas L, Ogulâ€¦\n\n\nOTHER\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nMarÃ­a C. JimÃ©nez MartÃ­nez\nHead of the Immunology Department, Research Unit\nPRINCIPAL_INVESTIGATOR\n2026-09\nESTIMATED\n\n\n\n\nFalse\n\n2025-09-17\nACTUAL\n2025-09-15\nNOT_YET_RECRUITING\n2026-09\nESTIMATED\n\n\n\n\n2026-01-01\nESTIMATED\n2025-09\n2025-09-12\nACTUAL\n2025-09-01\n2025-09-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Subjects aged between 5 and 30 years, of either sex.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Subjects with a confirâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Dâ€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Canceâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAZD2936â€, â€œdescriptionâ€: â€œAnti-TIGIT/Anti-PD-1 Bispecific Antibodyâ€, â€œarmâ€¦\nNon-Small-Cell Lung Carcinoma\nTIGIT, Anti-TIGIT, PD-1, Anti-PD-1, NSCLC, Non-small Cell Lung Cancer, Advanced, Metastatic, Solid Tâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œWITHDRAWNâ€, â€œcityâ€: â€œOrangeâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€â€¦\n\nThis is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antiâ€¦\nThis is a first-time-in-human (FTIH), open-label, multicenter, multi-part, dose-escalation and dose-â€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nThe study includes 5 parts: Part A: Dose escalation; B & C & E: Dose expansion non-randomized; D: â€¦\nNONE\n\n\n\nTREATMENT\n\n210\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n130 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARTEMIDE-01\nA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastaâ€¦\nNCT04995523\n\nPhase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokineticâ€¦\nD7020C00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2023-508262-15-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œEU CT Numberâ€}, {â€œidâ€: â€œ2021-000857-23â€,â€¦\nWhen a request has been approved AstraZeneca will provide access to the de-identified individual patâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagroup-dt.pharmacm.com/DT/Home\n\n[{â€œmeasureâ€: â€œPercentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), â€¦\n[{â€œmeasureâ€: â€œORRâ€, â€œdescriptionâ€: â€œPercentage of participants with a confirmed CR or PR according tâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2028-03-16\nESTIMATED\n\n\n\n\n\n\n2025-11-24\nACTUAL\n2025-11-21\nRECRUITING\n2026-08-18\nESTIMATED\n\n\n\n\n2021-09-14\nACTUAL\n2025-11\n2021-08-09\nACTUAL\n2021-07-16\n2021-07-29\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Written informed consent\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Aged 18 or above\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Part A and Part B: Unresectableâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009385â€, â€œtermâ€: â€œNeoplastic Processesâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œâ€¦\n[{â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Metastasisâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œOMP-313M32â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œIntravenous (in the vein) infusionsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOMP-313M32â€, â€œdescriptionâ€: â€œOMP-313M32 is a monoclonal antibody which biâ€¦\nLocally Advanced Cancer, Metastatic Cancer\n\n\n[{â€œfacilityâ€: â€œScottsdaleâ€, â€œcityâ€: â€œScottsdaleâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85258â€, â€œcountryâ€: â€œUnâ€¦\n[{â€œnameâ€: â€œJohn Lewicki, PhDâ€, â€œaffiliationâ€: â€œMereo BioPharmaâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to evaluate the safety and tolerability of OMP-31M32 as a single agent â€¦\nThis is an open-label, Phase 1a/b dose escalation study of OMP-31M32 administered as a single agent â€¦\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n33\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors\nNCT03119428\n\nA Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Admiâ€¦\n313M32-001\nINDUSTRY\nMereo BioPharma\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œIncidence of dose limiting toxicities (DLTs)â€, â€œdescriptionâ€: â€œThe Maximum tolerated dâ€¦\n[{â€œmeasureâ€: â€œPharmacokinetic Outcome Measures (AUC) - Phase 1aâ€, â€œdescriptionâ€: â€œArea under the plaâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ34844977â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œMettu NB, Ulahannan SV, Bendell JC, Garrido-Laâ€¦\n\n\nINDUSTRY\nOncoMed Pharmaceuticals, Inc.\n\n\n\nSPONSOR\n2019-05-15\nACTUAL\n\n\n\n\nFalse\n\n2020-08-11\nACTUAL\n2020-08-10\nTERMINATED\n2019-05-15\nACTUAL\n\n\n\n\n2017-05-02\nACTUAL\n2020-08\n2017-04-18\nACTUAL\n2017-03-29\n2017-04-17\nSponsor decision\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologic documentation of locally advanced, recurrent or metastatic solid â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD015658â€, â€œtermâ€: â€œHIV Infectionsâ€}, {â€œidâ€: â€œD000086982â€, â€œtermâ€: â€œBlood-Borne Infectionsâ€}â€¦\n[{â€œidâ€: â€œD000163â€, â€œtermâ€: â€œAcquired Immunodeficiency Syndromeâ€}]\n[{â€œidâ€: â€œD001645â€, â€œtermâ€: â€œBiguanidesâ€}, {â€œidâ€: â€œD006146â€, â€œtermâ€: â€œGuanidinesâ€}, {â€œidâ€: â€œD000578â€,â€¦\n[{â€œidâ€: â€œD008687â€, â€œtermâ€: â€œMetforminâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œMetforminâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œMetformin 500 mg Extended Release (Eâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œMetforminâ€, â€œdescriptionâ€: â€œMetformin 500 mg Extended Release (ER) qd incâ€¦\nHIV/AIDS\n\n[{â€œnameâ€: â€œCecilia M Shikuma, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ808 692-1328â€, â€œemailâ€: â€œshikuma@hawâ€¦\n[{â€œfacilityâ€: â€œJohn A. Burns School of Medicine, University of Hawaii - Manoaâ€, â€œstatusâ€: â€œRECRUITINâ€¦\n[{â€œnameâ€: â€œCecilia M Shikuma, MDâ€, â€œaffiliationâ€: â€œUniversity of Hawaiiâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIâ€¦\nNon-diabetic, aviremic HIV-infected individuals on antiretroviral therapy (ART) will be randomized tâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\nMetformin vs Observation\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nDIAGNOSTIC\n\n38\nESTIMATED\n\nPHASE2, PHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n40 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nImpact of Metformin on Immuno-virologic Parameters in HIV\nNCT04500678\n\nA 72 Week, Randomized, Open-label vs Observation Study to Assess the Potential Immuno-virologic Beneâ€¦\nH046\nOTHER\nUniversity of Hawaii\n\nDe-identified dataset will be provided upon request to legitimate researchers\nDataset will be available to other researchers upon request once the primary manuscript is written\nSTUDY_PROTOCOL, SAP, ICF\nYES\nAfter the study analyses are completed and primary manuscript is published, and for a duration of atâ€¦\n\n[{â€œmeasureâ€: â€œSafety and Tolerability: # of grade 2 or greater adverse events in each armâ€, â€œdescripâ€¦\n[{â€œmeasureâ€: â€œCD4 T cell PD1+TIGIT+â€, â€œdescriptionâ€: â€œComparison of change over time in percentage oâ€¦\n[{â€œmeasureâ€: â€œCD8 T cell PD1+TIGIT+â€, â€œdescriptionâ€: â€œComparison of change over time in percentage oâ€¦\nFalse\nTrue\nFalse\nFalse\n\n\n[{â€œnameâ€: â€œMerck Sharp & Dohme LLCâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nUniversity of Hawaii\nUniversity of Hawaii\nCecilia Shikuma\nProfessor, Medicine\nPRINCIPAL_INVESTIGATOR\n2022-12-31\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2020-08-05\nACTUAL\n2020-08-04\nUNKNOWN\n2022-02-01\nESTIMATED\n\n\n\n\n2019-02-01\nACTUAL\n2020-08\n2020-08-05\nACTUAL\n2020-07-31\n2020-08-04\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* HIV+\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* On suppressive ART stable for &gt; 1 year\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Plasma HIV RNA &lt; 50 copies/â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siteâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œD01â€¦\n[{â€œidâ€: â€œD006258â€, â€œtermâ€: â€œHead and Neck Neoplasmsâ€}, {â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œLocalized Head and Neck Squamous Cell Cancerâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œtâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTiragolumab and atezolizumabâ€, â€œdescriptionâ€: â€œthree weekly tiragolumab 1â€¦\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\natezolizumab, tiragolumab\n[{â€œnameâ€: â€œDerk JA de Groot, Md PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+31503612821â€, â€œemailâ€: â€œd.j.a.deâ€¦\n[{â€œfacilityâ€: â€œUniversity Medical Center Groningenâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œGroningenâ€, â€œzâ€¦\n[{â€œnameâ€: â€œDerk JA de Groot, MD PhDâ€, â€œaffiliationâ€: â€œUniversity Medical Center Groningenâ€, â€œroleâ€: â€¦\nIn this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and â€¦\nRationale:\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\nSimon 2 stage design with 4 cohorts.\nNONE\n\n\n\nTREATMENT\n\n97\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nTIRACAN\nOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors\nNCT05483400\n\nOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors: TIRACAN\n10389\nOTHER\nUniversity Medical Center Groningen\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œPathologic response in cohort 1â€, â€œdescriptionâ€: â€œpTR is defined as the presence of tuâ€¦\n[{â€œmeasureâ€: â€œClinical safetyâ€, â€œdescriptionâ€: â€œIncidence, nature and severity of adverse events, inâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n\nOTHER\nUniversity Medical Center Groningen\n\n\n\nSPONSOR\n2027-09\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-30\nACTUAL\n2025-03-28\nRECRUITING\n2025-09\nESTIMATED\n\n\n\n\n2023-10-18\nACTUAL\n2025-03\n2022-08-02\nACTUAL\n2022-07-26\n2022-08-01\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTumor immunotherapy has demonstrated that therapies focused on enhancing T cell responseâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Tumor lesion(s) of which a histological biopsy can be safely obtained accordiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplasms by Histologic Typeâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, â€¦\n[{â€œidâ€: â€œD008223â€, â€œtermâ€: â€œLymphomaâ€}, {â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Metastasisâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œExperimental Group(phase Ia)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPhase 1a uses accâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHLX301â€, â€œdescriptionâ€: â€œHLX301 will be administered as a single intravenâ€¦\nAdvanced Tumors, Lymphoma, Metastatic Tumors\n\n\n[{â€œfacilityâ€: â€œJilin Provincial Cancer Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œChangchunâ€, â€œstatâ€¦\n\nA Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, iâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nHLX301\nA Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGITÃ—PDL1 Bispeâ€¦\nNCT05390528\n\nA Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics andâ€¦\nHLX301-002\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œPhase 1a: The incidence, nature, and severity of adverse events according to the Natioâ€¦\n\nFalse\nFalse\n\nFalse\n\n\n\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\nSPONSOR\n2024-12-30\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2023-08-08\nACTUAL\n2023-08-07\nUNKNOWN\n2023-09-01\nESTIMATED\n\n\n\n\n2022-06-20\nACTUAL\n2023-04\n2022-05-25\nACTUAL\n2022-04-25\n2022-05-21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubjects who meet each of the following criteria are eligible for inclusion:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSingle agent zimberelimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œSingle agent zimbereâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œSingle agent zimberelimabâ€, â€œdescriptionâ€: â€œSingle agent zimberelimab (PDâ€¦\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-juncâ€¦\ndMMR, MMRd, MSI-H, gastric adenocarcinoma, GEJ adenocarcinoma, Gastroesophageal-junction adenocarcinâ€¦\n[{â€œnameâ€: â€œProject Managerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ02086613279â€, â€œemailâ€: â€œZODIAC@rmh.nhs.ukâ€â€¦\n[{â€œfacilityâ€: â€œAddenbrookeâ€™s Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œCambridgeâ€, â€œstateâ€: â€œCambrâ€¦\n[{â€œnameâ€: â€œNaureen Starlingâ€, â€œaffiliationâ€: â€œThe Royal Marsden NHSFT UKâ€, â€œroleâ€: â€œPRINCIPAL_INVESTâ€¦\nA phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectabâ€¦\nPrimary objective The primary objective of the trial is to evaluate the efficacy of zimberelimab +/-â€¦\n\n\nRANDOMIZED\nPARALLEL\nA UK multicentre, prospective, randomised open label phase II proof of concept study with screen selâ€¦\nNONE\n\n\n\nTREATMENT\n\n50\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion criteria\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nZODIAC\nZimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer\nNCT06250036\n\nA Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunâ€¦\nCCR5924\nOTHER\nRoyal Marsden NHS Foundation Trust\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œExploratory - Translational analyses to exploring response to immunotherapy. To reviewâ€¦\n[{â€œmeasureâ€: â€œEfficacy of zimberelimab +/- domvanalimab in patients with resectable MMRd/MSI-H gastrâ€¦\n[{â€œmeasureâ€: â€œEfficacy of zimberelimab +/- domvanalimab in patients with resectable MMRd/MSI-H gastrâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nRoyal Marsden NHS Foundation Trust\n\n\n\nSPONSOR\n2031-09-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-08-21\nACTUAL\n2025-08-19\nRECRUITING\n2027-03-20\nESTIMATED\n\n\n\n\n2025-02-20\nACTUAL\n2025-08\n2024-02-08\nACTUAL\n2023-12-11\n2024-01-31\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age: â‰¥18 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed gastric or gastro-oesophageal junctiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAK130â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œEach subject will receive a single dose â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAK130â€, â€œdescriptionâ€: â€œIV infusion, specified dose on specified days.â€, â€¦\nAdvanced Malignant Tumors\n\n\n[{â€œfacilityâ€: â€œThe Cancer Hospital Affiliated to Shandong First Medical Universityâ€, â€œcityâ€: â€œJinanâ€â€¦\n[{â€œnameâ€: â€œJinming Yuâ€, â€œaffiliationâ€: â€œThe Cancer Hospital Affiliated to Shandong First Medical Uniâ€¦\nA Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n19\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of AK130 in Patients With Advanced Malignant Tumors\nNCT05653284\n\nA Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AK13â€¦\nAK130-101\nINDUSTRY\nAkeso\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œIncidence and severity of participants with adverse events (AEs)â€, â€œtimeFrameâ€: â€œFrom â€¦\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œtimeFrameâ€: â€œUp to approximately 2 yearsâ€}, {â€œmeasureâ€¦\nFalse\nFalse\n\n\n\n\n\nINDUSTRY\nAkeso\n\n\n\nSPONSOR\n2024-05-30\nACTUAL\n\n\n\n\nFalse\n\n2024-08-13\nACTUAL\n2024-08-11\nCOMPLETED\n2023-12-12\nACTUAL\n\n\n\n\n2023-02-09\nACTUAL\n2024-08\n2022-12-16\nACTUAL\n2022-11-25\n2022-12-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Written and signed informed consent and any locally required authorization oâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPhase 1a dose-escalation stageâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPhase 1a uses tâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHLX301â€, â€œdescriptionâ€: â€œA Recombinant Humanized Anti-PDL1 and Anti-TIGITâ€¦\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œBlacktown Hospitalâ€, â€œstatusâ€: â€œNOT_YET_RECRUITINGâ€, â€œcityâ€: â€œBlacktownâ€, â€œstateâ€: â€œNâ€¦\n\nThis Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinicâ€¦\nUp to 150 patients will be included in this study. Up to 30 DLT evaluable patients will be enrolled â€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n150\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nHLX301 (TIGITÃ—PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors\nNCT05102214\n\nA Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, iâ€¦\nHLX301-001\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\n\nUNDECIDED\n\n\n[{â€œmeasureâ€: â€œExploratory biomarkers: To evaluate the correlation between biomarker expression levelâ€¦\n[{â€œmeasureâ€: â€œPhase 1a: Safety assessments in patients receiving the trial drugâ€, â€œdescriptionâ€: â€œinâ€¦\n[{â€œmeasureâ€: â€œPhase 1a: The pharmacokinetic parameters of HLX301: Peak concentration (Cmax, Cmax,ss)â€¦\nFalse\nFalse\n\n\n[{â€œpmidâ€: â€œ35522941â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œMu S, Liang Z, Wang Y, Chu W, Chen YL, Wang Q,â€¦\n\n\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\nSPONSOR\n2024-02\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2023-08-08\nACTUAL\n2023-08-07\nUNKNOWN\n2023-09-15\nESTIMATED\n\n\n\n\n2022-05-03\nACTUAL\n2023-04\n2021-11-01\nACTUAL\n2021-09-29\n2021-10-20\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 1. Patients who meet the following criteria will be enrolled:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Phase 1aâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œGP+PD-1+Tightâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTislelizumab 200mg IV Q3W + Ocipâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œGP+PD-1+Tightâ€, â€œdescriptionâ€: â€œDrug: Tislelizumab Tislelizumab 200mg IV â€¦\nBiliary Tract Carcinoma\n\n\n[{â€œfacilityâ€: â€œZhongshan hospitalâ€, â€œcityâ€: â€œShanghaiâ€, â€œzipâ€: â€œ200032â€, â€œcountryâ€: â€œChinaâ€, â€œgeoPoiâ€¦\n[{â€œnameâ€: â€œJia Fanâ€, â€œaffiliationâ€: â€œShanghai Zhongshan Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}â€¦\nThis is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of GP (Gemcitabâ€¦\nBiliary Tract Carcinoma (BTC) has an insidious onset, invasiveness, high malignancy, and no specificâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n45\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nGP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC\nNCT05023109\n\nA Study to Evaluate GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Tâ€¦\nZSAB-TOP\nOTHER\nShanghai Zhongshan Hospital\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œORR is defined as the proportion of suâ€¦\n[{â€œmeasureâ€: â€œDisease control rate (DCR)â€, â€œdescriptionâ€: â€œDCR is defined as the proportion of subjeâ€¦\nFalse\nFalse\n\nFalse\n\n\n[{â€œnameâ€: â€œJining Medical Universityâ€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œCancer Hospital of Guangxi Medicâ€¦\nOTHER\nShanghai Zhongshan Hospital\n\n\n\nSPONSOR\n2024-12-01\nESTIMATED\n\n\n\n\nFalse\nACTIVE_NOT_RECRUITING\n2023-08-15\nACTUAL\n2023-08-12\nUNKNOWN\n2023-01-18\nACTUAL\n\n\n\n\n2021-02-01\nACTUAL\n2023-08\n2021-08-26\nACTUAL\n2021-08-20\n2021-08-20\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â€¢ Subjects with a histopathological or cytologically diagnosis of BTC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Thâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œZimberelimab plus Domvanalimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTreatment Phaseâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œZimberelimabâ€, â€œdescriptionâ€: â€œZimberelimab is a fully human immunoglobulâ€¦\nMelanoma\n\n[{â€œnameâ€: â€œAmy Rose, RN, BSNâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ412-647-8587â€, â€œemailâ€: â€œkennaj@upmc.eduâ€¦\n[{â€œfacilityâ€: â€œUPMC Hillman Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œPittsburghâ€, â€œstateâ€: â€œâ€¦\n[{â€œnameâ€: â€œDiwakar Davar, MDâ€, â€œaffiliationâ€: â€œUPMC Hillman Cancer Centerâ€, â€œroleâ€: â€œPRINCIPAL_INVESâ€¦\nThe main goal of this study is to establish the proportion of patients with objective response to ziâ€¦\nThis is a single-arm two-stage phase II study of PD-1 inhibitor zimberelimab (AB122) in combination â€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n26\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nZimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma\nNCT05130177\n\nPhase II Study of PD-1 Inhibitor Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in Pâ€¦\nHCC 21-150\nOTHER\nUniversity of Pittsburgh\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œThe proportion of patients with Compleâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) (iRECIST)â€, â€œdescriptionâ€: â€œThe proportion of patients wâ€¦\nFalse\nTrue\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œArcus Biosciences, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nDiwakar Davar\nUniversity of Pittsburgh\nDiwakar Davar\nAssistant Professor of Medicine\nSPONSOR_INVESTIGATOR\n2031-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-05-07\nACTUAL\n2025-05-02\nRECRUITING\n2028-01\nESTIMATED\n\n\n\n\n2022-03-16\nACTUAL\n2025-05\n2021-11-23\nACTUAL\n2021-11-10\n2021-11-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male/female participants who are at least 18 years of age on the day of signiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD006147â€, â€œtermâ€: â€œGuanineâ€}, {â€œidâ€: â€œD007042â€, â€œtermâ€: â€œHypoxanthinesâ€}, {â€œidâ€: â€œD011688â€,â€¦\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œD000068437â€, â€œtermâ€: â€œPemetrexedâ€}, {â€œidâ€: â€œDâ€¦\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œPhase 1: Dose Escalation: Ociperlimab 50 mg + Tislelizumab 200 mgâ€, â€œtypeâ€: â€œEXPERIMENTAâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOciperlimabâ€, â€œdescriptionâ€: â€œAdministered as an intravenous (IV) injectiâ€¦\nLocally Advanced and Metastatic Solid Tumors\nBGB-A1217, Anti-TIGIT antibody, Tislelizumab, anti-PD-1 antibody, Ociperlimab\n\n[{â€œfacilityâ€: â€œMayo Clinic Phoenixâ€, â€œcityâ€: â€œPhoenixâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85254â€, â€œcountryâ€¦\n[{â€œnameâ€: â€œStudy Directorâ€, â€œaffiliationâ€: â€œBeiGeneâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe primary objectives of this study were: to assess the safety and tolerability, to determine the mâ€¦\n\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n446\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors\nNCT04047862\n\nPhase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monocloâ€¦\nBGB-900-105\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œAdvanTIG-105â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œBeiGeneâ€}, {â€œidâ€: â€œCTR20202608â€, â€œtypeâ€: â€œOTHERâ€â€¦\nSee plan description\nBeiGene shares data on completed studies responsibly and provides qualified scientific and medical râ€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\nSee plan description\nhttps://beigene.com/science/clinical-trials/\n\n[{â€œmeasureâ€: â€œPhase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treâ€¦\n[{â€œmeasureâ€: â€œPhase 1: ORR as Per RECIST v.1.1â€, â€œdescriptionâ€: â€œORR was defined as the percentage oâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ37857528â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œFrentzas S, Kao S, Gao R, Zheng H, Rizwan A, Buâ€¦\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2024-08-07\nACTUAL\n\n\n\n\nFalse\n\n2025-08-22\nACTUAL\n2025-08-04\nCOMPLETED\n2024-08-07\nACTUAL\n2025-08-22\nACTUAL\n2025-08-04\n2025-08-04\n2019-08-15\nACTUAL\n2025-08\n2019-08-07\nACTUAL\n2019-08-01\n2019-08-06\n\nAnalysis was performed on safety set.\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPhase 1: Dose Escalation: Ociperlimab 50 mg + Tislelizumab 200 mgâ€, â€œdescâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nAll cause-mortality data was collected from randomization through end of study (up to 5 years). SAEsâ€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ1â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaluâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPhase 1: Dose Escalation: Ociperlimab 50 mg + Tislelizumab 200 mgâ€, â€œdescâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nBaseline analysis included participants from safety analysis set, that is, (i.e.) participants who râ€¦\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene\n+1-877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œPhase 1: Number of Participants With Treatment Emergent Adverse Eventâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPhase 1: Dose Escalation: Ociperlimab 50 mg + Tislelizumab 200 mgâ€, â€œdescâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPhase 1 Key Inclusion Criteria\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Had Eastern Cooperative Oncology Group (â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPM1021 150 mg, 450 mg, 900 mg or 1200 mg monotherapy or in combination with PM8001 (20 mâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPM1021, PM8001â€, â€œdescriptionâ€: â€œParticipants will be administered with Pâ€¦\nAdvanced Solid Tumours\nPM1021, PM8001, monotherapy, combination therapy\n[{â€œnameâ€: â€œVineet Kwatra, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+61 883 592 565â€, â€œemailâ€: â€œvineet.kwatâ€¦\n\n[{â€œnameâ€: â€œVineet Kwatraâ€, â€œaffiliationâ€: â€œCancer Research South Australiaâ€, â€œroleâ€: â€œPRINCIPAL_INVEâ€¦\nThe purpose of this research is to assess the safety, tolerability and effectiveness of PM1021 Monotâ€¦\nThis is a single-arm, open-label, Phase I study including a first-in-human study for PM1021, and theâ€¦\n\n\n\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-Î²) in Patients With Advanced Sâ€¦\nNCT05537051\n\nA Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Effâ€¦\nPM10218001-A001C-ST-R\nINDUSTRY\nBiotheus Inc.\n\nNCI is committed to sharing data in accordance with NIH policy.\nThe data will be published or presented for publications (poster, abstract, articles or papers) or mâ€¦\n\nYES\nafter the trial completed\n\n\n[{â€œmeasureâ€: â€œDLTâ€, â€œdescriptionâ€: â€œThe incidence of DLTs in PM1021 monotherapy and PM1021 combinatiâ€¦\n[{â€œmeasureâ€: â€œRP2Dâ€, â€œdescriptionâ€: â€œTo determine the recommended Phase II Dose (RP2D) of PM1021 monâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nINDUSTRY\nBiotheus Inc.\n\n\n\nSPONSOR\n2025-12-31\nESTIMATED\n\n\n\n\nFalse\nNOT_YET_RECRUITING\n2023-02-08\nACTUAL\n2023-02-07\nUNKNOWN\n2024-10-30\nESTIMATED\n\n\n\n\n2023-10-30\nESTIMATED\n2022-09\n2022-09-13\nACTUAL\n2022-09-08\n2022-09-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female, aged 18-75 years (inclusive) on the day of signing the consenâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD018281â€, â€œtermâ€: â€œCholangiocarcinomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œGP+PD-1+Tightâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œExperimental: Tislelizumab 200mgâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œGP+PD-1+Tightâ€, â€œdescriptionâ€: â€œDrug: Tislelizumab Tislelizumab 200mg IV â€¦\nIntrahepatic Cholangiocarcinoma\n\n\n[{â€œfacilityâ€: â€œZhongshan hospital, Fudan Universityâ€, â€œcityâ€: â€œShanghaiâ€, â€œstateâ€: â€œShanghai Municipâ€¦\n[{â€œnameâ€: â€œJia Fanâ€, â€œaffiliationâ€: â€œShanghai Zhongshan Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}â€¦\nThis is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of GP (Gemcitabâ€¦\nBiliary Tract Carcinoma (BTC) have insidious onset, invasiveness, high malignancy, and no specific sâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nGP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advancedâ€¦\nNCT05019677\n\nA Study to Evaluate GP Chemotherapy in Combination With Tislelizumab(Anti-PD-1) and Ociperlimab(Antiâ€¦\nzs-BTC\nOTHER\nFudan University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œORR is defined as the proportion of suâ€¦\n[{â€œmeasureâ€: â€œDisease control rate (DCR)â€, â€œdescriptionâ€: â€œDCR is defined as the proportion of subjeâ€¦\nFalse\nFalse\n\nFalse\n\n\n\nOTHER\nFudan University\nFudan University\nJia Fan\nProfessor\nPRINCIPAL_INVESTIGATOR\n2024-12-01\nESTIMATED\n\n\n\n\nFalse\n\n2022-04-04\nACTUAL\n2022-03-22\nWITHDRAWN\n2024-12-01\nESTIMATED\n\n\n\n\n2021-09-01\nESTIMATED\n2021-08\n2021-08-25\nACTUAL\n2021-08-18\n2021-08-18\nRepeat registration\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â€¢ Subjects with a histopathological or cytologically diagnosis of BTC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Thâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000656314â€, â€œtermâ€: â€œtoripalimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œJS006 as Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œ1. JS006 as Monotherapy dâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œJS006 as Monotherapyâ€, â€œdescriptionâ€: â€œ1. JS006 as Monotherapy dose-escalâ€¦\nAdvanced Tumors\n\n[{â€œnameâ€: â€œBifeng Liuâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ18967116090â€, â€œemailâ€: â€œbifeng_liu@junshipharmaâ€¦\n[{â€œfacilityâ€: â€œSun Yat-Sen University Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œGuangzhouâ€, â€œâ€¦\n\nThis is an open-label, dose-escalation and dose-expansion phase I clinical study to evaluate the safâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n176\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nThe Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination Withâ€¦\nNCT05061628\n\nA Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recomâ€¦\nJS006-001-I\nOTHER\nShanghai Junshi Bioscience Co., Ltd.\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œPD-L1 expressionâ€, â€œdescriptionâ€: â€œThe relationship between efficacy and potential bioâ€¦\n[{â€œmeasureâ€: â€œTo evaluate the safety and tolerability of JS006 as Monotherapy and in combination witâ€¦\n[{â€œmeasureâ€: â€œPharmacokinetic (PK) profile: JS006â€, â€œdescriptionâ€: â€œJS006 concentrations in individuâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nShanghai Junshi Bioscience Co., Ltd.\n\n\n\nSPONSOR\n2024-09-30\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2021-09-29\nACTUAL\n2021-09-21\nUNKNOWN\n2023-08-14\nESTIMATED\n\n\n\n\n2021-04-21\nACTUAL\n2021-08\n2021-09-29\nACTUAL\n2021-08-19\n2021-09-21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Understanding and signature of the informed consent form voluntarily;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Age â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD001254â€, â€œtermâ€: â€œAstrocytomaâ€}, {â€œidâ€: â€œD005910â€, â€œtermâ€: â€œGliomaâ€}, {â€œidâ€: â€œD018302â€, â€œtâ€¦\n[{â€œidâ€: â€œD005909â€, â€œtermâ€: â€œGlioblastomaâ€}, {â€œidâ€: â€œD012008â€, â€œtermâ€: â€œRecurrenceâ€}]\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œZimberelimab (AB 122) + Domvanalimab (AB 154) Safety Cohort (Cohort A)â€, â€œtypeâ€: â€œEXPERIâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œZimberelimabâ€, â€œdescriptionâ€: â€œZimberelimab (AB122) is a fully human immuâ€¦\nGlioblastoma\nGlioblastoma, Recurrent, PD1, TIGIT, Immunotherapy\n\n[{â€œfacilityâ€: â€œUniversity of California San Franciscoâ€, â€œcityâ€: â€œSan Franciscoâ€, â€œstateâ€: â€œCaliforniâ€¦\n[{â€œnameâ€: â€œSylvia Kurz, MDâ€, â€œaffiliationâ€: â€œProfessor of Neurologyâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATOâ€¦\nThis is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will bâ€¦\nThis is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will bâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\nAfter the initial safety cohort confirms the safety of the dosing schedule an expansion surgical cohâ€¦\nTRIPLE\nMasking will only occur in the surgical cohort B (4 arms) during the first cycle prior to surgery. Tâ€¦\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n46\nESTIMATED\n\nEARLY_PHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAB154 Combined With AB122 for Recurrent Glioblastoma\nNCT04656535\n\nA Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody Aâ€¦\n2000028799\nOTHER\nYale University\n[{â€œidâ€: â€œR01CA266757â€, â€œtypeâ€: â€œNIHâ€, â€œlinkâ€: â€œhttps://reporter.nih.gov/quickSearch/R01CA266757â€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] associated wiâ€¦\n[{â€œmeasureâ€: â€œSingle cell RNA sequencing of tumor and blood after exposure to AB154 with and withoutâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œNational Cancer Institute (NCI)â€, â€œclassâ€: â€œNIHâ€}, {â€œnameâ€: â€œArcus Biosciences, Inc.â€, â€œcâ€¦\nOTHER\nYale University\nYale University\nSylvia Kurz\nAssociate Professor of Neurology\nPRINCIPAL_INVESTIGATOR\n2026-12-31\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-07\nACTUAL\n2026-01-06\nACTIVE_NOT_RECRUITING\n2026-07-30\nESTIMATED\n\n\n\n\n2021-04-21\nACTUAL\n2026-01\n2020-12-07\nACTUAL\n2020-11-18\n2020-11-30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Grade IV glioma (glioblastoma and its variants according to the World Healthâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œD004938â€, â€œtermâ€: â€œEsophageal Neoplasmsâ€}, {â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-â€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œBC008-1A 900mgâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œBiological: BC008-1A 900â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œBC008-1A 900mgâ€, â€œdescriptionâ€: â€œBC008-1A 900mg will be administereâ€¦\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPD-1, TIGIT, Esophageal Cancer, non-small cell lung cancer\n[{â€œnameâ€: â€œJianing Wangâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ86-13802107048â€, â€œemailâ€: â€œwangjianing@buchanâ€¦\n[{â€œfacilityâ€: â€œTianjin Medical University Cancer Institute and Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcâ€¦\n\nThe goal of this study is to learn if BC008-1A given 900mg or 1200mg intravenously once every 3 weekâ€¦\nThis is an open-label clinical study aims to evaluate the safety, pharmacokinetic characteristics anâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n80\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nPhase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors\nNCT06773507\n\nAn Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinâ€¦\nleadingpharm2022010\nINDUSTRY\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œObjective response rate per RECIST1.1â€â€¦\n[{â€œmeasureâ€: â€œDisease control rate (DCR)â€, â€œdescriptionâ€: â€œDefined as the proportion of subjects whoâ€¦\nFalse\nFalse\nFalse\nFalse\n\n\n[{â€œnameâ€: â€œCancer Institute and Hospital, Chinese Academy of Medical Sciencesâ€, â€œclassâ€: â€œOTHERâ€}]\nINDUSTRY\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n\n\n\nSPONSOR\n2027-06\nESTIMATED\n\n\n\n\nFalse\n\n2025-07-09\nACTUAL\n2025-07-07\nRECRUITING\n2026-06\nESTIMATED\n\n\n\n\n2025-05-12\nACTUAL\n2025-07\n2025-01-14\nACTUAL\n2025-01-02\n2025-01-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Cohort 1:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPatients with inoperable, locally advanced or metastatic esophâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000068258â€, â€œtermâ€: â€œBevacizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHLX53(1000mg)+ HLX10+ HLX04â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œHLX53+ HLX10+ HLX0â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHLX53 (1000mg)â€, â€œdescriptionâ€: â€œHLX53 will be administered by IV infusioâ€¦\nCarcinoma, Hepatocellular\n\n[{â€œnameâ€: â€œJia Fan, Drâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ021-64041990â€, â€œemailâ€: â€œfan.jia@zs-hospital.sâ€¦\n[{â€œfacilityâ€: â€œZhongshan Hospital, Fudan Universityâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œShanghaiâ€, â€œcâ€¦\n[{â€œnameâ€: â€œJia Fanâ€, â€œaffiliationâ€: â€œFudan Universityâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}, {â€œnameâ€: â€¦\nThe study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety aâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nQUADRUPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n117\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10â€¦\nNCT06349980\n\nA Randomized, Double-blind, Multi-center, Phase II Study to Evaluate the Anti-tumor Efficacy, Safetyâ€¦\nHLX53-HCC201\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œORRâ€, â€œdescriptionâ€: â€œObjective response rate (ORR) (assessed by the IRRC according toâ€¦\n[{â€œmeasureâ€: â€œORRâ€, â€œdescriptionâ€: â€œObjective response rate (ORR) (assessed by INV according to the â€¦\nFalse\nFalse\nFalse\nFalse\n\n\n\nINDUSTRY\nShanghai Henlius Biotech\n\n\n\nSPONSOR\n2027-02-10\nESTIMATED\n\n\n\n\nFalse\n\n2024-12-18\nACTUAL\n2024-12-15\nRECRUITING\n2027-02-10\nESTIMATED\n\n\n\n\n2024-08-05\nACTUAL\n2024-04\n2024-04-05\nACTUAL\n2024-04-01\n2024-04-01\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Volunteer to participate in clinical research;To fully understand and undersâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm 1â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTreatment with 0.03 mg/kg HB0030 injectiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHB0030 injectionâ€, â€œdescriptionâ€: â€œ0.03 mg/kg intravenously, every 3 weekâ€¦\nAdvanced Solid Tumor\n\n[{â€œnameâ€: â€œhuan zhou, Masterâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+8613665527160â€, â€œemailâ€: â€œzhouhuanbest@â€¦\n[{â€œfacilityâ€: â€œthe First Affiliated Hospital of Bengbu Medical Collegeâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œciâ€¦\n[{â€œnameâ€: â€œhuan zhou, masterâ€, â€œaffiliationâ€: â€œThe First Affiliated Hospital of Bengbu Medical Univeâ€¦\nThis is a phase Ia single-center, open-label, dose escalation study.The objectives of this study areâ€¦\nThe phase Ia study will enroll up to 19-36 subjects with advanced solid tumor who have progressing tâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nSubjects were enrolled from low to high doses. The dose groups were 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, â€¦\nNONE\n\n\n\nTREATMENT\n\n36\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of HB0030 Injection in Patients With Advanced Solid Tumors\nNCT05706207\n\nA Phase Ia,Single Center,Open-label,Dose-escalation Study to Evaluate the Safety and Pharmacokineticâ€¦\nHB0030-01\nINDUSTRY\nHuabo Biopharm Co., Ltd.\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œDose Limiting Toxicity(DLT)â€, â€œdescriptionâ€: â€œ* DLT refers to the following toxicity râ€¦\n[{â€œmeasureâ€: â€œMaximum serum concentration(Cmax)â€, â€œdescriptionâ€: â€œ* Cmax refers to The maximum bloodâ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œThe First Affiliated Hospital of Bengbu Medical Universityâ€, â€œclassâ€: â€œOTHERâ€}]\nINDUSTRY\nHuabo Biopharm Co., Ltd.\n\n\n\nSPONSOR\n2023-09-30\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2023-01-31\nACTUAL\n2023-01-20\nUNKNOWN\n2023-09-30\nESTIMATED\n\n\n\n\n2021-12-21\nACTUAL\n2023-01\n2023-01-31\nACTUAL\n2023-01-06\n2023-01-20\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female Age â‰¥ 18 years.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients with histologically or cytologicallâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD012142â€, â€œtermâ€: â€œRespiratory Tract Neoplasmsâ€}, {â€œidâ€: â€œD013899â€, â€œtermâ€: â€œThoracic Neoplâ€¦\n[{â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplasmsâ€}, {â€œidâ€: â€œD006258â€, â€œtermâ€: â€œHead and Neck Neoplasmsâ€}, â€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œC000719628â€, â€œtermâ€: â€œdostarlimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPart 1A - EOS-448 + pembrolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipantsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œEOS-448â€, â€œdescriptionâ€: â€œAnti-TIGIT monoclonal antibodyâ€, â€œarmGroupLabelâ€¦\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nEOS884448, GSK4428859A, TIGIT, Anti-TIGIT, EOS-448, pembrolizumab, dostarlimab, inupadenant, A2A Recâ€¦\n\n[{â€œfacilityâ€: â€œUniversity of California San Diegoâ€, â€œcityâ€: â€œSan Diegoâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€¦\n[{â€œnameâ€: â€œIteos Clinical Trialsâ€, â€œaffiliationâ€: â€œiTeos Belgium SAâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2â€¦\nThe combinations evaluated will be:\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n153\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nTIG-006\nStudy of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanceâ€¦\nNCT05060432\n\nA Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Câ€¦\nTIG-006\nINDUSTRY\niTeos Therapeutics\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œPercentage of participants with DLT and Adverse Eventsâ€, â€œtimeFrameâ€: â€œFrom first studâ€¦\n[{â€œmeasureâ€: â€œDuration of Response (DOR)â€, â€œtimeFrameâ€: â€œUntil disease progression or death - Approxâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œGlaxoSmithKlineâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œiTeos Therapeuticsâ€, â€œclassâ€: â€œINDUSTRYâ€¦\nINDUSTRY\niTeos Belgium SA\n\n\n\nSPONSOR\n2025-07\nESTIMATED\n\n\n\n\nFalse\n\n2024-06-21\nACTUAL\n2024-06-19\nACTIVE_NOT_RECRUITING\n2024-07\nESTIMATED\n\n\n\n\n2021-09-06\nACTUAL\n2024-06\n2021-09-29\nACTUAL\n2021-09-06\n2021-09-27\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* EOS-448 combined with pembrolizumab, an anti-PD-1 antibody\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Provide a signed written informed consent for the trial\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Have measurable disâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD012142â€, â€œtermâ€: â€œRespiratory Tract Neoplasmsâ€}, {â€œidâ€: â€œD013899â€, â€œtermâ€: â€œThoracic Neoplâ€¦\n[{â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplasmsâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA1 : the patients naÃ¯ve from systemic treatment - atezolizumab + tiragolumabâ€, â€œtypeâ€: â€œâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumab 1200 mg IVâ€, â€œdescriptionâ€: â€œatezolizumab (intravenous 1200mâ€¦\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\n\n[{â€œnameâ€: â€œAntoine ITALIANO, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+33 1 42 11 42 11â€, â€œemailâ€: â€œantoineâ€¦\n[{â€œfacilityâ€: â€œCentre Hospitalier Cote Basqueâ€, â€œcityâ€: â€œBayonneâ€, â€œzipâ€: â€œ64109â€, â€œcountryâ€: â€œFrancâ€¦\n\nThis study encompasses multicenter open-label, phase II trials.\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n115\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nINDIGO\nTargeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures\nNCT06713798\n\nTargeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures\n2023-503218-56-00\nOTHER\nGustave Roussy, Cancer Campus, Grand Paris\n[{â€œidâ€: â€œ2022/3418â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œCSET numberâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œBest overall response (BOR) rateâ€, â€œdescriptionâ€: â€œBest overall response (BOR) rate deâ€¦\n\nFalse\nFalse\nTrue\nTrue\n\n\n[{â€œnameâ€: â€œRoche Global Developmentâ€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nGustave Roussy, Cancer Campus, Grand Paris\n\n\n\nSPONSOR\n2030-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-06-24\nACTUAL\n2025-06-23\nNOT_YET_RECRUITING\n2028-01\nESTIMATED\n\n\n\n\n2025-07\nESTIMATED\n2025-06\n2024-12-03\nACTUAL\n2024-11-27\n2024-11-27\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPatients will be dispatched into 2 â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed TLS-positive advanced or metastatic NSCLC.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* NSCLC sâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAtezolizumab will be administeredâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œGiven by vein (IV)â€, â€œarmGroupLabelsâ€: [â€œAâ€¦\nMetastatic Malignancy\n\n[{â€œnameâ€: â€œPadmanee Sharma, MD, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ713-792-2830â€, â€œemailâ€: â€œPadSharmâ€¦\n[{â€œfacilityâ€: â€œM D Anderson Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œHoustonâ€, â€œstateâ€: â€œTexâ€¦\n[{â€œnameâ€: â€œPadmanee Sharma, MD, PhDâ€, â€œaffiliationâ€: â€œM.D.Â Anderson Cancer Centerâ€, â€œroleâ€: â€œPRINCIPâ€¦\nTo learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when â€¦\nPrimary Safety Objective:\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nSINGLE\n\nPARTICIPANT\n\nTREATMENT\n\n10\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nNeoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urotheâ€¦\nNCT05394337\n\nNeoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urotheâ€¦\n2021-0928\nOTHER\nM.D.Â Anderson Cancer Center\n[{â€œidâ€: â€œNCI-2022-04565â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œNCI-CTRP Clinical Trials Reporting Registryâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œTo evaluate relapse-free survival (RFS)â€, â€œtimeFrameâ€: â€œThrough study completion, an aâ€¦\n\nFalse\nTrue\nFalse\nTrue\n\n[{â€œlabelâ€: â€œMD Anderson Cancer Centerâ€, â€œurlâ€: â€œhttp://www.mdanderson.orgâ€}]\n\nOTHER\nM.D.Â Anderson Cancer Center\n\n\n\nSPONSOR\n2025-12-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-09\nACTUAL\n2025-10-07\nRECRUITING\n2025-12-31\nESTIMATED\n\n\n\n\n2023-02-23\nACTUAL\n2025-10\n2022-05-27\nACTUAL\n2022-05-23\n2022-05-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ€¢To evaluate the safety and tolerability oftiragolumab and atezolizumab iâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Signed Informed Consent Form\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Age &gt;18 years at time of signing Informed Câ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}]\n\n[{â€œidâ€: â€œC000656314â€, â€œtermâ€: â€œtoripalimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTAB006 60mg and Torpalimab 240mg repeat dose every 21 days up to 2 yearsâ€, â€œtypeâ€: â€œEXPEâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTAB006â€, â€œdescriptionâ€: â€œRecombinant humanized, IgG4Îº (immunoglobulin gamâ€¦\nPreviously Treated, Advanced, Malignancies\nimmunotherapy, advance malignancies, monoclonal antibody, phase 1 trial\n\n\n[{â€œnameâ€: â€œSheng Yao, PhDâ€, â€œaffiliationâ€: â€œTopAlliance Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€â€¦\nThe primary objective is to assess the safety and tolerability of TAB006 as monotherapy and in combiâ€¦\nOVERVIEW This is a Phase 1, multi-center, open-label, dose-escalation study of TAB006 in combinationâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies\nNCT05253105\n\nA Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and â€¦\nTAB006-01\nOTHER\nShanghai Junshi Bioscience Co., Ltd.\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œTIGIT receptor occupancy (RO) in peripheral blood mononuclear cells (PBMC) and tumorâ€,â€¦\n[{â€œmeasureâ€: â€œTo assess the safety and tolerability of multiple doses of TAB006 in combination with â€¦\n[{â€œmeasureâ€: â€œMaximum Observed Concentration (Cmax)â€, â€œtimeFrameâ€: â€œfrom first treatment visit thru â€¦\nFalse\nTrue\n\nFalse\n\n\n[{â€œnameâ€: â€œTopAlliance Biosciences, Inc.â€, â€œclassâ€: â€œUNKNOWNâ€}, {â€œnameâ€: â€œCTI Clinical Trial and Conâ€¦\nOTHER\nShanghai Junshi Bioscience Co., Ltd.\n\n\n\nSPONSOR\n2027-01\nESTIMATED\n\n\n\n\nFalse\n\n2022-05-31\nACTUAL\n2022-05-24\nWITHDRAWN\n2026-09\nESTIMATED\n\n\n\n\n2022-03-15\nESTIMATED\n2022-02\n2022-02-23\nACTUAL\n2022-01-17\n2022-02-15\ntransfer the study to another sponser\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 1. Able to understand and willing to sign the Informed Consent Form;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 2. Mâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD003920â€, â€œtermâ€: â€œDiabetes Mellitusâ€}, {â€œidâ€: â€œD044882â€, â€œtermâ€: â€œGlucose Metabolism Disorâ€¦\n[{â€œidâ€: â€œD003922â€, â€œtermâ€: â€œDiabetes Mellitus, Type 1â€}]\n\n[{â€œidâ€: â€œC502540â€, â€œtermâ€: â€œteplizumabâ€}]\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œTeplizumab treatedâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAdministration of teplizumaâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œteplizumab 1 mg/mLâ€, â€œdescriptionâ€: â€œSolution for infusion administered aâ€¦\nDiabetes Mellitus, Type 1\nRecent-onset type 1 diabetes, Teplizumab, T1D, Stage 3, Type 1 diabetes, New onset type 1 diabetes\n\n[{â€œfacilityâ€: â€œBarbara Davis Center for Diabetes Site Number : 04â€, â€œcityâ€: â€œAuroraâ€, â€œstateâ€: â€œColoâ€¦\n[{â€œnameâ€: â€œClinical Sciences & Operationsâ€, â€œaffiliationâ€: â€œSanofiâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861â€¦\nThe study was a single-arm, multicenter, open-label clinical trial. All participants received a 12-dâ€¦\n\n\n\nSINGLE_GROUP\nSingle-arm, multicenter, open-label clinical trial\nNONE\n\n\n\nTREATMENT\n\n6\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n\n\nALL\nCHILD, ADULT, OLDER_ADULT\n\n\nAt-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)\nNCT04270942\n\nAn Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop â€¦\nPRV-031-002\nINDUSTRY\nSanofi\n[{â€œidâ€: â€œSFY18115â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œSanofi Identifierâ€}]\n\nQualified researchers may request access to patient level data and related study documents includingâ€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergâ€¦\n[{â€œmeasureâ€: â€œSerum Concentration Immediately Prior to Administration of the Next Dose (Ctrough) of â€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nProvention Bio, a Sanofi Company\n\n\n\nSPONSOR\n2024-01-22\nACTUAL\n\n\n\n\nFalse\n\n2025-02-12\nACTUAL\n2025-01-20\nCOMPLETED\n2024-01-22\nACTUAL\n2025-02-12\nACTUAL\n2025-01-20\n2025-01-20\n2020-02-26\nACTUAL\n2025-01\n2020-02-17\nACTUAL\n2020-02-10\n2020-02-12\n\nThe safety analysis set included all participants who received at least 1 dose of teplizumab.\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œTeplizumabâ€, â€œdescriptionâ€: â€œParticipants received teplizumab 9 mg/m\\^2 â€¦\n5.0\n[{â€œtermâ€: â€œLeukopeniaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œâ€¦\n[{â€œtermâ€: â€œCompleted Suicideâ€, â€œorganSystemâ€: â€œPsychiatric disordersâ€, â€œsourceVocabularyâ€: â€œMedDra 2â€¦\nFrom the first dose of study drug administration (Day 1) up to approximately 78 weeks\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ6â€}]}]\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œTeplizumabâ€, â€œdescriptionâ€: â€œParticipants received teplizumab 9 mg/m\\^2 â€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe safety analysis set included all participants who received at least 1 dose of teplizumab.\nThe Sponsor supports publication of clinical trial results but may request that investigators temporâ€¦\nFalse\nOTHER\nTrue\n\nContact-US@sanofi.com\nSanofi aventis recherche & dÃ©veloppement\n800-633-1610\n#6\nTrial Transparency Team\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œNumber of Participants With Treatment-emergent Adverse Events (TEAEs)â€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œTeplizumabâ€, â€œdescriptionâ€: â€œParticipants received teplizumab 9 milligramâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nA total of 6 participants from the TN-10 study (NCT01030861) who developed clinical (stage 3) type 1â€¦\nThe study was conducted in the United States from 26-Feb-2020 to 22-Jan-2024.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Previous participant in the TN-10 study\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Participant had received a diagnoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD046110â€, â€œtermâ€: â€œHypertension, Pregnancy-Inducedâ€}, {â€œidâ€: â€œD011248â€, â€œtermâ€: â€œPregnancy â€¦\n[{â€œidâ€: â€œD011225â€, â€œtermâ€: â€œPre-Eclampsiaâ€}]\n[{â€œidâ€: â€œD016133â€, â€œtermâ€: â€œPolymerase Chain Reactionâ€}, {â€œidâ€: â€œD021141â€, â€œtermâ€: â€œNucleic Acid Ampâ€¦\n[{â€œidâ€: â€œD060888â€, â€œtermâ€: â€œReal-Time Polymerase Chain Reactionâ€}, {â€œidâ€: â€œD004797â€, â€œtermâ€: â€œEnzymeâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œpreeclampsiapregnant womenâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œInclusion criteria...\n[{â€œtypeâ€: â€œGENETICâ€, â€œnameâ€: â€œreal time PCRâ€, â€œdescriptionâ€: â€œdiagnostic testâ€, â€œarmGroupLabelsâ€: [â€œâ€¦\nPre-Eclampsia\ncoinhibtory receptor\n\n\n\nPreeclampsia is a form of hypertensive pregnancy disorder with multiorgan involvement. It is charactâ€¦\nT lymphocytes, as well as their regulatory subpopulations could possibly possess a part in PE . The â€¦\n\n\nRANDOMIZED\nPARALLEL\npreeclasmpsia pregnant women and normal pregnant women\nNONE\n\n\n\nPREVENTION\n\n82\nESTIMATED\n\nPHASE4\nINTERVENTIONAL\n\nInclusion Criteria:\nTrue\nfemale\nFalse\n\n\n\nFEMALE\nCHILD, ADULT, OLDER_ADULT\n\nasd\nco Ihibtory Receptor in Preeclampsia\nNCT05294952\n\nLevels of Co-inhibitory Receptors (TIM-3,LAG-3 and TIGIT)in Preeclampsia Patients\nzisdas\nOTHER\nAssiut University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œearly detection of preeclampsiaâ€, â€œdescriptionâ€: â€œdetection levels of co inhibtory recâ€¦\n\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nAssiut University\nAssiut University\nZeinab Ibrahim Sayed\nreal time PCR\nPRINCIPAL_INVESTIGATOR\n2025-11-04\nESTIMATED\n\n\n\n\nFalse\n\n2024-02-05\nACTUAL\n2024-02-01\nNOT_YET_RECRUITING\n2025-02-03\nESTIMATED\n\n\n\n\n2025-01-01\nESTIMATED\n2024-02\n2022-03-24\nACTUAL\n2022-03-04\n2022-03-22\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* total of 41 women in third trimester pregnancy complicated with PE showing:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment with Atezolizumab + Tiragolumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€:â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œGiven by veinâ€, â€œarmGroupLabelsâ€: [â€œTreatmâ€¦\nCancer\n\n[{â€œnameâ€: â€œRyan Huey, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ(713) 792-2828â€, â€œemailâ€: â€œrwhuey@mdandersonâ€¦\n[{â€œfacilityâ€: â€œThe University of Texas M. D. Anderson Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€â€¦\n[{â€œnameâ€: â€œRyan Huey, MDâ€, â€œaffiliationâ€: â€œM.D.Â Anderson Cancer Centerâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nThe goal of this clinical research study is to learn if the combination of atezolizumab and tiragoluâ€¦\nPrimary Objectives:\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n35\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition Witâ€¦\nNCT06754501\n\nA Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition Witâ€¦\n2024-0210\nOTHER\nM.D.Â Anderson Cancer Center\n[{â€œidâ€: â€œNCI-2024-10697â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œClinical Trials Reporting Program (CTRP)â€}]\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œSafety and Adverse Events (AEs)â€, â€œdescriptionâ€: â€œIncidence of Adverse Events, Graded â€¦\n\nFalse\nTrue\nFalse\nTrue\n\n[{â€œlabelâ€: â€œMD Anderson Cancer Center Websiteâ€, â€œurlâ€: â€œhttp://www.mdanderson.orgâ€}]\n[{â€œnameâ€: â€œGenentech, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œStrategic Allianceâ€, â€œclassâ€: â€œUNKNOWNâ€â€¦\nOTHER\nM.D.Â Anderson Cancer Center\n\n\n\nSPONSOR\n2029-07-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-07\nACTUAL\n2025-10-01\nRECRUITING\n2027-07-01\nESTIMATED\n\n\n\n\n2025-04-11\nACTUAL\n2025-08\n2024-12-31\nACTUAL\n2024-12-30\n2024-12-30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTo assess the anti-tumor activity of tiragolumab and atezolizumab in patients wâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ— Patients must have histopathological confirmed unresected, locally advanced, â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, â€¦\n\n[{â€œidâ€: â€œC000656314â€, â€œtermâ€: â€œtoripalimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDose Optimization Phase - Arm Aâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œAdvanced â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œCHS-006 (anti-TIGIT)â€, â€œdescriptionâ€: â€œArm A participants will receive CHâ€¦\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nTIGIT inhibitor, PD-1 inhibitor, Advanced Solid Tumor\n\n[{â€œfacilityâ€: â€œUniversity of Florida Health Cancer Centerâ€, â€œcityâ€: â€œOrlandoâ€, â€œstateâ€: â€œFloridaâ€, â€œâ€¦\n\nThis phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preâ€¦\nThe Dose Optimization phase will enroll participants with advanced/metastatic solid tumors (except pâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\nThis is a Phase 1, open-label, multiple-phase, multiple phase study. Participants within the advanceâ€¦\nNONE\n\n\n\nTREATMENT\n\n22\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advancedâ€¦\nNCT05757492\n\nA Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, andâ€¦\nCHS-006-01\nINDUSTRY\nCoherus Oncology, Inc.\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œAssessment of the number of participants with treatment-emergent adverse events (TEAEsâ€¦\n[{â€œmeasureâ€: â€œDescription of the PK profile of CHS-006 in combination with toripalimabâ€, â€œdescriptioâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œMedpace, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œShanghai Junshi Bioscience Co., Ltd.â€, â€œcâ€¦\nINDUSTRY\nCoherus Oncology, Inc.\n\n\n\nSPONSOR\n2024-07-31\nACTUAL\n\n\n\n\nFalse\n\n2025-05-01\nACTUAL\n2025-04-30\nTERMINATED\n2024-07-31\nACTUAL\n\n\n\n\n2023-04-26\nACTUAL\n2025-04\n2023-03-07\nACTUAL\n2023-01-02\n2023-02-23\nThe study was terminated for strategic reasons (not for safety concerns)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Males and females, â‰¥18 years old;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histopathologically or cytologically confâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD003131â€, â€œtermâ€: â€œCombined Modality Therapyâ€}, {â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, â€¦\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œD059248â€, â€œtermâ€: â€œChemoradiotherapyâ€}]\n\n\n2024-08-09\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œArm A: Ociperlimab + Tislelizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œOciperlimab â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOciperlimabâ€, â€œdescriptionâ€: â€œOciperlimab 900 milligrams (mg) administereâ€¦\nLimited Stage Small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œTennessee Cancer Specialistâ€, â€œcityâ€: â€œKnoxvilleâ€, â€œstateâ€: â€œTennesseeâ€, â€œzipâ€: â€œ3790â€¦\n[{â€œnameâ€: â€œBeiGeneâ€, â€œaffiliationâ€: â€œStudy Directorâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumabâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n126\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limitedâ€¦\nNCT04952597\n\nA Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy â€¦\nAdvanTIG-204\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œCTR20211531â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œChinaDrugTrialsâ€}, {â€œidâ€: â€œBGB-A317-A1217-204â€, â€œâ€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œProgression Free Survival (PFS)â€, â€œdescriptionâ€: â€œDefined as the time from the date ofâ€¦\n[{â€œmeasureâ€: â€œComplete Response Rate (CR)â€, â€œdescriptionâ€: â€œdefined as the percentage of participantâ€¦\nFalse\nTrue\n\n\n[{â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œYouling Gong, Qingsong Pang, Rong Yu, Zhengfei Zhu, Jiangqiong â€¦\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2023-07-26\nACTUAL\n\n\n\n\nFalse\n\n2024-10-26\nACTUAL\n2024-10-23\nCOMPLETED\n2023-07-26\nACTUAL\n2024-09-19\nACTUAL\n2024-07-16\n2024-08-16\n2021-07-15\nACTUAL\n2024-10\n2021-07-07\nACTUAL\n2021-06-28\n2021-06-28\n\nAll-cause mortality is reported for all randomized participants. Serious and other adverse events inâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œArm A: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œOciperlimab plus tislâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\nAll-cause mortality and adverse events (AEs): From the first dose of study drug(s) to 30 days after â€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ41â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œArm A: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œOciperlimab plus tislâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Intent-To-Treat (ITT) Analysis Set includes all randomized patients.\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene\n+1-877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œProgression Free Survival (PFS)â€, â€œdescriptionâ€: â€œDefined as the timeâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œArm A: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œOciperlimab plus tislâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\n\nParticipants were enrolled in multiple study centers in China, South Korea, and the United States.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participant has pathologically (histologically or cytologically) proven dâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD002292â€, â€œtermâ€: â€œCarcinoma, Renal Cellâ€}]\n[{â€œidâ€: â€œD001549â€, â€œtermâ€: â€œBenzamidesâ€}, {â€œidâ€: â€œD000577â€, â€œtermâ€: â€œAmidesâ€}, {â€œidâ€: â€œD009930â€, â€œteâ€¦\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD0â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A (Tobemstomig + Axitinib)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants wiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTobemstomigâ€, â€œdescriptionâ€: â€œParticipants will receive IV tobemstomig Q3â€¦\nRenal Cell Carcinoma\n\n\n[{â€œfacilityâ€: â€œUniversity of Alabama at Birminghamâ€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabamaâ€, â€œzipâ€â€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-LaRocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone orâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n199\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locâ€¦\nNCT05805501\n\nA Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in â€¦\nBO43936\nINDUSTRY\nHoffmann-La Roche\n\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œIncidence and Severity of Adverse Events (AEs)â€, â€œtimeFrameâ€: â€œUp to a maximum of 2 yeâ€¦\n\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2026-07-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-13\nACTUAL\n2025-11-12\nACTIVE_NOT_RECRUITING\n2026-07-31\nESTIMATED\n\n\n\n\n2023-04-21\nACTUAL\n2025-11\n2023-04-10\nACTUAL\n2023-03-28\n2023-03-28\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Iâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œtypeâ€: â€œRELEASEâ€, â€œdateâ€: â€œ2023-03-21â€}, {â€œtypeâ€: â€œRESETâ€, â€œdateâ€: â€œ2024-01-03â€}]\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\n\n2023-03-21\n\n\n[{â€œreleaseDateâ€: â€œ2023-03-21â€, â€œresetDateâ€: â€œ2024-01-03â€}]\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPembrolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œsubjects with PD-L1 low (PD-L1Loâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œhumanized antibody used in cancer immunotâ€¦\nNon Small Cell Lung Cancer (NSCLC)\n\n\n[{â€œfacilityâ€: â€œNational Cancer Instituteâ€, â€œcityâ€: â€œMilanâ€, â€œzipâ€: â€œ20133â€, â€œcountryâ€: â€œItalyâ€, â€œgeoâ€¦\n[{â€œnameâ€: â€œMarina Chiara Garassino, MDâ€, â€œaffiliationâ€: â€œNational Cancer Institute (NCI)â€, â€œroleâ€: â€œâ€¦\nThis is a prospective, monocentric, open label, phase II trial of intravenous (IV) Pembrolizumab monâ€¦\nApproximately 65 subjects with PD-L1 low (PD-L1Lo), EGFR wt, EML4/ALK fusion negative NSCLC will be â€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n65\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nPEOPLE\nPembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.\nNCT03447678\n\nPhase II Study to Test Pembrolizumab (MK-3475) in First Line Treatment of Advanced NSCLC Patients Wiâ€¦\nINT 178-17\nOTHER\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œImmune biomarkersâ€, â€œdescriptionâ€: â€œtumor infiltrating lymphocytes in patients whose tâ€¦\n[{â€œmeasureâ€: â€œImmune biomarkers distribution between pre and post Pembrolizumab treatmentâ€, â€œdescripâ€¦\nFalse\nFalse\n\nFalse\n[{â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œKorman A, Chen B, Wang C, Wu L, Cardarelli P, Selby M. Activityâ€¦\n\n\nOTHER\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\n\n\n\nSPONSOR\n2022-05-31\nESTIMATED\n\n\n\n\nFalse\nACTIVE_NOT_RECRUITING\n2021-06-09\nACTUAL\n2021-06-08\nUNKNOWN\n2022-05-31\nESTIMATED\n\n\n\n\n2018-05-23\nACTUAL\n2021-06\n2018-02-27\nACTUAL\n2018-02-13\n2018-02-26\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Have a confirmed diagnosis of NSCLC in stage IIIB/ IV. Do not have an EGFR sâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000632826â€, â€œtermâ€: â€œsintilimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œIBI939 in combination with Sintilimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œBâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œIBI939â€, â€œdescriptionâ€: â€œIBI939 injectionâ€, â€œarmGroupLabelsâ€: [â€œIBIâ€¦\nAdvanced Lung Cancer\n\n\n[{â€œfacilityâ€: â€œJilin Province Cancer Hospitalâ€, â€œcityâ€: â€œJilinâ€, â€œcountryâ€: â€œChinaâ€, â€œgeoPointâ€: {â€œlâ€¦\n[{â€œnameâ€: â€œYing Chengâ€, â€œaffiliationâ€: â€œJilin Province Cancer Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nThis study is an open-label, phase I clinical study to evaluate the efficacy, tolerability and safetâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n42\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced â€¦\nNCT04672369\n\nAn Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 inâ€¦\nCIBI939A102(Ib)\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate(ORR)â€, â€œdescriptionâ€: â€œProportion of subjects with complete reâ€¦\n[{â€œmeasureâ€: â€œadverse eventâ€, â€œtimeFrameâ€: â€œ3 monthsâ€}, {â€œmeasureâ€: â€œProgression-free survival(PFS)â€â€¦\nFalse\nFalse\n\nFalse\n\n\n\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\nSPONSOR\n2023-06-01\nACTUAL\n\n\n\n\nFalse\n\n2023-06-22\nACTUAL\n2023-06-18\nCOMPLETED\n2023-01-01\nACTUAL\n\n\n\n\n2021-06-06\nACTUAL\n2023-06\n2020-12-17\nACTUAL\n2020-12-13\n2020-12-16\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Signed the Informed Consent Form;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Male or female â‰¥ 18 andâ‰¤75 years of ageâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000632826â€, â€œtermâ€: â€œsintilimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPhase Ia: IBI939 in combination with Sintilimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€:â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œIBI939â€, â€œdescriptionâ€: â€œIBI939 injectionâ€, â€œarmGroupLabelsâ€: [â€œPhaâ€¦\nAdvanced Lung Cancer\n\n\n[{â€œfacilityâ€: â€œJilin Province Cancer Hospitalâ€, â€œcityâ€: â€œJilinâ€, â€œcountryâ€: â€œChinaâ€, â€œgeoPointâ€: {â€œlâ€¦\n[{â€œnameâ€: â€œYing Chengâ€, â€œaffiliationâ€: â€œJilin Province Cancer Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nThis study is an open-label, phase I clinical study to evaluate the efficacy, tolerability and safetâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n19\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab â€¦\nNCT04672356\n\nAn Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 inâ€¦\nCIBI939A102(Ia)\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œAdverse Eventsâ€, â€œtimeFrameâ€: â€œ3 monthsâ€}, {â€œmeasureâ€: â€œRecommended Phase II Dose(RP2Dâ€¦\n[{â€œmeasureâ€: â€œObjective response rate(ORR)â€, â€œdescriptionâ€: â€œProportion of subjects with complete reâ€¦\nFalse\nFalse\n\nFalse\n\n\n\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\nSPONSOR\n2023-06-01\nACTUAL\n\n\n\n\nFalse\n\n2023-06-22\nACTUAL\n2023-06-18\nCOMPLETED\n2023-01-01\nACTUAL\n\n\n\n\n2021-01-25\nACTUAL\n2023-06\n2020-12-17\nACTUAL\n2020-12-13\n2020-12-16\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Signed the Informed Consent Form;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Male or female â‰¥ 18 andâ‰¤75 years of ageâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD015179â€, â€œtermâ€: â€œColorectal Neoplasmsâ€}, {â€œidâ€: â€œD007414â€, â€œtermâ€: â€œIntestinal Neoplasmsâ€â€¦\n[{â€œidâ€: â€œD012004â€, â€œtermâ€: â€œRectal Neoplasmsâ€}]\n[{â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, {â€œidâ€: â€œD003841â€, â€œtermâ€: â€œDeoxycytidineâ€}, {â€œidâ€: â€œD003â€¦\n[{â€œidâ€: â€œD011878â€, â€œtermâ€: â€œRadiotherapyâ€}, {â€œidâ€: â€œD000069287â€, â€œtermâ€: â€œCapecitabineâ€}, {â€œidâ€: â€œD0â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezolizumab + Tiragolumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œWeeks 1-5: Radiotheâ€¦\n[{â€œtypeâ€: â€œRADIATIONâ€, â€œnameâ€: â€œRadiotherapyâ€, â€œdescriptionâ€: â€œWeeks 1-5: 45-50.4Gy in 25-28 fractioâ€¦\nRectal Neoplasms, Rectal Cancer\n\n\n[{â€œfacilityâ€: â€œBeijing Cancer Hospitalâ€, â€œcityâ€: â€œBeijingâ€, â€œzipâ€: â€œ100142â€, â€œcountryâ€: â€œChinaâ€, â€œgeâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the efficacy and safety of atezolizumab plus tiragolumab or atezolizumab alâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n58\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Partiâ€¦\nNCT05009069\n\nA Phase II, Randomized, Open Label, Parallel-group Study of Atezolizumab With or Without Tiragolumabâ€¦\nML43050\nINDUSTRY\nHoffmann-La Roche\n\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œPercentage of Participants With Pathological Complete Response (pCR)â€, â€œtimeFrameâ€: â€œAâ€¦\n[{â€œmeasureâ€: â€œPercentage of Participants With R0 Resectionâ€, â€œtimeFrameâ€: â€œAt Week 16, Day 1â€}, {â€œmeâ€¦\nFalse\nTrue\nTrue\n\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2026-11-06\nESTIMATED\n2024-10-15\nACTUAL\n2024-11-12\n\nFalse\n\n2026-01-22\nACTUAL\n2026-01-16\nACTIVE_NOT_RECRUITING\n2023-11-21\nACTUAL\n\n\n\n\n2022-03-18\nACTUAL\n2026-01\n2021-08-17\nACTUAL\n2021-08-10\n2021-08-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically confirmed diagnosis of adenocarcinoma of the â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPhase Ia Dose-Escalation Stage:IBI939â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œIBI939â€, â€œdescriptionâ€: â€œSeveral dose levels will be evaluated for IBI939â€¦\nAdvanced Malignancies\n\n\n[{â€œfacilityâ€: â€œPeking University Cancer Hospital & Instituteâ€, â€œcityâ€: â€œBeijingâ€, â€œcountryâ€: â€œChinaâ€â€¦\n\nThis is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacoâ€¦\n\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n34\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Iâ€¦\nNCT04353830\n\nA Phase 1a, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Initial Effiâ€¦\nCIBI939A101\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œNumber of subjects with AEs and SAEsâ€, â€œdescriptionâ€: â€œTo evaluate the safety and toleâ€¦\n[{â€œmeasureâ€: â€œPharmacokinetics: AUCâ€, â€œdescriptionâ€: â€œThe area under the curve (AUC) of serum concenâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nINDUSTRY\nInnovent Biologics (Suzhou) Co.Â Ltd.\n\n\n\nSPONSOR\n2022-05-11\nACTUAL\n\n\n\n\nFalse\n\n2023-03-01\nACTUAL\n2023-02-28\nCOMPLETED\n2022-05-11\nACTUAL\n\n\n\n\n2020-05-22\nACTUAL\n2023-02\n2020-04-20\nACTUAL\n2020-04-17\n2020-04-17\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Able to understand and willing to sign the ICF.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Adults 18 years of age orâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD018278â€, â€œtermâ€: â€œCarcinoma, Neuroendocrineâ€}]\n[{â€œidâ€: â€œD019984â€, â€œtermâ€: â€œQuality Indicators, Health Careâ€}, {â€œidâ€: â€œD011787â€, â€œtermâ€: â€œQuality ofâ€¦\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€: â€œD059039â€, â€œtermâ€: â€œStandard of Careâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œExperimental arm (EA) 61 patients prospectively enrolled to receive the experimental treâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œFOLFIRI + Zimberelimab + Domvanalimabâ€, â€œdescriptionâ€: â€œFOLFIRI every 14 â€¦\nCarcinoma, Neuroendocrine\nCarcinoma, Neuroendocrine, gastro-enteropancreatic or unknown origin, GEP/UK NEC\n[{â€œnameâ€: â€œThomas WALTER, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ4 72 11 73 98â€, â€œphoneExtâ€: â€œ+33â€, â€œemaiâ€¦\n[{â€œfacilityâ€: â€œCHU Amiens Picardieâ€, â€œcityâ€: â€œAmiensâ€, â€œcountryâ€: â€œFranceâ€, â€œcontactsâ€: [{â€œnameâ€: â€œVâ€¦\n[{â€œnameâ€: â€œThomas WALTER, MDâ€, â€œaffiliationâ€: â€œHospices Civils de Lyonâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGâ€¦\nBackground Neuroendocrine carcinomas (NECs) of gastro-entero-pancreatic (GEP) or unknown (UK) originâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n122\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nREWENEC 01\nTrial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Secâ€¦\nNCT07337447\n\nPRODIGE 113 (FFCD 2314) - REWENEC 01 STUDY Randomized Trial of FOLFIRI + Zimberelimab + Domvanalimabâ€¦\n69HCL24_0759\nOTHER\nHospices Civils de Lyon\n[{â€œidâ€: â€œ2024-519922-19-00â€, â€œtypeâ€: â€œCTISâ€}]\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œOverall survival (%) between FOLFIRI and FOLFIRI+Zimberelimab+Domvanalimabâ€, â€œdescriptâ€¦\n[{â€œmeasureâ€: â€œProgression free survival (PFS)â€, â€œdescriptionâ€: â€œTime from randomization to disease pâ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œFederation Francophone de Cancerologie Digestiveâ€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nHospices Civils de Lyon\n\n\n\nSPONSOR\n2030-04\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-13\nACTUAL\n2026-01-07\nNOT_YET_RECRUITING\n2029-04\nESTIMATED\n\n\n\n\n2026-04\nESTIMATED\n2026-01\n2026-01-13\nACTUAL\n2025-12-08\n2026-01-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Man or woman aged â‰¥ 18 years old,\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Poorly differentiated neuroendocrine carcâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004701â€, â€œtermâ€: â€œEndocrine Gland Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Sitâ€¦\n[{â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€}, {â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplasmsâ€}, {â€œidâ€:â€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCOM902 monotherapy dose escalation.â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œMonotherapâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDose escalation: COM902 monotherapy.â€, â€œdescriptionâ€: â€œCOM902 monotherapyâ€¦\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, â€¦\nTIGIT antibody, PVRIG antibody, COM701, Low Fc-effector function, Pembrolizumab\n\n[{â€œfacilityâ€: â€œFlorida Cancer Specialistsâ€, â€œcityâ€: â€œSarasotaâ€, â€œstateâ€: â€œFloridaâ€, â€œzipâ€: â€œ34230â€, â€¦\n[{â€œnameâ€: â€œCOM902 Study Director COM902 Study Directorâ€, â€œaffiliationâ€: â€œCompugen Ltdâ€, â€œroleâ€: â€œSTUâ€¦\nPhase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, toleâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n110\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCOM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies\nNCT04354246\n\nA Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies\nCPG-02-101\nINDUSTRY\nCompugen Ltd\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œEvaluation of the preliminary antitumor activity of COM902 as monotherapy and in combiâ€¦\n[{â€œmeasureâ€: â€œThe safety and tolerability of COM902 monotherapy and in combination with COM701.â€, â€œdâ€¦\n[{â€œmeasureâ€: â€œTo characterize immunogenicity of COM902 monotherapy and in combination with COM701.â€,â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nCompugen Ltd\n\n\n\nSPONSOR\n2025-12-30\nESTIMATED\n\n\n\n\nFalse\n\n2025-05-22\nACTUAL\n2025-05-18\nACTIVE_NOT_RECRUITING\n2025-12-30\nESTIMATED\n\n\n\n\n2020-03-31\nACTUAL\n2025-05\n2020-04-21\nACTUAL\n2020-04-15\n2020-04-16\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Subjects with histologically/cytologically confirmed advanced malignancy â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplasmsâ€}]\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezo + Tira + XELOXâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAtezolizumab plus tiragolâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œAtezolizumab 1200 mg will be administered â€¦\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\n\n\n[{â€œfacilityâ€: â€œBeijing Cancer Hospitalâ€, â€œcityâ€: â€œBeijingâ€, â€œzipâ€: â€œ100142â€, â€œcountryâ€: â€œChinaâ€, â€œgeâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study is designed to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combiâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n29\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st â€¦\nNCT04933227\n\nA Phase II, Single-Arm Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab andâ€¦\nML42913\nINDUSTRY\nHoffmann-La Roche\n\n\nQualified researchers may request access to individual patient level data through the clinical studyâ€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) in the Full Analysis Set (FAS) Populationâ€, â€œtimeFrameâ€:â€¦\n[{â€œmeasureâ€: â€œDuration of Response (DOR) in Responders of the FAS Populationâ€, â€œtimeFrameâ€: â€œThe timâ€¦\nFalse\nTrue\nTrue\n\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2023-11-17\nACTUAL\n2024-03-12\nACTUAL\n2024-11-11\n\nFalse\n\n2024-11-14\nACTUAL\n2024-11-11\nTERMINATED\n2023-11-17\nACTUAL\n\n\n\n\n2021-08-06\nACTUAL\n2024-11\n2021-06-21\nACTUAL\n2021-06-17\n2021-06-17\nSponsorâ€™s decision to terminate the study after Stage 1; will not proceed with Stage 2.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed (by enrolling center) gastric cancer or adenocarcinoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œMRD positive Cohort - Arm A (treatment)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDose fâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œAZD2936â€, â€œdescriptionâ€: â€œAZD2936 is a monovalent, bispecific, humaâ€¦\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\n\n[{â€œnameâ€: â€œLillian Siu, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ416-946-4501â€, â€œphoneExtâ€: â€œ2911â€, â€œemailâ€â€¦\n[{â€œfacilityâ€: â€œPrincess Margaret Cancer Centreâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œTorontoâ€, â€œcountryâ€¦\n[{â€œnameâ€: â€œLillian Siu, MDâ€, â€œaffiliationâ€: â€œPrincess Margaret Cancer Centreâ€, â€œroleâ€: â€œPRINCIPAL_INâ€¦\nThis is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residuaâ€¦\nThis is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residuaâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n200\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria for All Parts\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nMERIDIAN\nMolecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC\nNCT05414032\n\nResidual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC\nMERIDIAN\nOTHER\nUniversity Health Network, Toronto\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œPredictive value (in terms of predicting radiological recurrence of disease or death) â€¦\n[{â€œmeasureâ€: â€œEfficacy (in terms of ctDNA clearance) of AZD2936 compared to observation (Standard ofâ€¦\n[{â€œmeasureâ€: â€œEfficacy (in terms of delaying or preventing radiological recurrence of disease or deaâ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œAstraZenecaâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œNeoGenomics Laboratories, Inc.â€, â€œclassâ€: â€œâ€¦\nOTHER\nUniversity Health Network, Toronto\n\n\n\nSPONSOR\n2026-07\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-30\nACTUAL\n2025-03-25\nRECRUITING\n2026-07\nESTIMATED\n\n\n\n\n2023-07-12\nACTUAL\n2025-03\n2022-06-10\nACTUAL\n2022-05-26\n2022-06-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Age â‰¥ 18 years at the time of screening or age of consent accorâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTiragolumab and atezolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œ96 patients will â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œTiragolumabâ€, â€œdescriptionâ€: â€œ600mg IV every 21 days from Cycle 1 Dâ€¦\nSolid Tumor, Adult\n\n[{â€œnameâ€: â€œSimone Jacobyâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+61 2 8052 4300â€, â€œemailâ€: â€œmost-tap@georgeiâ€¦\n[{â€œfacilityâ€: â€œBorder Medical Oncology Research Unitâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œAlburyâ€, â€œstâ€¦\n[{â€œnameâ€: â€œDavid Thomas, PHD, FRACPâ€, â€œaffiliationâ€: â€œOmico; UNSW Sydneyâ€, â€œroleâ€: â€œPRINCIPAL_INVESTâ€¦\nThis phase II study will explore the effect of 2 monoclonal antibodies, tiragolumab and atezolizumabâ€¦\nPatients who are enrolled in the MoST or CaSP cancer screening programs, and whose tumour is assesseâ€¦\n\n\n\nSINGLE_GROUP\nProspective, multicentre, single-arm, open-label, phase II signal-seeking trial\nNONE\n\n\n\nTREATMENT\n\n96\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nMoST-TAP\nTiragolumab and Atezolizumab in Advanced Pan-cancer Patients\nNCT06003621\n\nA Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients â€¦\nML43743\nOTHER\nOmico\n\n\nSubject to further IRB review and protocol amendment\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œProgression Free Survival (PFS) rate at 6 Monthsâ€, â€œdescriptionâ€: â€œThe primary outcomeâ€¦\n[{â€œmeasureâ€: â€œObjective tumour response rate (OTRR) as per iRECIST or RANO criteriaâ€, â€œdescriptionâ€:â€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œHoffmann-La Rocheâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œThe George Institute for Global Healtâ€¦\nOTHER\nOmico\n\n\n\nSPONSOR\n2028-11-01\nESTIMATED\n\n\n\n\nFalse\n\n2024-11-15\nACTUAL\n2024-11-13\nRECRUITING\n2026-05-01\nESTIMATED\n\n\n\n\n2023-12-15\nACTUAL\n2024-06\n2023-08-22\nACTUAL\n2023-08-07\n2023-08-15\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Provision of written informed consent.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Aged â‰¥18 years old.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n3. Histologicaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œC562730â€, â€œtermâ€: â€œAdenocarcinoma Of Esophagusâ€}, {â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplaâ€¦\n[{â€œidâ€: â€œD003841â€, â€œtermâ€: â€œDeoxycytidineâ€}, {â€œidâ€: â€œD003562â€, â€œtermâ€: â€œCytidineâ€}, {â€œidâ€: â€œD011741â€â€¦\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€: â€œD000069287â€, â€œtermâ€: â€œCapecitabineâ€}, {â€œidâ€: â€¦\nGreece\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDomvanalimab + Zimberelimab + FOLFOX/CAPOX (PI Choice)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œIntravenous (IV) Aqueous Solutionâ€, â€œarmGrâ€¦\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nDomvanalimab, Zimberelimab, Nivolumab, Advanced upper gastrointestinal tract adenocarcinoma, Gastroeâ€¦\n\n[{â€œfacilityâ€: â€œGenesis Cancer Center and Blood Institute - Hot Springsâ€, â€œcityâ€: â€œHot Springsâ€, â€œstaâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciencesâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n1040\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSTAR-221\nA Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, fâ€¦\nNCT05568095\n\nA Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy â€¦\nSTAR-221\nINDUSTRY\nArcus Biosciences, Inc.\n[{â€œidâ€: â€œjRCT2051220179â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œJapan Registry of Clinical Trialsâ€}, {â€œidâ€:â€¦\n\nArcus will provide access to individual de-identified participant data and related study documents ...\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n\n[{â€œmeasureâ€: â€œOverall survivalâ€, â€œtimeFrameâ€: â€œFrom date of randomization until date of death from aâ€¦\n[{â€œmeasureâ€: â€œProgression-free survival (PFS)â€, â€œtimeFrameâ€: â€œFrom date of randomization to date of â€¦\nFalse\nTrue\n\nTrue\n\n[{â€œlabelâ€: â€œSTAR-221 Public Websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=STAR-221â€}]\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œTaiho Pharmaceutical Co., Ltd.â€, â€œclassâ€¦\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2026-06\nESTIMATED\n\n\n\n\nFalse\n\n2026-02-02\nACTUAL\n2026-01-30\nACTIVE_NOT_RECRUITING\n2026-06\nESTIMATED\n\n\n\n\n2022-11-21\nACTUAL\n2025-04\n2022-10-05\nACTUAL\n2022-10-03\n2022-10-03\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Capable of giving signed informed consent which is in compliance with theâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}]\n[{â€œidâ€: â€œD043924â€, â€œtermâ€: â€œAngiogenesis Modulating Agentsâ€}, {â€œidâ€: â€œD006133â€, â€œtermâ€: â€œGrowth Subsâ€¦\n[{â€œidâ€: â€œD020533â€, â€œtermâ€: â€œAngiogenesis Inhibitorsâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHCC patientsâ€, â€œdescriptionâ€: â€œPatients with advanced HCC undergoing immunotherapyâ€, â€œinâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œImmunochemotherapy combined with antiangiogenicâ€, â€œdescriptionâ€: â€œImmunocâ€¦\nLiver Cancer, Adult\nimmunophenotype, HCC patients, immunotherapy\n[{â€œnameâ€: â€œLaura Gramantieri, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0512142579â€, â€œemailâ€: â€œlaura.gramantâ€¦\n[{â€œfacilityâ€: â€œIRCCS-Azienda Ospedaliero-Universitaria di Bolognaâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€¦\n[{â€œnameâ€: â€œLaura Gramantieriâ€, â€œaffiliationâ€: â€œIRCCS Azienda Ospedaliero-Universitaria di Bolognaâ€, â€¦\nThe study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay toâ€¦\n* To assess the accuracy of biomarkers from an immunophenotypic test (CD8+, PD1+, PD-L1+, CTLA4+, LAâ€¦\nperipheral blood mononuclear cells separated by Ficoll gradient\nSAMPLES_WITHOUT_DNA\n\n\n\n\n\n\nCASE_ONLY\n\nPROSPECTIVE\n100\nESTIMATED\nTrue\n\nOBSERVATIONAL\n3 Years\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\npatients with advanced hepatocellular carcinoma\nImmunecheck\nImmunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma\nNCT06777628\n\nImmunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in â€¦\nImmunecheck\nOTHER\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œTo find predictive biomarkers of response to immunotherapy in HCCâ€, â€œdescriptionâ€: â€œSeâ€¦\n[{â€œmeasureâ€: â€œTo compare the transcriptomic signatures of PBMC of responders and non-respondersâ€, â€œdâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\n\n\n\nSPONSOR\n2028-10-15\nESTIMATED\n\n\n\n\nFalse\n\n2025-01-16\nACTUAL\n2025-01-14\nRECRUITING\n2026-10-15\nESTIMATED\n\n\n\n\n2024-09-15\nACTUAL\n2024-09\n2025-01-16\nACTUAL\n2024-11-28\n2025-01-14\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* age â‰¥ 18 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* diagnosis of HCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* execution of laboratory tests and subsequâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018302â€, â€œtermâ€: â€œNeoplasms, Neuroepithelialâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermalâ€¦\n[{â€œidâ€: â€œD005910â€, â€œtermâ€: â€œGliomaâ€}, {â€œidâ€: â€œD005909â€, â€œtermâ€: â€œGlioblastomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œBC008-1A 900mgâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œBiological: BC008-1Aâ€]},â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œBC008-1Aâ€, â€œdescriptionâ€: â€œBiological: 900 mg BC008-1A will be intrâ€¦\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHOâ€¦\nglioma, PD-1, TIGIT, bispecific antibody, glioblastoma\n[{â€œnameâ€: â€œJianing Wangâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ86-13802107048â€, â€œemailâ€: â€œwangjianing@buchanâ€¦\n[{â€œfacilityâ€: â€œBeijing Tiantan Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œBeijingâ€, â€œstateâ€: â€œBeijiâ€¦\n\nThe purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmâ€¦\nBC008-1A is an innovative bispecific antibody targeting TIGIT and PD-1, which is developed by Sichuaâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n40\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nBC008-1A Injection for Recurrent CNS WHO G4 Glioma\nNCT06773481\n\nA Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of BC008-1A Injection in Suâ€¦\nBC0081A-103\nINDUSTRY\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œSafetyâ€, â€œdescriptionâ€: â€œAssesing the type, frequency, severity, and duration of adverâ€¦\n[{â€œmeasureâ€: â€œobjective response rate (ORR)â€, â€œdescriptionâ€: â€œDefined as the proportion of patients â€¦\nFalse\nFalse\nFalse\nFalse\n\n\n[{â€œnameâ€: â€œBeijing Tiantan Hospitalâ€, â€œclassâ€: â€œOTHERâ€}]\nINDUSTRY\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\n\n\n\nSPONSOR\n2026-12\nESTIMATED\n\n\n\n\nFalse\n\n2025-07-09\nACTUAL\n2025-07-07\nRECRUITING\n2026-06\nESTIMATED\n\n\n\n\n2025-04-07\nACTUAL\n2025-07\n2025-01-14\nACTUAL\n2025-01-02\n2025-01-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Voluntarily sign the informed consent form;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Recurrent CNS WHO grade 4 gliâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009375â€, â€œtermâ€: â€œNeoplasms, Glandular and Epithelialâ€}, {â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplaâ€¦\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD002294â€, â€œâ€¦\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC502936â€, â€œtermâ€: â€œtocilizumabâ€}, {â€œidâ€: â€œC00â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezolizumab Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants will recâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œGiven intravenously (IV)â€, â€œarmGroupâ€¦\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nCancer, Non-Virally Associated Squamous Cell Carcinoma, Head and Neck\n[{â€œnameâ€: â€œUCSF HDFCCC Cancer Immunotherapy Program (CIP)â€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ(877) 827-3â€¦\n[{â€œfacilityâ€: â€œUniversity of San Francisco, Californiaâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œSan Franciâ€¦\n[{â€œnameâ€: â€œAlain Algazi, MDâ€, â€œaffiliationâ€: â€œUniversity of California, San Franciscoâ€, â€œroleâ€: â€œPRIâ€¦\nTo determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulaâ€¦\nPRIMARY OBJECTIVES:\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n55\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nPreoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck\nNCT03708224\n\nA Phase II Study of Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head â€¦\n177018\nOTHER\nUniversity of California, San Francisco\n[{â€œidâ€: â€œNCI-2018-01992â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œClinical Trials Reporting Program (CTRP)â€}, {â€œâ€¦\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œProportion of subjects with a &gt;= 40% increase in the cluster of differentiation 3 (CD3â€¦\n[{â€œmeasureâ€: â€œChanges in immune parameters using mass cytometry (CyTOF), histology and gene expressiâ€¦\nFalse\nTrue\nFalse\nTrue\n[{â€œpmidâ€: â€œ36931243â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œRahim MK, Okholm TLH, Jones KB, McCarthy EE, Lâ€¦\n\n[{â€œnameâ€: â€œGenentech, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œAmerican Head and Neck Societyâ€, â€œclassâ€¦\nOTHER\nAlain Algazi\nUniversity of California, San Francisco\nAlain Algazi\nAssociate Professor\nSPONSOR_INVESTIGATOR\n2028-06-30\nESTIMATED\n\n\n\n\nFalse\n\n2025-01-28\nACTUAL\n2025-01-24\nRECRUITING\n2028-06-30\nESTIMATED\n\n\n\n\n2019-03-08\nACTUAL\n2024-11\n2018-10-17\nACTUAL\n2018-10-12\n2018-10-12\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nI. To determine the effect of neoadjuvant atezolizumab alone or in combination â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Patients must have clinically suspected SCCHN that is amenable to surgical râ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD012919â€, â€œtermâ€: â€œSocial Behaviorâ€}, {â€œidâ€: â€œD001519â€, â€œtermâ€: â€œBehaviorâ€}]\n[{â€œidâ€: â€œD012059â€, â€œtermâ€: â€œRejection, Psychologyâ€}]\n[{â€œidâ€: â€œD017582â€, â€œtermâ€: â€œRenal Replacement Therapyâ€}, {â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, â€¦\n[{â€œidâ€: â€œD016030â€, â€œtermâ€: â€œKidney Transplantationâ€}, {â€œidâ€: â€œD020869â€, â€œtermâ€: â€œGene Expression Proâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œkidney transplantationâ€, â€œdescriptionâ€: â€œsamples additional to the sâ€¦\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nKidney, Allogenic transplantation, Cohort study, Rejection, Biomarkers, Response to treatment, Integâ€¦\n\n[{â€œfacilityâ€: â€œHÃ´pital du Kremlin BicÃªtreâ€, â€œcityâ€: â€œLe Kremlin-BicÃªtreâ€, â€œstateâ€: â€œParisâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œAlexandre Loupy, Prâ€, â€œaffiliationâ€: â€œInstitut National de la SantÃ© Et de la Recherche MÃ©â€¦\nMain objective: To design a precision risk stratification system that predicts individual risk of reâ€¦\nAllograft rejection is still a major threat to allografts with thousands of allografts failing everyâ€¦\nblood samples, kidney biopsy samples for these analysis : Transcriptomics analysis Characteristics oâ€¦\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n558\nACTUAL\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n100 Years\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nNew kidney transplants patients\nEU-TRAIN\nPrecision Risk Stratification in Kidney Transplant Patients - EU-TRAIN\nNCT03652402\n\nThe EUropean TRAnsplantation and INnovation Consortium for Risk Stratification in Kidney Transplant â€¦\nK170203J\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n[{â€œidâ€: â€œIDRCB 2018-A00733-52â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œAssistance Publique HÃ´pitaux de Parisâ€}]\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œCapacity of non-invasive biomarkers and intragraft gene expression profiles combined tâ€¦\n[{â€œmeasureâ€: â€œCorrelation of blood biomarkers concentration with allograft rejection (rejection asseâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ31165086â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œMontero N, Farouk S, Gandolfini I, Crespo E, Jaâ€¦\n[{â€œlabelâ€: â€œSecure Distribution of Factor Analysis of Mixed Data (FAMD) and Its Application to Persoâ€¦\n\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\nSPONSOR\n2021-10-28\nACTUAL\n\n\n\n\nFalse\n\n2024-06-05\nACTUAL\n2024-06-04\nCOMPLETED\n2021-10-28\nACTUAL\n\n\n\n\n2018-11-27\nACTUAL\n2024-06\n2018-08-29\nACTUAL\n2018-07-16\n2018-08-27\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Men and women, Age â‰¥ 18 years old at the time of transplantation.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œnivolumabâ€, â€œdescriptionâ€: â€œSubjects will be treated with 3mg/kg in nivoâ€¦\nNon -Small Cell Lung Cancer\nNon -small cell lung cancer\n\n[{â€œfacilityâ€: â€œDepartment of Oncology, Yonsei University College of Medicineâ€, â€œcityâ€: â€œSeoulâ€, â€œstaâ€¦\n\nThe study aimed to elucidate predictive immune related biomarker to the responsiveness to the PD-1 bâ€¦\nNon-small cell lung cancer (NSCLC) is the leading cause of cancer related mortality worldwide. Immunâ€¦\n\n\n\n\n\n\n\n\nOTHER\n\nPROSPECTIVE\n60\nACTUAL\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n20 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nThe sample size is not based on statistical consideration. This is pilot study designed to explore bâ€¦\n\nA Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy â€¦\nNCT03486119\n\nA Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy â€¦\n4-2017-0788\nOTHER\nYonsei University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œMDSC markersâ€, â€œdescriptionâ€: â€œCD11b, Gr11b,â€, â€œtimeFrameâ€: â€œchange from baseline blooâ€¦\n[{â€œmeasureâ€: â€œORR(Objective response rate)â€, â€œtimeFrameâ€: â€œevery 6 months up to 5years.â€}, {â€œmeasureâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ33302114â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œKim CG, Hong MH, Kim KH, Seo IH, Ahn BC, Pyo Kâ€¦\n\n\nOTHER\nYonsei University\n\n\n\nSPONSOR\n2020-07-07\nACTUAL\n\n\n\n\nFalse\n\n2020-10-19\nACTUAL\n2020-10-14\nCOMPLETED\n2020-07-07\nACTUAL\n\n\n\n\n2018-02-05\nACTUAL\n2020-10\n2018-04-03\nACTUAL\n2018-03-07\n2018-04-02\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Ageâ‰¥ 18 years old.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed advanced NSCLC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Metastatic or â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA/ Accelerated titrationâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œ1mg of BAT6021â€, â€œintâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œBAT6021â€, â€œdescriptionâ€: â€œâ…£ infusionsâ€, â€œarmGroupLabelsâ€: [â€œA/ Accelerateâ€¦\nSolid Tumor\n\n\n[{â€œfacilityâ€: â€œGuangdong Provincial Peopleâ€™s Hospitalâ€, â€œcityâ€: â€œGuangzhouâ€, â€œstateâ€: â€œGuangdongâ€, â€œâ€¦\n[{â€œnameâ€: â€œYilong Wu, M.D, Ph.Dâ€, â€œaffiliationâ€: â€œGuangdong Provincial Peopleâ€™s Hospitalâ€, â€œroleâ€: â€œâ€¦\nMain purpose:\nThis study design for center, openness, dose escalation, and expand the research of phase I clinicalâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n5\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAssessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China\nNCT05120375\n\nA Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Prelâ€¦\nBAT-6021-001-CR\nINDUSTRY\nBio-Thera Solutions\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œDose-limiting toxicity(DLT)â€, â€œdescriptionâ€: â€œDose-limiting toxicity (DLT) is defined â€¦\n[{â€œmeasureâ€: â€œPharmacokinetics (PK)â€, â€œdescriptionâ€: â€œCmaxâ€, â€œtimeFrameâ€: â€œevery cycle until cycle 6â€¦\nFalse\nFalse\n\n\n\n\n\nINDUSTRY\nBio-Thera Solutions\n\n\n\nSPONSOR\n2023-04-07\nACTUAL\n\n\n\n\nFalse\n\n2023-10-11\nACTUAL\n2023-10-08\nTERMINATED\n2023-04-07\nACTUAL\n\n\n\n\n2022-02-17\nACTUAL\n2023-10\n2021-11-15\nACTUAL\n2021-11-03\n2021-11-03\nBased on the disclosed global research data on the same target drugs, the company has carefully consâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* To evaluate the safety and tolerability of BAT6021 injection in the treatment of loâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Age: â‰¥18 years old, gender: male or female;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. The expected survival was assâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD009375â€, â€œtermâ€: â€œNeoplasms, Glandular and Epithelâ€¦\n[{â€œidâ€: â€œD002295â€, â€œtermâ€: â€œCarcinoma, Transitional Cellâ€}, {â€œidâ€: â€œD001749â€, â€œtermâ€: â€œUrinary Bladdâ€¦\n\n[{â€œidâ€: â€œC000609138â€, â€œtermâ€: â€œavelumabâ€}, {â€œidâ€: â€œC000608132â€, â€œtermâ€: â€œsacituzumab govitecanâ€}, {â€œâ€¦\nDenmark\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œGroup A: Avelumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: Avelumabâ€]}, {â€œâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAvelumabâ€, â€œdescriptionâ€: â€œParticipants will receive avelumab intravenousâ€¦\nLocally Advanced or Metastatic Urothelial Carcinoma\nAvelumab, Avelumab in combination, Bladder cancer, M6223 (anti-TIGIT antibody), PD-L1, Sacituzumab gâ€¦\n\n[{â€œfacilityâ€: â€œBeacon Cancer Careâ€, â€œcityâ€: â€œCoeur dâ€™Aleneâ€, â€œstateâ€: â€œIdahoâ€, â€œzipâ€: â€œ83814â€, â€œcounâ€¦\n[{â€œnameâ€: â€œMedical Responsibleâ€, â€œaffiliationâ€: â€œMerck Healthcare KGaA, Darmstadt, Germany, an affilâ€¦\nThe purpose of this study is to assess the safety and efficacy of avelumab in combination with otherâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n256\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanceâ€¦\nNCT05327530\n\nA Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB001071â€¦\nMS100070_0119\nINDUSTRY\nEMD Serono\n[{â€œidâ€: â€œ2021-003669-36â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œ2023-510139-12-00â€, â€œtypeâ€: â€œCTISâ€}]\nQualified scientific and medical researchers can request the data. Such requests must be submitted iâ€¦\nWe are committed to enhancing public health through responsible sharing of clinical trial data. Follâ€¦\nSTUDY_PROTOCOL, SAP, CSR, ANALYTIC_CODE\nYES\nWithin six months after the approval of a new product or a new indication for an approved product inâ€¦\nhttp://bit.ly/IPD21\n\n[{â€œmeasureâ€: â€œProgression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œtimeFrameâ€: â€œTime from randomization of study drug until deatâ€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ39929671â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œNaing A, McKean M, Tolcher A, Victor A, Hu P, â€¦\n[{â€œlabelâ€: â€œTrial Awareness and Transparency websiteâ€, â€œurlâ€: â€œhttps://clinicaltrials.emdgroup.com/eâ€¦\n[{â€œnameâ€: â€œMerck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeuticsâ€, â€œclassâ€: â€œUNKNOWNâ€â€¦\nINDUSTRY\nEMD Serono Research & Development Institute, Inc.\n\n\n\nSPONSOR\n2026-06-25\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-26\nACTUAL\n2026-01-23\nACTIVE_NOT_RECRUITING\n2025-06-20\nACTUAL\n\n\n\n\n2022-08-17\nACTUAL\n2026-01\n2022-04-14\nACTUAL\n2022-04-05\n2022-04-13\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants with histologically confirmed, unresectable locally advanced or â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014594â€, â€œtermâ€: â€œUterine Neoplasmsâ€}, {â€œidâ€: â€œD005833â€, â€œtermâ€: â€œGenital Neoplasms, Femalâ€¦\n[{â€œidâ€: â€œD016889â€, â€œtermâ€: â€œEndometrial Neoplasmsâ€}, {â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€},â€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDose Escalation Cohorts.â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œUp to 5 sequential doâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œCOM701 in combination with BMS-986207 and nivolumab.â€, â€œdescriptionâ€: â€œStâ€¦\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nTIGIT, PVRIG, checkpoint inhibitor, Immune checkpoint, Immuno-oncology, CD226, CD112, CD155, Solid tâ€¦\n\n[{â€œfacilityâ€: â€œUniversity of Chicago Medical Centerâ€, â€œcityâ€: â€œChicagoâ€, â€œstateâ€: â€œIllinoisâ€, â€œzipâ€:â€¦\n[{â€œnameâ€: â€œLead COM701 ClinInfoâ€, â€œaffiliationâ€: â€œCompugen Ltdâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the â€¦\nThis phase 1/2 study evaluates the safety/tolerability, pharmacokinetics and preliminary antitumor aâ€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nSequential dose escalation, followed by an expansion cohort upon determination of the recommended doâ€¦\nNONE\n\n\n\nTREATMENT\n\n48\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCOM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.\nNCT04570839\n\nA Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 iâ€¦\nCPG-03-101.\nINDUSTRY\nCompugen Ltd\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œThe proportion of subjects with adverse events on the study.â€, â€œdescriptionâ€: â€œThe proâ€¦\n[{â€œmeasureâ€: â€œThe objective response rate of subjects enrolled in cohorts 1-4.â€, â€œdescriptionâ€: â€œObjâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nCompugen Ltd\n\n\n\nSPONSOR\n2024-05-15\nACTUAL\n\n\n\n\nFalse\n\n2024-07-18\nACTUAL\n2024-07-17\nCOMPLETED\n2024-05-15\nACTUAL\n\n\n\n\n2020-08-31\nACTUAL\n2024-07\n2020-09-30\nACTUAL\n2020-09-18\n2020-09-25\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically confirmed, locally advanced or metastaticâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œChronic Cannabinoid Usersâ€, â€œdescriptionâ€: â€œIb or II Melanoma patients who are chronic câ€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œHigh-performance liquid chromatography-tandem mass spectrometry assaysâ€,â€¦\nMelanoma\n\n\n[{â€œfacilityâ€: â€œUniversity of Colorado Denverâ€, â€œcityâ€: â€œAuroraâ€, â€œstateâ€: â€œColoradoâ€, â€œzipâ€: â€œ80045â€â€¦\n[{â€œnameâ€: â€œCamille Stewart, MDâ€, â€œaffiliationâ€: â€œUniversity of Colorado, Denverâ€, â€œroleâ€: â€œPRINCIPALâ€¦\nThe goal of this proposal is to determine how cannabinoid use affects the tumor immune microenvironmâ€¦\nSpecific Aim 1.Assess how systemic cannabinoids remodel tumor infiltrating lymphocytes (TILs) withinâ€¦\nParaffin Tissue Blocks Whole Blood\nSAMPLES_WITHOUT_DNA\n\n\n\n\n\n\nOTHER\n\nPROSPECTIVE\n90\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\n\n100 Years\n21 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nDescription of Population to be Enrolled:\n\nEvaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocyteâ€¦\nNCT05520294\n\nEvaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocyteâ€¦\n22-1132\nOTHER\nUniversity of Colorado, Denver\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œGrade of TIL in melanoma biopsyâ€, â€œdescriptionâ€: â€œHematoxylin and eosin slide assessmeâ€¦\n\nFalse\nFalse\n\nFalse\n\n\n[{â€œnameâ€: â€œCancer League of Coloradoâ€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nUniversity of Colorado, Denver\n\n\n\nSPONSOR\n2024-08-31\nESTIMATED\n\n\n\n\nFalse\n\n2024-04-17\nACTUAL\n2024-04-15\nACTIVE_NOT_RECRUITING\n2024-08-31\nESTIMATED\n\n\n\n\n2022-09-01\nACTUAL\n2024-04\n2022-08-29\nACTUAL\n2022-08-25\n2022-08-25\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Biopsy proven melanoma, any stage\n\n\n\n\n\n\n\n\nPatients who are either chronic cannabis/cannabinoid userâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Biopsy obtained within 4 weeks of antiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHB0036â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œHB0036 IV every 3 weeks (q3w)â€, â€œintervâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œHB0036â€, â€œdescriptionâ€: â€œPatients will be assigned to dose regimens in thâ€¦\nAdvanced Solid Tumor, NSCLC\n\n[{â€œnameâ€: â€œJingjing Wang, Masterâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ021-51320053â€, â€œphoneExtâ€: â€œ6029â€, â€œâ€¦\n[{â€œfacilityâ€: â€œHorizon Oncologyâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œLafayetteâ€, â€œstateâ€: â€œIndianaâ€, â€œâ€¦\n[{â€œnameâ€: â€œYang Yang, MD/PHDâ€, â€œaffiliationâ€: â€œShanghai Huaota Biopharmaceutical Co., Ltd.â€, â€œroleâ€:â€¦\nIt is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacoâ€¦\nThis is a phase â… /â…¡, multicenter, open-label, first-in-human study in patients with advanced solid tâ€¦\n\n\n\nSEQUENTIAL\nA single-subject cohort will be enrolled at the protocol starting dose of HB0036 every 3 weeks (Q3W)â€¦\nNONE\n\n\n\nTREATMENT\n\n80\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors\nNCT05417321\n\nA Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamiâ€¦\nHB0036-01\nINDUSTRY\nShanghai Huaota Biopharmaceutical Co., Ltd.\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œORR assessment in dose-escalation phaseâ€, â€œdescriptionâ€: â€œOverall response rate (ORR) â€¦\n[{â€œmeasureâ€: â€œSafety and tolerabilityâ€, â€œdescriptionâ€: â€œNumber of participants with a Dose Limiting â€¦\n[{â€œmeasureâ€: â€œAUCâ€, â€œdescriptionâ€: â€œArea Under concentration-time Curve (AUC)â€, â€œtimeFrameâ€: â€œUp to â€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nShanghai Huaota Biopharmaceutical Co., Ltd.\n\n\n\nSPONSOR\n2025-08-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-01-03\nACTUAL\n2025-01-02\nRECRUITING\n2025-08-01\nESTIMATED\n\n\n\n\n2022-08-25\nACTUAL\n2025-01\n2022-06-14\nACTUAL\n2022-05-30\n2022-06-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPatients must meet all the following criteria to be eligible for participation iâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD001254â€, â€œtermâ€: â€œAstrocytomaâ€}, {â€œidâ€: â€œD005910â€, â€œtermâ€: â€œGliomaâ€}, {â€œidâ€: â€œD018302â€, â€œtâ€¦\n[{â€œidâ€: â€œD005909â€, â€œtermâ€: â€œGlioblastomaâ€}]\n[{â€œidâ€: â€œD019411â€, â€œtermâ€: â€œClinical Laboratory Techniquesâ€}, {â€œidâ€: â€œD019937â€, â€œtermâ€: â€œDiagnostic â€¦\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œD013048â€, â€œtermâ€: â€œSpecimen Handlingâ€}, {â€œidâ€â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œGROUP A (neoadjuvant atezolizumab, tiragolumab)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€:â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œGiven IVâ€, â€œarmGroupLabelsâ€: [â€œGROUPâ€¦\nRecurrent Glioblastoma, IDH-Wildtype\n\n\n\n[{â€œnameâ€: â€œMegan Manticaâ€, â€œaffiliationâ€: â€œUniversity of Pittsburgh Cancer Institute LAOâ€, â€œroleâ€: â€œâ€¦\nThis phase II trial compares the safety, side effects and effectiveness of atezolizumab with tiragolâ€¦\nPRIMARY OBJECTIVE:\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nTesting the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Paâ€¦\nNCT06328036\n\nPhase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients With Recurrent Glioblastoma\nNCI-2024-02185\nNIH\nNational Cancer Institute (NCI)\n[{â€œidâ€: â€œNCI-2024-02185â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTRP (Clinical Trial Reporting Program)â€}, â€¦\n\nNCI is committed to sharing data in accordance with NIH policy. For more details on how clinical triâ€¦\n\nYES\n\nhttps://grants.nih.gov/policy/sharing.htm\n[{â€œmeasureâ€: â€œTumor response signatures including for T-cells, interferon and cell cycleâ€, â€œdescriptâ€¦\n[{â€œmeasureâ€: â€œProgression free survival (PFS)â€, â€œdescriptionâ€: â€œWill be assessed and compared betweeâ€¦\n[{â€œmeasureâ€: â€œTumor infiltrating T lymphocyte densityâ€, â€œdescriptionâ€: â€œWill be assessed and compareâ€¦\nFalse\nTrue\nFalse\nFalse\n\n\n\nNIH\nNational Cancer Institute (NCI)\n\n\n\nSPONSOR\n2025-07-01\nESTIMATED\n\n\n\n\nFalse\n\n2024-12-30\nACTUAL\n2024-12-27\nWITHDRAWN\n2025-07-01\nESTIMATED\n\n\n\n\n2025-04-30\nESTIMATED\n2024-12\n2024-03-25\nACTUAL\n2024-03-22\n2024-03-22\nOther - Protocol moved to Disapproved\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nI. To evaluate the impact of combination atezolizumab plus tiragolumab on progreâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients must have histologically confirmed IDH wildtype World Health Organizâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009380â€, â€œtermâ€: â€œNeoplasms, Nerve Tissueâ€}, {â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplasms by Histoâ€¦\n[{â€œidâ€: â€œD018317â€, â€œtermâ€: â€œNerve Sheath Neoplasmsâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}, {â€œidâ€: â€œD000074324â€, â€œtermâ€: â€œIpilimumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œImmunotherapy with Nivolumab and Ipilimumabâ€, â€œtypeâ€: â€œOTHERâ€, â€œdescriptionâ€: â€œNivolumabâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œNivolumabâ€, â€œdescriptionâ€: â€œNivolumab 4.5 mg/kg Q3W x 2â€, â€œarmGroupLabelsâ€¦\nNerve Sheath Tumors\n\n\n[{â€œfacilityâ€: â€œJohns Hopkins Medical Institutionâ€, â€œcityâ€: â€œBaltimoreâ€, â€œstateâ€: â€œMarylandâ€, â€œzipâ€: â€¦\n[{â€œnameâ€: â€œJaishri Blakeley, MDâ€, â€œaffiliationâ€: â€œJohns Hopkins Universityâ€, â€œroleâ€: â€œPRINCIPAL_INVEâ€¦\nThe purpose of the study is to evaluate safety and feasibility of neoadjuvant nivolumab plus ipilimuâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n13\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n100 Years\n12 Years\n\nALL\nCHILD, ADULT, OLDER_ADULT\n\n\nNeoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor\nNCT04465643\n\nNeoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor\nJ20112\nOTHER\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\n[{â€œidâ€: â€œIRB00215437â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œJohns Hopkins Universityâ€}, {â€œidâ€: â€œW81XWH-22-1-0â€¦\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œProportion of participants who had meaâ€¦\n[{â€œmeasureâ€: â€œSafety of combination nivolumab and ipilimumab as assessed by number of participants wâ€¦\n[{â€œmeasureâ€: â€œSafety as assessed by number of treatment-emergent adverse events in patients on combiâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œCongressionally Directed Medical Râ€¦\nOTHER\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\n\n\n\nSPONSOR\n2025-07-30\nACTUAL\n\n\n\n\nFalse\n\n2025-10-08\nACTUAL\n2025-10-02\nCOMPLETED\n2025-07-30\nACTUAL\n\n\n\n\n2021-06-08\nACTUAL\n2025-10\n2020-07-10\nACTUAL\n2020-07-07\n2020-07-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed diagnosis of atypical neurofibromatous neoplasms of â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplaâ€¦\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm 1 (zimberelimab monotherapy)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œDomvanalimab is a humanized monoclonal antâ€¦\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Canâ€¦\nNon Small Cell Lung Cancer, Lung Cancer, NSCLC\n\n[{â€œfacilityâ€: â€œUniversity of Alabama at Birminghamâ€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabamaâ€, â€œzipâ€â€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB12â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n151\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARC-7\nStudy to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Noâ€¦\nNCT04262856\n\nA Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With â€¦\nARC-7 (AB154CSP0002)\nINDUSTRY\nArcus Biosciences, Inc.\n\n\nArcus will provide access to individual de-identified participant data and related study documents (â€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œORR as assessed by RECIST v1.1â€, â€œtimeâ€¦\n[{â€œmeasureâ€: â€œDuration of response (DoR)â€, â€œdescriptionâ€: â€œDoR as assessed by RECIST v1.1â€, â€œtimeFraâ€¦\nFalse\nTrue\n\n\n\n[{â€œlabelâ€: â€œARC-7 - Public websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=ARC-7â€}]\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2025-07-09\nACTUAL\n\n\n\n\nFalse\n\n2025-08-26\nACTUAL\n2025-08-25\nCOMPLETED\n2025-06-05\nACTUAL\n\n\n\n\n2020-05-28\nACTUAL\n2024-08\n2020-02-10\nACTUAL\n2020-01-23\n2020-02-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female participants; age â‰¥ 18 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed, treatâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplaâ€¦\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD01â€¦\nBangladesh, Belarus, Brazil, Egypt, France, India, Peru, Russia, Serbia, Slovakia, Ukraine\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A - Study Part 1 (Platinum-based Chemotherapy)â€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescrâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œDomvanalimab is a humanized monoclonal antâ€¦\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Canâ€¦\nDomvanalimab, Zimberelimab, Non Small Cell Lung Cancer, Lung Cancer, NSCLC\n\n[{â€œfacilityâ€: â€œHope and Healing Cancer Serviceâ€, â€œcityâ€: â€œHinsdaleâ€, â€œstateâ€: â€œIllinoisâ€, â€œzipâ€: â€œ60â€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in frontâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n169\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARC-10\nStudy Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer\nNCT04736173\n\nOfficial Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, â€¦\nARC-10\nINDUSTRY\nArcus Biosciences, Inc.\n[{â€œidâ€: â€œ2020-003562-39â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œPHRR210222-003371â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nArcus will provide access to individual de-identified participant data and related study documents (â€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n\n[{â€œmeasureâ€: â€œProgression-free Survival (PFS)â€, â€œtimeFrameâ€: â€œFrom randomization until death from anâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œtimeFrameâ€: â€œFrom randomization until death from any cause (uâ€¦\nFalse\nTrue\n\nTrue\n\n[{â€œlabelâ€: â€œARC-10 - Public Websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=ARC-10â€}]\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2027-05\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-15\nACTUAL\n2025-12-09\nACTIVE_NOT_RECRUITING\n2027-05\nESTIMATED\n\n\n\n\n2021-02-08\nACTUAL\n2025-04\n2021-02-03\nACTUAL\n2021-01-29\n2021-01-29\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed, treatment naÃ¯ve, locally advanced or metastaticâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHealth volunteersâ€, â€œdescriptionâ€: â€œHealth volunteers as control groupâ€, â€œinterventionNaâ€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œno interventionâ€, â€œdescriptionâ€: â€œprospective and observational study wiâ€¦\n28 Day Mortality\nsepsis immunosuppression Treg\n[{â€œnameâ€: â€œSongqiao Liu, MD. PhD.â€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ086-2583262550â€, â€œemailâ€: â€œliusongqâ€¦\n[{â€œfacilityâ€: â€œZhongda Hospital, Southeast Universityâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œNanjingâ€, â€œâ€¦\n[{â€œnameâ€: â€œQingxiang Liu, MD.â€, â€œaffiliationâ€: â€œZhongda Hospitalâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}â€¦\nthere is high mortality rate of sepsis, 36% in 90-days of sepsis in China, and there is no effectiveâ€¦\n1. peripheral blood Treg cells and their surface PD-1ã€CTLA-4 and TIGIT levels in sepsis patients werâ€¦\nVenous blood was extracted according to time points and stored\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nOTHER\n\nPROSPECTIVE\n100\nESTIMATED\nTrue\n\nOBSERVATIONAL\n28 Days\nInclusion Criteria:\n\n\nTrue\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\npatients diagnosed with sepsis\n\nCo-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis\nNCT05126537\n\nAn Observational Study on the Relationship Between Expression of Co-inhibitory Molecules on Treg andâ€¦\n2020ZDSYLL041-Y01\nOTHER\nSoutheast University, China\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œ28 day mortalityâ€, â€œdescriptionâ€: â€œall patients followed up to 28 daysâ€, â€œtimeFrameâ€: â€¦\n\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nSoutheast University, China\nSoutheast University, China\nSongqiao Liu\nChief\nPRINCIPAL_INVESTIGATOR\n2022-12-31\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2022-11-30\nACTUAL\n2022-11-25\nUNKNOWN\n2022-12-31\nESTIMATED\n\n\n\n\n2022-01-01\nACTUAL\n2022-11\n2021-11-19\nACTUAL\n2021-11-08\n2021-11-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* sepsis 3.0 diagnositic criteria are met. older than 18 years old. total coursâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD054219â€, â€œtermâ€: â€œNeoplasms, Plasma Cellâ€}, {â€œidâ€: â€œD009370â€, â€œtermâ€: â€œNeoplasms by Histolâ€¦\n[{â€œidâ€: â€œD009101â€, â€œtermâ€: â€œMultiple Myelomaâ€}]\n[{â€œidâ€: â€œD011246â€, â€œtermâ€: â€œPregnadienetriolsâ€}, {â€œidâ€: â€œD011245â€, â€œtermâ€: â€œPregnadienesâ€}, {â€œidâ€: â€œâ€¦\n[{â€œidâ€: â€œC000624220â€, â€œtermâ€: â€œiberdomideâ€}, {â€œidâ€: â€œD003907â€, â€œtermâ€: â€œDexamethasoneâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA: Participants will receive EOS884448â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œEOS8844â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œEOS884448â€, â€œdescriptionâ€: â€œEOS884448 will be administered in arm A,B andâ€¦\nMultiple Myeloma\nMultiple Myeloma, EOS884448, GSK4428859A, TIGIT, Anti-TIGIT, iberdomide, CELMoD, CC-220, EOS-448, Beâ€¦\n\n[{â€œfacilityâ€: â€œBanner MD Andersonâ€, â€œcityâ€: â€œGilbertâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85234â€, â€œcountryâ€â€¦\n[{â€œnameâ€: â€œIteos Clinical Trialsâ€, â€œaffiliationâ€: â€œiTeos Belgium SAâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, anâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n16\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Novel Regimens in Relapsed or Refractory Multiple Myeloma\nNCT05289492\n\nStudy of EOS884448 Alone, and in Combination with Iberdomide with or Without Dexamethasone, in Partiâ€¦\nTIG-007\nINDUSTRY\niTeos Therapeutics\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œNumber of participants with any adverse events (AEs) and serious adverse events (SAEs)â€¦\n[{â€œmeasureâ€: â€œProgression-free-survival (PFS)â€, â€œtimeFrameâ€: â€œUntil disease progression or death - Aâ€¦\nFalse\nTrue\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œGlaxoSmithKlineâ€, â€œclassâ€: â€œINDUSTâ€¦\nINDUSTRY\niTeos Therapeutics\n\n\n\nSPONSOR\n2023-11-29\nACTUAL\n\n\n\n\nFalse\n\n2024-10-26\nACTUAL\n2024-10-23\nTERMINATED\n2023-11-29\nACTUAL\n\n\n\n\n2022-05-01\nACTUAL\n2024-10\n2022-03-21\nACTUAL\n2022-03-11\n2022-03-18\nCompany operational decision. Decision to stop study is not due to safety or efficacy concerns\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* All participants must have a documented diagnosis of relapse/refractory Multiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€},â€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œModule 1â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAZD6750 administered intravenously (Iâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAZD6750â€, â€œdescriptionâ€: â€œAZD6750- CD8 guided IL-2â€, â€œarmGroupLabelsâ€: [â€œâ€¦\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Câ€¦\n\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œGrand Rapidsâ€, â€œstateâ€: â€œMichiganâ€, â€¦\n\nA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Soâ€¦\nA Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokineticsâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\nModule 1 consists of treatment with AZD6750 administered as a single agent to enroll participants wiâ€¦\nNONE\n\n\n\nTREATMENT\n\n60\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Soâ€¦\nNCT07115043\n\nA Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokineticsâ€¦\nD7350C00001\nINDUSTRY\nAstraZeneca\n\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œSafety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)â€, â€œdescriptioâ€¦\n[{â€œmeasureâ€: â€œPharmacodynamic- Part 1A & Part 2A (dose escalation) and Part B (dose expansion)â€, â€œdeâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-10-02\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-19\nACTUAL\n2025-12-18\nRECRUITING\n2029-10-02\nESTIMATED\n\n\n\n\n2025-07-29\nACTUAL\n2025-12\n2025-08-11\nACTUAL\n2025-07-16\n2025-08-04\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participant â‰¥ 18 year\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* ECOG PS of 0 to 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Provision of â€˜archivalâ€™ tumor speâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD043823â€, â€œtermâ€: â€œTaxoidsâ€}, {â€œidâ€: â€œD043822â€, â€œtermâ€: â€œCyclodecanesâ€}, {â€œidâ€: â€œD003516â€, â€¦\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œImmunotherapy with CCRT before surgeryâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTiragolâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTiragolumabâ€, â€œdescriptionâ€: â€œNeoadjuvant Tiragolumab, Atezolizumab, Paclâ€¦\nLocally Advanced Esophageal Squamous Cell Carcinoma\n\n[{â€œnameâ€: â€œChia-Hsien Cheng, câ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+886-2-2352-2846â€, â€œemailâ€: â€œjasonchenâ€¦\n[{â€œfacilityâ€: â€œNational Taiwan University Hospitalâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œTaipeiâ€, â€œzipâ€â€¦\n[{â€œnameâ€: â€œChia-Hsien Cheng, Chengâ€, â€œaffiliationâ€: â€œEmployeeâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nThe prognosis of ESCC is poor with a five-year overall survival rate of 10 to 30 %. Randomized cliniâ€¦\nEsophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancy worldwide. The prognoâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n32\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n20 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nImmunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients\nNCT05743504\n\nA Phase Ib/II Trial of Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapyâ€¦\n202111099MIPC\nOTHER\nNational Taiwan University Hospital\n[{â€œidâ€: â€œML43431â€, â€œtypeâ€: â€œOTHER_GRANTâ€, â€œdomainâ€: â€œF. Hoffmann-La Roche Ltdâ€}]\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œPathological complete response rateâ€, â€œdescriptionâ€: â€œPathological complete response râ€¦\n[{â€œmeasureâ€: â€œSide effect evaluationâ€, â€œdescriptionâ€: â€œmajor morbidity rate after completion of protâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n\nOTHER\nNational Taiwan University Hospital\n\n\n\nSPONSOR\n2025-11-30\nESTIMATED\n\n\n\n\nFalse\nRECRUITING\n2024-02-02\nACTUAL\n2024-01-31\nUNKNOWN\n2025-05-31\nESTIMATED\n\n\n\n\n2023-09-18\nACTUAL\n2023-09\n2023-02-24\nACTUAL\n2023-01-30\n2023-02-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically proved squamous cell carcinoma of esophagus\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Locally advancâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004333â€, â€œtermâ€: â€œDrug Administration Routesâ€}, {â€œidâ€: â€œD004358â€, â€œtermâ€: â€œDrug Therapyâ€},â€¦\n[{â€œidâ€: â€œD007267â€, â€œtermâ€: â€œInjectionsâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œ10 mg of BAT6021â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œBAT6021 100mg/vialï¼Œ10mg â…£ infâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œBAT6021â€, â€œdescriptionâ€: â€œâ…£ infusionsâ€, â€œarmGroupLabelsâ€: [â€œ10 mg of BAT6â€¦\nAdvanced Solid Tumor\n\n\n[{â€œfacilityâ€: â€œLiverpool Hospitalâ€, â€œcityâ€: â€œLiverpoolâ€, â€œstateâ€: â€œNew South Walesâ€, â€œcountryâ€: â€œAusâ€¦\n[{â€œnameâ€: â€œAbhijit Pal, M.D, Ph.Dâ€, â€œaffiliationâ€: â€œMedical Oncologist at cancer Therapy, Liverpool â€¦\nThis first-in-human open-label, multi center, dose-escalation and expansion study is designed to evaâ€¦\nAnti-PD-1 and anti-PD-L1 antibodies targeting the immuno-inhibitory PD-1 pathway (thus activating T â€¦\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n13\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAssessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients\nNCT05073484\n\nA Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Prelâ€¦\nBAT-6021-002-CR\nINDUSTRY\nBio-Thera Solutions\n\n\nno plan to share IPD\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œDose-limiting toxicity(DLT)â€, â€œdescriptionâ€: â€œDLT is defined as one of the following aâ€¦\n[{â€œmeasureâ€: â€œPharmacokinetics (PK)â€, â€œdescriptionâ€: â€œCmaxâ€, â€œtimeFrameâ€: â€œevery cycle until cycle 6â€¦\nFalse\nFalse\nFalse\nFalse\n\n\n\nINDUSTRY\nBio-Thera Solutions\n\n\n\nSPONSOR\n2023-03-30\nACTUAL\n\n\n\n\nFalse\n\n2023-10-11\nACTUAL\n2023-10-09\nTERMINATED\n2023-03-30\nACTUAL\n\n\n\n\n2021-10-29\nACTUAL\n2023-10\n2021-10-11\nACTUAL\n2021-09-09\n2021-09-28\nBased on the disclosed global research data on the same target drugs, the company has carefully consâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Able to give voluntary informed consent and understand the study and are wilâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAdvanced NSCLC or Melanoma - Anti-PD-(L)1 Therapyâ€, â€œdescriptionâ€: â€œThis cohort includesâ€¦\n\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nstandard treatment with anti-PD-(L)1 monotherapy or combination therapy\n[{â€œnameâ€: â€œCourÃ¨che CK KADERBHAI, Doctorâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ03 80 73 75 28â€, â€œphoneExtâ€:â€¦\n[{â€œfacilityâ€: â€œCHU BesanÃ§on - Service Dermatologieâ€, â€œcityâ€: â€œBesanÃ§onâ€, â€œzipâ€: â€œ25000â€, â€œcountryâ€: â€¦\n[{â€œnameâ€: â€œJessica JG GOBBO, Clinical Research Scientistâ€, â€œaffiliationâ€: â€œCentre Georges FranÃ§ois Lâ€¦\nThe objective of this prospective multicenter study is to evaluate whether the analysis of immunologâ€¦\nImmune checkpoint inhibitors (anti-PD-1/PD-L1) have become standard treatment for patients with advaâ€¦\n\n\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n378\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nPatients with non-small cell lung cancer (NSCLC) or melanoma, locally advanced or metastatic, and unâ€¦\nEVpredict\nPredicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis\nNCT07376512\n\nPredicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis\n2025-A01783-46\nOTHER\nCentre Georges Francois Leclerc\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œTarget protein levels in plasma-derived extracellular vesicles (EVs) measured by multiâ€¦\n\nFalse\nFalse\n\nFalse\n\n\n\nOTHER\nCentre Georges Francois Leclerc\n\n\n\nSPONSOR\n2030-03-01\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-29\nACTUAL\n2026-01-22\nNOT_YET_RECRUITING\n2029-03-01\nESTIMATED\n\n\n\n\n2026-03-01\nESTIMATED\n2026-01\n2026-01-29\nACTUAL\n2026-01-22\n2026-01-22\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age â‰¥18 years.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed diagnosis of non-small cell lung caâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œD000068258â€, â€œtermâ€: â€œBevacizumabâ€}, {â€œidâ€: â€œâ€¦\nMorocco\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAtezolizumab + Bevacizumab + Tiragolumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œAtezoâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œAtezolizumab will be administered by intraâ€¦\nHepatocellular Carcinoma\n\n\n[{â€œfacilityâ€: â€œGenesis Cancer Centerâ€, â€œcityâ€: â€œHot Springsâ€, â€œstateâ€: â€œArkansasâ€, â€œzipâ€: â€œ71913â€, â€œâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monocloâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nQUADRUPLE\nThe study has been unblinded as of amendment version 5.\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n687\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSKYSCRAPER-14\nA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Uâ€¦\nNCT05904886\n\nA Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating Atezolizumab and Bevacizuâ€¦\nCO44668\nINDUSTRY\nHoffmann-La Roche\n[{â€œidâ€: â€œ2023-503422-39-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œEU CT Numberâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œInvestigator-assessed Progression-free Survival (PFS) According to Response Evaluationâ€¦\n[{â€œmeasureâ€: â€œInvestigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1â€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ38861301â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œBadhrinarayanan S, Cotter C, Zhu H, Lin YC, Kuâ€¦\n\n[{â€œnameâ€: â€œChugai Pharmaceuticalâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2026-09-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-31\nACTUAL\n2025-12-30\nACTIVE_NOT_RECRUITING\n2025-05-08\nACTUAL\n\n\n\n\n2023-09-14\nACTUAL\n2025-12\n2023-06-15\nACTUAL\n2023-05-23\n2023-06-14\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}â€¦\n[{â€œidâ€: â€œD043823â€, â€œtermâ€: â€œTaxoidsâ€}, {â€œidâ€: â€œD043822â€, â€œtermâ€: â€œCyclodecanesâ€}, {â€œidâ€: â€œD003516â€, â€¦\n[{â€œidâ€: â€œD000077143â€, â€œtermâ€: â€œDocetaxelâ€}, {â€œidâ€: â€œD000074324â€, â€œtermâ€: â€œIpilimumabâ€}, {â€œidâ€: â€œC000â€¦\nAustralia, Denmark\n\n2025-05-22\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProt_SAPâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: true, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Prâ€¦\nTrue\n[{â€œlabelâ€: â€œPart 1: Participants receiving feladilimab and ipilimumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œintâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDocetaxelâ€, â€œdescriptionâ€: â€œDocetaxel will be administered.â€, â€œarmGroupLaâ€¦\nNeoplasms\nNon-small cell lung cancer, Inducible t-cell co-stimulator (ICOS), Docetaxel, Standard of care, Immuâ€¦\n\n[{â€œfacilityâ€: â€œGSK Investigational Siteâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€: â€œ9002â€¦\n[{â€œnameâ€: â€œGSK Clinical Trialsâ€, â€œaffiliationâ€: â€œGlaxoSmithKlineâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will compare the clinical activity of novel regimens (in combination or as single agents)â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\nThe study will be open-label.\n\n\nTREATMENT\n\n175\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nPlatform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lâ€¦\nNCT03739710\n\nA Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimenâ€¦\n205801\nINDUSTRY\nGlaxoSmithKline\n[{â€œidâ€: â€œ2018-001316-29â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\nAccess is provided after a research proposal is submitted and has received approval from the Indepenâ€¦\nIPD for this study will be made available via the Clinical Study Data Request site.\nSTUDY_PROTOCOL, SAP, ICF, CSR\nYES\nIPD will be made available within 6 months of publishing the results of the primary endpoints, key sâ€¦\nhttp://clinicalstudydatarequest.com\n\n[{â€œmeasureâ€: â€œNumber of Participants Randomized Across Sub-studiesâ€, â€œdescriptionâ€: â€œNumber of Partiâ€¦\n\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œiTeos Belgium SAâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nGlaxoSmithKline\n\n\n\nSPONSOR\n2024-05-02\nACTUAL\n\n\n\n\nFalse\n\n2025-06-15\nACTUAL\n2025-06-13\nCOMPLETED\n2024-05-02\nACTUAL\n2025-06-15\nACTUAL\n2025-05-02\n2025-06-13\n2019-01-24\nACTUAL\n2025-06\n2018-11-14\nACTUAL\n2018-11-09\n2018-11-09\n\nAdverse event(s) of special interest [AESIs] and Serious Adverse Event(s) [SAEs] assessed as relâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œAll Screened Participantsâ€, â€œdescriptionâ€: â€œParticipants with Non-Small Câ€¦\n0.0\n\n\nScreening (-28 to 0 days)\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ256â€}]}]\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œAll Screened Participantsâ€, â€œdescriptionâ€: â€œParticipants with Non-Small Câ€¦\n[{â€œtitleâ€: â€œAge, Customizedâ€, â€œparamTypeâ€: â€œCOUNT_OF_PARTICIPANTSâ€, â€œunitOfMeasureâ€: â€œParticipantsâ€,â€¦\n\nGSK agreements may vary with individual investigators, but will not prohibit any investigator from pâ€¦\nFalse\nOTHER\nTrue\n\nGSKClinicalSupportHD@gsk.com\nGlaxoSmithKline\n866-435-7343\n\nGSK Response Center\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œNumber of Participants Randomized Across Sub-studiesâ€, â€œdescriptionâ€:â€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œAll Screened Participantsâ€, â€œdescriptionâ€: â€œParticipants with Non-Small Câ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œcommentâ€: â€œAll participants who wereâ€¦\nA total of 256 participants started the overall study which includes all who were screened prior to â€¦\nThis master record includes data of screened participants for its sub-studies, 205801-001 (NCT055538â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants capable of giving signed informed consent/assent.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or femaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCohort A: Zimberelimab + Domvanalimab + Etrumadenantâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œZimberelimabâ€, â€œdescriptionâ€: â€œZimberelimab will be supplied by Arcus Bioâ€¦\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œWashington University School of Medicineâ€, â€œcityâ€: â€œSt Louisâ€, â€œstateâ€: â€œMissouriâ€, â€œâ€¦\n[{â€œnameâ€: â€œDaniel Morgensztern, M.D.â€, â€œaffiliationâ€: â€œWashington University School of Medicineâ€, â€œrâ€¦\nSince anti-PD1, anti-TIGIT, and A2R antagonists have complementary mechanisms of action, and the latâ€¦\n\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n30\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSafety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenanâ€¦\nNCT04791839\n\nA Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanâ€¦\n202104122\nOTHER\nWashington University School of Medicine\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œ* Defined as the proportion of patientâ€¦\n[{â€œmeasureâ€: â€œNumber of study treatment related adverse eventsâ€, â€œdescriptionâ€: â€œ\\- Adverse events â€¦\nFalse\nTrue\nFalse\nTrue\n\n[{â€œlabelâ€: â€œAlvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University Schooâ€¦\n[{â€œnameâ€: â€œArcus Biosciences, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nWashington University School of Medicine\n\n\n\nSPONSOR\n2030-06-30\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-05\nACTUAL\n2025-11-04\nACTIVE_NOT_RECRUITING\n2026-04-30\nESTIMATED\n\n\n\n\n2021-08-04\nACTUAL\n2025-11\n2021-03-10\nACTUAL\n2021-03-05\n2021-03-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed metastatic squamous or non-squamous non-small cell lâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD009375â€, â€œtermâ€: â€œNeoplasms, Glandular and Epithelâ€¦\n[{â€œidâ€: â€œD002280â€, â€œtermâ€: â€œCarcinoma, Basal Cellâ€}]\n[{â€œidâ€: â€œD007982â€, â€œtermâ€: â€œLevulinic Acidsâ€}, {â€œidâ€: â€œD007651â€, â€œtermâ€: â€œKeto Acidsâ€}, {â€œidâ€: â€œD002â€¦\n[{â€œidâ€: â€œD000622â€, â€œtermâ€: â€œAminolevulinic Acidâ€}, {â€œidâ€: â€œC008848â€, â€œtermâ€: â€œ1-phenyl-3,3-dimethyltâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPhotodynamic therapy (PDT)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œEach participant wiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œALAâ€, â€œdescriptionâ€: â€œAt first visit, ALA applied to one BCC lesionâ€, â€œarâ€¦\nBasal Cell Carcinoma\n\n[{â€œnameâ€: â€œEdward V Maytin, MD, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ216-444-5139â€, â€œemailâ€: â€œmaytine@â€¦\n[{â€œfacilityâ€: â€œCleveland Clinic, Case Comprehensive Cancer Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€¦\n[{â€œnameâ€: â€œEdward V Maytin, MD, PhDâ€, â€œaffiliationâ€: â€œCleveland Clinic, Case Comprehensive Cancer Ceâ€¦\nThe purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) â€¦\nPDT is a technique that works by combining a photosensitizing topical agent and an intense light to â€¦\n\n\n\nSINGLE_GROUP\nEach participant will serve as their own control - one tumor will be PDT-treated and other left as uâ€¦\nNONE\n\n\n\nTREATMENT\n\n28\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAlteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy\nNCT05020912\n\nAlteration of the Immune Microenvironment in Basal Cell Carcinoma (BCC) Following Photodynamic Theraâ€¦\nCASE2621\nOTHER\nCase Comprehensive Cancer Center\n\n\nAll IPD that underlie results in publication\nSTUDY_PROTOCOL, SAP, ICF, CSR\nYES\n\n\n\n[{â€œmeasureâ€: â€œTime to maximum expression of immune checkpoint moleculesâ€, â€œdescriptionâ€: â€œTime (daysâ€¦\n[{â€œmeasureâ€: â€œProportion of tumor-activated CD8+ T-cells after PDTâ€, â€œdescriptionâ€: â€œDifference in Câ€¦\nFalse\nTrue\n\nFalse\n\n\n\nOTHER\nCase Comprehensive Cancer Center\n\n\n\nSPONSOR\n2027-12\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-26\nACTUAL\n2025-11-25\nRECRUITING\n2027-09\nESTIMATED\n\n\n\n\n2021-12-13\nACTUAL\n2025-11\n2021-08-25\nACTUAL\n2021-08-19\n2021-08-19\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Adults scheduled to undergo Mohs surgery within the Dermatologic Surgery unitâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014571â€, â€œtermâ€: â€œUrologic Neoplasmsâ€}, {â€œidâ€: â€œD014565â€, â€œtermâ€: â€œUrogenital Neoplasmsâ€},â€¦\n[{â€œidâ€: â€œD001749â€, â€œtermâ€: â€œUrinary Bladder Neoplasmsâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCohort Aâ€, â€œdescriptionâ€: â€œPatients treated with intravesical instillations for non-invaâ€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œBiological samplesâ€, â€œdescriptionâ€: â€œBlood samples will be collected at â€¦\nBladder Cancer\n\n[{â€œnameâ€: â€œJihane Boustani, MD, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+33 3 70 63 23 02â€, â€œemailâ€: â€œjboâ€¦\n\n\nThe main objective of this study is to evaluate the induction of Th1 anti-TERT responses by treatmenâ€¦\n\n\n\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n33\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nPROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nPatients treated for a bladder cancer\nimmunoBLAD\nAntitumor T Cell Responses in Patients With Bladder Cancer\nNCT06334406\n\nStudy of Antitumor T Cell Immune Responses in Patients With Bladder Cancer\n098 DRC 210 ER03 012\nOTHER\nCentre Hospitalier Universitaire de Besancon\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œTumor antigen specific T-cell responsesâ€, â€œdescriptionâ€: â€œIncrease in the post-treatmeâ€¦\n[{â€œmeasureâ€: â€œMonitoring of T cells in the bloodâ€, â€œdescriptionâ€: â€œFlow cytometry analysis using T câ€¦\nFalse\nFalse\n\n\n\n\n\nOTHER\nCentre Hospitalier Universitaire de Besancon\n\n\n\nSPONSOR\n2026-04-02\nESTIMATED\n\n\n\n\nFalse\n\n2024-03-28\nACTUAL\n2024-03-19\nNOT_YET_RECRUITING\n2026-04-02\nESTIMATED\n\n\n\n\n2024-04-02\nESTIMATED\n2024-03\n2024-03-28\nACTUAL\n2024-02-28\n2024-03-19\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients undergoing transurethral resection of the bladder (TURBT) for a tumoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD011129â€, â€œtermâ€: â€œPolyradiculoneuropathyâ€}, {â€œidâ€: â€œD020274â€, â€œtermâ€: â€œAutoimmune Diseasesâ€¦\n[{â€œidâ€: â€œD020277â€, â€œtermâ€: â€œPolyradiculoneuropathy, Chronic Inflammatory Demyelinatingâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œKINE-101 120mgâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œSubjects received a single intrâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œKINE-101â€, â€œdescriptionâ€: â€œKINE-101 injection, 12.5 mg/mL, administered oâ€¦\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\n\n\n[{â€œfacilityâ€: â€œKangbuk Samsung Hospitalâ€, â€œcityâ€: â€œSeoulâ€, â€œstateâ€: â€œSeoulâ€, â€œzipâ€: â€œ03181â€, â€œcountrâ€¦\n[{â€œnameâ€: â€œHanna Parkâ€, â€œaffiliationâ€: â€œKine Sciences Co., Ltd.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a multicenter, open-label, single-dose, dose-escalation study evaluating the safety and toleâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nSequential dose escalation in single experimental arm with cohorts receiving 120 mg, 240 mg, or 360 â€¦\nNONE\n\n\n\nTREATMENT\n\n9\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n19 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP\nNCT07343310\n\nMulti-Center, Open-label, Single Dosing, Dose-Ascending, Phase 1 Study to Evaluate the Safety and Toâ€¦\nCIDP101-CR1-001P\nINDUSTRY\nKine Sciences Co., Ltd.\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œChange From Baseline in Inflammatory Neuropathy Cause and Treatment (INCAT) Disabilityâ€¦\n[{â€œmeasureâ€: â€œIncidence of Adverse Events (AEs)â€, â€œdescriptionâ€: â€œIncidence, severity, and relationsâ€¦\n\nFalse\nFalse\n\n\n\n\n\nINDUSTRY\nKine Sciences Co., Ltd.\n\n\n\nSPONSOR\n2025-04-14\nACTUAL\n\n\n\n\nFalse\n\n2026-01-20\nACTUAL\n2026-01-15\nCOMPLETED\n2025-04-14\nACTUAL\n\n\n\n\n2024-08-27\nACTUAL\n2026-01\n2026-01-15\nACTUAL\n2025-12-10\n2026-01-06\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Adults aged â‰¥19 years at informed consent.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Diagnosed with CIDP and refractoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004701â€, â€œtermâ€: â€œEndocrine Gland Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Sitâ€¦\n[{â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€}, {â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplasmsâ€}, {â€œiâ€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}, {â€œidâ€: â€œD000074324â€, â€œtermâ€: â€œIpilimumabâ€}]\n\n2022-01-25\n\n\n[{â€œreleaseDateâ€: â€œ2022-01-25â€, â€œresetDateâ€: â€œ2022-02-16â€, â€œmcpReleaseNâ€: 10}]\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œNeoadjuvant Breast Cancerâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œNewly diagnosed patiâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œNivolumabâ€, â€œdescriptionâ€: â€œNivolumab 240 mg administered by IV infâ€¦\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nbreast cancer, ovarian cancer, gastric cancer\n\n[{â€œfacilityâ€: â€œHoffman Oncologyâ€, â€œcityâ€: â€œThe Bronxâ€, â€œstateâ€: â€œNew Yorkâ€, â€œzipâ€: â€œ10469â€, â€œcountryâ€¦\n[{â€œnameâ€: â€œAnthony Hoffman, MDâ€, â€œaffiliationâ€: â€œExcellaBio LLCâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nSafety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with â€¦\nOpen-Label, Non-Randomization and Safety Run-In: Part 1 of the study is a Phase 2 clinical trial in â€¦\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\nOpen-Label, Non-Randomization Phase 2 clinical trial with Safety Run-In (3 parts): Part 1 in 20 newlâ€¦\nNONE\n\n\n\nTREATMENT\n\n5\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria: Patients must meet all inclusion criteria before enrollment:\nTrue\nPart 1. Neoadjuvant Breast (Females â‰¥18 years of age)\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCombination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients\nNCT03342417\n\nPhase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Unâ€¦\nCA209-929\nINDUSTRY\nExcellaBio LLC\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œPart 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Tumor Genomics and Biomarâ€¦\n[{â€œmeasureâ€: â€œNumber of participants with treatment-related adverse events as assessed by CTCAE v4.0â€¦\n[{â€œmeasureâ€: â€œPart 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - BCTâ€, â€œdescriptionâ€: â€œChaâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nExcellaBio LLC\n\n\n\nSPONSOR\n2019-05-29\nACTUAL\n\n\n\n\nFalse\n\n2021-11-09\nACTUAL\n2021-11-05\nTERMINATED\n2019-05-29\nACTUAL\n\n\n\n\n2018-02-14\nACTUAL\n2021-11\n2017-11-17\nACTUAL\n2017-10-20\n2017-11-09\nSlow patient accrual\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFor Part 1 of the â€¦\n\nPart 2. Platinum-resistant refractory ovarianâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD015179â€, â€œtermâ€: â€œColorectal Neoplasmsâ€}, {â€œidâ€: â€œD007414â€, â€œtermâ€: â€œIntestinal Neoplasmsâ€â€¦\n[{â€œidâ€: â€œD003110â€, â€œtermâ€: â€œColonic Neoplasmsâ€}]\n\n[{â€œidâ€: â€œC035276â€, â€œtermâ€: â€œeicosapentaenoic acid ethyl esterâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œExperimentalâ€, â€œdescriptionâ€: â€œPatients randomized to the experimental arm of the EMT2 tâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œIcosapent Ethyl Oral Capsuleâ€, â€œdescriptionâ€: â€œSoft gelatin capsules contâ€¦\nColon Cancer Liver Metastasis\nColon Cancer, Liver Metastases, Microbiome\n\n[{â€œfacilityâ€: â€œSt Jamesâ€™s University Hospitalâ€, â€œcityâ€: â€œLeedsâ€, â€œcountryâ€: â€œUnited Kingdomâ€, â€œgeoPoâ€¦\n[{â€œnameâ€: â€œMark Hullâ€, â€œaffiliationâ€: â€œUniversity of Leedsâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€}]\nA significant proportion of patients who undergo liver surgery to remove bowel cancer that has spreaâ€¦\nDespite advance in the diagnosis and treatment of colorectal cancer (CRC), it remains the second mosâ€¦\nWhole blood, serum, stool, urine, tumour tissue (colorectal cancer liver metastases).\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n81\nACTUAL\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nAny participant who has already been enrolled in the EMT2 trial is eligible for inclusion in the bioâ€¦\n\nPrebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases\nNCT04682665\n\nBiospecimen Collection for:Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancerâ€¦\n20/YH/0306\nOTHER\nUniversity of Leeds\n[{â€œidâ€: â€œ1R01CA243454-01A1â€, â€œtypeâ€: â€œNIHâ€, â€œlinkâ€: â€œhttps://reporter.nih.gov/quickSearch/1R01CA2434â€¦\n\nAnonymised individual patient experimental data may be shared depending on experimental outcomes\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œAbundance of individual bacterial taxa in the gut microbiome (eg. Bifidobacterium, Lacâ€¦\n\nFalse\nTrue\nTrue\nTrue\n\n\n[{â€œnameâ€: â€œNational Cancer Institute (NCI)â€, â€œclassâ€: â€œNIHâ€}, {â€œnameâ€: â€œMassachusetts General Hospitâ€¦\nOTHER\nUniversity of Leeds\nUniversity of Leeds\nMark A Hull, PhD FRCP\nProfessor of Gastroenterology\nPRINCIPAL_INVESTIGATOR\n2024-07-31\nACTUAL\n\n\n\n\nFalse\n\n2024-12-04\nACTUAL\n2024-12-03\nCOMPLETED\n2024-07-31\nACTUAL\n\n\n\n\n2021-09-16\nACTUAL\n2024-12\n2020-12-24\nACTUAL\n2020-12-02\n2020-12-18\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Only individuals who have already been enrolled in the EMT2 trial are eligiblâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siteâ€}, {â€œidâ€: â€œD001941â€, â€œtermâ€: â€œBreast Diseasesâ€}, {â€œidâ€â€¦\n[{â€œidâ€: â€œD001943â€, â€œtermâ€: â€œBreast Neoplasmsâ€}, {â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€}, {â€œidâ€¦\n\n[{â€œidâ€: â€œC000722772â€, â€œtermâ€: â€œAZD5305â€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSub-Study 1 AZD8205 Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œSub-Study 1 haâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAZD8205â€, â€œdescriptionâ€: â€œAZD8205 is an antibody drug conjugate that has â€¦\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell â€¦\nFirst In Human, antibody drug conjugate, cancer, solid tumour, Phase I, Phase IIa\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œDuarteâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€¦\n\nThis research study is studying a new compound, AZD8205, as a possible treatment for advanced or metâ€¦\nThis study is a Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Sâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\nThe study consists a master protocol with sub studies each evaluating the safety and tolerability ofâ€¦\nNONE\n\n\n\nTREATMENT\n\n460\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solâ€¦\nNCT05123482\n\nA Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD820â€¦\nD6900C00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2022-502759-70-01â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTIS (EU)â€}, {â€œidâ€: â€œ2021-000736-66â€, â€œtâ€¦\nWhen a request has been approved AstraZeneca will provide access to the deidentified individual patiâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagroup-dt.pharmacm.com/DT/Home\n\n[{â€œmeasureâ€: â€œThe number of patients with adverse eventsâ€, â€œdescriptionâ€: â€œNumber of patients with aâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œThe percentage of patients with a confâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ39392424â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œHuang Y, Tan HY, Yuan J, Mu R, Yang J, Ball K,â€¦\n[{â€œlabelâ€: â€œFirst in Human Study to Evaluate AZD8205â€, â€œurlâ€: â€œhttps://www.breastcancerstudylocatorâ€¦.\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2027-09-29\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-08\nACTUAL\n2025-12-02\nRECRUITING\n2027-09-29\nESTIMATED\n\n\n\n\n2021-10-18\nACTUAL\n2025-11\n2021-11-17\nACTUAL\n2021-10-13\n2021-11-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age â‰¥ 18 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Relapsed/metastatic solid tumors treated with prior adeqâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Dominant Lewy Bodyâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPart 1 (dose finding): Cohort A - SC Rilvegostomig Dose Level 1 (DL1) and rHuâ€, â€œtypeâ€: â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œIV Rilvegostomigâ€, â€œdescriptionâ€: â€œRilvegostomig administered IV.â€, â€œarmGâ€¦\nAdvanced Solid Tumors\nRecombinant Human Hyaluronidase, Immunooncology monotherapy, T cell Immunoglobulin and Immunoreceptoâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œHuntersvilleâ€, â€œstateâ€: â€œNorth Carolâ€¦\n\nThe purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposuâ€¦\nThis is a Phase I, open-label, multicenter, multi-part, dose finding and dose confirmation study to â€¦\n\n\nRANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n40\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARTEMIDE-subQ\nA Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Particâ€¦\nNCT07161414\n\nA Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokineticsâ€¦\nD702EC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2025-521614-26-00â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œEU CT Numberâ€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\n\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œArea under the Concentration-time Curve During One Dosing Interval (AUCtau)â€, â€œdescripâ€¦\n[{â€œmeasureâ€: â€œNumber of participants with adverse events (AEs)â€, â€œdescriptionâ€: â€œTo assess safety anâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œParexelâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-07-24\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-24\nACTUAL\n2025-12-18\nRECRUITING\n2027-07-19\nESTIMATED\n\n\n\n\n2025-11-25\nACTUAL\n2025-12\n2025-09-08\nACTUAL\n2025-09-03\n2025-09-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented advanced (metastatic and/or unreseâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œidentification of clinical and immunological parametersâ€, â€œdescriptionâ€: â€œIdentificationâ€¦\n\nHIV\nHIV, antiretroviral treatment, viral reservoir, persistent viremia\n[{â€œnameâ€: â€œJade GHOSN, professorâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0140258000â€, â€œemailâ€: â€œjade.ghosn@apâ€¦\n[{â€œfacilityâ€: â€œHÃ´pital Bichat, service des Maladies Infectieuses et Tropicalesâ€, â€œcityâ€: â€œParisâ€, â€œsâ€¦\n\nLow-level HIV replication in a patient on effective antiretroviral therapy is a relatively frequent â€¦\nThe aim of antiretroviral (ARV) treatment is to inhibit viral replication in order to achieve an undâ€¦\n\n\n\n\n\n\n\n\nCASE_CONTROL\n\nCROSS_SECTIONAL\n80\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nPLHIV with persistent low plasma viral load on ARV therapy :\n\n\nFalse\n\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nAdults living with HIV-1, under antiretroviral therapy (ART) for at least 2 years, recruited from a â€¦\nViPer\nRole of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia inâ€¦\nNCT07015164\n\nRole of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia inâ€¦\nAPHP240349\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œQuantification of HIV-1 cellular reservoir parameters using molecular techniquesâ€, â€œdeâ€¦\n[{â€œmeasureâ€: â€œGenetic diversity of HIV-1 proviruses integrated in cellular genomesâ€, â€œdescriptionâ€: â€¦\nFalse\nFalse\n\nFalse\n\n\n\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\nSPONSOR\n2026-09-11\nESTIMATED\n\n\n\n\nFalse\n\n2025-06-11\nACTUAL\n2025-06-03\nNOT_YET_RECRUITING\n2026-09-10\nESTIMATED\n\n\n\n\n2025-06-10\nESTIMATED\n2025-05\n2025-06-11\nACTUAL\n2025-06-03\n2025-06-03\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* PLHIV &gt; 18 years of age\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* On ARV trâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplasmsâ€}]\n[{â€œidâ€: â€œD014498â€, â€œtermâ€: â€œUracilâ€}, {â€œidâ€: â€œD011744â€, â€œtermâ€: â€œPyrimidinonesâ€}, {â€œidâ€: â€œD011743â€, â€¦\n[{â€œidâ€: â€œC410216â€, â€œtermâ€: â€œFolfox protocolâ€}, {â€œidâ€: â€œC519688â€, â€œtermâ€: â€œXELOXâ€}, {â€œidâ€: â€œD005472â€,â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSubstudy 1â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œVolrustomig plus XELOX (oxaliplatinâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œan anti PD-1 and anti-TIGIT bispecific anâ€¦\nGastric Cancer\nLocally advanced, Metatstatic, Gastric adenocarcinoma, GEJ adenocarcinoma, GEMINI-Gastric\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCaliforniaâ€,â€¦\n\nThis is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safeâ€¦\nApproximately 240 participants will be assigned across 6 substudies, with approximately 40 evaluableâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n240\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nNovel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastrâ€¦\nNCT05702229\n\nAn Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerabiliâ€¦\nD7986C00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2022-002840-29â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\nWhen a request has been approved AstraZeneca will provide access to the deidentified individual patiâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\n\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagroup-dt.pharmacm.com/DT/Home\n\n[{â€œmeasureâ€: â€œORR (per RECIST 1.1 as assessed by Investigator)â€, â€œdescriptionâ€: â€œthe proportion of pâ€¦\n[{â€œmeasureâ€: â€œPFS per RECIST 1.1 as assessed by the Investigatorâ€, â€œdescriptionâ€: â€œthe time from theâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2027-09-28\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-17\nACTUAL\n2025-11-14\nRECRUITING\n2026-07-03\nESTIMATED\n\n\n\n\n2023-01-16\nACTUAL\n2025-11\n2023-01-27\nACTUAL\n2022-12-07\n2023-01-18\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 18 years or older at the time of signing the ICF.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Body weight &gt; 35 kg.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Pâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD016399â€, â€œtermâ€: â€œLymphoma, T-Cellâ€}, {â€œidâ€: â€œD008228â€, â€œtermâ€: â€œLymphoma, Non-Hodgkinâ€}, â€¦\n[{â€œidâ€: â€œD016410â€, â€œtermâ€: â€œLymphoma, T-Cell, Cutaneousâ€}, {â€œidâ€: â€œD009182â€, â€œtermâ€: â€œMycosis Fungoiâ€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œsingle agent DT-7012â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: DT-7012â€]}]\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDT-7012â€, â€œdescriptionâ€: â€œThis study use the Bayesian one-stage time-to-eâ€¦\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nCutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome\n[{â€œnameâ€: â€œCaroline RAM WOLFF, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+33142499961â€, â€œphoneExtâ€: â€œ+33â€, â€œâ€¦\n\n\nCutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lymphomas characterized by a primary â€¦\n\n\n\n\nSINGLE_GROUP\nSingle arm, open-label, multicenter prospective phase 1 dose-escalation study\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nEARLY_PHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nCITY\nA Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Doâ€¦\nNCT07213882\n\nA Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Doâ€¦\nAPHP240605\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\n\nUNDECIDED\n\n\n[{â€œmeasureâ€: â€œPercentage of of positive cells within the infiltrate by immunohistochemistryâ€, â€œdescrâ€¦\n[{â€œmeasureâ€: â€œDose limiting toxicity (DLT) defined by any treatment-emergent adverse event (TEAE) noâ€¦\n[{â€œmeasureâ€: â€œIncidence of Adverse eventsâ€, â€œdescriptionâ€: â€œAdverse Events (AEs), Serious Adverse Evâ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œDomain Therapeutics SAâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nAssistance Publique - HÃ´pitaux de Paris\n\n\n\nSPONSOR\n2028-08-01\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-09\nACTUAL\n2025-10-02\nNOT_YET_RECRUITING\n2028-08-01\nESTIMATED\n\n\n\n\n2026-01-01\nESTIMATED\n2025-10\n2025-10-09\nACTUAL\n2025-10-02\n2025-10-02\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Adult Patients (â‰¥18 years) with no upper age limit\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Confirmed diagnosis ofâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDomvanalimab Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œVarying Doses of domvâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œDomvanalimabis a fully human immunoglobuliâ€¦\nSolid Tumor, Unspecified, Adult\n\n\n[{â€œfacilityâ€: â€œThe Angeles Clinic and Research Instituteâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCalifornâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerabiliâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\nDose Escalation Design\nNONE\n\n\n\nTREATMENT\n\n75\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies\nNCT03628677\n\nA Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapyâ€¦\nAB154CSP0001\nINDUSTRY\nArcus Biosciences, Inc.\n\n\nArcus will provide access to individual de-identified participant data and related study documents ...\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n[{â€œmeasureâ€: â€œDomvanalimab Receptor Occupancyâ€, â€œdescriptionâ€: â€œReceptor Occupancy May be Summarizedâ€¦\n[{â€œmeasureâ€: â€œNumber of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by Câ€¦\n[{â€œmeasureâ€: â€œAB154 Peak Plasma Concentration (Cmax)â€, â€œdescriptionâ€: â€œPeak Plasma Concentration (Cmâ€¦\nFalse\nTrue\n\nFalse\n\n[{â€œlabelâ€: â€œAB154CSP0001 - Public Websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=AB154CSP00â€¦\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2025-01-23\nACTUAL\n\n\n\n\nFalse\n\n2025-02-04\nACTUAL\n2025-02-03\nCOMPLETED\n2025-01-23\nACTUAL\n\n\n\n\n2018-09-12\nACTUAL\n2024-05\n2018-08-14\nACTUAL\n2018-07-26\n2018-08-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Capable of giving signed informed consent\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female participants â‰¥ 18 â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005831â€, â€œtermâ€: â€œGenital Diseases, Femaleâ€}, {â€œidâ€: â€œD052776â€, â€œtermâ€: â€œFemale Urogenitalâ€¦\n[{â€œidâ€: â€œD004715â€, â€œtermâ€: â€œEndometriosisâ€}, {â€œidâ€: â€œD003884â€, â€œtermâ€: â€œDermoid Cystâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œstudy groupâ€, â€œdescriptionâ€: â€œpre-menopausal adult women with clinically and/or ultrasouâ€¦\n\nEndometriosis\nendometriosis, dermoid cyst, immune system\n[{â€œnameâ€: â€œMarek Gogacz, professorâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œmarekgogacz@umlub.plâ€, â€œemailâ€: â€œmâ€¦\n\n[{â€œnameâ€: â€œJarogniew Åuszczki, professorâ€, â€œaffiliationâ€: â€œUNIWERSYTET MEDYCZNY W LUBLINIEâ€, â€œroleâ€:â€¦\nThe EUmetriosis project aims to address the most important unmet needs of endometriosis sufferers toâ€¦\nEUmetriosis will generate new knowledge in the field of endometriosis, its drivers and consequences,â€¦\nperipheral blood, menstrual effluent/blood\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCASE_CONTROL\n\nOTHER\n60\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nTrue\n40 Years\n18 Years\nNON_PROBABILITY_SAMPLE\nFEMALE\nADULT\nThe University Clinical Hospital No.4 and No.1, 1 Military Clinical Hospital in Lublin SPZOZ\nEUmetriosis\nCharacterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients\nNCT06897436\n\nâ€œEUmetriosis: Transforming Endometriosis Care in Europe: an Integrated Approach to Enhance Understanâ€¦\n101157146\nOTHER\nMedical University of Lublin\n[{â€œidâ€: â€œProject 101157146-EUmetriosisâ€, â€œtypeâ€: â€œOTHER_GRANTâ€, â€œdomainâ€: â€œEuropean Unionâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œAlterations in immune system cell phenotype and activity associated with endometriosisâ€¦\n\nFalse\nFalse\nFalse\nFalse\n\n[{â€œlabelâ€: â€œCORDIS belongs to the Research and Innovation community platform of the European Commissâ€¦\n[{â€œnameâ€: â€œEuropean Commissionâ€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nMedical University of Lublin\nMedical University of Lublin\nIwona Wertel\nprofessor\nPRINCIPAL_INVESTIGATOR\n2029-12-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-27\nACTUAL\n2025-03-24\nNOT_YET_RECRUITING\n2029-12-31\nESTIMATED\n\n\n\n\n2025-05-01\nESTIMATED\n2025-01\n2025-03-27\nACTUAL\n2025-03-14\n2025-03-24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Women with a clinical and/or ultrasound diagnosis of endometriosis who are caâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000086982â€, â€œtermâ€: â€œBlood-Borne Infectionsâ€}, {â€œidâ€: â€œD003141â€, â€œtermâ€: â€œCommunicable Disâ€¦\n[{â€œidâ€: â€œD015658â€, â€œtermâ€: â€œHIV Infectionsâ€}]\n[{â€œidâ€: â€œD014765â€, â€œtermâ€: â€œViral Vaccinesâ€}, {â€œidâ€: â€œD014612â€, â€œtermâ€: â€œVaccinesâ€}, {â€œidâ€: â€œD001688â€¦\n[{â€œidâ€: â€œD000086663â€, â€œtermâ€: â€œCOVID-19 Vaccinesâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œNon-immunological responderâ€, â€œdescriptionâ€: â€œPatients who start ART with \\&lt;350 CD4+ T â€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œSARS-CoV-2 Vaccineâ€, â€œdescriptionâ€: â€œAnalyse humoral and cellular râ€¦\nSARS-CoV-2 RNA Vaccines, HIV Infection\n\n\n[{â€œfacilityâ€: â€œVirgen del Rocio University Hospitalâ€, â€œcityâ€: â€œSevilleâ€, â€œzipâ€: â€œ41013â€, â€œcountryâ€: â€¦\n\nProspective, non-equality, cohort study, where investigators propose to analyze humoral and cellularâ€¦\n\n\n\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n48\nACTUAL\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\nPROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nThe study was designed as a cohort study comparing the immune response after vaccination of HIV-infeâ€¦\n\nHumoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed\nNCT05633927\n\nProspective Study to Evaluate the Persistence and Characteristics of Humoral and Cellular Immunity Aâ€¦\nCoVa-VIH-2021\nOTHER\nHospitales Universitarios Virgen del RocÃ­o\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œAntibodiesâ€, â€œdescriptionâ€: â€œAnalyse the percentage of subjects with SARS-CoV-2-specifâ€¦\n\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ37006309â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œLopez-Cortes LF, Saborido-Alconchel A, Trujilloâ€¦\n[{â€œlabelâ€: â€œRelated Infoâ€, â€œurlâ€: â€œhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1129753/fâ€¦\n\nOTHER\nHospitales Universitarios Virgen del RocÃ­o\nHospitales Universitarios Virgen del RocÃ­o\nLuis F. Lopez-Cortes\nPrincipal Investigator\nPRINCIPAL_INVESTIGATOR\n2022-12-01\nACTUAL\n\n\n\n\nFalse\n\n2024-10-15\nACTUAL\n2024-10-09\nCOMPLETED\n2022-03-31\nACTUAL\n\n\n\n\n2021-04-01\nACTUAL\n2024-10\n2022-12-01\nACTUAL\n2022-11-21\n2022-11-21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. HIV-infected subjects over 18 years old and â‰¤200 CD4/Î¼l who have completed vâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD016393â€, â€œtermâ€: â€œLymphoma, B-Cellâ€}, {â€œidâ€: â€œD008228â€, â€œtermâ€: â€œLymphoma, Non-Hodgkinâ€}, â€¦\n[{â€œidâ€: â€œD016403â€, â€œtermâ€: â€œLymphoma, Large B-Cell, Diffuseâ€}]\n[{â€œidâ€: â€œD010752â€, â€œtermâ€: â€œPhosphoramide Mustardsâ€}, {â€œidâ€: â€œD009588â€, â€œtermâ€: â€œNitrogen Mustard Coâ€¦\n[{â€œidâ€: â€œC024352â€, â€œtermâ€: â€œfludarabineâ€}, {â€œidâ€: â€œD003520â€, â€œtermâ€: â€œCyclophosphamideâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCRC01â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œA conditioning chemotherapy regimen of fâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œCRC01â€, â€œdescriptionâ€: â€œA single infusion of chimeric antigen recepâ€¦\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBâ€¦\nCRC01, anti-CD19 CAR-T, CAR-T, CAR T cells, Chimeric antigen receptor, PD-1 knock down, TIGIT knock â€¦\n[{â€œnameâ€: â€œBom-I Kwon, BScâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+82428633698â€, â€œemailâ€: â€œbikwon@curocellbtâ€¦\n[{â€œfacilityâ€: â€œSamsung Medical Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œSeoulâ€, â€œzipâ€: â€œ06351â€, â€œcoâ€¦\n\nThis is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patiâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n91\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n19 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients\nNCT04836507\n\nAn Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy â€¦\nCRC01-01\nINDUSTRY\nCurocell Inc.\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œPhase 1 Study: Maximum Tolerated Dose (MTD) which will be the Recommended Phase 2 Doseâ€¦\n[{â€œmeasureâ€: â€œTime to response (TTR)â€, â€œtimeFrameâ€: â€œ5 yearsâ€}, {â€œmeasureâ€: â€œDuration of overall resâ€¦\nFalse\nFalse\n\nTrue\n[{â€œpmidâ€: â€œ34628052â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œLee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Huppereâ€¦\n\n\nINDUSTRY\nCurocell Inc.\n\n\n\nSPONSOR\n2028-02\nESTIMATED\n\n\n\n\nFalse\n\n2021-05-03\nACTUAL\n2021-04-29\nRECRUITING\n2023-05\nESTIMATED\n\n\n\n\n2021-03-02\nACTUAL\n2021-04\n2021-04-08\nACTUAL\n2021-04-05\n2021-04-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. â‰¥ 19 years of age and provided written informed consent\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Histologically coâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}, {â€œidâ€: â€œD001661â€, â€œtermâ€: â€œBiliary Tract Neâ€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000068258â€, â€œtermâ€: â€œBevacizumabâ€}, {â€œidâ€: â€œC531958â€, â€œtermâ€: â€œlenvatinibâ€}, {â€œidâ€: â€œD0000â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCohort 1Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œVolrustomig monotherapyâ€, â€œinterventâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œVolrustomigâ€, â€œdescriptionâ€: â€œCTLA-4/Anti-PD-1 Bispecific Antibodyâ€, â€œarmâ€¦\nHepatocellular Carcinoma, Biliary Tract Cancer\nHepatobiliary cancer, Hepatocellular carcinoma, Biliary tract cancer, GEMINI-Hepatobiliary, MEDI5752â€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabamaâ€, â€œziâ€¦\n\nGEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulatoâ€¦\nThis Phase II, open-label, uncontrolled, multicentre study evaluating the preliminary efficacy and sâ€¦\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n294\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participâ€¦\nNCT05775159\n\nA Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safetâ€¦\nD7987C00001\nINDUSTRY\nAstraZeneca\n\nWhen a request has been approved AstraZeneca will provide access to the de-identified individual patâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagroup-dt.pharmacm.com/DT/Home\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR)â€, â€œdescriptionâ€: â€œORR is defined as the proportion of paâ€¦\n[{â€œmeasureâ€: â€œDuration Of Response (DOR)â€, â€œdescriptionâ€: â€œDoR is defined as the time from the date â€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2027-10-28\nESTIMATED\n\n\n\n\nFalse\n\n2025-11-13\nACTUAL\n2025-11-12\nRECRUITING\n2026-10-27\nESTIMATED\n\n\n\n\n2023-04-24\nACTUAL\n2025-11\n2023-03-20\nACTUAL\n2023-03-02\n2023-03-17\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age â‰¥18 years at the time of signing the ICF.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Provision of a signed and datâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002294â€, â€œtermâ€: â€œCarcinoma, Squamous Cellâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD000077195â€, â€œtermâ€: â€œSquamous Cell Carcinoma of Head and Neckâ€}]\n[{â€œidâ€: â€œD019411â€, â€œtermâ€: â€œClinical Laboratory Techniquesâ€}, {â€œidâ€: â€œD019937â€, â€œtermâ€: â€œDiagnostic â€¦\n[{â€œidâ€: â€œD013048â€, â€œtermâ€: â€œSpecimen Handlingâ€}, {â€œidâ€: â€œD009682â€, â€œtermâ€: â€œMagnetic Resonance Spectâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment (FID-007)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients receive FID-007 Iâ€¦\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œBiospecimen Collectionâ€, â€œdescriptionâ€: â€œUndergo blood sample collecâ€¦\nHead and Neck Squamous Cell Carcinoma\n\n\n[{â€œfacilityâ€: â€œLos Angeles General Medical Centerâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzâ€¦\n[{â€œnameâ€: â€œJacob Thomas, MDâ€, â€œaffiliationâ€: â€œUniversity of Southern Californiaâ€, â€œroleâ€: â€œPRINCIPALâ€¦\nThis phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) aâ€¦\nPRIMARY OBJECTIVE:\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n1\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nFID-007 Followed by Standard of Care Surgery in Head and Neck Cancer\nNCT06338657\n\nA Window of Opportunity Study of Taxanes in Head and Neck Cancer\n7H-23-5\nOTHER\nUniversity of Southern California\n[{â€œidâ€: â€œNCI-2024-01367â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTRP (Clinical Trial Reporting Program)â€}, â€¦\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œEvaluate the phenotypical and functional changes of different T cell subsets within thâ€¦\n[{â€œmeasureâ€: â€œIncidence of adverse events (AEs)â€, â€œdescriptionâ€: â€œA summary table at subject level fâ€¦\nFalse\nTrue\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œNational Cancer Institute (NCI)â€, â€œclassâ€: â€œNIHâ€}]\nOTHER\nUniversity of Southern California\n\n\n\nSPONSOR\n2025-09-09\nACTUAL\n\n\n\n\n\n\n2025-09-16\nACTUAL\n2025-09-09\nTERMINATED\n2025-09-03\nACTUAL\n\n\n\n\n2024-04-01\nACTUAL\n2025-09\n2024-03-29\nACTUAL\n2024-03-14\n2024-03-22\nSlow accrual\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nI. To describe the phenotypical and functional changes of different T cell subseâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients must have histopathologically / cytologically confirmed diagnosis ofâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siteâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œD00â€¦\n[{â€œidâ€: â€œD001943â€, â€œtermâ€: â€œBreast Neoplasmsâ€}]\n[{â€œidâ€: â€œD003581â€, â€œtermâ€: â€œCytodiagnosisâ€}, {â€œidâ€: â€œD003584â€, â€œtermâ€: â€œCytological Techniquesâ€}, {â€œâ€¦\n[{â€œidâ€: â€œD001706â€, â€œtermâ€: â€œBiopsyâ€}, {â€œidâ€: â€œD013048â€, â€œtermâ€: â€œSpecimen Handlingâ€}, {â€œidâ€: â€œC00062â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment (cemiplimab, Y90 SIR-Spheres, TARE)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œâ€¦\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œBiopsyâ€, â€œdescriptionâ€: â€œUndergo tumor biopsyâ€, â€œarmGroupLabelsâ€: [â€œâ€¦\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liâ€¦\n\n\n[{â€œfacilityâ€: â€œCity of Hope Medical Centerâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œDuarteâ€, â€œstateâ€: â€œCalâ€¦\n[{â€œnameâ€: â€œJonathan Kesslerâ€, â€œaffiliationâ€: â€œCity of Hope Medical Centerâ€, â€œroleâ€: â€œPRINCIPAL_INVESâ€¦\nThis phase II trial tests how well cemiplimab and transarterial radioembolization (TARE) with yttriuâ€¦\nPRIMARY OBJECTIVE:\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n11\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Diâ€¦\nNCT06860815\n\nPilot Study of Cemiplimab and Hepatic Radioembolization in Patients With Liver Dominant Metastatic Bâ€¦\n23768\nOTHER\nCity of Hope Medical Center\n[{â€œidâ€: â€œNCI-2025-00340â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTRP (Clinical Trial Reporting Program)â€}, â€¦\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œCD8+ T cell infiltration in tumor microenvironment (TME): baselineâ€, â€œdescriptionâ€: â€œWâ€¦\n[{â€œmeasureâ€: â€œIncidence of adverse eventsâ€, â€œdescriptionâ€: â€œWill be assessed and graded using Nationâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œNational Cancer Institute (NCI)â€, â€œclassâ€: â€œNIHâ€}]\nOTHER\nCity of Hope Medical Center\n\n\n\nSPONSOR\n2027-01-30\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-28\nACTUAL\n2026-01-27\nRECRUITING\n2027-01-30\nESTIMATED\n\n\n\n\n2026-04-01\nESTIMATED\n2026-01\n2025-03-06\nACTUAL\n2025-02-04\n2025-02-28\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nI. To describe the effect of cemiplimab and yttrium Y90 resin microspheres (90Y â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Documented informed consent of the participant and/or legally authorized reprâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, {â€œidâ€: â€œD006727â€, â€œtermâ€: â€œHormone Antagonistsâ€}, {â€œidâ€:â€¦\n[{â€œidâ€: â€œD011878â€, â€œtermâ€: â€œRadiotherapyâ€}, {â€œidâ€: â€œD000726â€, â€œtermâ€: â€œAndrogen Antagonistsâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œStereotactic body radiation treatment (SBRT)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œRâ€¦\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œRadiotherapyâ€, â€œdescriptionâ€: â€œRT treatment Schedule as for clinicalâ€¦\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\n\n\n[{â€œfacilityâ€: â€œHumanitas Research Hospitalâ€, â€œcityâ€: â€œRozzanoâ€, â€œstateâ€: â€œMilanoâ€, â€œzipâ€: â€œ20089â€, â€œâ€¦\n\nAt the moment there is a lack of data in the setting of oligometastatic PC in particular regarding tâ€¦\nProstate cancer (PC) represents the second most common cancer in men worldwide, managed with surgeryâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nOTHER\n\n40\nESTIMATED\n\n\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nMALE\nADULT, OLDER_ADULT\n\nIOSCAR\nImmune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated Wâ€¦\nNCT04624828\n\nPilot Study of Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patâ€¦\n2683\nOTHER\nIstituto Clinico Humanitas\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œimmune evaluationâ€, â€œdescriptionâ€: â€œAnalysis of the immunitary background performed beâ€¦\n[{â€œmeasureâ€: â€œProgression free survivalâ€, â€œdescriptionâ€: â€œEvaluation of Progression free survival (Pâ€¦\nFalse\nFalse\nFalse\nFalse\n\n\n[{â€œnameâ€: â€œIpsenâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nIstituto Clinico Humanitas\n\n\n\nSPONSOR\n2026-07\nESTIMATED\n\n\n\n\nFalse\n\n2025-04-24\nACTUAL\n2025-04-22\nACTIVE_NOT_RECRUITING\n2026-07\nESTIMATED\n\n\n\n\n2020-10-19\nACTUAL\n2025-04\n2020-11-12\nACTUAL\n2020-11-02\n2020-11-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age â‰¥ 18years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Written informed consent according to ICH/GCP regulations befâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD003920â€, â€œtermâ€: â€œDiabetes Mellitusâ€}, {â€œidâ€: â€œD044882â€, â€œtermâ€: â€œGlucose Metabolism Disorâ€¦\n[{â€œidâ€: â€œD003922â€, â€œtermâ€: â€œDiabetes Mellitus, Type 1â€}]\n\n[{â€œidâ€: â€œC544394â€, â€œtermâ€: â€œsiplizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAdults with T1D 0.08 mg/kg SQ doseâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œCohort 1 Grâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œSiplizumabâ€, â€œdescriptionâ€: â€œWeekly siplizumab doses for a total of 12 weâ€¦\nType 1 Diabetes Mellitus\ndiabetic, Type 1 diabetes, T1DM, siplizumab\n\n[{â€œfacilityâ€: â€œUniversity of Colorado School of Medicine: Barbara Davis Center for Diabetesâ€, â€œcityâ€â€¦\n[{â€œnameâ€: â€œStephen Gitelman, M.D.â€, â€œaffiliationâ€: â€œUniversity of California San Francisco, School oâ€¦\nThis is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n8\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n45 Years\n8 Years\n\nALL\nCHILD, ADULT\n\nDESIGNATE\nSiplizumab in T1DM\nNCT05574335\n\nA T Cell Phenotype Signature Driven Dose Finding Study With Siplizumab in Type 1 Diabetes Mellitus (â€¦\nDAIT ITN095AI\nNIH\nNational Institute of Allergy and Infectious Diseases (NIAID)\n\nOpen access.\nImmunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic dâ€¦\n\nYES\nOn average, within 24 months after database lock for the trial.\nhttps://www.immport.org/home\n\n[{â€œmeasureâ€: â€œNumber of Participants with a T cell phenotype signature responseâ€, â€œdescriptionâ€: â€œEvâ€¦\n[{â€œmeasureâ€: â€œFrequency of Adverse Events (AEs) in all siplizumab dosing armsâ€, â€œdescriptionâ€: â€œAE wâ€¦\nFalse\nTrue\n\nTrue\n\n[{â€œlabelâ€: â€œImmune Tolerance Network (ITN)â€, â€œurlâ€: â€œhttps://www.immunetolerance.org/â€}, {â€œlabelâ€: â€œâ€¦\n\nNIH\nNational Institute of Allergy and Infectious Diseases (NIAID)\n\n\n\nSPONSOR\n2025-10-20\nACTUAL\n\n\n\n\nFalse\n\n2026-01-06\nACTUAL\n2026-01-05\nTERMINATED\n2025-05-14\nACTUAL\n\n\n\n\n2023-04-26\nACTUAL\n2026-01\n2022-10-10\nACTUAL\n2022-09-19\n2022-10-06\nPrior to termination the DESIGNATE study was an on enrollment hold due to greater than anticipated lâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Ability to provide informed consent (parental permission and informed assentâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œLung re-transplant cohortâ€, â€œdescriptionâ€: â€œThis cohort includes consecutive participantâ€¦\n[{â€œtypeâ€: â€œDIAGNOSTIC_TESTâ€, â€œnameâ€: â€œImmune checkpoints analysisâ€, â€œdescriptionâ€: â€œThe researcher wâ€¦\nLung Transplant Rejection\nLung transplantation, Immune checkpoint, Acute rejection, Chronic rejection, Chronic lung allograft â€¦\n[{â€œnameâ€: â€œMario Nosotti, Medicineâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ3393924679â€, â€œemailâ€: â€œmario.nosotâ€¦\n[{â€œfacilityâ€: â€œFondazione IRCCS CÃ  Granda, Ospedale Maggiore Policlinicoâ€, â€œcityâ€: â€œMilanâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œMario Nosotti, Medicineâ€, â€œaffiliationâ€: â€œUniversity of Milan, Italyâ€, â€œroleâ€: â€œPRINCIPALâ€¦\nThe goal of this observational study is to learn about rejection in lung transplantation.\nLung transplantation is the less common solid organ transplant performed; it is the treatment of choâ€¦\nLung tissue, bronchoalveolar lavage\nSAMPLES_WITH_DNA\n\n\n\n\n\n\nCOHORT\n\nOTHER\n280\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nFalse\n70 Years\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT, OLDER_ADULT\nCohort 1: Participants who received lung re-transplantation for chronic lung allograft dysfunction.\nILTRA\nThe Role of Immune Checkpoints in Lung Transplant (ILTRA)\nNCT06302556\n\nThe Role of Immune Checkpoints in Lung Transplant: the Pathways of Rejection and the Immunomodulatorâ€¦\n2022XJ9W4F\nOTHER\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\n[{â€œidâ€: â€œG53D2300526 0006â€, â€œtypeâ€: â€œOTHER_GRANTâ€, â€œdomainâ€: â€œMinistry of University and Research. Nâ€¦\nAccess to IPD can be requested by qualified researchers engaging in independent scientific research,â€¦\nThe anonymized data collected will be recorded on a database available online by other researchers uâ€¦\nSTUDY_PROTOCOL\nYES\nData requests can be submitted starting 9 months after closing of recruitment and the data will be mâ€¦\n\n\n[{â€œmeasureâ€: â€œLung-tissue immune-checkpoint profile and bronchoalveolar immune-cells mRNA signature â€¦\n\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ36703976â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œRighi I, Vaira V, Morlacchi LC, Croci GA, Râ€¦\n\n[{â€œnameâ€: â€œUniversity of Milanâ€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œUniversity of Padovaâ€, â€œclassâ€: â€œOTHERâ€¦\nOTHER\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\n\n\n\nSPONSOR\n2026-02\nESTIMATED\n\n\n\n\nFalse\n\n2024-03-08\nACTUAL\n2024-03-06\nNOT_YET_RECRUITING\n2026-01\nESTIMATED\n\n\n\n\n2024-04\nESTIMATED\n2024-02\n2024-03-08\nACTUAL\n2024-02-28\n2024-03-06\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe main â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Lung transplant patients\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nExclusion Criteria:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Hyperimmunized patients\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Hiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD009385â€, â€œtermâ€: â€œNeoplastic Processesâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}, {â€œidâ€: â€œâ€¦\n[{â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Metastasisâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n2025-02-24\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œCohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naiveâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œEtigilimabâ€, â€œdescriptionâ€: â€œIV infusion of IV etigilimab every 2 weeksâ€,â€¦\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\netigilimab, nivolumab, anti-TIGIT antibody, MPH313, Opdivo, ACTIVATE\n\n[{â€œfacilityâ€: â€œMereo Investigator Siteâ€, â€œcityâ€: â€œPhoenixâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85054â€, â€œcouâ€¦\n\nThis is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, toleâ€¦\nThis is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, toleâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\nBasket study\nNONE\n\n\n\nBASIC_SCIENCE\n\n76\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors\nNCT04761198\n\nA Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combâ€¦\nMPH313-1-02\nINDUSTRY\nMereo BioPharma\n[{â€œidâ€: â€œ2020-004222-37â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) as Assessed Based on Response Evaluation Criteria in Solâ€¦\n[{â€œmeasureâ€: â€œNumber of Participants WithTreatment-emergent Adverse Events (TEAEs), Any Adverse Evenâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œICON Clinical Researchâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nMereo BioPharma\n\n\n\nSPONSOR\n2023-10-30\nACTUAL\n2025-03-17\nACTUAL\n2024-10-28\n\nFalse\n\n2025-03-17\nACTUAL\n2025-03-07\nCOMPLETED\n2023-10-30\nACTUAL\n2025-03-17\nACTUAL\n2025-01-31\n2025-03-07\n2021-03-23\nACTUAL\n2025-03\n2021-02-18\nACTUAL\n2021-02-12\n2021-02-17\n\nSafety Analysis Set included all participants who received any amount of study drug.\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œCohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naiveâ€, â€œdescriptionâ€: â€œParâ€¦\n5.0\n[{â€œtermâ€: â€œNauseaâ€, â€œorganSystemâ€: â€œGastrointestinal disordersâ€, â€œsourceVocabularyâ€: â€œMedDRA 26.0â€, â€¦\n[{â€œtermâ€: â€œPneumoniaâ€, â€œorganSystemâ€: â€œInfections and infestationsâ€, â€œsourceVocabularyâ€: â€œMedDRA 26â€¦.\nFrom first dose of study drug until 100 days after the last dose of study drug or the initiation of â€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ11â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œCohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naiveâ€, â€œdescriptionâ€: â€œParâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nSafety Analysis Set included all participants who received any amount of study drug.\nAll PIs must seek written permission from the sponsor before publication of any trial results.\nFalse\nOTHER\nTrue\n\nenquiries@mereobiopharma.com\nMereo BioPharma\nPlease Email\n\nMereo BioPharma\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œObjective Response Rate (ORR) as Assessed Based on Response Evaluatioâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œCohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naiveâ€, â€œdescriptionâ€: â€œParâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nCohort D (Recurrent advanced and/or metastatic gastric or gastroesophageal junction adenocarcinoma) â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histological or cytological diagnosis of a relevant tumor type as per the stuâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014594â€, â€œtermâ€: â€œUterine Neoplasmsâ€}, {â€œidâ€: â€œD005833â€, â€œtermâ€: â€œGenital Neoplasms, Femalâ€¦\n[{â€œidâ€: â€œD002583â€, â€œtermâ€: â€œUterine Cervical Neoplasmsâ€}]\n\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}]\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œCohort 1: Ociperlimab + Tislelizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œTislelizuâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œTislelizumabâ€, â€œdescriptionâ€: â€œ200 mg administered intravenously onâ€¦\nCervical Cancer\n\n\n[{â€œfacilityâ€: â€œ\"Mhat uni hospital\" oodâ€, â€œcityâ€: â€œPanagyurishteâ€, â€œzipâ€: â€œ4500â€, â€œcountryâ€: â€œBulgaâ€¦\n[{â€œnameâ€: â€œStudy Directorâ€, â€œaffiliationâ€: â€œBeiGeneâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study tested how well and how safely the drug tislelizumab, given either alone or with another â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n178\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\nTrue\n\nFalse\n\n18 Years\n\nFEMALE\nADULT, OLDER_ADULT\n\n\nAdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIâ€¦\nNCT04693234\n\nPhase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-Aâ€¦\nBGB-A317-A1217-202\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œ2020-004657-77â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œAdvanTIG-202â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œCohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (Iâ€¦\n[{â€œmeasureâ€: â€œCohort 2: Objective Response Rate (ORR) Assessed by an Independent Review Committee inâ€¦\nFalse\nFalse\nFalse\nFalse\n[{â€œpmidâ€: â€œ40411966â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œLee JY, Boonyapipat S, Yuan G, Kim HS, Lee â€¦\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2023-08-31\nACTUAL\n\n\n\n\nFalse\n\n2025-04-27\nACTUAL\n2025-04-09\nCOMPLETED\n2022-06-16\nACTUAL\n2025-04-27\nACTUAL\n2024-08-22\n2025-04-09\n2021-02-15\nACTUAL\n2025-04\n2021-01-05\nACTUAL\n2020-12-22\n2020-12-30\n\n\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œCohort 1: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nAll-cause mortality: From randomization through the end of study; up to 24.5 months. Adverse events:â€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ138â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œCohort 1: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Safety Analysis Set is defined as all participants who received &gt;= 1 dose of any study drug forâ€¦\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene\n+1-877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œCohort 1: Objective Response Rate (ORR) Assessed by an Independent Reâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œCohort 1: Ociperlimab + Tislelizumabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nThe study was composed of an initial screening phase (up to 28 days), a treatment phase, an end of tâ€¦\nParticipants were enrolled in multiple study centers in China, South Korea, and Europe.The first parâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically or cytologically confirmed squamous cell carcinoma, adenosquaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\nBrazil, Poland, Romania\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProt_SAPâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: true, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Prâ€¦\nTrue\n[{â€œlabelâ€: â€œPlacebo + Atezolizumabâ€, â€œtypeâ€: â€œPLACEBO_COMPARATORâ€, â€œdescriptionâ€: â€œParticipants willâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œAtezolizumab at a fixed dose of 1200 mg wiâ€¦\nNon-small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œArizona Oncology Associates, PC - HALâ€, â€œcityâ€: â€œTempeâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nTREATMENT\n\n135\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-NaÃ¯ve Patients With Locally â€¦\nNCT03563716\n\nA Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, Inâ€¦\nGO40290\nINDUSTRY\nGenentech, Inc.\n[{â€œidâ€: â€œ2018-000280-81â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œ2023-508083-30-00â€, â€œtypeâ€: â€œCTISâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œORR, defined as a complete response (Câ€¦\n[{â€œmeasureâ€: â€œDuration of Objective Response (DOR)â€, â€œdescriptionâ€: â€œDOR, defined as the time from tâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ38418879â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œGuan X, Hu R, Choi Y, Srivats S, Nabet BY, Silâ€¦\n\n\nINDUSTRY\nGenentech, Inc.\n\n\n\nSPONSOR\n2025-11-24\nACTUAL\n\n\n\n\nFalse\n\n2026-01-20\nACTUAL\n2025-12-30\nCOMPLETED\n2019-06-30\nACTUAL\n2020-07-09\nACTUAL\n2020-06-19\n2020-06-19\n2018-08-10\nACTUAL\n2025-12\n2018-06-20\nACTUAL\n2018-04-17\n2018-06-19\n\nThe safety population included all participants who received at least one dose of study medication.\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œParticipants received atezolizumâ€¦\n5.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAtrial fibrillationâ€, â€œorganSystemâ€: â€œCardiac disordersâ€, â€œsourceVocabularyâ€: â€œMedDRA 22â€¦.\nUp to primary completion date (approximately 11 months)\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ68â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œParticipants received atezolizumâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\n\nThe Study being conducted under this Agreement is part of the Overall Study. Investigator is free toâ€¦\nFalse\nOTHER\nTrue\n\ngenentech@druginfo.com\nHoffmann-La Roche\n800 821-8590\n\nMedical Communications\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œORR, defined as a comâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œParticipants received atezolizumâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nEligible patients with previously untreated, locally advanced unresectable or metastatic PD-L1-selecâ€¦\nParticipants were recruited at study sites in 6 countries.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* ECOG Performance Status of 0 or 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documenteâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œKINE-101â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: KINE-101â€]}, {â€œlabelâ€: â€œâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œKINE-101â€, â€œdescriptionâ€: â€œKINE-101 injection, 12.5 mg/mL, intravenous inâ€¦\nHealthy Volunteers\n\n\n[{â€œfacilityâ€: â€œChungbuk National University Hospitalâ€, â€œcityâ€: â€œCheongju-siâ€, â€œstateâ€: â€œNorth Chungcâ€¦\n[{â€œnameâ€: â€œHanna Parkâ€, â€œaffiliationâ€: â€œKine Sciences Co., Ltd.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a randomized, single-center, single-blind, placebo-controlled, dose-escalation Phase 1 cliniâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nSINGLE\n\nPARTICIPANT\n\nTREATMENT\n\n24\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nTrue\n55 Years\n19 Years\n\nALL\nADULT\n\n\nA Phase 1 MAD Study of KINE-101 in Healthy Volunteers\nNCT07324642\n\nA Randomized, Single-center, Single-blind, Placebo-controlled, Dose Escalation Phase 1 Clinical Triaâ€¦\nCIDP101-CR1-002P\nINDUSTRY\nKine Sciences Co., Ltd.\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œChange from baseline in serum biomarkers following KINE-101 administrationâ€, â€œdescriptâ€¦\n[{â€œmeasureâ€: â€œIncidence of Treatment-Emergent Adverse Eventsâ€, â€œdescriptionâ€: â€œNumber and percentageâ€¦\n[{â€œmeasureâ€: â€œMaximum plasma concentration (Cmax)â€, â€œdescriptionâ€: â€œMaximum plasma concentration (Cmâ€¦\nFalse\nFalse\n\nFalse\n\n\n[{â€œnameâ€: â€œChungbuk National University Hospitalâ€, â€œclassâ€: â€œOTHERâ€}]\nINDUSTRY\nKine Sciences Co., Ltd.\n\n\n\nSPONSOR\n2025-08-25\nACTUAL\n\n\n\n\nFalse\n\n2026-01-07\nACTUAL\n2025-12-24\nCOMPLETED\n2025-08-25\nACTUAL\n\n\n\n\n2025-05-26\nACTUAL\n2025-12\n2026-01-07\nACTUAL\n2025-12-09\n2025-12-24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Healthy male or female adults aged 19 to 55 years\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Body weight â‰¥ 50.0 kg andâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD001943â€, â€œtermâ€: â€œBreast Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siteâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD064726â€, â€œtermâ€: â€œTriple Negative Breast Neoplasmsâ€}]\n[{â€œidâ€: â€œD043823â€, â€œtermâ€: â€œTaxoidsâ€}, {â€œidâ€: â€œD043822â€, â€œtermâ€: â€œCyclodecanesâ€}, {â€œidâ€: â€œD003516â€, â€¦\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œD017239â€, â€œtermâ€: â€œPaclitaxelâ€}, {â€œidâ€: â€œC520â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A: ociperlimab+tislelizumab+chemotherapy (PD-L1 CPS â‰¥ 10)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOciperlimabâ€, â€œdescriptionâ€: â€œ900 mg intravenously (IV) every 3 weeks (Q3â€¦\nTriple Negative Breast Cancer\nTNBC, Triple Negative Breast Cancer, PD-L1, Ociperlimab, Tislelizumab, WCD118 (BGB-A1217), VDT482 (Bâ€¦\n\n\n[{â€œnameâ€: â€œNovartis Pharmaceuticalsâ€, â€œaffiliationâ€: â€œNovartis Pharmaceuticalsâ€, â€œroleâ€: â€œSTUDY_DIREâ€¦\nThe primary scientific question of interest of this study is whether the combination of ociperlimab,â€¦\nThis is a randomized, double-blind, placebo-controlled, multicenter, Phase II study evaluating the eâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\nParticipants will be randomized to Arms A, B and C in a double-blind manner Participants will be enrâ€¦\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nAdvanTIG-211\nPhase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab anâ€¦\nNCT05809895\n\nAdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Evaluating the Efficacyâ€¦\nCWCD118B12201\nINDUSTRY\nNovartis\n[{â€œidâ€: â€œ2022-503099-99-00â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œEU CTIS numberâ€}]\n\nNovartis is committed to sharing with qualified external researchers, access to patient-level data aâ€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œProgression-free Survival (PFS) based on investigator assessment using RECIST 1.1 critâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS) based on investigator assessment using RECIST 1.1 criteria in Arâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nNovartis Pharmaceuticals\n\n\n\nSPONSOR\n2029-07-18\nESTIMATED\n\n\n\n\nFalse\n\n2023-07-24\nACTUAL\n2023-07-21\nWITHDRAWN\n2029-07-17\nESTIMATED\n\n\n\n\n2023-09-15\nESTIMATED\n2023-07\n2023-04-12\nACTUAL\n2023-03-30\n2023-03-30\nBusiness decision, not driven by safety concerns; no new safety signals have been observed in the ocâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participant has histologically confirmed diagnosis of advanced (loco-regiâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002294â€, â€œtermâ€: â€œCarcinoma, Squamous Cellâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD000077277â€, â€œtermâ€: â€œEsophageal Squamous Cell Carcinomaâ€}]\n\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}]\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œArm A: Tislelizumab plus Ociperlimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipaâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œTislelizumabâ€, â€œdescriptionâ€: â€œTislelizumab is a monoclonal antibodâ€¦\nEsophageal Squamous Cell Carcinoma\n\n\n[{â€œfacilityâ€: â€œAnhui Provincial Cancer Hospitalâ€, â€œcityâ€: â€œHefeiâ€, â€œstateâ€: â€œAnhuiâ€, â€œzipâ€: â€œ230088â€â€¦\n[{â€œnameâ€: â€œStudy Directorâ€, â€œaffiliationâ€: â€œBeiGeneâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nA study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n125\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nAdvanTIG-203\nAnti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonalâ€¦\nNCT04732494\n\nA Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Moâ€¦\nBGB-A317-A1217-203\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œ2020-004658-32â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œCTR20213241/CTR20210243â€, â€œtypeâ€: â€œOTHEâ€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) Assessed by the Investigatorâ€, â€œdescriptionâ€: â€œObjectiveâ€¦\n[{â€œmeasureâ€: â€œOverall Survivalâ€, â€œdescriptionâ€: â€œOverall survival (OS) is defined as the time from tâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2023-12-26\nACTUAL\n\n\n\n\nFalse\n\n2025-01-31\nACTUAL\n2024-12-23\nCOMPLETED\n2023-02-01\nACTUAL\n2025-01-31\nACTUAL\n2024-12-23\n2024-12-23\n2021-03-31\nACTUAL\n2024-12\n2021-02-01\nACTUAL\n2021-01-25\n2021-01-28\n\n\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œArm A: Tislelizumab Plus Ociperlimabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\nAll-cause mortality is reported from randomization through the end of study; up to 30 months. AEs arâ€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ62â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œArm A: Tislelizumab Plus Ociperlimabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n[{â€œtitleâ€: â€œAge, Categoricalâ€, â€œparamTypeâ€: â€œCOUNT_OF_PARTICIPANTSâ€, â€œunitOfMeasureâ€: â€œParticipantsâ€â€¦\n\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene, Ltd.\n1 877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œObjective Response Rate (ORR) Assessed by the Investigatorâ€, â€œdescripâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œArm A: Tislelizumab Plus Ociperlimabâ€, â€œdescriptionâ€: â€œParticipants receiâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nParticipants were randomized equally to one of two treatment groups. Randomization was stratified byâ€¦\nThe study was conducted at 52 study centers in 7 countries/regions in Chinese mainland, Chinese Taiwâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically confirmed diagnosis of esophageal squamous cell carcinomaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm Aâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œParticipants will receive intravenoâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œParticipants will receive 1200 mg IV atezoâ€¦\nUrothelial Cancer\n\n\n[{â€œfacilityâ€: â€œCleveland Clinicâ€, â€œcityâ€: â€œClevelandâ€, â€œstateâ€: â€œOhioâ€, â€œzipâ€: â€œ44106â€, â€œcountryâ€: â€œâ€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-LaRocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the safety of tobemstomig alone or in combination with tiragolumab comparedâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n204\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-Lâ€¦\nNCT05645692\n\nA Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combinaâ€¦\nBO44157\nINDUSTRY\nHoffmann-La Roche\n\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œIncidence and Severity of Adverse Eventsâ€, â€œtimeFrameâ€: â€œUp to approximately 30 monthsâ€¦\n\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2026-12-31\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-30\nACTUAL\n2026-01-28\nACTIVE_NOT_RECRUITING\n2026-12-31\nESTIMATED\n\n\n\n\n2023-04-13\nACTUAL\n2026-01\n2022-12-09\nACTUAL\n2022-11-28\n2022-12-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of â‰¤ 2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histoloâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œtypeâ€: â€œRELEASEâ€, â€œdateâ€: â€œ2025-12-11â€}, {â€œtypeâ€: â€œRESETâ€, â€œdateâ€: â€œ2025-12-31â€}]\nEMD Serono Research & Development Institute, Inc.\n\n\n\n[{â€œidâ€: â€œC000723824â€, â€œtermâ€: â€œbintrafusp alfa protein, humanâ€}]\nGermany\n2025-12-11\n\n\n[{â€œreleaseDateâ€: â€œ2025-12-11â€, â€œresetDateâ€: â€œ2025-12-31â€}, {â€œreleaseDateâ€: â€œ2026-01-23â€}]\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPart 1A: M6223 Monotherapyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: M6223â€â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œM6223â€, â€œdescriptionâ€: â€œParticipants will receive an intravenous (IV) infâ€¦\nMetastatic Solid Tumors\nM6223, Bintrafusp alfa, Metastatic Solid Tumors\n\n[{â€œfacilityâ€: â€œSarah Cannon Research Instituteâ€, â€œcityâ€: â€œNashvilleâ€, â€œstateâ€: â€œTennesseeâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œMedical Responsibleâ€, â€œaffiliationâ€: â€œMerck Healthcare KGaA, Darmstadt, Germany, an affilâ€¦\nThe main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), immuâ€¦\n\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n58\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nFirst in Human Study of M6223\nNCT04457778\n\nPhase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Toleraâ€¦\nMS201430_0001\nINDUSTRY\nEMD Serono\n\n\nWe are committed to enhancing public health through responsible sharing of clinical trial data. Follâ€¦\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œPart 1A and 1B: Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observatiâ€¦\n[{â€œmeasureâ€: â€œPart 1A and Part 1B: Area Under the Serum Concentration-Time Curve From Time Zero to tâ€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ39929671â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œNaing A, McKean M, Tolcher A, Victor A, Hu P, â€¦\n[{â€œlabelâ€: â€œTrial Awareness and Transparency websiteâ€, â€œurlâ€: â€œhttps://clinicaltrials.emdgroup.com/eâ€¦\n[{â€œnameâ€: â€œMerck KGaA, Darmstadt, Germanyâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nEMD Serono Research & Development Institute, Inc.\n\n\n\nSPONSOR\n2023-06-23\nACTUAL\n\n\n\n\nFalse\n\n2023-12-08\nACTUAL\n2023-12-07\nCOMPLETED\n2023-06-23\nACTUAL\n\n\n\n\n2020-07-10\nACTUAL\n2023-11\n2020-07-07\nACTUAL\n2020-06-30\n2020-06-30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants have histologically or cytologically proven locally advanced or â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œStudy Interventionâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œFecal Microbial Transplantaâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œFecal Microbial Transplantationâ€, â€œdescriptionâ€: â€œAll patients in this trâ€¦\nMelanoma\n\n\n[{â€œfacilityâ€: â€œLondon Regional Cancer Programâ€, â€œcityâ€: â€œLondonâ€, â€œstateâ€: â€œOntarioâ€, â€œzipâ€: â€œN6A 5Wâ€¦\n[{â€œnameâ€: â€œJohn Lenehan, MDâ€, â€œaffiliationâ€: â€œLondon Regional Cancer Programâ€, â€œroleâ€: â€œPRINCIPAL_INâ€¦\nImmunotherapy has helped many cancer patients in the last 5 years by enhancing a patientâ€™s immune syâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n20\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n19 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nFecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)\nNCT03772899\n\nFecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)\nMIMic\nOTHER\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œTo evaluate the safety of combining Fecal Microbial Transplantation (FMT) using intestâ€¦\n[{â€œmeasureâ€: â€œAssess Objective Response Rateâ€, â€œdescriptionâ€: â€œTo evaluate whether combination of FMâ€¦\nFalse\nFalse\nFalse\nTrue\n[{â€œpmidâ€: â€œ37414899â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œRouty B, Lenehan JG, Miller WH Jr, Jamal R, Meâ€¦\n\n\nOTHER\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\n\n\n\nSPONSOR\n2026-08\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-28\nACTUAL\n2025-03-26\nACTIVE_NOT_RECRUITING\n2021-09-14\nACTUAL\n\n\n\n\n2019-03-27\nACTUAL\n2025-03\n2018-12-11\nACTUAL\n2018-11-16\n2018-12-10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients must be 18-years old or older\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Patients must have a confirmed diagnâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD002292â€, â€œtermâ€: â€œCarcinoma, Renal Cellâ€}, {â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocelâ€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œC000656314â€, â€œtermâ€: â€œtoripalimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPart A Monotherapy Dose Escalationâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œThe Part A â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œCHS-388â€, â€œdescriptionâ€: â€œCHS-388 is a fully human IgG1 antibody against â€¦\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lungâ€¦\nmetastatic solid tumors, advanced solid tumors, Phase 1, CHS-388, IL-27, safety, efficacy, immunotheâ€¦\n\n[{â€œfacilityâ€: â€œCity of Hopeâ€, â€œcityâ€: â€œDuarteâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€: â€œ91010â€, â€œcountryâ€: â€œUâ€¦\n[{â€œnameâ€: â€œKoho Iizuka, MDâ€, â€œaffiliationâ€: â€œCoherus BioSciencesâ€, â€œroleâ€: â€œSTUDY_CHAIRâ€}]\nThis is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a â€¦\nThis is a Phase 1/1b, open-label, first-in-human (FIH), dose-escalation and expansion study of CHS-3â€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n145\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nPart A and Part B Abbreviated Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors\nNCT04374877\n\nA Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors\nSRF388-101\nINDUSTRY\nCoherus Oncology, Inc.\n[{â€œidâ€: â€œKEYNOTE-C16â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMerck Sharp & Dohme LLCâ€}, {â€œidâ€: â€œMK-3475-C16â€, â€¦\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œ[Part A] Dose Limiting Toxicity (DLT)â€, â€œdescriptionâ€: â€œEvaluation of DLT of CHS-388 aâ€¦\n[{â€œmeasureâ€: â€œ[Part A, Part B] Safety Analysis: Summary of adverse events (AEs) and based on treatmeâ€¦\nFalse\nTrue\n\nFalse\n\n\n[{â€œnameâ€: â€œMerck Sharp & Dohme LLCâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nCoherus Oncology, Inc.\n\n\n\nSPONSOR\n2025-06-05\nACTUAL\n\n\n\n\nFalse\n\n2025-11-10\nACTUAL\n2025-11-06\nCOMPLETED\n2025-05-28\nACTUAL\n\n\n\n\n2020-04-22\nACTUAL\n2025-11\n2020-05-05\nACTUAL\n2020-04-30\n2020-04-30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â‰¥ 18 years of age\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Locally advanced or metastaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplasmsâ€}, {â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Metastasisâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œC000720935â€, â€œtermâ€: â€œbalstilimabâ€}, {â€œidâ€: â€œC410216â€, â€œtermâ€: â€œFolfox protocolâ€}, {â€œidâ€: â€œâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œExperimental armâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients treated with Botensiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œBalstilimabâ€, â€œdescriptionâ€: â€œBalstilimab: 240mg, IV, Q2W, until disease â€¦\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\n\n[{â€œnameâ€: â€œChristelle DE LA FOUCHARDIERE, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ04 91 22 35 03â€, â€œemailâ€â€¦\n[{â€œfacilityâ€: â€œCentre LÃ©on BÃ©rardâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œLyonâ€, â€œcountryâ€: â€œFranceâ€, â€œcoâ€¦\n\nCIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the surâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n132\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nCIME\nCombination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomâ€¦\nNCT06346197\n\nA Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patieâ€¦\nET23-185\nOTHER\nCentre Leon Berard\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œGene expression and genomic profile descriptionâ€, â€œdescriptionâ€: â€œRNA Sequencingâ€, â€œtiâ€¦\n[{â€œmeasureâ€: â€œSurvival of patientsâ€, â€œdescriptionâ€: â€œComparison of survival of patients under Botensâ€¦\n[{â€œmeasureâ€: â€œProgression free survivalâ€, â€œtimeFrameâ€: â€œAt least 2 yearsâ€}, {â€œmeasureâ€: â€œObjective râ€¦\nFalse\nFalse\n\nTrue\n\n\n[{â€œnameâ€: â€œAgenus Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nCentre Leon Berard\n\n\n\nSPONSOR\n2028-05-15\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-26\nACTUAL\n2025-12-19\nRECRUITING\n2028-05-15\nESTIMATED\n\n\n\n\n2025-12-08\nACTUAL\n2025-12\n2024-04-03\nACTUAL\n2024-03-08\n2024-03-28\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Male or female patient â‰¥18 years of age at time of informed consent form signâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD013844â€, â€œtermâ€: â€œThiazolesâ€}, {â€œidâ€: â€œD013457â€, â€œtermâ€: â€œSulfur Compoundsâ€}, {â€œidâ€: â€œD009â€¦\n[{â€œidâ€: â€œD000069439â€, â€œtermâ€: â€œDasatinibâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDasatinibâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDasatinib 70 mg/daily, orally adminiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDasatinib 70 mgâ€, â€œdescriptionâ€: â€œCommercially available tablets containiâ€¦\nHIV Infection Primary\nSAMHD1 phosphorylation, T-cell activation, Dasatinib, Suppressive combined Anti Retroviral Treatment\n\n[{â€œfacilityâ€: â€œHospital Universitari Germans Trias i Pujolâ€, â€œcityâ€: â€œBadalonaâ€, â€œstateâ€: â€œBarcelonaâ€¦\n[{â€œnameâ€: â€œJosÃ© MoltÃ³, MD, PhDâ€, â€œaffiliationâ€: â€œFundaciÃ³ Lluita contra les Infeccions - Hospital Unâ€¦\nThe goal of this clinical trial is to evaluate the safety, tolerability and Impact of low dose Dasatâ€¦\nThis is a Phase II, single-center, randomized, double-blind, placebo-controlled clinical trial in Peâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nQUADRUPLE\nDasatinib capsules re-capsulated with identical appearance with Placebo\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n60\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSafety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antireâ€¦\nNCT05780073\n\nSafety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antireâ€¦\nBCN04-Dasa\nOTHER\nFundaciÃ³ Institut Germans Trias i Pujol\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œChanges in the contributors to the reservoir repertoireâ€, â€œdescriptionâ€: â€œMeasured by â€¦\n[{â€œmeasureâ€: â€œGrade 3 or 4 treatment-related adverse events or laboratory abnormalities during the sâ€¦\n[{â€œmeasureâ€: â€œProviral reactivation capacity upon in-vitro T-cell activation: Proportion of intracelâ€¦\nFalse\nFalse\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œSpanish Clinical Research Network - SCReNâ€, â€œclassâ€: â€œNETWORKâ€}, {â€œnameâ€: â€œIrsiCaixaâ€, â€œcâ€¦\nOTHER\nFundaciÃ³ Institut Germans Trias i Pujol\n\n\n\nSPONSOR\n2025-04-01\nACTUAL\n\n\n\n\nFalse\n\n2025-09-22\nACTUAL\n2025-09-16\nCOMPLETED\n2025-04-01\nACTUAL\n\n\n\n\n2023-10-16\nACTUAL\n2025-09\n2023-03-22\nACTUAL\n2023-02-27\n2023-03-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 1. Males and females aged at least 18 years on the day of screening.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* 2. Câ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004701â€, â€œtermâ€: â€œEndocrine Gland Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Sitâ€¦\n[{â€œidâ€: â€œD010051â€, â€œtermâ€: â€œOvarian Neoplasmsâ€}, {â€œidâ€: â€œD001943â€, â€œtermâ€: â€œBreast Neoplasmsâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000077594â€, â€œtermâ€: â€œNivolumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œP1a Arm A (Monotherapy Dose Escalation).â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œCOM70â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œCOM701â€, â€œdescriptionâ€: â€œCOM701 monotherapy.â€, â€œarmGroupLabelsâ€: [â€œP1a Arâ€¦\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Tâ€¦\nPVRIG, advanced cancer, checkpoint inhibitor, DNAM (DNAX Accessory molecule 1), PD-1 inhibitor, CD11â€¦\n\n[{â€œfacilityâ€: â€œUniversity of California Los Angeles (UCLA).â€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCalifâ€¦\n[{â€œnameâ€: â€œCOM701 Study Directorâ€, â€œaffiliationâ€: â€œCompugen USA, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the saâ€¦\nThis Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary clinicaâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n121\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nCOM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.\nNCT03667716\n\nA Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjecâ€¦\nCPG-01-001\nINDUSTRY\nCompugen Ltd\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œIncidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Tâ€¦\n[{â€œmeasureâ€: â€œIncidence of subjects with Anti-COM701 antibody.â€, â€œdescriptionâ€: â€œImmunogenicity of Câ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œBristol-Myers Squibbâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nCompugen Ltd\n\n\n\nSPONSOR\n2024-01-30\nACTUAL\n\n\n\n\nFalse\n\n2025-01-17\nACTUAL\n2025-01-15\nCOMPLETED\n2024-01-30\nACTUAL\n\n\n\n\n2018-09-06\nACTUAL\n2025-01\n2018-09-12\nACTUAL\n2018-09-10\n2018-09-11\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Subject has Eastern Cooperative Oncology Group (ECOG) performance status â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002526â€, â€œtermâ€: â€œCerebellar Diseasesâ€}, {â€œidâ€: â€œD001927â€, â€œtermâ€: â€œBrain Diseasesâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD013132â€, â€œtermâ€: â€œSpinocerebellar Degenerationsâ€}, {â€œidâ€: â€œD015179â€, â€œtermâ€: â€œColorectal Nâ€¦\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment with Biopsyâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients in Cohort A wilâ€¦\n[{â€œtypeâ€: â€œPROCEDUREâ€, â€œnameâ€: â€œPre-Treatment Biopsyâ€, â€œdescriptionâ€: â€œThe pre-treatment biopsy shouâ€¦\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal â€¦\nimmunotherapy, microsatellite stable colorectal cancer, tiragolumab, metastatic colorectal cancer, aâ€¦\n\n[{â€œfacilityâ€: â€œUniverstiy of Colorado Hospitalâ€, â€œcityâ€: â€œAuroraâ€, â€œstateâ€: â€œColoradoâ€, â€œzipâ€: â€œ8004â€¦\n[{â€œnameâ€: â€œHannah Robinson, MDâ€, â€œaffiliationâ€: â€œUniversity of Colorado, Denverâ€, â€œroleâ€: â€œPRINCIPALâ€¦\nThe goal of this study is to learn if a new combination treatment is effective for patients with micâ€¦\nThis is a phase II study investigating the efficacy and safety of a triple-combination immunotherapyâ€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n13\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nTrial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatâ€¦\nNCT06784947\n\nA Phase II Trial of Tiragolumab in Combination With Atezolizumab and Bevacizumab in Patients With Prâ€¦\n24-0547.cc\nOTHER\nUniversity of Colorado, Denver\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œDisease Control Rate (DCR)â€, â€œdescriptionâ€: â€œThe disease control rate (DCR) is definedâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œThe primary outcome of this trial is oâ€¦\n[{â€œmeasureâ€: â€œProgression Free Survival (PFS)â€, â€œdescriptionâ€: â€œProgression free survival (PFS) measâ€¦\nFalse\nTrue\nFalse\nTrue\n\n\n[{â€œnameâ€: â€œGenentech, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nOTHER\nUniversity of Colorado, Denver\n\n\n\nSPONSOR\n2028-05\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-02\nACTUAL\n2025-10-01\nACTIVE_NOT_RECRUITING\n2025-09-18\nACTUAL\n\n\n\n\n2025-03-25\nACTUAL\n2025-10\n2025-01-20\nACTUAL\n2025-01-08\n2025-01-16\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Able to sign the consent form.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Stated willingness and ability to comply wâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Meâ€¦\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD01â€¦\nPoland, Turkey (TÃ¼rkiye)\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œArm A (O+T+C)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDuring the induction phase, partâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œOciperlimabâ€, â€œdescriptionâ€: â€œ900 mg intravenously (IV) once every 3 weekâ€¦\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung â€¦\nmetastatic, Lung Cancer, Non-Squamous, Ociperlimab, Tislelizumab, Anti-PD-1, BGB-A317, BGB-A1217, Anâ€¦\n\n[{â€œfacilityâ€: â€œValkyrie Clinical Trialsâ€, â€œcityâ€: â€œLos Angelesâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€: â€œ9006â€¦\n\nThis study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab â€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nTREATMENT\n\n272\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nOciperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Câ€¦\nNCT05014815\n\nAdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherâ€¦\nAdvanTIG-205\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œ2021-001075-17â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œCTR20212782â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€â€¦\nSee plan description\nBeiGene shares data on completed studies responsibly and provides qualified scientific and medical râ€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\nSee plan description\n\n\n[{â€œmeasureâ€: â€œProgression-free Survival (PFS)â€, â€œdescriptionâ€: â€œPFS was defined as the time from ranâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œObjective response rate is defined as â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2024-09-04\nACTUAL\n\n\n\n\nFalse\n\n2025-09-16\nACTUAL\n2025-08-28\nCOMPLETED\n2024-09-04\nACTUAL\n2025-09-16\nACTUAL\n2025-08-28\n2025-08-28\n2021-11-16\nACTUAL\n2025-08\n2021-08-20\nACTUAL\n2021-08-16\n2021-08-16\n\nAll-cause mortality is reported for all randomized participants. Serious and other adverse events arâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œArm A (O+T+C)â€, â€œdescriptionâ€: â€œOciperlimab (900 mg IV), tislelizumab (20â€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nAll-cause mortality is reported from randomization up to study completion date cut-off date of 04 Seâ€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ136â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œArm A (O+T+C)â€, â€œdescriptionâ€: â€œOciperlimab (900 mg IV), tislelizumab (20â€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Intent-to-Treat Analysis Set is defined as all randomized participants\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@beigene.com\nBeiGene\n1 877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œProgression-free Survival (PFS)â€, â€œdescriptionâ€: â€œPFS was defined as â€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œArm A (O+T+C)â€, â€œdescriptionâ€: â€œOciperlimab (900 mg IV), tislelizumab (20â€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nEligible participants were randomized in a 1:1 ratio to receive either ociperlimab or placebo treatmâ€¦\nThis study was conducted at 75 study centers in 8 countries (China, South Korea, United States of Amâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Participants had histologically or cytologically confirmed locally advanâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œBL-B01D1 Armâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants receive BL-B01D1 injâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œBL-B01D1â€, â€œdescriptionâ€: â€œBL-B01D1 is a first-in-class novel ADC consistâ€¦\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nRare Tumors, Platform Trial, Precision Medicine, Immunotherapy, Targeted Therapy, Cell and gene therâ€¦\n[{â€œnameâ€: â€œNing Li, MDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ86-010-87788713â€, â€œemailâ€: â€œlining@cicams.ac.câ€¦\n\n[{â€œnameâ€: â€œNing Li, MDâ€, â€œaffiliationâ€: â€œCancer Hospital of CICAMSâ€, â€œroleâ€: â€œPRINCIPAL_INVESTIGATORâ€¦\nThe goal of this Phase I/II observational and interventional platform study is to evaluate the safetâ€¦\nThis is an open-label, non-randomized, multi-arm, single-center Phase I/II platform study (PLATFORM2â€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n600\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nRare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)\nNCT07307053\n\nAn Open-Label, Single-Arm, Phase I/II Platform Trial of Innovative Therapies and Technologies Primarâ€¦\nPLATFORM2\nOTHER\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR)â€, â€œdescriptionâ€: â€œAssessed by BICR and Investigator per â€¦\n[{â€œmeasureâ€: â€œProgression-Free Survival (PFS)â€, â€œdescriptionâ€: â€œAssessed by BICR and Investigator.â€,â€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\n\n\n\nSPONSOR\n2031-01-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-29\nACTUAL\n2025-12-13\nNOT_YET_RECRUITING\n2029-01-31\nESTIMATED\n\n\n\n\n2026-01-01\nESTIMATED\n2025-12\n2025-12-29\nACTUAL\n2025-12-12\n2025-12-13\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Subjects must meet all of the following inclusion criteria:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Male or femaleâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD009362â€, â€œtermâ€: â€œNeoplasm Meâ€¦\n\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\nMexico\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A: Tislelizumab plus Ociperlimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipaâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTislelizumabâ€, â€œdescriptionâ€: â€œTislelizumab is a monoclonal antibody formâ€¦\nNon-small Cell Lung Cancer, NSCLC\nLocally Advanced, Unresectable, Metastatic, Tislelizumab, BGB-A317, Ociperlimab, BGB-A1217, Pembroliâ€¦\n\n[{â€œfacilityâ€: â€œProvidence Medical Foundation St Jude Heritage Healthcareâ€, â€œcityâ€: â€œFullertonâ€, â€œstaâ€¦\n\nThe purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compaâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n662\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Luâ€¦\nNCT04746924\n\nA Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination Witâ€¦\nAdvanTIG-302\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œBGB-A317-A1217-302â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œBeiGeneâ€}, {â€œidâ€: â€œCTR20211476/CTR20211464â€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œdescriptionâ€: â€œOS will be defined as the time from the date oâ€¦\n[{â€œmeasureâ€: â€œProgression-free Survival (PFS) As Assessed By Investigatorsâ€, â€œdescriptionâ€: â€œPFS wilâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2026-03-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-06-24\nACTUAL\n2025-06-23\nACTIVE_NOT_RECRUITING\n2025-05-30\nACTUAL\n\n\n\n\n2021-06-08\nACTUAL\n2025-06\n2021-02-10\nACTUAL\n2021-02-05\n2021-02-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically or cytologically documented locally advanced or recurrentâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD061067â€, â€œtermâ€: â€œAntibodies, Monoclonal, Humanizedâ€}, {â€œidâ€: â€œD000911â€, â€œtermâ€: â€œAntibodiâ€¦\n[{â€œidâ€: â€œD000096662â€, â€œtermâ€: â€œRamucirumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSub-study 1, investigate rilvegostomigÂ± ramucirumab in 1L non-AGA NSCLC with PD-L1 â‰¥50%â€â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œRilvegostomig will be administered as IV â€¦\nNon-Small Cell Lung Cancer\nNon-Small Cell Lung Cancer(NSCLC), Antibody-Drug Conjugates (ADCs), T-cell immunoreceptor with Ig anâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œNOT_YET_RECRUITINGâ€, â€œcityâ€: â€œSanta Monicaâ€, â€œstateâ€: â€œCalâ€¦\n\nThis is a Phase II, multi-center, open-label platform study evaluating novel combination treatment oâ€¦\nThe master protocol will include 3 sub-studies, each focused on a specific disease population.\n\n\nNON_RANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n278\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria for All Sub-studies:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nLIBRA\nA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)\nNCT07098338\n\nAn Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmaâ€¦\nD6187C00001\nINDUSTRY\nAstraZeneca\n\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œNumber of participants with adverse events (AE) and serious adverse events (SAE)â€, â€œdeâ€¦\n[{â€œmeasureâ€: â€œBest Overall Response(BOR)â€, â€œdescriptionâ€: â€œBOR is the best response a participant haâ€¦\nFalse\nTrue\n\nFalse\n\n\n[{â€œnameâ€: â€œDaiichi Sankyoâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-04-06\nESTIMATED\n\n\n\n\nFalse\n\n2025-09-30\nACTUAL\n2025-09-25\nRECRUITING\n2027-03-21\nESTIMATED\n\n\n\n\n2025-08-07\nACTUAL\n2025-09\n2025-08-01\nACTUAL\n2025-07-04\n2025-07-25\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Suâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participant must be â‰¥ 18 years of age at the time of signâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014594â€, â€œtermâ€: â€œUterine Neoplasmsâ€}, {â€œidâ€: â€œD005833â€, â€œtermâ€: â€œGenital Neoplasms, Femalâ€¦\n[{â€œidâ€: â€œD016889â€, â€œtermâ€: â€œEndometrial Neoplasmsâ€}, {â€œidâ€: â€œD009364â€, â€œtermâ€: â€œNeoplasm Recurrence,â€¦\n[{â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}]\n[{â€œidâ€: â€œC111043â€, â€œtermâ€: â€œTP protocolâ€}, {â€œidâ€: â€œD011878â€, â€œtermâ€: â€œRadiotherapyâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTreatment Armâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œChemotherapyï¼šTP (Paclitaxel and â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPaclitaxel and Cisplatinâ€, â€œdescriptionâ€: â€œPaclitaxel and Cisplatin Pacliâ€¦\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nImmunotherapy, Cadonilimab, Paclitaxel, Cisplatin, Radiation Therapy, Combined Modality Therapy, Cliâ€¦\n[{â€œnameâ€: â€œJing Liuâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+86 13065077425â€, â€œemailâ€: â€œ13065077425@126.comâ€}â€¦\n[{â€œfacilityâ€: â€œShandong Cancer Hospital Affiliated to Shandong First Medical Universityâ€, â€œstatusâ€: â€¦\n[{â€œnameâ€: â€œPeng Xieâ€, â€œaffiliationâ€: â€œShandong Cancer Hospital and Instituteâ€, â€œroleâ€: â€œPRINCIPAL_INâ€¦\nThe goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combinationâ€¦\n\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n80 Years\n18 Years\n\nFEMALE\nADULT, OLDER_ADULT\n\n\nCadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma\nNCT06532539\n\nA Phase II, Single-arm, Multicenter Clinical Trial of Definitive Treatment With Cadonilimab, Paclitaâ€¦\nSDZLEC2024-160-01\nOTHER\nShandong Cancer Hospital and Institute\n\n\n\nSTUDY_PROTOCOL\nYES\n\n\n[{â€œmeasureâ€: â€œBiomarkerâ€, â€œdescriptionâ€: â€œCD8A, PD-1, PD-L1, CD68, panCK, CD56, CD155, TIGIT, TMB, Mâ€¦\n[{â€œmeasureâ€: â€œProgression-Free Survivalâ€, â€œdescriptionâ€: â€œProgression-Free Survival (PFS) will be asâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rateâ€, â€œdescriptionâ€: â€œORR refers to the proportion of patients whoâ€¦\nFalse\nFalse\n\n\n\n\n\nOTHER\nShandong Cancer Hospital and Institute\nShandong Cancer Hospital and Institute\nPeng Xie\nDirector\nPRINCIPAL_INVESTIGATOR\n2026-05\nESTIMATED\n\n\n\n\nFalse\n\n2024-08-01\nACTUAL\n2024-07-29\nRECRUITING\n2025-05\nESTIMATED\n\n\n\n\n2024-06-13\nACTUAL\n2024-06\n2024-08-01\nACTUAL\n2024-07-22\n2024-07-29\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. A written informed consent form must be signed before the implementation of â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD007154â€, â€œtermâ€: â€œImmune System Diseasesâ€}]\n[{â€œidâ€: â€œD006086â€, â€œtermâ€: â€œGraft vs Host Diseaseâ€}]\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n\n\nGraft-versus-host Disease (GVHD)\nallogeneic hematopoietic stem cell transplantation, Graft-versus-host disease, CD8 regulatory precurâ€¦\n\n[{â€œfacilityâ€: â€œNo.Â 11 Xizhimen South Street, Xicheng District, Beijing, Chinaâ€, â€œcityâ€: â€œBeijingâ€, â€œâ€¦\n\nAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective treatment for aâ€¦\n\n\n\n\n\n\n\n\n\nCOHORT\n\nPROSPECTIVE\n100\nESTIMATED\nFalse\n\nOBSERVATIONAL\n\nInclusion Criteria:\n\n\nTrue\n60 Years\n18 Years\nNON_PROBABILITY_SAMPLE\nALL\nADULT\nAbout 100 patients to be recruited for allogeneic hematopoietic stem cell transplantation in the Depâ€¦\n\nThe Application of Novel Identified CD8 Regulatory Precursors in Inducing Immune Tolerance After Allâ€¦\nNCT06864598\n\nThe Application of Novel Identified CD8 Regulatory Precursors in Inducing Immune Tolerance After Allâ€¦\n2025PHB050-001\nOTHER\nPeking University Peopleâ€™s Hospital\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œProportion of CD8 Trp subgroupsâ€, â€œdescriptionâ€: â€œHealthy donor samples will be collecâ€¦\n[{â€œmeasureâ€: â€œT-cell functionâ€, â€œdescriptionâ€: â€œHealthy donor samples will be collected at the onsetâ€¦\nFalse\nFalse\nFalse\nFalse\n\n\n\nOTHER\nPeking University Peopleâ€™s Hospital\nPeking University Peopleâ€™s Hospital\nXiao-Jun Huang\nPrincipal Investigator\nPRINCIPAL_INVESTIGATOR\n2026-10-31\nESTIMATED\n\n\n\n\nFalse\n\n2025-03-07\nACTUAL\n2025-03-04\nENROLLING_BY_INVITATION\n2026-02-01\nESTIMATED\n\n\n\n\n2025-01-09\nACTUAL\n2025-02\n2025-03-07\nACTUAL\n2025-02-21\n2025-03-04\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Patients proposed for allogeneic haematopoietic stem cell transplantation;\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD007414â€, â€œtermâ€: â€œIntestinal Neoplasmsâ€}, {â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neopâ€¦\n[{â€œidâ€: â€œD003110â€, â€œtermâ€: â€œColonic Neoplasmsâ€}, {â€œidâ€: â€œD011127â€, â€œtermâ€: â€œPolypsâ€}, {â€œidâ€: â€œD01517â€¦\n[{â€œidâ€: â€œD004042â€, â€œtermâ€: â€œDietary Fats, Unsaturatedâ€}, {â€œidâ€: â€œD004041â€, â€œtermâ€: â€œDietary Fatsâ€}, â€¦\n[{â€œidâ€: â€œC035276â€, â€œtermâ€: â€œeicosapentaenoic acid ethyl esterâ€}, {â€œidâ€: â€œD015525â€, â€œtermâ€: â€œFatty Acâ€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œOmega-3 treatmentâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œDaily 4-gram marine omeâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAMR101 (VASCEPA, icosapent ethyl)â€, â€œdescriptionâ€: â€œOral administration, â€¦\nColon Cancer\nNutrition, Omega-3 fatty acid, Fish oil, Tumor microenvironment, Immune response, Gut microbiota, Poâ€¦\n\n[{â€œfacilityâ€: â€œMassachusetts General Hospitalâ€, â€œcityâ€: â€œBostonâ€, â€œstateâ€: â€œMassachusettsâ€, â€œzipâ€: â€œâ€¦\n[{â€œnameâ€: â€œAndrew T. Chan, MD, MPHâ€, â€œaffiliationâ€: â€œMassachusetts General Hospitalâ€, â€œroleâ€: â€œPRINCâ€¦\nThis is a prospective, double-blind, placebo-controlled, randomized clinical trial to assess the effâ€¦\nThis research study is evaluating the effect of AMR101, as a chemopreventive agent to reduce risk ofâ€¦\n\n\nRANDOMIZED\nPARALLEL\nDouble-blind, placebo-controlled, stratified, randomized clinical trial\nQUADRUPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n0\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nOMICC\nOMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer\nNCT03661047\nNCT03419455\nOMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer\n18-097\nOTHER\nMassachusetts General Hospital\n\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œThe change in the marine omega-3 polyunsaturated fatty acid (MO3PUFA) composition in câ€¦\n[{â€œmeasureâ€: â€œThe change in Tumor CD8+ T cells in the tumor tissue between pre- and post- AMR101 treâ€¦\nFalse\nTrue\nFalse\nTrue\n[{â€œpmidâ€: â€œ30834441â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œHang D, Kvaerner AS, Ma W, Hu Y, Tabung FK, Naâ€¦\n\n[{â€œnameâ€: â€œHarvard School of Public Health (HSPH)â€, â€œclassâ€: â€œOTHERâ€}]\nOTHER\nMassachusetts General Hospital\nMassachusetts General Hospital\nAndrew T. Chan, MD, MPH\nPrinicipal Investigator\nPRINCIPAL_INVESTIGATOR\n2021-11-30\nESTIMATED\n\n\n\n\nFalse\n\n2021-11-17\nACTUAL\n2021-11-10\nWITHDRAWN\n2021-11-30\nESTIMATED\n\n\n\n\n2019-11-30\nACTUAL\n2021-11\n2018-09-07\nACTUAL\n2018-08-31\n2018-09-06\nStudy will be closed due to zero enrollment in over 2 years.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParticipants must meet the following criteria on screening examination to be eliâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD013812â€, â€œtermâ€: â€œTherapeuticsâ€}, {â€œidâ€: â€œD003131â€, â€œtermâ€: â€œCombined Modality Therapyâ€}]\n[{â€œidâ€: â€œC000707970â€, â€œtermâ€: â€œtislelizumabâ€}, {â€œidâ€: â€œC000613593â€, â€œtermâ€: â€œdurvalumabâ€}, {â€œidâ€: â€œDâ€¦\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œOciperlimab + Tislelizumab + cCRTâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipantsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTislelizumabâ€, â€œdescriptionâ€: â€œ200 mg intravenously every three weeksâ€, â€œâ€¦\nNon Small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œXCancer/Centeral Care Centerâ€, â€œcityâ€: â€œBolivarâ€, â€œstateâ€: â€œMissouriâ€, â€œzipâ€: â€œ65613â€â€¦\n\nThe purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination withâ€¦\nThe study initiated with Protocol Amendment 1.0 (PA 1; dated on 16 April 2021). In April 2022 Protocâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n63\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiothâ€¦\nNCT04866017\n\nA Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A3â€¦\nBGB-A317-A1217-301\nINDUSTRY\nBeiGene\n[{â€œidâ€: â€œ2020-004656-14â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œAdvanTIG-301â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€¦\n\n\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œProgression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)â€â€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œdescriptionâ€: â€œDefined as the time from the date of randomizaâ€¦\nFalse\nTrue\nTrue\nTrue\n\n\n\nINDUSTRY\nBeiGene\n\n\n\nSPONSOR\n2023-10-17\nACTUAL\n\n\n\n\nFalse\n\n2024-10-31\nACTUAL\n2024-10-09\nTERMINATED\n2023-10-17\nACTUAL\n2024-10-31\nACTUAL\n2024-10-09\n2024-10-09\n2021-06-17\nACTUAL\n2024-10\n2021-04-29\nACTUAL\n2020-10-28\n2021-04-26\nThis decision was conducted by the sponsor and not driven by safety concerns as no new safety signalâ€¦\nAll-cause mortality is reported for all randomized participants. Serious and other adverse events inâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œOciperlimab + Tislelizumab + cCRTâ€, â€œdescriptionâ€: â€œParticipants enrolledâ€¦\n3.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œmedâ€¦\n[{â€œtermâ€: â€œStomatitisâ€, â€œorganSystemâ€: â€œGastrointestinal disordersâ€, â€œsourceVocabularyâ€: â€œmeddra 26â€¦.\nFrom first dose to 30 days after the last dose or initiation of a new anticancer therapy, whichever â€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ22â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œOciperlimab + Tislelizumab + cCRTâ€, â€œdescriptionâ€: â€œParticipants enrolledâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Intent-to-Treat (ITT) Analysis Set is defined as all randomized participants.\nBeiGene has 18 months from the end of the study at all sites to publish overall study results. Afterâ€¦\nFalse\nOTHER\nTrue\nSince no participants were enrolled under PA 2, no analyses of the primary or secondary endpoints weâ€¦\nclinicaltrials@beigene.com\nBeiGene\n1-877-828-5568\n\nStudy Director\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œProgression-Free Survival (PFS) as Assessed by the Independent Reviewâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œOciperlimab + Tislelizumab + cCRTâ€, â€œdescriptionâ€: â€œParticipants enrolledâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nThis study was initiated under Protocol Amendment (PA) 1. PA 2 was subsequently implemented; howeverâ€¦\nParticipants were enrolled in multiple study centers in Taiwan, China, Spain , United States, and Auâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Age â‰¥ 18 years on the day of signing the informed consent form (or the lâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD002292â€, â€œtermâ€: â€œCarcinoma, Renal Cellâ€}]\n\n[{â€œidâ€: â€œC558660â€, â€œtermâ€: â€œcabozantinibâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œHLA-A2 postiveâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œThe study will include 21 partiâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œAutologous alpha-DC1/TBVA vaccineâ€, â€œdescriptionâ€: â€œDendritic cellsâ€¦\nCarcinoma, Renal Cell\nClear Cell Renal Cell Carcinoma\n[{â€œnameâ€: â€œMorgan Pokora, RNâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ412-623-4886â€, â€œemailâ€: â€œpokoraml3@upmcâ€¦.\n[{â€œfacilityâ€: â€œUPMC Department of Urologyâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œPittsburghâ€, â€œstateâ€: â€œâ€¦\n[{â€œnameâ€: â€œJodi Maranchie, MDâ€, â€œaffiliationâ€: â€œUPMC Department of Urologyâ€, â€œroleâ€: â€œPRINCIPAL_INVEâ€¦\nThe purpose of this study is to estimate the probability of immune response for the combination treaâ€¦\nParticipants with newly diagnosed, non-metastatic, histologically confirmed, clear cell renal cell câ€¦\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n42\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nAutologous Dendritic Cell Vaccine in Kidney Cancer\nNCT05127824\n\nA Phase 2a Study to Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Veâ€¦\nHCC 19-126\nOTHER\nUniversity of Pittsburgh\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œTo assess the impact of treatment on formation of tertiary lymphoid structures in pre-â€¦\n[{â€œmeasureâ€: â€œProbability of immune responseâ€, â€œdescriptionâ€: â€œProportion of HLA-A2+ ccRCC patients â€¦\n[{â€œmeasureâ€: â€œMarkers of vascular normalizationâ€, â€œdescriptionâ€: â€œChange in presence of mature CD31+â€¦\nFalse\nTrue\nFalse\nTrue\n[{â€œpmidâ€: â€œ29487224â€, â€œtypeâ€: â€œBACKGROUNDâ€, â€œcitationâ€: â€œTannir NM, Pal SK, Atkins MB. Second-Line Tâ€¦\n\n\nOTHER\nJodi Maranchie\nUniversity of Pittsburgh\nJodi Maranchie\nAssociate Professor Urology & Urologic Oncology\nSPONSOR_INVESTIGATOR\n2026-12\nESTIMATED\n\n\n\n\nFalse\n\n2025-05-04\nACTUAL\n2025-04-30\nRECRUITING\n2026-12\nESTIMATED\n\n\n\n\n2023-07-06\nACTUAL\n2025-04\n2021-11-19\nACTUAL\n2021-10-22\n2021-11-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Histologically proven clear cell renal cancer that is non-metastatic and ameâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Doâ€¦\n[{â€œidâ€: â€œD014801â€, â€œtermâ€: â€œVitamin Aâ€}, {â€œidâ€: â€œD012176â€, â€œtermâ€: â€œRetinoidsâ€}, {â€œidâ€: â€œD002338â€, â€œâ€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD014212â€, â€œtermâ€: â€œTretinoinâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPembrolizumab + Vibostolimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPrior to tumor reâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œAdministered via IV infusion at a sâ€¦\nMelanoma\nprogrammed cell death 1 (PD-1, PD1), programmed cell death ligand 1 (PD-L1, PDL1), Coxsackievirus A2â€¦\n\n[{â€œfacilityâ€: â€œThe Angeles Clinic and Research Institute ( Site 3009)â€, â€œcityâ€: â€œLos Angelesâ€, â€œstatâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œMerck Sharp & Dohme LLCâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nSubstudy 02C is part of a larger research study that is testing experimental treatments for melanomaâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n146\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n120 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSubstudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pemâ€¦\nNCT04303169\n\nA Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Withouâ€¦\n3475-02C\nINDUSTRY\nMerck Sharp & Dohme LLC\n[{â€œidâ€: â€œMK-3475-02Câ€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMSDâ€}, {â€œidâ€: â€œKEYMAKER-U02â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nhttps://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf\n\nYES\n\nhttps://externaldatasharing-msd.com/\n\n[{â€œmeasureâ€: â€œPercentage of participants who experience an adverse event (AE)â€, â€œdescriptionâ€: â€œAn Aâ€¦\n[{â€œmeasureâ€: â€œNear pathological complete response (near pCR) rateâ€, â€œdescriptionâ€: â€œNear pCR is defiâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ39775043â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œDummer R, Robert C, Scolyer RA, Taube JM, Tetzlâ€¦\n[{â€œlabelâ€: â€œMerck Clinical Trials Informationâ€, â€œurlâ€: â€œhttps://www.merckclinicaltrials.com/â€}, {â€œlaâ€¦\n\nINDUSTRY\nMerck Sharp & Dohme LLC\n\n\n\nSPONSOR\n2025-09-24\nACTUAL\n\n\n\n\nFalse\n\n2025-10-27\nACTUAL\n2025-10-23\nCOMPLETED\n2025-09-24\nACTUAL\n\n\n\n\n2020-06-26\nACTUAL\n2025-10\n2020-03-10\nACTUAL\n2020-03-09\n2020-03-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has histologically or cytologically confirmed melanoma\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has clinically detecâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005770â€, â€œtermâ€: â€œGastrointestinal Neoplasmsâ€}, {â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive Systeâ€¦\n[{â€œidâ€: â€œC562730â€, â€œtermâ€: â€œAdenocarcinoma Of Esophagusâ€}, {â€œidâ€: â€œD013274â€, â€œtermâ€: â€œStomach Neoplaâ€¦\n[{â€œidâ€: â€œD014498â€, â€œtermâ€: â€œUracilâ€}, {â€œidâ€: â€œD011744â€, â€œtermâ€: â€œPyrimidinonesâ€}, {â€œidâ€: â€œD011743â€, â€¦\n[{â€œidâ€: â€œC000723779â€, â€œtermâ€: â€œquemliclustatâ€}, {â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€:â€¦\nArgentina\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA1: First Line - Treatment NaÃ¯ve Participantsâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œAdministered as specified in the treatmentâ€¦\nGastrointestinal Tract Malignancies\nDomvanalimab, Quemliclustat, Zimberelimab, Esophageal adenocarcinoma, Gastric adenocarcinoma, Gastriâ€¦\n\n[{â€œfacilityâ€: â€œMayo Clinic - Arizonaâ€, â€œcityâ€: â€œPhoenixâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œ85054â€, â€œcountâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œArcus Biosciences, Inc.â€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to evaluate the safety and preliminary clinical activity of treatment câ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n332\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nEDGE-Gastric\nA Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Particiâ€¦\nNCT05329766\n\nA Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advancâ€¦\nARC-21\nINDUSTRY\nArcus Biosciences, Inc.\n[{â€œidâ€: â€œ2021-006291-16â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œ2024-511917-40-00â€, â€œtypeâ€: â€œCTISâ€}]\n\nArcus will provide access to individual de-identified participant data and related study documents (â€¦\nSTUDY_PROTOCOL, SAP, CSR\nYES\n\nhttps://trials.arcusbio.com/our-transparency-policy\n\n[{â€œmeasureâ€: â€œNumber of Participants with Adverse Events (AEs)â€, â€œtimeFrameâ€: â€œUp to 18 monthsâ€}, {â€œâ€¦\n[{â€œmeasureâ€: â€œObjective Response Rate (ORR) as measured by PD-L1 Expression Levelâ€, â€œtimeFrameâ€: â€œUpâ€¦\nFalse\nTrue\n\nFalse\n[{â€œpmidâ€: â€œ41109921â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œJanjigian YY, Oh DY, Pelster M, Wainberg ZA, Pâ€¦\n[{â€œlabelâ€: â€œARC-21 - Public websiteâ€, â€œurlâ€: â€œhttps://trials.arcusbio.com/study/?id=ARC-21â€}]\n[{â€œnameâ€: â€œGilead Sciencesâ€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nArcus Biosciences, Inc.\n\n\n\nSPONSOR\n2027-06\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-29\nACTUAL\n2026-01-27\nACTIVE_NOT_RECRUITING\n2027-01\nESTIMATED\n\n\n\n\n2022-06-10\nACTUAL\n2025-03\n2022-04-15\nACTUAL\n2022-04-08\n2022-04-08\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants with histologically confirmed diagnosis of locally advanced â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018070â€, â€œtermâ€: â€œBiological Specimen Banksâ€}, {â€œidâ€: â€œD006268â€, â€œtermâ€: â€œHealth Facilitieâ€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD014015â€, â€œtermâ€: â€œTissue Banksâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPermbrolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants will undergo fine â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œPost Fine-cut CT: 4 doses of pembrolizumaâ€¦\nBasal Cell Carcinoma of the Head and Neck\n\n\n[{â€œfacilityâ€: â€œCleveland Clinic, Case Comprehensive Cancer Centerâ€, â€œcityâ€: â€œClevelandâ€, â€œstateâ€: â€œOâ€¦\n[{â€œnameâ€: â€œJames Isaacs, MDâ€, â€œaffiliationâ€: â€œCleveland Clinic, Case Comprehensive Cancer Centerâ€, â€œâ€¦\nThe purpose of this study is to evaluate anti-PD-1 Neoadjuvant therapy in Basal cell carcinoma to prâ€¦\nThis is a phase 1 study looking at anti-PD-1 Neoadjuvant therapy in Basal cell carcinoma in participâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n13\nACTUAL\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nNeoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N\nNCT04323202\n\nA Phase 1B, Single Arm Study of Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cellâ€¦\nCASE10319\nOTHER\nCase Comprehensive Cancer Center\n\n\nIndividual participant data will not be shared but the study team expects to publish the data from tâ€¦\n\nNO\n\n\n[{â€œmeasureâ€: â€œNumber of Tumor Infiltrating Lymphocytes (TILs)â€, â€œdescriptionâ€: â€œNumber of Tumor Infiâ€¦\n[{â€œmeasureâ€: â€œPathologic response as assessed by change in tumor volume (RECIST 1.1)â€, â€œdescriptionâ€â€¦\n[{â€œmeasureâ€: â€œNumber of participants experiencing a grade 3 or higher Adverse Eventâ€, â€œdescriptionâ€:â€¦\nFalse\nTrue\n\nTrue\n\n\n\nOTHER\nCase Comprehensive Cancer Center\n\n\n\nSPONSOR\n2025-06-25\nACTUAL\n\n\n\n\nFalse\n\n2025-10-24\nACTUAL\n2025-10-23\nCOMPLETED\n2024-07-23\nACTUAL\n\n\n\n\n2020-08-04\nACTUAL\n2025-10\n2020-03-26\nACTUAL\n2020-03-20\n2020-03-24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Advanced basal cell carcinoma for the purposes of this study will be defined â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD004067â€, â€œtermâ€: â€œDigestive System Neoplasmsâ€}, {â€œidâ€: â€œD009371â€, â€œtermâ€: â€œNeoplasms by Siâ€¦\n[{â€œidâ€: â€œD001661â€, â€œtermâ€: â€œBiliary Tract Neoplasmsâ€}, {â€œidâ€: â€œD012008â€, â€œtermâ€: â€œRecurrenceâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD006571â€, â€œtermâ€: â€œHeterocyclic Compoundsâ€}, {â€œidâ€: â€œD003841â€, â€œtermâ€: â€œDeoxycytidineâ€}, {â€œâ€¦\n[{â€œidâ€: â€œC000613593â€, â€œtermâ€: â€œdurvalumabâ€}, {â€œidâ€: â€œD000093542â€, â€œtermâ€: â€œGemcitabineâ€}, {â€œidâ€: â€œD0â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œControl Armâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œDurvalumab IV infusion + chemâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œRilvegostomig IV (intravenous) Q3Wâ€, â€œarmâ€¦\nBiliary Tract Cancer\nRilvegostomig, Durvalumab, Biliary Tract Cancer, Bispecific Antibody, PD-L1, TIGIT, Initially Unreseâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œNOT_YET_RECRUITINGâ€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabaâ€¦\n\nThe purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\nOpen label\n\n\nTREATMENT\n\n1100\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nKey inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nAB02\nA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Câ€¦\nNCT07221253\n\nPhase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combiâ€¦\nD702NC00001\nINDUSTRY\nAstraZeneca\n\nWhen a request has been approved AstraZeneca will provide access to the de-identified individual patâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure\n\n[{â€œmeasureâ€: â€œOverall Survival (OS) in the PDL1 â‰¥ 1% populationâ€, â€œdescriptionâ€: â€œOverall Survival iâ€¦\n[{â€œmeasureâ€: â€œOverall Survival in the intent to treat (ITT) populationâ€, â€œdescriptionâ€: â€œOverall Surâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-07-04\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-08\nACTUAL\n2026-01-07\nRECRUITING\n2029-07-04\nESTIMATED\n\n\n\n\n2025-12-04\nACTUAL\n2025-12\n2025-10-27\nACTUAL\n2025-10-01\n2025-10-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically confirmed adenocarcinoma of the biliary tract, including iâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD043823â€, â€œtermâ€: â€œTaxoidsâ€}, {â€œidâ€: â€œD043822â€, â€œtermâ€: â€œCyclodecanesâ€}, {â€œidâ€: â€œD003516â€, â€¦\n[{â€œidâ€: â€œC000723779â€, â€œtermâ€: â€œquemliclustatâ€}, {â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}, {â€œidâ€:â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œA1: Domvanalimab + Zimberelimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDomvanalimab aâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDomvanalimabâ€, â€œdescriptionâ€: â€œAdministered as specified in the treatmentâ€¦\nAdvanced Non-Small Cell Lung Cancer\nAdvanced Non-Small Cell Lung Cancer, Domvanalimab, Zimberelimab, Quemliclustat, Anti-TIGIT antibody,â€¦\n\n[{â€œfacilityâ€: â€œUniversity of Alabama at Birmingham (UAB)â€, â€œcityâ€: â€œBirminghamâ€, â€œstateâ€: â€œAlabamaâ€,â€¦\n[{â€œnameâ€: â€œGilead Study Directorâ€, â€œaffiliationâ€: â€œGilead Sciencesâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combâ€¦\nThe study includes multiple substudy arms (Substudy A, B, C), which will evaluate immunotherapy-baseâ€¦\n\n\nRANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n400\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nEDGE-Lung\nStudy With Various Immunotherapy Treatments in Participants With Lung Cancer\nNCT05676931\n\nA Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participantsâ€¦\nEDGE-Lung\nINDUSTRY\nGilead Sciences\n[{â€œidâ€: â€œ2022-502916-35-01â€, â€œtypeâ€: â€œCTISâ€}]\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œObjective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œtimeFrameâ€: â€œFrom date of first dose until the date of death â€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œArcus Biosciences, Inc.â€, â€œclassâ€: â€œINDUSTRYâ€}]\nINDUSTRY\nGilead Sciences\n\n\n\nSPONSOR\n2027-12\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-02\nACTUAL\n2025-09-29\nACTIVE_NOT_RECRUITING\n2027-12\nESTIMATED\n\n\n\n\n2023-02-21\nACTUAL\n2025-09\n2023-01-09\nACTUAL\n2022-12-09\n2023-01-05\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented Stage IV metastatic, NSCLC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Easteâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD014328â€, â€œtermâ€: â€œTrophoblastic Neoplasmsâ€}, {â€œidâ€: â€œD009373â€, â€œtermâ€: â€œNeoplasms, Germ Ceâ€¦\n[{â€œidâ€: â€œD031901â€, â€œtermâ€: â€œGestational Trophoblastic Diseaseâ€}, {â€œidâ€: â€œD013945â€, â€œtermâ€: â€œThymomaâ€â€¦\n\n[{â€œidâ€: â€œC000719848â€, â€œtermâ€: â€œzimberelimabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCohort 1: Peritoneal mesotheliomasâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients wiâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œDOMVANALIMAB + ZIMBERELIMABâ€, â€œdescriptionâ€: â€œPatients will be treated wiâ€¦\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Tâ€¦\nRare cancers, Immunotherapy, Peritoneal mesothelioma, Gestational Trophoblastic Tumors, Thymomas andâ€¦\n[{â€œnameâ€: â€œBenoit YOU, Prof; MD/PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0478864385â€, â€œphoneExtâ€: â€œ+33â€, â€œâ€¦\n[{â€œfacilityâ€: â€œInstitut de Cancerologie de lâ€™Ouest , medical oncology departmentâ€, â€œstatusâ€: â€œNOT_YEâ€¦\n\nImmune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, â€¦\n\n\n\nNON_RANDOMIZED\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n154\nESTIMATED\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nIMMUNORARE5\nIMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospitâ€¦\nNCT06790706\n\nIMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospitâ€¦\n69HCL24_0656\nOTHER\nHospices Civils de Lyon\n\n\n\n\nUNDECIDED\n\n\n\n[{â€œmeasureâ€: â€œProgression-free survival rate (cohort 1, 3 and 5)â€, â€œdescriptionâ€: â€œProportion of patâ€¦\n[{â€œmeasureâ€: â€œOverall response rate (cohorts 1, 3, 4 and 5)â€, â€œdescriptionâ€: â€œOverall response rate â€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nHospices Civils de Lyon\n\n\n\nSPONSOR\n2031-06\nESTIMATED\n\n\n\n\nFalse\n\n2025-10-06\nACTUAL\n2025-10-01\nRECRUITING\n2028-11\nESTIMATED\n\n\n\n\n2025-10-01\nACTUAL\n2025-10\n2025-01-24\nACTUAL\n2025-01-16\n2025-01-22\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nGeneral inclusion criteria for all cohorts\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically proven advanced soâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002294â€, â€œtermâ€: â€œCarcinoma, Squamous Cellâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€¦\n[{â€œidâ€: â€œD000077277â€, â€œtermâ€: â€œEsophageal Squamous Cell Carcinomaâ€}]\n\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}]\nBrazil, Czechia\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A: Tiragolumab + Atezolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipantsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTiragolumabâ€, â€œdescriptionâ€: â€œTiragolumab at a fixed dose of 600 milligraâ€¦\nEsophageal Squamous Cell Carcinoma\n\n\n[{â€œfacilityâ€: â€œFlorida Cancer Specialists - Fort Myers (Broadway)â€, â€œcityâ€: â€œFort Myersâ€, â€œstateâ€: â€œâ€¦\n[{â€œnameâ€: â€œClinical Trialâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab coâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nQUADRUPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n760\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nKey Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSKYSCRAPER-07\nA Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squâ€¦\nNCT04543617\n\nA Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiraâ€¦\nYO42137\nINDUSTRY\nHoffmann-La Roche\n[{â€œidâ€: â€œ2020-001178-31â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œArm A vs Arm C: Investigator-Assessed Progression-Free Survival (PFS)â€, â€œtimeFrameâ€: â€œâ€¦\n[{â€œmeasureâ€: â€œArm B vs Arm C: Investigator-Assessed PFSâ€, â€œtimeFrameâ€: â€œFrom randomization to the fiâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2027-03-31\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-20\nACTUAL\n2026-01-16\nACTIVE_NOT_RECRUITING\n2027-03-31\nESTIMATED\n\n\n\n\n2020-09-28\nACTUAL\n2026-01\n2020-09-10\nACTUAL\n2020-09-03\n2020-09-03\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Doâ€¦\n[{â€œidâ€: â€œD014801â€, â€œtermâ€: â€œVitamin Aâ€}, {â€œidâ€: â€œD012176â€, â€œtermâ€: â€œRetinoidsâ€}, {â€œidâ€: â€œD002338â€, â€œâ€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œC531958â€, â€œtermâ€: â€œlenvatinibâ€}, {â€œidâ€: â€œD01421â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPembrolizumab + Quavonlimab + Vibostolimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œAdministered via IV infusion at a sâ€¦\nMelanoma\nreceptor tyrosine kinase inhibitor, programmed cell death 1 (PD-1, PD1), programmed cell death liganâ€¦\n\n[{â€œfacilityâ€: â€œThe Angeles Clinic and Research Institute ( Site 1009)â€, â€œcityâ€: â€œLos Angelesâ€, â€œstatâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œMerck Sharp & Dohme LLCâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nSubstudy 02A is part of a larger research study that is testing experimental treatments for melanomaâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n100\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n120 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSubstudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Parâ€¦\nNCT04305041\n\nA Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Withouâ€¦\n3475-02A\nINDUSTRY\nMerck Sharp & Dohme LLC\n[{â€œidâ€: â€œMK-3475-02Aâ€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMSDâ€}, {â€œidâ€: â€œKEYMAKER-U02â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nhttps://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf\n\nYES\n\nhttps://externaldatasharing-msd.com/\n\n[{â€œmeasureâ€: â€œPercentage of participants who experience an adverse event (AE)â€, â€œdescriptionâ€: â€œAn Aâ€¦\n[{â€œmeasureâ€: â€œDuration of Response (DOR) per RECIST 1.1â€, â€œdescriptionâ€: â€œFor participants in the anâ€¦\nFalse\nTrue\n\nFalse\n\n[{â€œlabelâ€: â€œMerck Clinical Trials Informationâ€, â€œurlâ€: â€œhttps://www.merckclinicaltrials.com/â€}, {â€œlaâ€¦\n\nINDUSTRY\nMerck Sharp & Dohme LLC\n\n\n\nSPONSOR\n2025-08-25\nACTUAL\n\n\n\n\nFalse\n\n2025-08-29\nACTUAL\n2025-08-28\nCOMPLETED\n2025-08-25\nACTUAL\n\n\n\n\n2020-06-26\nACTUAL\n2025-08\n2020-03-12\nACTUAL\n2020-03-09\n2020-03-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has histologically or cytologically confirmed melanoma\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has unresectable Staâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD017606â€, â€œtermâ€: â€œChlorine Compoundsâ€}, {â€œidâ€: â€œD007287â€, â€œtermâ€: â€œInorganic Chemicalsâ€}, â€¦\n[{â€œidâ€: â€œD002945â€, â€œtermâ€: â€œCisplatinâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD00006843â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œSub study 2 Part A: Safety run-inâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipantsâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œRilvegostomig will be administered as an â€¦\nAdvanced or Metastatic Non-small Cell Lung Cancer\nCheckpoint inhibitor (CPI), Platinum-based chemotherapy, T-cell immunoreceptor with lg and Immunorecâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œPhoenixâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€:â€¦\n\nThe purpose of this study is to assess the safety and efficacy of multiple study interventions incluâ€¦\nThis is a multicentre, open-label study to evaluate the safety and efficacy of various combinations â€¦\n\n\nRANDOMIZED\nSEQUENTIAL\n\nNONE\n\n\n\nTREATMENT\n\n152\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nALTAIR\nA Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nNCT06996782\n\nA Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants Wâ€¦\nD702KC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2024-519786-22â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œEU CT numberâ€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\n\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œPart A and Part B: Number of participants with adverse events (AEs) and serious adversâ€¦\n[{â€œmeasureâ€: â€œPart A: Objective response (OR)â€, â€œdescriptionâ€: â€œThe OR is defined as a BOR of confirâ€¦\nFalse\nTrue\n\nFalse\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-02-23\nESTIMATED\n\n\n\n\n\n\n2026-01-14\nACTUAL\n2026-01-13\nRECRUITING\n2029-02-23\nESTIMATED\n\n\n\n\n2025-11-24\nACTUAL\n2026-01\n2025-05-30\nACTUAL\n2025-05-05\n2025-05-21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants with confirmed squamous or non-squamous NSCLC with a current Staâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Doâ€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\n\n\n2025-03-25\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProt_SAPâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: true, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Prâ€¦\nTrue\n[{â€œlabelâ€: â€œPembrolizumab/Vibostolimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants receivâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œPembrolizumab/Vibostolimabâ€, â€œdescriptionâ€: â€œCo-formulation of pembâ€¦\nMelanoma\nProgrammed Cell Death-1 (PD1, PD-1), T-cell immunoreceptor with immunoglobulin and immunoreceptor tyâ€¦\n\n[{â€œfacilityâ€: â€œMoores Cancer Center ( Site 0116)â€, â€œcityâ€: â€œLa Jollaâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€:â€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œMerck Sharp & Dohme LLCâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with resâ€¦\nWith Amendment 4, participants will discontinue treatment with pembrolizumab/vibostolimab.\n\n\nRANDOMIZED\nPARALLEL\n\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nTREATMENT\n\n1594\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n12 Years\n\nALL\nCHILD, ADULT, OLDER_ADULT\n\n\nA Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risâ€¦\nNCT05665595\n\nA Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684â€¦\n7684A-010\nINDUSTRY\nMerck Sharp & Dohme LLC\n[{â€œidâ€: â€œMK-7684A-010â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMSDâ€}, {â€œidâ€: â€œKEYVIBE-010â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nhttps://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf\n\nYES\n\nhttps://externaldatasharing-msd.com/\n\n[{â€œmeasureâ€: â€œRecurrence-Free Survival (RFS)â€, â€œdescriptionâ€: â€œRFS is defined as the time from randoâ€¦\n[{â€œmeasureâ€: â€œNumber of Participants Who Experienced at Least One Adverse Event (AE)â€, â€œdescriptionâ€â€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ39230120â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œShapira-Frommer R, Niu J, Perets R, Peters S, â€¦\n[{â€œlabelâ€: â€œMerck Clinical Trials Informationâ€, â€œurlâ€: â€œhttps://www.merckclinicaltrials.com/â€}, {â€œlaâ€¦\n\nINDUSTRY\nMerck Sharp & Dohme LLC\n\n\n\nSPONSOR\n2025-09-26\nACTUAL\n\n\n\n\nFalse\n\n2025-10-15\nACTUAL\n2025-10-03\nCOMPLETED\n2024-03-06\nACTUAL\n2025-04-06\nACTUAL\n2025-02-07\n2025-03-19\n2023-01-19\nACTUAL\n2025-10\n2022-12-27\nACTUAL\n2022-12-16\n2022-12-16\n\nAll-cause mortality: all participants randomized by the primary completion data cut-off. AEs: all paâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPembrolizumab/Vibostolimabâ€, â€œdescriptionâ€: â€œParticipants received pembroâ€¦\n5.0\n[{â€œtermâ€: â€œHyperthyroidismâ€, â€œorganSystemâ€: â€œEndocrine disordersâ€, â€œsourceVocabularyâ€: â€œMedDRA 26.1â€â€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nUp to approximately 13 months\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ701â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPembrolizumab/Vibostolimabâ€, â€œdescriptionâ€: â€œParticipants received pembroâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nPer protocol, analysis population consisted of all participants randomized by the primary completionâ€¦\nIf publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscâ€¦\nFalse\nOTHER\nTrue\n\nClinicalTrialsDisclosure@msd.com\nMerck Sharp & Dohme LLC\n1-800-672-6372\n\nSenior Vice President, Global Clinical Development\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œRecurrence-Free Survival (RFS)â€, â€œdescriptionâ€: â€œRFS is defined as thâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPembrolizumab/Vibostolimabâ€, â€œdescriptionâ€: â€œParticipants received pembroâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nProtocol-specified final analysis for the following results, including the participant flow, was perâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe protâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has surgically resected and histologically or pathologically confirmed diagnoâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œDrug: rilvegostomigâ€, â€œinterventionNamesâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œAdministered intravenously (IV) on â€¦\nCarcinoma, Non-Small Cell Lung\nARTEMIDE-Lung04, Rilvegostomig (AZD2936), Non-small cell lung cancer (NSCLC), Bi-specific antibody, â€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œBay Pinesâ€, â€œstateâ€: â€œFloridaâ€, â€œzipâ€¦\n\nThe purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pâ€¦\nThis is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the effiâ€¦\n\n\nRANDOMIZED\nPARALLEL\nParticipants will be randomized in a 1:1 ratio to one of the following intervention arms:\nQUADRUPLE\nDouble blind masking\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n830\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nARTEMIDELung04\nA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of Pâ€¦\nNCT06868277\n\nA Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Mâ€¦\nD702GC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2024-517780-24-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTIS (EU)â€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual participant-level data from AstraZâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Daâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œdescriptionâ€: â€œOS is defined as the time from randomization uâ€¦\n[{â€œmeasureâ€: â€œLandmark Overall Survival (OS) ratesâ€, â€œdescriptionâ€: â€œOS is defined as the time from â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2030-12-02\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-13\nACTUAL\n2026-01-12\nRECRUITING\n2030-01-17\nESTIMATED\n\n\n\n\n2025-04-10\nACTUAL\n2026-01\n2025-03-10\nACTUAL\n2025-03-07\n2025-03-07\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nArm A : Râ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented NSCLC (non small lung cancer), incâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD0172â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œRilvegostomig in combination with carbopâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œAdministered intravenously (IV) on Day 1 â€¦\nNon-small Cell Lung Cancer\nARTEMIDE-Lung02, Rilvegostomig (AZD2936), Non-small cell lung cancer (NSCLC), Bi-specific antibody, â€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œNOT_YET_RECRUITINGâ€, â€œcityâ€: â€œTucsonâ€, â€œstateâ€: â€œArizonaâ€,â€¦\n\nThe purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination â€¦\nThis is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the effiâ€¦\n\n\nRANDOMIZED\nPARALLEL\nArm A: Rilvegostomig in combination with carboplatin and paclitaxel or nab-paclitaxel followed by riâ€¦\nQUADRUPLE\nDouble-blind masking\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n880\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatmenâ€¦\nNCT06692738\n\nA Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab iâ€¦\nD702BC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2024-514281-39-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTIS (EU)â€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the European Federaâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œOverall survival (OS)â€, â€œdescriptionâ€: â€œOS is defined as the time from randomization uâ€¦\n[{â€œmeasureâ€: â€œLandmark overall survival (OS) ratesâ€, â€œdescriptionâ€: â€œOS is defined as the time from â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2029-10-08\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-21\nACTUAL\n2026-01-20\nRECRUITING\n2029-02-05\nESTIMATED\n\n\n\n\n2024-11-18\nACTUAL\n2026-01\n2024-11-18\nACTUAL\n2024-10-04\n2024-11-14\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented squamous NSCLC.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Stage IV mNSCLC â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD051436â€, â€œtermâ€: â€œRenal Insufficiency, Chronicâ€}, {â€œidâ€: â€œD051437â€, â€œtermâ€: â€œRenal Insuffiâ€¦\n[{â€œidâ€: â€œD007676â€, â€œtermâ€: â€œKidney Failure, Chronicâ€}, {â€œidâ€: â€œD009043â€, â€œtermâ€: â€œMotor Activityâ€}, â€¦\n[{â€œidâ€: â€œD064797â€, â€œtermâ€: â€œPhysical Conditioning, Humanâ€}, {â€œidâ€: â€œD015444â€, â€œtermâ€: â€œExerciseâ€}, {â€¦\n[{â€œidâ€: â€œD000072696â€, â€œtermâ€: â€œHigh-Intensity Interval Trainingâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œAll subjects will be in one armâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œBoth Lean and â€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œHigh Intensity Interval Trainingâ€, â€œdescriptionâ€: â€œAfter the acclimatizaâ€¦\nEnd Stage Renal Disease\nhigh intensity, interval training, exercise, obesity, inflammation, Treg\n\n[{â€œfacilityâ€: â€œUniversity of Kentucky Transplant Centerâ€, â€œcityâ€: â€œLexingtonâ€, â€œstateâ€: â€œKentuckyâ€, â€¦\n[{â€œnameâ€: â€œFrancesc Marti, PhDâ€, â€œaffiliationâ€: â€œUniversity of Kentucky, College of Medicine / Transâ€¦\nRegulatory T cells (Tregs) are a small population of T cells compromising of 1% to 5% of the total Tâ€¦\nTregs have been studied in clinical practice for different therapeutic applications. In the past sevâ€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n0\nACTUAL\n\n\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nTrue\n65 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nHigh-Intensity Interval Training and Regulatory T Cells\nNCT04774484\n\nImpact of High-Intensity Interval Training on Regulatory T Cells\n0001\nOTHER\nUniversity of Kentucky\n\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œChange from baseline Serum IL10 at 12 weeks post HIIT interventionâ€, â€œdescriptionâ€: â€œCâ€¦\n[{â€œmeasureâ€: â€œChange from baseline concentration of circulating Regulatory T cells (Tregs) in blood â€¦\n[{â€œmeasureâ€: â€œChange from baseline Serum Interleukin-6 (IL6) at 12 weeks post HIIT interventionâ€, â€œdâ€¦\nFalse\nFalse\n\nTrue\n\n\n\nOTHER\nFrancesc Marti\nUniversity of Kentucky\nFrancesc Marti\nAssociate Professor\nSPONSOR_INVESTIGATOR\n2026-06-30\nESTIMATED\n\n\n\n\nFalse\n\n2023-02-14\nACTUAL\n2023-02-10\nWITHDRAWN\n2026-06-30\nESTIMATED\n\n\n\n\n2023-01\nESTIMATED\n2023-02\n2021-03-01\nACTUAL\n2020-10-11\n2021-02-24\nFunding was not available.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Age between 18 and 65 years old.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* BMI between 18.5 and 25 or above 30. Ratioâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD055752â€, â€œtermâ€: â€œSmall Cell Lung Carcinomaâ€}]\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}, {â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œâ€¦\nFrance\n\n2025-09-15\nACTUAL\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œPlacebo + Atezolizumab + CEâ€, â€œtypeâ€: â€œACTIVE_COMPARATORâ€, â€œdescriptionâ€: â€œParticipants â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTiragolumabâ€, â€œdescriptionâ€: â€œTiragolumab 600 milligrams (mg) administereâ€¦\nSmall Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œRocky Mountain Cancer Centers - Lone Treeâ€, â€œcityâ€: â€œLone Treeâ€, â€œstateâ€: â€œColoradoâ€,â€¦\n[{â€œnameâ€: â€œClinical Trialsâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThis study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposideâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n490\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSKYSCRAPER-02\nA Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With â€¦\nNCT04256421\n\nA Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin andâ€¦\nGO41767\nINDUSTRY\nHoffmann-La Roche\n[{â€œidâ€: â€œ2019-003301-97â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œInvestigator-Assessed Progression Free Survival (PFS) in the Primary Analysis Set (PASâ€¦\n[{â€œmeasureâ€: â€œPFS in the FASâ€, â€œdescriptionâ€: â€œPFS was defined as the time from randomization to theâ€¦\nFalse\nTrue\n\nTrue\n[{â€œpmidâ€: â€œ37976444â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œRudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee Jâ€¦\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2025-07-31\nACTUAL\n2025-10-22\nACTUAL\n2023-09-01\n\nFalse\n\n2026-01-28\nACTUAL\n2026-01-09\nCOMPLETED\n2022-09-06\nACTUAL\n2025-10-22\nACTUAL\n2025-08-26\n2025-10-07\n2020-02-04\nACTUAL\n2026-01\n2020-02-05\nACTUAL\n2020-01-31\n2020-02-03\n\nAll-cause mortality- FAS: All randomized participants, whether or not the participant received the aâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œDuring induction treatment partiâ€¦\n5.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\nUp to approximately 24 months\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ247â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œDuring induction treatment partiâ€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nFull analysis set (FAS): All randomized participants, whether or not the participant received the asâ€¦\nThe Study being conducted under this Agreement is part of the Overall Study. Investigator is free toâ€¦\nFalse\nOTHER\nTrue\n\ngenentech@druginfo.com\nHoffmann-La Roche\n800 821-8590\n\nMedical Communications\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œInvestigator-Assessed Progression Free Survival (PFS) in the Primary â€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPlacebo + Atezolizumabâ€, â€œdescriptionâ€: â€œDuring induction treatment partiâ€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nParticipants were randomized to receive Placebo + Atezolizumab (P+A) or Tiragolumab + Atezolizumab (â€¦\nA total of 490 participants with extensive stage small cell lung cancer (SCLC) took part at 139 centâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically confirmed extensive-stage small cell lung canâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD005833â€, â€œtermâ€: â€œGenital Neoplasms, Femaleâ€}, {â€œidâ€: â€œD014565â€, â€œtermâ€: â€œUrogenital Neoplâ€¦\n[{â€œidâ€: â€œD016889â€, â€œtermâ€: â€œEndometrial Neoplasmsâ€}, {â€œidâ€: â€œD014594â€, â€œtermâ€: â€œUterine Neoplasmsâ€},â€¦\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC000614160â€, â€œtermâ€: â€œtrastuzumab deruxtecanâ€}, {â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€},â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm A: T-DXd + Rilvegostomigâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œT-DXd IV Q3W plusâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œTrastuzumab deruxtecanâ€, â€œdescriptionâ€: â€œExperimental therapy by intravenâ€¦\nEndometrial Cancer\nEndometrial Cancer, Uterine Cancer, Endometrial Carcinoma, Human epidermal growth factor receptor 2 â€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œWITHDRAWNâ€, â€œcityâ€: â€œTucsonâ€, â€œstateâ€: â€œArizonaâ€, â€œzipâ€: â€œâ€¦\n\nDESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/â€¦\n\n\n\nRANDOMIZED\nPARALLEL\nParticipants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent ECâ€¦\nNONE\nThis is an open-label, Sponsor-blinded study. To maintain the integrity of the study, Sponsor personâ€¦\n\n\nTREATMENT\n\n600\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\n* Key Inclusion Criteria:\n\n\nFalse\n\n18 Years\n\nFEMALE\nADULT, OLDER_ADULT\n\nDE-01\nDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumâ€¦\nNCT06989112\n\nDESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase IIâ€¦\nD781DC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2023-508056-19-00â€, â€œtypeâ€: â€œREGISTRYâ€, â€œdomainâ€: â€œCTIS (EU)â€}, {â€œidâ€: â€œGOG-3098â€, â€œtypeâ€: â€¦\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œProgression-free survival (PFS), as assessed by BICRâ€, â€œdescriptionâ€: â€œDefined as timeâ€¦\n[{â€œmeasureâ€: â€œOverall Survival (OS)â€, â€œdescriptionâ€: â€œDefined as the time from randomization until tâ€¦\nFalse\nTrue\n\nTrue\n\n\n[{â€œnameâ€: â€œDaiichi Sankyo Co., Ltd.â€, â€œclassâ€: â€œINDUSTRYâ€}, {â€œnameâ€: â€œGynecologic Oncology Group (GOâ€¦\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2031-02-19\nESTIMATED\n\n\n\n\nFalse\n\n2026-01-15\nACTUAL\n2026-01-14\nRECRUITING\n2029-01-19\nESTIMATED\n\n\n\n\n2025-03-27\nACTUAL\n2026-01\n2025-05-25\nACTUAL\n2025-03-11\n2025-05-15\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Participants must be â‰¥ 18 years of age at the time of screening. Otheâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD020919â€, â€œtermâ€: â€œSleep Disorders, Intrinsicâ€}, {â€œidâ€: â€œD020920â€, â€œtermâ€: â€œDyssomniasâ€}, {â€¦\n[{â€œidâ€: â€œD007319â€, â€œtermâ€: â€œSleep Initiation and Maintenance Disordersâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œDigital Cognitive Behavioural Therapy for Insomnia (dCBT-I)â€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdâ€¦\n[{â€œtypeâ€: â€œOTHERâ€, â€œnameâ€: â€œDigital Cognitive Behavioural Therapy for Insomnia (dCBT-I)â€, â€œdescriptiâ€¦\nInsomnia, Cancer\nCancer, Insomnia, Sleep, Survivorship, Quality of life, Anxiety, Depression, Fatigue, Hot Flushes\n[{â€œnameâ€: â€œDonal Brennan, PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ+353879577510â€, â€œemailâ€: â€œdonal.brennanâ€¦\n[{â€œfacilityâ€: â€œUniversity College Dublinâ€, â€œcityâ€: â€œDublinâ€, â€œzipâ€: â€œD04V1W8â€, â€œcountryâ€: â€œIrelandâ€,â€¦\n[{â€œnameâ€: â€œDonal Brennan, PhDâ€, â€œaffiliationâ€: â€œUniversity College Dublinâ€, â€œroleâ€: â€œPRINCIPAL_INVESâ€¦\nThis study will recruit women over the age of 18 with a current or prior cancer diagnosis who have câ€¦\nWomen who are eligible and provide informed consent will be enrolled into this 2-armed, parallel groâ€¦\n\n\nRANDOMIZED\nPARALLEL\n2-armed, parallel group open label randomised controlled trial. Participants will be randomised 1:1 â€¦\nNONE\n\n\n\nTREATMENT\n\n308\nESTIMATED\n\n\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nFEMALE\nADULT, OLDER_ADULT\n\nSACS\nThe Sleepio After Cancer Study\nNCT05816460\n\nThe Sleepio After Cancer Study (SACS). Digital CBT for Insomnia in Women Cancer Patients - A Randomiâ€¦\nWHI22BRE\nOTHER\nUniversity College Dublin\n[{â€œidâ€: â€œWHI22BREâ€, â€œtypeâ€: â€œOTHER_GRANTâ€, â€œdomainâ€: â€œIrish Cancer Society, Womenâ€™s Health Initiativâ€¦\n\n\n\nNO\n\n\n[{â€œmeasureâ€: â€œImmune cell countâ€, â€œdescriptionâ€: â€œWe will collect a blood sample from a cohort of paâ€¦\n[{â€œmeasureâ€: â€œMean continuous change in the intervention group compared to the control arm as measurâ€¦\n[{â€œmeasureâ€: â€œSleep related Quality of life as measured by Glasgow Sleep Impact Index (GSII)â€, â€œdescâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ41170811â€, â€œtypeâ€: â€œDERIVEDâ€, â€œcitationâ€: â€œCai Z, Tang Y, Liu C, Li H, Zhao G, Zhao Z, Zhâ€¦\n\n[{â€œnameâ€: â€œIrish Cancer Societyâ€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œBig Health Ltd.â€, â€œclassâ€: â€œUNKNOWNâ€}â€¦\nOTHER\nUniversity College Dublin\n\n\n\nSPONSOR\n2024-06-10\nESTIMATED\n\n\n\n\nFalse\nNOT_YET_RECRUITING\n2023-05-23\nACTUAL\n2023-05-19\nUNKNOWN\n2024-06-10\nESTIMATED\n\n\n\n\n2023-05-22\nESTIMATED\n2023-05\n2023-04-18\nACTUAL\n2023-03-13\n2023-04-14\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Women\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Aged 18 and over\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Sleep Condition Indicator (SCI) score of 16 or lesâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD056831â€, â€œtermâ€: â€œCoordination Complexesâ€}, {â€œidâ€: â€œD009930â€, â€œtermâ€: â€œOrganic Chemicalsâ€}â€¦\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œD016190â€, â€œtermâ€: â€œCarboplatinâ€}, {â€œidâ€: â€œD0029â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œArm Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œRilvegostomig in combination with platinâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œRilvegostomigâ€, â€œdescriptionâ€: â€œAdministered as one intravenously (IV) onâ€¦\nNon-squamous Non-small Cell Lung Cancer\nARTEMIDE-Lung03, Rilvegostomig (AZD2936), Non-squamous non-small cell lung cancer (NSCLC), Bi-specifâ€¦\n[{â€œnameâ€: â€œAstraZeneca Clinical Study Information Centerâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ1-877-240-94â€¦\n[{â€œfacilityâ€: â€œResearch Siteâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œcityâ€: â€œMobileâ€, â€œstateâ€: â€œAlabamaâ€, â€œzipâ€: â€¦\n\nThe purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pâ€¦\nThis is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the effiâ€¦\n\n\nRANDOMIZED\nPARALLEL\nArm A: Rilvegostomig in combination with platinum-based doublet chemotherapy followed by rilvegostomâ€¦\nQUADRUPLE\nDouble-blind masking\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR\n\nTREATMENT\n\n878\nESTIMATED\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatmenâ€¦\nNCT06627647\n\nA Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab iâ€¦\nD702FC00001\nINDUSTRY\nAstraZeneca\n[{â€œidâ€: â€œ2024-515008-38-00â€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œCTIS IDâ€}]\nWhen a request has been approved AstraZeneca will provide access to the anonymized individual patienâ€¦\nQualified researchers can request access to anonymized individual patient-level data from AstraZenecâ€¦\nSTUDY_PROTOCOL, SAP\nYES\nAstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Datâ€¦\nhttps://vivli.org/\n\n[{â€œmeasureâ€: â€œOverall survival (OS)â€, â€œdescriptionâ€: â€œOS is defined as the time from randomization uâ€¦\n[{â€œmeasureâ€: â€œLandmark overall survival (OS) ratesâ€, â€œdescriptionâ€: â€œOS is defined as the time from â€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nAstraZeneca\n\n\n\nSPONSOR\n2030-03-25\nESTIMATED\n\n\n\n\nFalse\n\n2025-12-22\nACTUAL\n2025-12-19\nRECRUITING\n2029-05-10\nESTIMATED\n\n\n\n\n2024-11-27\nACTUAL\n2025-12\n2024-10-04\nACTUAL\n2024-10-03\n2024-10-03\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically documented non-squamous NSCLC.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Stage IV mNSâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD018358â€, â€œtermâ€: â€œNeuroendocrine Tumorsâ€}, {â€œidâ€: â€œD017599â€, â€œtermâ€: â€œNeuroectodermal Tumoâ€¦\n[{â€œidâ€: â€œD008545â€, â€œtermâ€: â€œMelanomaâ€}, {â€œidâ€: â€œC565324â€, â€œtermâ€: â€œParkinson Disease 4, Autosomal Doâ€¦\n\n[{â€œidâ€: â€œC582435â€, â€œtermâ€: â€œpembrolizumabâ€}, {â€œidâ€: â€œC531958â€, â€œtermâ€: â€œlenvatinibâ€}]\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œPembrolizumab + Vibostolimabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants willâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œPembrolizumabâ€, â€œdescriptionâ€: â€œAdministered via IV infusion at a sâ€¦\nMelanoma\nprogrammed cell death 1 (PD-1, PD1), programmed cell death ligand 1 (PD-L1, PDL1), T cell immunoreceâ€¦\n\n[{â€œfacilityâ€: â€œThe Angeles Clinic and Research Institute ( Site 2009)â€, â€œcityâ€: â€œLos Angelesâ€, â€œstatâ€¦\n[{â€œnameâ€: â€œMedical Directorâ€, â€œaffiliationâ€: â€œMerck Sharp & Dohme LLCâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nSubstudy 02B is part of a larger research study where researchers are looking for new ways to treat â€¦\nWith Amendment 6, all arms are closed to enrollment. Participants in arms 2 (pembrolizumab), 3 (cofoâ€¦\n\n\nRANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n315\nESTIMATED\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n120 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nSubstudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pemâ€¦\nNCT04305054\n\nA Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Withouâ€¦\n3475-02B\nINDUSTRY\nMerck Sharp & Dohme LLC\n[{â€œidâ€: â€œMK-3475-02Bâ€, â€œtypeâ€: â€œOTHERâ€, â€œdomainâ€: â€œMSDâ€}, {â€œidâ€: â€œKEYMAKER-U02â€, â€œtypeâ€: â€œOTHERâ€, â€œdâ€¦\n\nhttps://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf\n\nYES\n\nhttps://externaldatasharing-msd.com/\n\n[{â€œmeasureâ€: â€œPercentage of participants who experience a dose-limiting toxicity (DLT): Safety lead-â€¦\n[{â€œmeasureâ€: â€œDuration of Response (DOR) per RECIST 1.1â€, â€œdescriptionâ€: â€œFor participants in the anâ€¦\nFalse\nTrue\n\nFalse\n\n[{â€œlabelâ€: â€œMerck Clinical Trials Informationâ€, â€œurlâ€: â€œhttps://www.merckclinicaltrials.com/â€}, {â€œlaâ€¦\n\nINDUSTRY\nMerck Sharp & Dohme LLC\n\n\n\nSPONSOR\n2026-04-20\nESTIMATED\n\n\n\n\nFalse\n\n2025-08-29\nACTUAL\n2025-08-28\nACTIVE_NOT_RECRUITING\n2026-04-20\nESTIMATED\n\n\n\n\n2020-07-01\nACTUAL\n2025-08\n2020-03-12\nACTUAL\n2020-03-09\n2020-03-09\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has histologically or cytologically confirmed melanoma\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Has unresectable Staâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}]\n\n[{â€œidâ€: â€œC000594389â€, â€œtermâ€: â€œatezolizumabâ€}, {â€œidâ€: â€œC000730814â€, â€œtermâ€: â€œTiragolumabâ€}]\nArgentina, Denmark, France\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œTiragolumab + Atezolizumabâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œParticipants will râ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œAtezolizumabâ€, â€œdescriptionâ€: â€œAtezolizumab 1200 milligrams (mg) administâ€¦\nNon-Small Cell Lung Cancer\n\n\n[{â€œfacilityâ€: â€œRocky Mountain Cancer Center - Denverâ€, â€œcityâ€: â€œDenverâ€, â€œstateâ€: â€œColoradoâ€, â€œzipâ€:â€¦\n[{â€œnameâ€: â€œClinical Trialâ€, â€œaffiliationâ€: â€œHoffmann-La Rocheâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nThe purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab comâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nTRIPLE\n\nPARTICIPANT, CARE_PROVIDER, INVESTIGATOR\n\nTREATMENT\n\n620\nACTUAL\n\nPHASE3\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\nSKYSCRAPER-01\nA Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atâ€¦\nNCT04294810\n\nA Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antiâ€¦\nGO41717\nINDUSTRY\nHoffmann-La Roche\n[{â€œidâ€: â€œ2019-002925-31â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œ2022-502482-17-00â€, â€œtypeâ€: â€œCTISâ€}]\n\nFor eligible studies, qualified researchers may request access to individual patient level clinical â€¦\n\nYES\n\n\n\n[{â€œmeasureâ€: â€œInvestigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Setâ€, â€œtâ€¦\n[{â€œmeasureâ€: â€œInvestigator-Assessed PFS in the Secondary Analysis Setâ€, â€œtimeFrameâ€: â€œFrom randomizaâ€¦\nFalse\nTrue\n\nTrue\n\n\n\nINDUSTRY\nHoffmann-La Roche\n\n\n\nSPONSOR\n2025-12-30\nACTUAL\n\n\n\n\nFalse\n\n2026-01-30\nACTUAL\n2026-01-29\nCOMPLETED\n2025-12-30\nACTUAL\n\n\n\n\n2020-03-04\nACTUAL\n2026-01\n2020-03-04\nACTUAL\n2020-03-02\n2020-03-02\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD000230â€, â€œtermâ€: â€œAdenocarcinomaâ€}, {â€œidâ€: â€œD002277â€, â€œtermâ€: â€œCarcinomaâ€}, {â€œidâ€: â€œD00937â€¦\n[{â€œidâ€: â€œD006528â€, â€œtermâ€: â€œCarcinoma, Hepatocellularâ€}, {â€œidâ€: â€œC537340â€, â€œtermâ€: â€œSimpson-Golabi-Bâ€¦\n\n\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCAR-T cell therapy groupâ€, â€œtypeâ€: â€œOTHERâ€, â€œdescriptionâ€: â€œAppropriate patients who couâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œGPC3 and/or TGFÎ² targeting CAR-T cellsâ€, â€œdescriptionâ€: â€œEngineerinâ€¦\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Canâ€¦\nHepatocellular carcinoma, immunotherapy, CAR-T cell therapy, GPC3 or TGFÎ² targeting, Phase I clinicaâ€¦\n[{â€œnameâ€: â€œZhenfeng Zhang, MD,PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0086-020-34153532â€, â€œemailâ€: â€œzhangâ€¦\n[{â€œfacilityâ€: â€œThe First Affiliated Hospital of Sun Yat-sen Universityâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œciâ€¦\n[{â€œnameâ€: â€œZhenfeng Zhang, MD,PhDâ€, â€œaffiliationâ€: â€œSecond Affiliated Hospital of Guangzhou Medical â€¦\nThe third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFÎ² (GPâ€¦\n1. Choose appropriate patients with advanced hepatocellular carcinoma,with written consent for this â€¦\n\n\n\nSINGLE_GROUP\n\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression\nNCT03198546\n\nCAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial\nZZCART-003\nOTHER\nSecond Affiliated Hospital of Guangzhou Medical University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œNumber of Patients with Dose Limiting Toxicityâ€, â€œdescriptionâ€: â€œA dose limiting toxicâ€¦\n[{â€œmeasureâ€: â€œPercent of Patients with best response as either complete remission or partial remissiâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ28123387â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œJiang Z, Jiang X, Chen S, Lai Y, Wei X, Li B, Lâ€¦\n\n[{â€œnameâ€: â€œHunan Zhaotai Yongren Medical Innovation Co.Â Ltd.â€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œGuangdonâ€¦\nOTHER\nSecond Affiliated Hospital of Guangzhou Medical University\n\n\n\nSPONSOR\n2036-08-01\nESTIMATED\n\n\n\n\nFalse\n\n2024-06-25\nACTUAL\n2024-06-22\nRECRUITING\n2029-08-01\nESTIMATED\n\n\n\n\n2017-07-01\nACTUAL\n2024-06\n2017-06-26\nACTUAL\n2017-06-21\n2017-06-23\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. patients with advanced HCC,which express GPC3 protein.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2. Life expectancy &gt;â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD012142â€, â€œtermâ€: â€œRespiratory Tract Neoplasmsâ€}, {â€œidâ€: â€œD013899â€, â€œtermâ€: â€œThoracic Neoplâ€¦\n[{â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplasmsâ€}, {â€œidâ€: â€œD009369â€, â€œtermâ€: â€œNeoplasmsâ€}]\n[{â€œidâ€: â€œD058851â€, â€œtermâ€: â€œGPI-Linked Proteinsâ€}, {â€œidâ€: â€œD008562â€, â€œtermâ€: â€œMembrane Glycoproteinsâ€¦\n[{â€œidâ€: â€œD000090204â€, â€œtermâ€: â€œMesothelinâ€}, {â€œidâ€: â€œD006162â€, â€œtermâ€: â€œGuanylate Cyclaseâ€}, {â€œidâ€: â€¦\n\n\n\n\n\n2026-02-02\n\nFalse\n[{â€œlabelâ€: â€œCAR-T cell therapy groupâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œPatients will receiveâ€¦\n[{â€œtypeâ€: â€œBIOLOGICALâ€, â€œnameâ€: â€œCAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3,â€¦\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nLung Cancer, CAR-T Cell Therapy, PSCA, MUC1, HER2, Mesothelin, Lewis-Y, GPC3, AXL, EGFR, B7-H3, Clauâ€¦\n[{â€œnameâ€: â€œZhenfeng Zhang, MD,PhDâ€, â€œroleâ€: â€œCONTACTâ€, â€œphoneâ€: â€œ0086-020-34153532â€, â€œemailâ€: â€œzhangâ€¦\n[{â€œfacilityâ€: â€œThe First Affiliated Hospital of Sun Yat-sen Universityâ€, â€œstatusâ€: â€œRECRUITINGâ€, â€œciâ€¦\n[{â€œnameâ€: â€œZhenfeng Zhang, MD,PhDâ€, â€œaffiliationâ€: â€œSecond Affiliated Hospital of Guangzhou Medical â€¦\nThe third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, â€¦\n1. Choose appropriate patients with advanced lung or other cancers,with written consent for this stuâ€¦\n\n\n\nSINGLE_GROUP\nUse engineered CAR-T cells to kill cancer cells with certain targets.\nNONE\n\n\n\nTREATMENT\n\n30\nESTIMATED\n\nPHASE1\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n75 Years\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nGPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFÎ²/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Againâ€¦\nNCT03198052\n\nCAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFÎ², HER2, Lewis-Y,â€¦\nZZCART-002\nOTHER\nSecond Affiliated Hospital of Guangzhou Medical University\n\n\n\n\nNO\n\n\n\n[{â€œmeasureâ€: â€œNumber of Patients with Dose Limiting Toxicityâ€, â€œdescriptionâ€: â€œA dose limiting toxicâ€¦\n[{â€œmeasureâ€: â€œPercent of Patients with best response as either complete remission or partial remissiâ€¦\nFalse\nFalse\n\nFalse\n[{â€œpmidâ€: â€œ28405515â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œWei X, Lai Y, Li J, Qin L, Xu Y, Zhao R, Li B, â€¦\n\n[{â€œnameâ€: â€œHunan Zhaotai Yongren Medical Innovation Co.Â Ltd.â€, â€œclassâ€: â€œOTHERâ€}, {â€œnameâ€: â€œGuangdonâ€¦\nOTHER\nSecond Affiliated Hospital of Guangzhou Medical University\n\n\n\nSPONSOR\n2036-08-01\nESTIMATED\n\n\n\n\nFalse\n\n2024-06-25\nACTUAL\n2024-06-22\nRECRUITING\n2026-08-01\nESTIMATED\n\n\n\n\n2017-07-01\nACTUAL\n2024-06\n2017-06-23\nACTUAL\n2017-06-22\n2017-06-22\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1. Patients with advanced cancer that expresses GPC3/Mesothelin/Claudin18.2/GUâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD002283â€, â€œtermâ€: â€œCarcinoma, Bronchogenicâ€}, {â€œidâ€: â€œD001984â€, â€œtermâ€: â€œBronchial Neoplasmâ€¦\n[{â€œidâ€: â€œD002289â€, â€œtermâ€: â€œCarcinoma, Non-Small-Cell Lungâ€}, {â€œidâ€: â€œD008175â€, â€œtermâ€: â€œLung Neoplaâ€¦\n[{â€œidâ€: â€œD001549â€, â€œtermâ€: â€œBenzamidesâ€}, {â€œidâ€: â€œD000577â€, â€œtermâ€: â€œAmidesâ€}, {â€œidâ€: â€œD009930â€, â€œteâ€¦\n[{â€œidâ€: â€œC000601108â€, â€œtermâ€: â€œencorafenibâ€}, {â€œidâ€: â€œC581313â€, â€œtermâ€: â€œbinimetinibâ€}, {â€œidâ€: â€œD000â€¦\nCanada, United Kingdom\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œSub-Study Aâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œdescriptionâ€: â€œSasanlimab will be administered suâ€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œSasanlimab Prefilled syringeâ€, â€œdescriptionâ€: â€œprefilled syringeâ€, â€œarmGrâ€¦\nCarcinoma, Non-Small-Cell Lung\nNon-Small-Cell Lung Carcinoma, NSCLC, non small cell lung cancer, non-small cell lung cancer, BRAF mâ€¦\n\n[{â€œfacilityâ€: â€œCity of Hope Investigational Drug Services (IDS)â€, â€œcityâ€: â€œDuarteâ€, â€œstateâ€: â€œCalifoâ€¦\n[{â€œnameâ€: â€œPfizer CT.gov Call Centerâ€, â€œaffiliationâ€: â€œPfizerâ€, â€œroleâ€: â€œSTUDY_DIRECTORâ€}]\nPhase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study.\nLandscape 1011 is a clinical research study for people with advanced (stage 3b or 4) non-small cell â€¦\n\n\nNON_RANDOMIZED\nPARALLEL\n\nNONE\n\n\n\nTREATMENT\n\n34\nACTUAL\n\nPHASE1, PHASE2\nINTERVENTIONAL\n\nInclusion Criteria Umbrella Phase 1b & 2:\n\n\nFalse\n\n18 Years\n\nALL\nADULT, OLDER_ADULT\n\n\nStudy of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Nâ€¦\nNCT04585815\n\nA Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Mâ€¦\nB8011011\nINDUSTRY\nPfizer\n[{â€œidâ€: â€œ2020-002829-28â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}]\n\nPfizer will provide access to individual de-identified participant data and related study documents â€¦\n\nYES\n\nhttps://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests\n\n[{â€œmeasureâ€: â€œPhase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLTâ€¦\n[{â€œmeasureâ€: â€œPhase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded Accorâ€¦\nFalse\nTrue\n\nFalse\n\n[{â€œlabelâ€: â€œTo obtain contact information for a study center near you, click here.â€, â€œurlâ€: â€œhttps:/â€¦\n\nINDUSTRY\nPfizer\n\n\n\nSPONSOR\n2024-10-29\nACTUAL\n\n\n\n\nFalse\n\n2026-01-09\nACTUAL\n2025-12-18\nTERMINATED\n2023-05-17\nACTUAL\n2023-06-22\nACTUAL\n2023-05-30\n2023-05-30\n2020-11-10\nACTUAL\n2025-12\n2020-10-14\nACTUAL\n2020-09-30\n2020-10-09\nStudy was terminated due to portfolio re-prioritization and strategic considerations. The decision wâ€¦\nSame event may appear as both non-serious adverse event (non-SAE) and SAE but are distinct events. Aâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (â€¦\n5.0\n[{â€œtermâ€: â€œAnaemiaâ€, â€œorganSystemâ€: â€œBlood and lymphatic system disordersâ€, â€œsourceVocabularyâ€: â€œMedâ€¦\n[{â€œtermâ€: â€œChest painâ€, â€œorganSystemâ€: â€œGeneral disordersâ€, â€œsourceVocabularyâ€: â€œMedDRA v27.1â€, â€œassâ€¦\nFrom the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maâ€¦\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ4â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvaluâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (â€¦\n[{â€œtitleâ€: â€œAge, Categoricalâ€, â€œparamTypeâ€: â€œCOUNT_OF_PARTICIPANTSâ€, â€œunitOfMeasureâ€: â€œParticipantsâ€â€¦\nFull analysis set included all participants who received at least 1 dose of study drug. Participantsâ€¦\nPfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator wiâ€¦\nFalse\nOTHER\nTrue\nDue to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 waâ€¦\nClinicalTrials.gov_Inquiries@pfizer.com\nPfizer Inc.\n1-800-718-1021\n\nPfizer ClinicalTrials.gov Call Center\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œPhase 1b of Sub-Study A: Percentage of Participants With Dose-Limitinâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (â€¦\n[{â€œtitleâ€: â€œSub-study A- Treatment Phaseâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroâ€¦\n57 participants signed informed consent and 34 participants were enrolled in the study. Of these 34 â€¦\nSub-study A (SSA) was planned to be conducted in 2 parts: Phase 1b and Phase 2. Due to a business deâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSasanlimab (a PD-1â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Histologically or cytologically confirmed locally advaâ€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[{â€œidâ€: â€œD044882â€, â€œtermâ€: â€œGlucose Metabolism Disordersâ€}, {â€œidâ€: â€œD008659â€, â€œtermâ€: â€œMetabolic Disâ€¦\n[{â€œidâ€: â€œD003920â€, â€œtermâ€: â€œDiabetes Mellitusâ€}, {â€œidâ€: â€œD003922â€, â€œtermâ€: â€œDiabetes Mellitus, Type â€¦\n[{â€œidâ€: â€œD052216â€, â€œtermâ€: â€œGlucagon-Like Peptide 1â€}, {â€œidâ€: â€œD004763â€, â€œtermâ€: â€œGlucagon-Like Peptâ€¦\n[{â€œidâ€: â€œD000069450â€, â€œtermâ€: â€œLiraglutideâ€}]\n\n\n\n\n\n2026-02-02\n[{â€œtypeAbbrevâ€: â€œProtâ€, â€œhasProtocolâ€: true, â€œhasSapâ€: false, â€œhasIcfâ€: false, â€œlabelâ€: â€œStudy Protoâ€¦\nTrue\n[{â€œlabelâ€: â€œNNC0114-0006 + Liraglutideâ€, â€œtypeâ€: â€œEXPERIMENTALâ€, â€œinterventionNamesâ€: [â€œDrug: NNC011â€¦\n[{â€œtypeâ€: â€œDRUGâ€, â€œnameâ€: â€œNNC0114-0006â€, â€œdescriptionâ€: â€œNNC0114-0006 12 mg/kg administered i.v (inâ€¦\nDiabetes, Diabetes Mellitus, Type 1\n\n\n[{â€œfacilityâ€: â€œNovo Nordisk Investigational Siteâ€, â€œcityâ€: â€œLa Jollaâ€, â€œstateâ€: â€œCaliforniaâ€, â€œzipâ€:â€¦\n[{â€œnameâ€: â€œGlobal Clinical Registry (GCR, 1452)â€, â€œaffiliationâ€: â€œNovo Nordisk A/Sâ€, â€œroleâ€: â€œSTUDY_â€¦\nThis trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principleâ€¦\n\n\n\nRANDOMIZED\nPARALLEL\n\nDOUBLE\n\nPARTICIPANT, INVESTIGATOR\n\nTREATMENT\n\n308\nACTUAL\n\nPHASE2\nINTERVENTIONAL\n\nInclusion Criteria:\n\n\nFalse\n45 Years\n18 Years\n\nALL\nADULT\n\n\nA Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus â€¦\nNCT02443155\n\nA Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Pâ€¦\nNN9828-4150\nINDUSTRY\nNovo Nordisk A/S\n[{â€œidâ€: â€œ2014-001215-39â€, â€œtypeâ€: â€œEUDRACT_NUMBERâ€}, {â€œidâ€: â€œU1111-1154-7172â€, â€œtypeâ€: â€œOTHERâ€, â€œdomâ€¦\n\n\n\n\n\n\n\n[{â€œmeasureâ€: â€œArea Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT)â€¦\n[{â€œmeasureâ€: â€œAUC0-2h of C-peptide at Week 54 Relative to Baselineâ€, â€œdescriptionâ€: â€œArea under the â€¦\n\n\n\nFalse\n[{â€œpmidâ€: â€œ33662334â€, â€œtypeâ€: â€œRESULTâ€, â€œcitationâ€: â€œvon Herrath M, Bain SC, Bode B, Clausen JO, Copâ€¦\n[{â€œlabelâ€: â€œClinical Trials at Novo Nordiskâ€, â€œurlâ€: â€œhttp://novonordisk-trials.comâ€}]\n\nINDUSTRY\nNovo Nordisk A/S\n\n\n\nSPONSOR\n2019-02-27\nACTUAL\n2019-08-19\nACTUAL\n2019-08-16\n2019-08-16\nFalse\n\n2021-04-09\nACTUAL\n2021-03-10\nCOMPLETED\n2018-08-31\nACTUAL\n2021-01-11\nACTUAL\n2020-12-11\n2020-12-11\n2015-11-10\nACTUAL\n2021-03\n2015-05-13\nESTIMATED\n2015-05-11\n2015-05-11\n\nAll reported adverse events are treatment-emergent. Results are based on the safety analysis set (SAâ€¦\n[{â€œidâ€: â€œEG000â€, â€œtitleâ€: â€œNNC0114-0006 + Liraglutideâ€, â€œdescriptionâ€: â€œParticipants received 12 mg/â€¦\n5.0\n[{â€œtermâ€: â€œAbdominal discomfortâ€, â€œorganSystemâ€: â€œGastrointestinal disordersâ€, â€œsourceVocabularyâ€: â€œâ€¦\n[{â€œtermâ€: â€œAbdominal painâ€, â€œorganSystemâ€: â€œGastrointestinal disordersâ€, â€œsourceVocabularyâ€: â€œMedDRAâ€¦\nWeeks 0-80\n[{â€œunitsâ€: â€œParticipantsâ€, â€œcountsâ€: [{â€œgroupIdâ€: â€œBG000â€, â€œvalueâ€: â€œ77â€}, {â€œgroupIdâ€: â€œBG001â€, â€œvalâ€¦\n[{â€œidâ€: â€œBG000â€, â€œtitleâ€: â€œNNC0114-0006 + Liraglutide (Experimental)â€, â€œdescriptionâ€: â€œParticipants â€¦\n[{â€œtitleâ€: â€œAge, Continuousâ€, â€œparamTypeâ€: â€œMEANâ€, â€œdispersionTypeâ€: â€œSTANDARD_DEVIATIONâ€, â€œunitOfMeâ€¦\nThe Full analysis set (FAS) included all randomised participants.\nAt the end of the trial, one or more scientific publications may be prepared collaboratively by the â€¦\nFalse\nOTHER\nTrue\n\nclinicaltrials@novonordisk.com\nNovo Nordisk A/S\n(+1) 866-867-7178\n\nClinical Reporting Anchor and Disclosure (1452)\n[{â€œtypeâ€: â€œPRIMARYâ€, â€œtitleâ€: â€œArea Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Toleâ€¦\n[{â€œidâ€: â€œFG000â€, â€œtitleâ€: â€œNNC0114-0006 + Liraglutide (Experimental)â€, â€œdescriptionâ€: â€œParticipants â€¦\n[{â€œtitleâ€: â€œOverall Studyâ€, â€œmilestonesâ€: [{â€œtypeâ€: â€œSTARTEDâ€, â€œachievementsâ€: [{â€œgroupIdâ€: â€œFG000â€,â€¦\nParticipants were randomised in a 1:1:1:1 manner to one of the four treatment groups. One participanâ€¦\nThe trial was conducted at 94 sites in Austria, Belgium, Canada, Denmark, Finland, Ireland, Israel, â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n* Informed consent obtained before any trial-related activities. Trial-related â€¦\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBack to Status Summary"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site"
  }
]